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ABSTRACT 
Imprinted genes, displaying monoallelic parent of origin specific expression, 
are known to regulate fetal growth and placental development. Work in 
animal models also suggests that imprinted genes regulate placental 
hormone signalling to the mother, which is required for induction of maternal 
adaptation to pregnancy. Aberrant placental imprinted gene expression may 
therefore have a causative role in pregnancies characterised by abnormal 
fetal growth and/or inadequate maternal adaptation to pregnancy. Given 
these important functions, identifying environmental stimuli responsible for 
perturbed imprinted gene expression is also of interest.  
This thesis examined human placental expression of the imprinted 
genes PHLDA2, CDKN1C, PEG3 and PEG10 in three independent cohorts, 
including pregnancies complicated by fetal growth restriction, fetal 
overgrowth, preeclampsia, gestational diabetes and maternal mood 
disorders. Placental imprinted gene expression was also analysed in relation 
to placental hormone (hPL and PGH) gene expression and in relation to 
maternal lifestyle factors. The effect of maternal diet on placental imprinted 
gene expression was further explored in a mouse model to provide evidence 
for a cause or effect relationship.  
Placental PHLDA2 expression was significantly increased in growth-
restricted pregnancies, supporting a role for PHLDA2 in the negative 
regulation of fetal growth. In contrast, placental PEG10 expression was 
positively associated with fetal growth. This study did not support a role for 
PEG3 in the control of fetal growth, but did suggest a role in maternal 
adaptation to pregnancy with aberrant gene expression observed in 
pregnancies complicated by maternal depression. Finally, this study provided 
evidence that PHLDA2, CDKN1C, PEG3 and PEG10 expression is 
responsive to environmental stimuli, particularly maternal diet, in both human 
pregnancies and in a mouse model. Thus, this thesis highlights the 
importance of imprinted genes in achieving a successful pregnancy for both 
mother and fetus and the possible role of maternal lifestyle in influencing this.  
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1.1. Fetal growth 
 
1.1.1. Normal fetal growth 
In a healthy pregnancy, a carefully orchestrated series of cell divisions and 
cell differentiation steps comprise the embryonic period during which the 
major internal and external structures of the embryo are formed. The human 
fetal period of development subsequently begins at the end of the first 
trimester, continuing to delivery and is characterised by fetal and placental 
growth as well as maturation of the fetal organs. Fetal growth velocity 
typically peaks at 30 – 36 weeks of gestation, decreasing thereafter till birth 
in contrast to placental growth, which is relatively consistent from 28 weeks, 
as shown in Figure 1.1(A) (Johnson 2007).  
 
 
 
 
 
 
Figure 1.1: Fetal growth in a normal, healthy pregnancy. (A) Weight changes 
during pregnancy are shown for the total conceptus, fetus, amniotic fluid and 
placenta. (B) Growth velocity (represented as % of the estimated size at 40 weeks).  
is shown for head circumference (HC) and abdominal circumference (AC). Adapted 
from (Johnson 2007) and (Bertino et al. 1996).  
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Head circumference growth velocity peaks earlier in pregnancy (around 17 
weeks) compared with abdominal circumference growth velocity (around 22 
weeks) likely reflecting the increased deposition of subcutaneous fat towards 
term (Bertino et al. 1996), Figure 1.1(B). The fetal genome and the maternal-
placental environment in which the fetus develops (including nutrient and 
oxygen supply as well as hormonal signalling) determine growth.  
 
1.1.2. Fetal growth restriction  
Fetal growth restriction (FGR) or intrauterine growth restriction (IUGR) is the 
failure of a fetus to achieve its optimal growth potential during gestation 
(Ergaz et al. 2005). Causes of growth restriction (ranging from fetal, 
placental, maternal and/or environmental) are difficult to measure and 
therefore growth restriction hard to diagnose (Ergaz et al. 2005). Thus, the 
outcomes of being born low birth weight (LBW) or small for gestational age 
(SGA) are commonly used to indicate growth restriction (Ergaz et al. 2005).  
The World Health Organisation defines LBW as birth weight < 2,500g 
at any gestational age (United Nations Children's Fund and World Health 
Organization 2004). One issue with the use of LBW as an indicator of growth 
restriction is that this definition does not distinguish between infants born 
small due to prematurity (< 37 weeks gestation) and those born small due to 
growth restriction. Another issue is that birth weight is a continuum with there 
being little clinical difference between an infant born weighing 2,500g 
(classified as normal birth weight) and an infant born weighing 2,499g 
(classified as LBW) (Adams et al. 2009). Benefits of using LBW to indicate 
growth restriction include wide availability of birth weight data, the possibility 
of comparing international research data and the ability to easily identify a 
population of high-risk infants (Adams et al. 2009). 
 A small for gestational age (SGA) infant is commonly defined as an 
infant whose birth weight is below the 10th centile relative to a population 
birth weight standard at a given week of gestation (Zhang et al. 2010). In 
contrast to use of the LBW cut off, this definition takes in to account 
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gestational age at delivery and can therefore identify those infants born small 
due to growth restriction rather than prematurity. One concern with the use of 
the SGA definition to identify fetal growth restriction is that population based 
centiles do not taken in to account maternal or fetal factors which impact on 
an individual fetus’ growth potential (Zhang et al. 2010). Therefore, using 
population based centiles it is not possible to distinguish between infants 
born constitutionally small (for example because their mother is short and 
thin) and those born pathologically small due to in utero growth restriction.  
 Using computer-based software, customised birth weight centiles can 
be generated that are adjusted for maternal height, weight, ethnicity, parity, 
fetal sex and gestational age, factors known to affect fetal growth (Gardosi et 
al. 1992). Based on this information, it is possible to predict the optimal 
weight at term for an individual fetus and therefore also identify cases of fetal 
growth restriction where the fetus has not achieved its optimal growth 
potential (Gardosi et al. 1992), Figure 1.2 (A).  
Use of custom birth weight centiles has been found to identify growth 
restricted infants not otherwise recognised as SGA by population centiles (de 
Jong et al. 1998; Clausson et al. 2001; Gardosi 2009). These include, for 
example, normal birth weight infants born to obese mothers that while 
average for gestational age (AGA) by population centiles, are growth 
restricted relative to the customised optimal term birth weight for that 
individual fetus, Figure 1.2 (B). In addition, use of custom birth weight 
centiles has been found to reduce the incidence of false SGA diagnosis 
(Gardosi 2009). By adjusting for maternal height and weight, custom birth 
weight centiles are able to distinguish between pathologically small infants 
and constitutionally small infants such as those born to short, thin mothers 
(which would otherwise be diagnosed as SGA by population centiles), Figure 
1.2 (C). Importantly, use of custom birth weight centiles better predicts 
adverse outcomes such as stillbirth, fetal distress, delivery complications, low 
apgar scores and neonatal intensive care unit (NICU) admission (de Jong et 
al. 1998; Clausson et al. 2001; Gardosi 2009; Figueras and Gardosi 2011).
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Figure 1.2: The use of custom growth centiles in identifying SGA 
pregnancies. (A) For a normal BMI woman, an infant born at term weighing ≤ 
2.5kg would be considered SGA by custom birth weight centiles and 
population (WHO) centiles. However, (B) a normal birth weight baby (e.g. 
3.1kg) born at term to an obese mother may also be considered SGA by 
custom birth weight centiles. (C) In contrast, a baby born weighing 2.75kg to a 
short, thin mother, would be considered AGA for this mother. Custom centiles 
were generated using GROW version 6.7.5 (Gardosi and Francis 2014). WHO 
centiles (population centiles) are shown for comparison. Adapted from 
(Perinatal Institute 2014). Red growth curves indicate the cut off for SGA (< 
10th centile) or LGA (> 90th centile). Green growth curves indicate 50th centile.  
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Growth restricted infants can be further classified as symmetrically or 
asymmetrically growth restricted, typically based on ultrasound head (HC) 
and abdominal (AC) circumferences (reviewed in (Monk and Moore 2004; 
Ergaz et al. 2005; Mullis and Tonella 2008; Rosenberg 2008).  Symmetrically 
growth restricted infants (approximately 25% of SGA cases) display 
proportionally smaller head and abdominal circumferences, which is thought 
to result from growth restriction in early gestation caused for example by 
genetic anomalies or viral infection (Rosenberg 2008). In contrast, 
asymmetrically growth restricted infants (approximately 75% of SGA cases) 
display reduced length, weight and abdominal circumference but relative 
sparing of the head resulting in an increased HC:AC ratio (Rosenberg 2008). 
Asymmetric growth restriction is thought to result from growth restriction 
occurring in late gestation due to nutrient deficiency and/or placental 
insufficiency with head sparing resulting from a subsequent preferential 
allocation of nutrients to the developing fetal brain (Rosenberg 2008). 
Asymmetrically growth restricted infants are at an increased risk of poor 
perinatal outcomes (such as low apgar scores, fetal distress and NICU 
admission) compared with AGA and symmetrically growth restricted infants 
(Dashe et al. 2000).  
 
1.1.3. Prevalence of growth restriction 
Prevalence of LBW was 7.1% in England (46,624 births) and Wales (2,378 
births) in 2013, affecting a combined total of 49,000 births (Office for National 
Statistics 2014). LBW prevalence has not changed significantly in Wales 
between 1993 and 2012 despite health care improvements (Statistics for 
Wales 2014). Within Wales, Abertawe Bro Morgannwg (7.7%), Cwm Taf 
(9%) and Aneurin Bevan (7.4%) health boards have higher rates of LBW 
than the Welsh average (7.1%)(Statistics for Wales 2014), Figure 1.3 (A).   
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Figure 1.3: Co-occurrence of low birth weight (LBW), adult diseases and poor 
lifestyle factors in Wales. Colour coding indicates Welsh health boards with 
prevalence of each factor below (green), average (amber) or above (red) the Welsh 
Average (with the reverse shown for fruit consumption). Generated based on data 
from (Statistics for Wales 2013) and (Statistics for Wales 2014). HB = health board. 
A) LBW prevalence B) Cardiovascular disease mortality 
C) Rates of Hypertension D) Prevalence Mental Illness 
E) Overweight/Obese residents F) Fruit Consumption 
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1.1.4. Consequences of growth restriction 
During the perinatal period, growth restricted infants are at an increased risk 
of morbidity including respiratory complications, hypothermia, hypoglycemia 
(Rosenberg 2008) and reduced measures of infant wellbeing (such as Apgar 
Scores and umbilical artery pH) (McIntire et al. 1999).  
 Importantly, these infants are also at an increased risk of perinatal 
mortality (Dunham and McAlenney 1936; Chase 1969; Saugstad 1981; 
Wilcox and Russell 1983; McIntire et al. 1999; Matthews and MacDorman 
2010). This is highlighted in that 2010 UK mortality rates of LBW infants 
(36.8/1,000 live births) are higher compared with normal BW infants 
(1.4/1,000 live births) (Office for National Statistics 2011). In particular, there 
is a strong link between fetal growth restriction and stillbirth with 
approximately 66% of stillbirths in 2013 occurring in LBW infants (Office for 
National Statistics 2014). This association has been found to be independent 
of gestational age, with a 6 fold higher risk of stillbirth at term in infants with 
fetal growth restriction (M. Kady and Gardosi 2004). Therefore, further 
understanding of growth restriction is essential in the prevention of infant 
perinatal morbidity and mortality.  
 The fetal programming hypothesis proposes that an insult during 
development, such as fetal growth restriction, can have lasting effects on the 
individual, increasing their risk of certain diseases in adulthood (Barker 
1998). Fetal growth restriction has been associated with decreased fertility 
(Ibanez et al. 2002) and an increased risk of hypertension, cardiovascular 
disease, stroke, type II diabetes and some types of cancer in adulthood 
(reviewed in (Godfrey and Barker 2001)). For example, LBW infants are 
almost seven times more likely to develop type II diabetes in adulthood than 
normal BW infants (Godfrey and Barker 2001). The fetal programming 
hypothesis was originally developed based on the observation that 
geographical differences in coronary heart disease mirrored those of 
newborn death rates typically associated with LBW (reviewed in (Barker 
2007)). Indeed, in Wales, death due to cardiovascular disease and rates of 
hypertension are highest in health boards previously identified as having 
higher rates of LBW deliveries, as shown in Figure 1.3 (B) and (C).  
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Growth restriction may also impact on offspring neurodevelopment, 
behaviour and mental health in later life (reviewed in (Schlotz and Phillips 
2009)). For example, LBW infants are at an increased risk of developing 
symptoms of ADHD, emotional problems and behavioural problems in 
childhood and are seven times more likely to suffer from schizophrenia in 
adulthood (Schlotz and Phillips 2009). Indeed, the percentage of patients 
being treated for mental illness is greatest in the Welsh health boards also 
having higher rates of LBW (Statistics for Wales 2013), Figure 1.3 (D).  
Recent studies also suggest that being pregnant with an SGA baby 
can significantly increase the risk of maternal cardiovascular disease and 
metabolic syndrome in later life (Catov et al. 2011; Bukowski et al. 2012; 
Pariente et al. 2013; Ngo et al. 2015). Importantly, the association remains 
significant after controlling for confounders such as family history and 
associated cardiovascular disease risk factors (Bukowski et al. 2012) 
suggesting that the relationship may not be due to shared genetic and/or 
environmental sources alone. Maternal adaptation to pregnancy includes 
changes to the cardiovascular system which increase oxygenated blood flow 
to the fetus (Tan and Tan 2013); it has been suggested that perturbed 
adaptation of the maternal cardiovascular system to pregnancy, involving 
maternal, placental and fetal hormones, could underlie the association 
between fetal growth restriction and an elevated maternal risk of 
cardiovascular disease in later life (Ngo et al. 2015).   
Thus, fetal growth restriction is of clinical and public health relevance 
due to the negative impacts on offspring health in the perinatal period and in 
adulthood, as well as long-term effects on maternal health.  
 
1.1.5. Causes of growth restriction 
Fetal growth restriction is associated with preterm delivery with the two 
pregnancy complications sharing several risk factors and consequences 
(Goldenberg et al. 2008). Studying only term infants therefore enables 
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examination of the specific causes and effects of growth restriction in utero 
independently from those of being born prematurely.  
Fetal growth restriction may be driven by fetal, placental, maternal or 
environmental factors (Sankaran and Kyle 2009). While paternal factors are 
also known to affect fetal growth, the maternal contribution to FGR risk is 
estimated to be greater (Magnus et al. 2001; Jaquet et al. 2005; Mattsson 
and Rylander 2013). Of note is the inconsistency in definitions of growth 
restriction used in previous studies investigating causes of FGR, with the risk 
of delivering a LBW infant typically examined. Fetal causes of growth 
restriction include genetic and chromosomal abnormalities (e.g. single gene 
mutations, chromosomal trisomy, triploidy and uniparental disomy), 
congenital abnormalities, intrauterine infection (most frequently 
toxoplasmosis and cytomegalovirus) and pregnancies with multiples (Hendrix 
and Berghella 2008).  
Placental causes of growth restriction include placental previa 
(placental growth over the cervix), tumors in the placenta, placental infarcts 
(associated with decreased placental blood flow) and cord insertion 
abnormalities (Hendrix and Berghella 2008). These abnormalities result in 
placental insufficiency when the placenta is unable to provide the fetus with 
the optimum nutrients and oxygen needed to support growth (Hendrix and 
Berghella 2008). Placental insufficiency is recognised as a major cause of 
FGR (Brodsky and Christou 2004).  
Maternal causes of growth restriction are related to maternal 
demographics, disease, pregnancy complications and/or obstetric history 
(reviewed in (Valero de Bernabé et al. 2004; McCowan and Horgan 2009)). 
In terms of maternal demographics, advanced maternal age and teenage 
pregnancy are both associated with an increased risk of LBW (Jacobsson et 
al. 2004; Chen et al. 2007). Risk of LBW has also been demonstrated to vary 
by ethnicity (Valero de Bernabé et al. 2004) with the prevalence of LBW 
births in non-Caucasian women in the UK increased by 62% compared with 
Caucasian women (Collingwood Bakeo and Clarke 2006). In addition, socio-
economic disadvantage in the UK (indicated by e.g. living in a deprived area, 
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council housing residence and maternal unemployment) significantly 
increases the risk of LBW (Collingwood Bakeo and Clarke 2006).  
Short stature, low pre-pregnancy maternal BMI and poor weight gain 
during pregnancy are also associated with a significantly increased risk of 
LBW (Valero de Bernabé et al. 2004) . Although maternal obesity is generally 
thought to be protective against growth restriction, the use of custom birth 
weight centiles reveals a significantly higher number of SGA infants and 
increased perinatal mortality rates in obese women compared with normal 
BMI controls (Gardosi 2009). Although no pregnancy specific data is 
available, it is estimated that 58% of people in Wales are overweight and 
23% obese with rates highest in the Aneurin Bevan and Cwm Taf health 
boards (Statistics for Wales 2013), Figure 1.3 (E).  
Thus, there are a number of maternal demographic factors that affect 
fetal growth, which must be controlled for in any study looking at 
environmental causes of fetal growth restriction. 
 
1.2. Environmental causes of FGR 
Given that there are currently limited treatment options for FGR, 
environmental causes of growth restriction are of particular interest as these 
are most amenable to intervention (Sankaran and Kyle 2009). 
  
1.2.1. Maternal smoking 
In Wales, an estimated 33% of women in 2010 smoked before pregnancy 
and 16% throughout pregnancy (Health and Social Care Information Centre 
2012). This was higher than the 12% of mothers smoking during pregnancy 
in England (Health and Social Care Information Centre 2012). Studies by 
Pollack et al. (2000), Figueras et al. (2008) and Rasmussen and Irgens 
(2006) reported an approximate two fold increase in the risk of LBW in 
smokers compared with non-smokers. The Pollack et al. (2000) study further 
estimated that 11% of LBW pregnancies in their study population were a 
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result of maternal smoking thereby highlighting smoking as a significant 
modifiable risk factor for FGR (Figueras et al. 2008).   
The mechanisms underlying the association between maternal 
smoking and fetal growth restriction are not well defined. It has been 
proposed that growth restriction occurs as a result of carbon monoxide and 
nicotine restriction of placental oxygen supply (Pollack et al. 2000), placental 
transport of smoking-related toxic compounds to the fetus and/or direct 
effects of these compounds on placental development and function 
(Zdravkovic et al. 2005). Indeed, the expression of over 200 genes in the 
placentas of smokers is altered compared to non-smokers (Bruchova et al. 
2010). However, more research is required to fully determine the role of 
placental gene expression in mediating the association between smoking 
and FGR.  
 
1.2.2. Alcohol and illegal drug use 
In Wales, 87% of women drank alcohol before pregnancy and 39% during 
pregnancy in 2010, similar to rates in the rest of the UK (Health and Social 
Care Information Centre 2012). Of the women drinking alcohol during 
pregnancy, the majority reported drinking less compared with pre-pregnancy 
levels, with less than 1 unit consumed per week (Health and Social Care 
Information Centre 2012).  
A review of 28 studies investigating the effect of maternal alcohol 
consumption before or during pregnancy found a small but non-significant 
increase in the risk of LBW (Patra et al. 2011). The review reported a dose-
dependent increase in LBW risk with increasing alcohol consumption, 
although the risk of LBW only begins to increase above 1-1.5 drinks/day 
(Patra et al. 2011). Thus, although alcohol consumption in high quantities 
may negatively impact on birth weight, it is unclear whether light to moderate 
drinking has any effect (Henderson et al. 2007; Patra et al. 2011).  
In terms of illegal drug use, a UK study of women using drugs during 
pregnancy found an almost 4 fold increase in the risk of LBW and IUGR 
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compared with controls (Pinto et al. 2010). The increased risk of LBW and 
IUGR was similar among cocaine, heroin and methadone users and those 
using multiple drugs (Pinto et al. 2010). Thus, illegal drug-use significantly 
increases the risk of growth restriction.  
 
1.2.3. Maternal diet 
Several individual components of maternal diet have been demonstrated to 
negatively or positively impact on birth weight as shown in Table 1. Although 
no pregnancy specific data is available, it is estimated that only 33% of 
people in Wales consume the government recommended amount of fruit and 
vegetables (≥ 5/day)(Statistics for Wales 2013), Figure 1.3 (F). This may 
have an impact on LBW prevalence given the positive association reported 
between fruit and vegetable consumption and birth weight (Table 1). In the 
case of some diet components, e.g. carbohydrate and protein consumption, 
conflicting results have been reported (Table 1) which may be due to 
differences in study methodology or population. Micronutrients in the form of 
maternal folate and iron supplementation are also positively associated with 
birth weight (Godfrey et al. 1996; Mitchell et al. 2004).  
 Birth outcomes associated with maternal diet are related to the timing 
of exposure (Godfrey et al. 1996; Moore et al. 2004; Thompson et al. 2010). 
For example, Thompson et al. (2010) demonstrated a significant positive 
effect of a traditional diet (characterised by high intake of fruit, vegetables 
and lean meat) on SGA risk in early but not late pregnancy. Pre-pregnancy 
maternal diet may also be important with, for example, maternal pre-
conception vegetable consumption positively associated with birth weight 
(Weisman et al. 2011).  
Several recent studies of maternal diet have examined the effects of 
diet patterns on pregnancy outcomes (Crozier et al. 2008; Knudsen et al. 
2008; Thompson et al. 2010). Examining diet patterns, in contrast to 
individual diet components, may provide more information on the interacting 
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effects of food items and has been suggested to be of greater relevance for 
designing healthy eating interventions (Crozier et al. 2008). 
 
Table 1: Components of maternal diet during pregnancy and their relationship 
to birth weight. (-) indicates a diet component negatively associated with birth 
weight and (+) a diet component positively associated with birth weight.  
 Maternal Diet 
Component 
Reference 
 
 
 
 
 
 
Positively associated 
with birth weight (+) 
Fruit consumption (Mikkelsen et al. 2006) 
(Rao et al. 2001) 
(Thompson et al. 2010) 
(Mathews et al. 1999) 
Vegetable consumption (Mikkelsen et al. 2006) 
(Rao et al. 2001) 
(Thompson et al. 2010) 
Dairy consumption (Ford 2011)  
(Xue et al. 2008) 
(Olsen et al. 2007) 
(Ludvigsson and 
Ludvigsson 2004) 
Fish consumption (Makrides et al. 2006) 
(Ricci et al. 2010) 
(Rogers et al. 2004) 
 
Negatively associated 
with birth weight (-) 
Fat consumption (Godfrey et al. 1996) 
Caffeine consumption (Santos et al. 1998) 
(Xue et al. 2008) 
(Vik et al. 2003) 
 
 
 
 
Conflicting reports 
Carbohydrate 
consumption 
(-) (Godfrey et al. 1996) 
(-) (Moore et al. 2004) 
(+) (Mitchell et al. 2004) 
(+) (Thompson et al. 2010) 
Protein consumption (+) (Godfrey et al. 1996) 
(+) (Ford 2011) 
(+) (Thompson et al. 2010) 
(+) (Moore et al. 2004) 
(-) (Knudsen et al. 2008) 
(-) (Campbell et al. 1996) 
(-) (Ricci et al. 2010) 
 
Finally, it is important to note that maternal diet is associated with 
other lifestyle factors such as smoking and maternal BMI, as well as ethnicity 
and socioeconimic status (Robinson et al. 2000; Northstone et al. 2008; 
Thompson et al. 2010) and therefore these potential confounders should be 
considered in the analysis of maternal diet effects on birth outcomes. Overall, 
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more research is required into the effect of maternal pre-conception and 
pregnancy diet on birth weight in the UK, as well as the possible mechanisms 
mediating these effects.  
 
1.2.4. Maternal exercise 
Although no pregnancy specific data is available, it is estimated that 29% of 
people in Wales are physically active ≥ 5 days/week (Statistics for Wales 
2013). Juhl et al. (2010) found an inverse association between the frequency 
of maternal exercise during pregnancy and birth weight, as well as other 
indicators of fetal growth including abdominal and head circumference. 
Similarly, Clapp (2003) and Bell et al. (1995) reported decreased birth weight 
of infants whose mothers carried out strenuous exercise during pregnancy. 
Hopkins et al. (2010) even found an effect of modest-intensity exercise on 
birth weight. One of the mechanisms proposed for the association between 
exercise during pregnancy and FGR is an exercise associated decrease in 
placental blood supply and placental weight (Clapp 2003; Juhl et al. 2010). 
However more research is needed into the direct effects of exercise on 
placental development and function, such as changes in gene expression, 
and how this may mediate the effect of exercise on fetal growth.  
 
1.3. Role of the placenta 
Located at the boundary between the maternal and fetal environment, the 
placenta controls fetal growth through nutrient and oxygen delivery to the 
fetus and production and metabolism of growth-related hormones (reviewed 
in (Fowden et al. 2009)). Therefore, alterations in placental structure and 
function are likely to play a key role in fetal growth restriction.  
 
1.3.1. Placental development and structure 
The human blastocyst (the pre-implantation conceptus) is comprised of a 
layer of trophoblast cells surrounding the blastocoelic cavity and the inner 
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cell mass. While the inner cell mass will form the embryo proper, the layer of 
trophoblast cells represents the first extra-embryonic lineage, which 
facilitates diffusional transport of oxygen and nutrients from maternal uterine 
secretions to the developing embryo. This histiotrophic nutrition continues 
throughout the first trimester (Johnson 2007).  
   
 
 
 
 
 
 
 
Figure 1.4: Structure of the human term placenta. The major structures of the 
placenta are the chorionic plate (fetal surface), intervillous space and basal plate 
(maternal surface). Direction of deoxygenated blood is indicated by blue arrows and 
oxygenated blood flow by red arrows. Adapted from (Sood et al. 2006).  
 
Implantation of the blastocyst in the maternal uterine wall, around 6 -7 
days after conception, signifies the beginning of placental development. 
During implantation, the first trophoblast cells to attach to the uterine 
epithelium fuse to form an invasive syncytiotrophoblast layer. The remaining 
trophoblast cells retain their cells walls and form a cytotrophoblast layer. 
Cytotrophoblast cells undergo constant proliferation and fusion with the 
syncytiotrophoblast layer, enabling the syncytiotrophoblast layer to expand 
and further invade the uterine wall (Huppertz 2008).   
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Within the syncytiotrophoblast layer, fluid filled spaces (lacunae) form 
surrounded by syncytiotrophoblast (trabeculae). Expansion of the 
syncytiotrophoblast layer into the endometrium results in erosion of maternal 
blood vessels such that maternal blood fills the lacunae (although maternal 
blood flow to the placenta is only established after 10-12 weeks). At this 
stage, the basic structure of the placenta is apparent, including (1) the 
chorionic plate (the fetal surface), (2) the intervillous space 
(syncytiotrophoblast trabeculae separated by lacunae) and (3) the basal 
plate (the maternal surface) (Huppertz 2008), Figure 1.4.  
During placental development, a subset of cytotrophoblast cells 
migrate through the syncytiotrophoblast layer and into the maternal 
endometrium. These cytotrophoblast cells differentiate to become 
extravillous cytotrophoblasts (EVTs) that invade the maternal uterine spiral 
arteries inducing their remodelling (Huppertz 2008). Maternal spiral artery 
remodelling results in increased blood flow and reduced resistance in these 
vessels, thereby maximising placental perfusion (Gude et al. 2004). The 
remodelled spiral arteries deliver oxygenated blood to the intervillous space 
where it bathes the placental villi (Gude et al. 2004), Figure 1.4. 
 Progressive differentiation and branching of the trabeculae forms the 
placental villous tree with a large surface area for exchange. Deoxygenated 
fetal blood is carried via the umbilical arteries and the extensive capillary 
network within the placental villous tree to the terminal villi (Figure 1.4). The 
terminal villi extend into the intervillous space and are the main site of 
exchange between the maternal and fetal circulations, with only a thin layer 
of syncytiotrophoblast separating the two (Huppertz 2008). The resulting 
oxygenated blood is transported to the fetus by chorionic veins and the 
umbilical vein (Gude et al. 2004), Figure 1.4.  
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1.3.2. Placental functions  
The placenta supports fetal growth and development through three main 
functions: (1) transport and metabolism, (2) production and metabolism of 
hormones and (3) acting as a barrier for fetal protection (Gude et al. 2004). 
 As described, the trophoblast facilitates histiotrophic nutrition of the 
embryo before maternal blood flow to the placenta is established at 10 - 12 
weeks. Once maternal blood flow is established, transfer of oxygen and 
nutrients to the fetus and removal of carbon dioxide and waste products can 
occur readily across the syncytiotrophoblast layer of the terminal villi. For 
example glucose, which acts as a major source of energy for the developing 
fetus, is transferred from the maternal circulation via glucose transporters 
(GLUTs) on the syncytiotrophoblast membrane. This transfer of glucose to 
the fetus is vital as fetal glucose production is limited. In addition to 
facilitating transport, the placenta itself utilises maternal oxygen and nutrients 
with the resulting products of metabolism released into the maternal and fetal 
circulations (Gude et al. 2004).  
 The placenta acts as an endocrine organ during pregnancy, 
synthesising hormones (mainly in the syncytiotrophoblast), which are 
released into the maternal and fetal circulations, to bring about a variety of 
functions. Progesterone produced by the placenta signals the presence of a 
conceptus (thereby preventing menstruation) and suppresses contractions of 
the uterus. The placenta is also a source of oestrogen that acts on the 
mother’s breasts, uterus, cervix and vagina inducing adaptations of the 
maternal reproductive organs to pregnancy (Gude et al. 2004). In addition, 
placental production of human placental lactogen (hPL) and placental growth 
hormone (PGH) is important in the regulation of fetal growth and maternal 
adaptation to pregnancy, as is further described in section 1.8.  
 Finally, the placenta acts to reduce exposure of the fetus to 
xenobiotics, maternal bacteria and/or viruses. However, it is important to note 
that this barrier is not complete with substances such as caffeine and alcohol 
as well as some maternal viruses such as Rubella, still able to cross the 
placenta (Gude et al. 2004).  
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1.3.3. Placental abnormalities in FGR 
Examining the placenta is a practical method for assessing fetal growth as 
the placenta serves as a record of in utero events and samples for research 
can be obtained non-invasively (Ryan et al. 2012). Indeed, it has been 
proposed that assessment of placental phenotype provides a better indicator 
of a perturbed in utero environment than birth weight, particularly in cases of 
fetal growth restriction resulting in delivery of a normal birth weight infant 
(Sibley et al. 2005; Jansson and Powell 2007).  
 There are a number of placental abnormalities associated with FGR, 
as reviewed by Sibley et al. (2005). For example a decreased 
syncytiotrophoblast surface area for exchange, coupled with an increased 
exchange barrier has been reported in IUGR placentas, which could affect 
transfer of nutrients and oxygen to the developing fetus. Increased apoptosis 
within IUGR placentas has also been noted and is likely to impact on 
placental size and structure. Furthermore, inadequate uterine spiral artery 
remodelling resulting in increased vessel resistance and a reduction in 
uteroplacental blood flow has been demonstrated in IUGR pregnancies. 
Finally, changes in placental gene expression (for example of nutrient 
transporters) have been reported highlighting the possibility of identifying a 
placental biomarker for in utero growth restriction (Sibley et al. 2005).  
 
1.3.4. The placenta as an environmental sensor 
The growth regulating functions of the placenta are susceptible to 
environmental factors (Fowden et al. 2011), providing a possible mechanism 
by which environmental signals (such as those discussed in section 1.2) 
could result in fetal growth restriction and program an increased risk of 
disease in adult life (see Figure 1.5).  
An adverse maternal environment may result in changes to the 
placenta structure and/or function. For example, maternal dietary 
manipulation (such as calorie restriction or a low protein diet) in an animal 
model results in a decrease in placental growth preceding any adverse effect 
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on fetal growth (Jansson and Powell 2007).  It has also been proposed that 
the placenta acts as a nutrient sensor, responding to changes in the maternal 
environment by altering placental transport (Jansson and Powell 2007). For 
example, activity of placental amino acid transporters is impaired in IUGR 
placentas, which has been suggested to slow fetal growth in parallel with 
changes in maternal nutrient supply (Jansson and Powell 2007).   
 Imprinted genes expressed in the placenta have been demonstrated 
to be susceptible to environmental factors (reviewed in (Fowden et al. 2011)). 
As some of these genes regulate fetal growth (see section 1.4), their 
aberrant expression may play a role in mediating the effects of an adverse 
environment on fetal growth (Figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Role of imprinted genes and the placenta in mediating the effect of 
the maternal environment on fetal growth. Adapted from (Fowden et al. 2011) 
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1.4. Imprinted gene control of fetal growth 
Imprinting is an epigenetic process, involving DNA methylation and histone 
modification, resulting in monoallelic expression of a gene, with the active 
allele depending on the parent of origin (Surani 1998). 
Discovery of genomic imprinting arose from studies in which 
gynogenetic (containing two female pronuclei) and androgenetic (containing 
two male pronuclei) mouse embryos were created. Although these embryos 
contained the normal numerical complement of DNA, gynogenetic embryos 
were found to be unviable, exhibiting growth restriction and inadequate 
placental development while androgenetic embryos failed to develop properly 
with excessive placental growth (Kaufman et al. 1977; Barton et al. 1984; 
McGrath and Solter 1984; Surani et al. 1986).  
The growth abnormalities observed in mice with uniparental disomies 
(UPD) for particular chromosomes, i.e. in which both copies of a 
chromosome or part of a chromosome are inherited from one parent 
(reviewed in (Tycko and Morison 2002)) further support a role for imprinted 
genes in the control of fetal growth. In mice, maternal disomy for proximal 
chromosome 11 results in growth restriction whereas paternal disomy is 
associated with over growth (Cattanach and Kirk 1985). It was therefore 
suggested that genes which are maternally-inherited function differently from 
those which are paternally-inherited due to epigenetic changes occurring 
during gametogenesis i.e. imprinting (Tycko and Morison 2002). Thus, 
normal development is dependent upon both parental genomes and not 
simply inheritance of a full genetic complement.  
A role for imprinted genes in controlling human fetal growth is 
highlighted by the abnormal growth phenotypes seen in some human 
disorders resulting from imprinting defects (Lim and Ferguson-Smith 2010). 
For example, 50% of Beckwith-Wiedemann Syndrome cases, characterised 
by pre- and postnatal overgrowth, are thought to involve UPD of paternal 
chromosome 11p15 (Enklaar et al. 2006). In contrast, Silver Russell 
Syndrome, which is characterised by pre-, and postnatal growth restriction, 
may result from UPD of maternal chromosome 11p15 in up to 63% of 
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patients (Eggermann et al. 2010). Finally, a high frequency of inappropriate 
imprinted gene expression has been reported in the human placenta of IUGR 
pregnancies at 17% (of 52 genes) (Diplas et al. 2009) and 22% (of 27 genes) 
(McMinn et al. 2006).  
There are numerous hypotheses that have been proposed to explain 
the evolution of genomic imprinting. One theory is that of conflict between the 
maternal and paternal genome for allocation of maternal resources to the 
fetus (Moore and Haig 1991). This theory proposes that the paternal genome 
silences genes that restrict fetal growth in order to maximise allocation of 
maternal resources to an offspring that shares the paternal genes. In contrast 
the maternal genome acts to silence genes that promote fetal growth in order 
to maintain current health and future reproductive fitness and to ensure equal 
division of resources amongst offspring (Hitchins and Moore 2002). While no 
hypothesis proposed to explain the evolution of imprinting fully accounts for 
the numerous functions of the genes known to be subject to this epigenetic 
process, it is clear that many of these genes have dosage sensitive functions 
in both the regulation of fetal growth and the development of the placenta. 
Thus, alterations in their expression may have a causative role in FGR.  
 
1.5. PHLDA2  
Evidence supporting a role for PHLDA2 in human growth restricted 
pregnancies has recently been reviewed by Jensen et al. (2014) 
PHLDA2 (alternative names: Ipl, Tssc3, and Bwr1c) is a maternally 
expressed imprinted gene, which is located on human chromosome 11p15.5 
and mouse distal chromosome 7. The PHLDA2 gene is relatively small gene, 
containing 2 exons and 1 intron (Lee and Feinberg 1998; Frank et al. 1999). 
Imprinting of the PHLDA2 gene is controlled by the centromeric imprinting 
control region 2 (IC2 or KvDMR1), which spans the promoter of the long, 
non-coding RNA KCNQ1OT1 (Smilinich et al. 1999; Fitzpatrick et al. 2002; 
Thakur et al. 2004; Mancini-Dinardo et al. 2006).  
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PHLDA2 encodes the pleckstrin homology-like domain family A 
member 2 protein, the biochemical function of which has not yet been 
determined. The 144 amino acid long protein (Frank et al. 1999) is comprised 
of a highly conserved pleckstrin-homology (PH) domain, flanked by short N 
and C-terminal extensions (Saxena et al. 2002). PHLDA2 is able to bind to 
phosphatidlyinositol lipids with moderate affinity via its PH domain (Saxena et 
al. 2002). This suggests that PHLDA2 may be active in intracellular 
trafficking, cell signalling and membrane-cytoskeletal interactions, 
characteristic functions of proteins with PH domains (Saxena et al. 2002). 
PHLDA2 has also been suggested to play a role in apoptosis or growth 
restriction based on homology and co-expression of PHLDA2 to TDAG51, 
involved in Fas-mediated apoptosis (Hu et al. 1997; Qian et al. 1997) and the 
induction of protein kinase B mediated apoptosis by the closely related 
Phlda3 gene (Kawase et al. 2009). However, these suggested functions of 
PHLDA2 have yet to be determined experimentally.  
 
1.5.1. Animal models investigating Phlda2 and fetal growth  
There is high sequence conservation between the mouse Phlda2 and human 
PHLDA2 genes (Qian et al. 1997). Maternal monoallelic gene expression has 
been demonstrated in both the mouse and human placenta (Qian et al. 1997) 
demonstrating conservation of the direction of imprinting. In the mouse, 
Phlda2 expression has been demonstrated in the fetal liver, lung, limb and 
kidney in addition to the adult kidneys and prostate (Qian et al. 1997; Frank 
et al. 1999). Highest Phlda2 expression is seen in the extraembryonic tissues 
including the placenta and yolk sac (Qian et al. 1997; Frank et al. 1999). 
Placental mRNA and protein is localised to the labyrinth zone of the mouse 
placenta, which is the main site of nutrient exchange (Frank et al. 1999; 
Frank et al. 2002). A gradual decrease in placental Phlda2 expression is 
observed towards the end of gestation (Frank et al. 1999; Frank et al. 2002). 
 As reviewed by Jensen et al. (2014), a number of studies in mice 
support a role for Phlda2 in the control of placental development. Frank et al. 
(2002) examined fetal and placental growth in Phlda2 knockout (KO) mice. 
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These mice exhibited increased placental weights, attributed to a specific 
increase in the junctional zone of the placenta (Frank et al. 2002). 
Importantly, the increased placental growth observed was shown to be 
independent of any effects on expression of other imprinted genes within the 
same imprinting cluster, such as Igf2 (Frank et al. 2002). Loss of function of 
Phlda2 was not associated with increased fetal weight at birth, as predicted, 
but instead transient fetal growth restriction was observed from mid to late 
gestation (Frank et al. 2002; Salas et al. 2004).  
 Effects of Phlda2 over expression on fetal growth have been 
examined by adding extra copies of the Phlda2 gene via a bacterial artificial 
chromosome (BAC) transgene (John et al. 2001; Andrews et al. 2007; 
Tunster et al. 2010). Two fold Phlda2 expression, modelling loss of 
imprinting, resulted in significantly decreased placental weight (Tunster et al. 
2010). This could be rescued by combining the transgene with a maternally 
inherited targeted deletion of Phlda2, which normalised Phlda2 expression 
levels (Tunster et al. 2010). Phlda2 over expression resulted in a specific 
60% reduction in the junctional zone of the placenta (Tunster et al. 2010). 
Within the junctional zone, expression of a spongiotrophoblast marker was 
reduced suggesting a decrease in these cells (Tunster et al. 2010). In 
addition, there was a decrease in glycogen storage within the placenta and 
migration of glycogen cells into the maternal decidua impaired (Tunster et al. 
2010). Phlda2 transgenic embryos carrying three copies of the transgene 
were 13% lighter at birth indicating a gradual decrease in fetal growth 
velocity during gestation (Tunster et al. 2010). A more recent study, focused 
on a single copy line, demonstrated that a double dose of Phlda2 was 
sufficient to induce FGR and importantly, that growth restriction was 
asymmetric with evidence of brain sparing and was followed by rapid 
postnatal catch-up growth (Tunster et al. 2014). These characteristics are 
typical of human pregnancies complicated by placental insufficiency.  
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1.5.2. Human studies of PHLDA2 and fetal growth 
PHLDA2 is highly expressed in the human placenta (Qian et al. 1997; 
Piedrahita 2011) with expression highest in the first trimester, decreasing 
thereafter till term (Saxena et al. 2003; Kumar et al. 2012; Sitras et al. 2012). 
In particular, cytotrophoblast cells of the placental villi are sites of localised 
high PHLDA2 expression (Saxena et al. 2002; McMinn et al. 2006). 
Relatively lower levels of PHLDA2 expression have also been demonstrated 
in the fetal brain, liver, lung and kidney, as well as the adult liver, lung, 
kidney, pancreas, prostate and colon (Qian et al. 1997; Lee and Feinberg 
1998; Piedrahita 2011).  
Monoallelic expression of PHLDA2 from the maternal allele has been 
demonstrated in the human placenta (Qian et al. 1997; Frank et al. 1999) 
and the kidney, intestine, limb, liver and lung of the human fetus (Lee and 
Feinberg 1998). Another line of evidence demonstrating PHLDA2 as a 
maternally expressed imprinted gene is the absence of PHLDA2 expression 
in human complete hydatidiform moles, which contain only paternal 
chromosomes (Saxena et al. 2003; Thaker et al. 2004).  
Studies investigating the role of aberrant PHLDA2 expression in 
human growth restricted pregnancies have been reviewed by Jensen et al. 
(2014), as summarised in Table 2. Thus far, three studies have reported 
increased placental PHLDA2 expression in IUGR compared with control 
pregnancies (McMinn et al. 2006; Diplas et al. 2009; Kumar et al. 2012). 
Diplas et al. (2009) observed three fold increased PHLDA2 expression, with 
McMinn et al. (2006) estimating that 25% of the placentas examined 
demonstrated aberrant placental PHLDA2 expression.  
Placental PHLDA2 expression has also been demonstrated to be 
significantly inversely associated with birth weight in a cohort of term, normal 
birth weight infants (Apostolidou et al. 2007). Examination of a PHLDA2 
single nucleotide polymorphism (SNP) in the placenta and parental DNA 
demonstrated that PHLDA2 was expressed from the maternal allele only and 
therefore that loss of imprinting (LOI) did not underlie the observed 
association between gene expression and birth weight (Apostolidou et al. 
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2007). Similarly, Guo et al. (2008) reported monoallelic maternal expression 
of PHLDA2 in all SGA placentas examined, although gene expression was 
not analysed with respect to birth weight. A significant inverse association 
between PHLDA2 expression and birth weight, in the absence of LOI, has 
also been demonstrated in umbilical cord tissue (Lim et al. 2012).  
 
Table 2: Previous studies analysing the association between human fetal 
growth and placental PHLDA2 expression. IUGR = Intrauterine Growth 
Restriction, SGA = Small for Gestational Age, AGA = Appropriate for Gestational 
Age, LGA = Large for Gestational Age, BMI = Body Mass Index, CVS = Chorionic 
Villus Samples. (Jensen et al. 2014).  
Study Cohort Factors controlled for Results 
(McMinn et al. 
2006) 
38 IUGR 
75 Controls 
Placental weight, 
Gestational age 
Increased PHLDA2 
expression in IUGR 
placentas 
(Apostolidou 
et al. 2007) 
200 term 
placentas 
Gender, Parity, 
Gestational age, 
Maternal Weight 
Significant inverse 
association between 
PHLDA2 expression and 
birth weight 
(Diplas et al. 
2009) 
7 IUGR 
10 Controls 
None described Increased PHLDA2 
expression in IUGR 
placentas 
(Kumar et al. 
2012) 
10 IUGR 
10 Controls 
Maternal age, Gender, 
Pregnancy induced 
hypertension, Ethnicity 
Increased PHLDA2 
expression in IUGR 
placentas 
 
 
(Lambertini et 
al. 2012) 
33 SGA 
51 AGA 
22 LGA 
Maternal age, Ethnicity, 
Insurance, Gestational 
age, Mode of Delivery, 
Gender 
No significant 
association between 
PHLDA2 expression and 
birth weight 
(Lewis et al. 
2012) 
102 term 
placentas 
Gender Significant inverse 
association between 
PHLDA2 expression and 
fetal skeletal growth 
(Demetriou et 
al. 2014) 
260 first 
trimester 
CVS  
Gestational age, Gender, 
Parity, Maternal age, 
Smoking, Maternal BMI 
No significant 
association between 
PHLDA2 expression and 
birth weight 
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A study by Ishida et al. (2012) demonstrated that maternal inheritance 
of a variant of a promoter sequence upstream of the PHLDA2 transcription 
start site (RS1) was associated with significantly increased birth weight. The 
RS1 variant was demonstrated in vitro to decrease PHLDA2 promoter 
activity, which was suggested to be due to a reduced number of transcription 
factor binding sites (Ishida et al. 2012). Thus, the RS1 variant (conferring 
reduced PHLDA2 promoter activity) was positively associated with birth 
weight, further supporting a role for PHLDA2 in the negative regulation of 
fetal growth.  
Three studies have reported no significant association between 
placental PHLDA2 expression and birth weight (Lambertini et al. 2012; Lewis 
et al. 2011; Demetriou et al. 2014). These conflicting results may be due to 
differences in study methodology or population. For example, Lambertini et 
al. (2012) analysed PHLDA2 expression in relation to birth weight within a 
cohort including AGA, SGA and LGA infants, in contrast to previous studies 
comparing IUGR and control placentas only. In addition, the study by 
Demetriou et al. (2014) examined PHLDA2 expression in chorionic villus 
samples from the first trimester. The authors proposed that the absence of 
an association between first trimester PHLDA2 expression and birth weight 
demonstrates that PHLDA2 regulates fetal growth in late pregnancy only 
(Demetriou et al. 2014). Although placental PHLDA2 expression was not 
significantly associated with birth weight, Lewis et al. (2012) did demonstrate 
an inverse association between growth velocity of the fetal femur between 19 
and 34 weeks gestation and placental PHLDA2 expression. There was also 
an association between increased PHLDA2 expression and decreased bone 
mineral content, bone area and bone mineral density at 4 years (Lewis et al. 
2012).  
Thus, a number of studies have demonstrated increased human 
placental PHLDA2 in FGR pregnancies, with work in animal models 
supporting a causal role for PHLDA2 in the negative control of fetal growth 
(Jensen et al. 2014). However, as shown in Table 2, the number of growth 
restricted placentas examined in these studies has been relatively small 
prompting further investigation in large cohort studies. In addition, participant 
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demographics have not been clearly described and few confounders known 
to be associated with growth restriction (section 1.2) have been controlled 
for, Table 2.  
Importantly, previous studies did not distinguish between infants born 
SGA due to growth restriction from those born constitutionally small. 
Comparing placental PHLDA2 expression between these two groups may 
indicate whether placental gene expression can specifically identify infants 
that have been growth restricted in utero with the aim of optimising postnatal 
care (Jensen et al. 2014). Similarly, although animal models suggest a role 
for Phlda2 in asymmetric growth restriction (Tunster et al. 2014) previous 
human studies have not examined placental PHLDA2 expression in 
symmetric compared with asymmetric growth restricted pregnancies.  
No study to date has examined placental PHLDA2 expression in 
relation to birth outcomes. Increased expression of placental PHLDA2 has 
been reported in cases of spontaneous miscarriage or fetal death (Doria et 
al. 2010) and more specifically in cases of fetal death attributed to fetal 
growth restriction (Cordeiro et al. 2014). However, little is known about infant 
outcomes in pregnancies resulting in a live birth but characterised by 
abnormal PHLDA2 expression. Investigating placental PHLDA2 expression 
in relation to infant outcomes will establish whether PHLDA2 could serve as 
a biomarker to identify at risk infants (Jensen et al. 2014).  
In conclusion, previous studies have demonstrated an inverse 
association between placental PHLDA2 and fetal growth. The mouse model 
of Phlda2 over expression suggests that aberrant PHLDA2 expression is 
causal of fetal growth restriction, rather than a consequence of an abnormal 
intrauterine environment. Jensen et al. (2014) propose that altered PHLDA2 
expression may result in fetal growth restriction through direct effects on the 
fetus and/or placenta. Phlda2 over expression in a mouse model is 
associated with perturbed placental growth and development, which could 
act to limit fetal growth (Tunster et al. 2010). For example, glycogen storage 
required for fetal growth in late gestation was reduced and expression of 
glucose transporters altered in Phlda2 transgenic placentas (Tunster et al. 
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2010).  In addition, Phlda2 has been demonstrated to regulate the endocrine 
lineage of the mouse placenta (the spongiotrophoblast cells of the junctional 
zone) thereby indirectly controlling production of placental hormones, which 
are known to regulate fetal growth (reviewed in (John 2013)), as further 
described in section 1.8. 
 
1.5.3. Factors affecting PHLDA2 expression 
Given the association between perturbed PHLDA2 and fetal growth 
restriction, it is important to determine factors responsible for altered 
PHLDA2 expression (Jensen et al. 2014).  
 In terms of maternal demographics, advanced maternal age in mice is 
associated with fetal growth restriction and increased Phlda2 expression in 
ovarian tissue (Paczkowski et al. 2015). In addition, Moore et al. (2015) 
reported no significant association between pre-pregnancy maternal weight 
or BMI and placental PHLDA2 expression in two large independent cohorts.  
 Shukla et al. (2011) demonstrated significantly increased placental 
Phlda2 expression in response to maternal ethanol consumption in pregnant 
rat dams. The same study also showed increased placental Phlda2 
expression in response to a calorie-restricted diet (Shukla et al. 2011). In 
contrast Lillycrop et al. (2010) reported no significant difference in Phlda2 
expression in the liver following protein restriction in pregnant rat dams but 
did note a significant increase in hepatic Phlda2 expression following folic 
acid supplementation. A maternal high sugar/high fat diet has been 
demonstrated not to be associated with significantly altered Phlda2 
expression in the mouse placenta (Sferruzzi-Perri et al. 2013). Thus, it is 
possible that human placental PHLDA2 expression is affected by maternal 
diet during pregnancy, e.g. calorie restriction or folate supplementation.  
 A significant increase in placental PHLDA2 expression has been 
reported in response to maternal smoking during pregnancy (Bruchova et al. 
2010). However, Moore et al. (2015) observed no significant correlation 
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between placental PHLDA2 expression and maternal smoking in two 
independent cohorts. Finally, Lewis et al. 2012 demonstrated significantly 
increased placental PHLDA2 expression in mothers undertaking strenuous 
exercise.  
 In terms of pregnancy specific factors, placental PHLDA2 expression 
was demonstrated to be reduced in association with a severe fetal 
abnormality (McMinn et al. 2006). In addition, studies suggest an effect of 
twin pregnancy on placental PHLDA2 expression with differential expression 
in IUGR twin pregnancies compared with IUGR singleton pregnancies (Roh 
et al. 2005; McMinn et al. 2006). Finally, Feng et al. (2011) demonstrated 
decreased PHLDA2 expression, in the absence of LOI, in the umbilical cord 
blood of children conceived using assisted reproductive technology (ART). 
Thus studies analysing placental PHLDA2 expression in human pregnancies 
should exclude or control for ART pregnancies, pregnancies with multiples 
and those in which the fetus suffers from a severe abnormality. 
In summary, these studies suggest that placental PHLDA2 expression 
may be altered in response to environmental signals. However, the majority 
of previous studies examining factors affecting Phlda2 expression have been 
carried out in animal models and not always in the placenta. Thus, further 
research is required into factors affecting human placental PHLDA2 
expression.  
 
1.6. Other imprinted genes of interest 
Three additional imprinted genes were identified as being of interest with 
respect to human FGR based on animal data or preliminary human studies: 
the maternally expressed imprinted gene CDKN1C and the paternally 
expressed imprinted genes PEG3 and PEG10.  
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1.6.1. CDKN1C 
CDKN1C (alternative names: p57, Kip2) is a maternally expressed imprinted 
gene nearby to PHLDA2 on human chromosome 11p15.5 and under control 
of the same centromeric imprinting control region 2 (IC2 or KvDMR1). 
Cdkn1c encodes the cyclin-dependent kinase inhibitor 1C protein, which is a 
negative regulator of cell proliferation (reviewed in (Coan et al. 2005)).  
Cdkn1c is imprinted in the mouse placenta with expression from the 
maternal allele only (Wang et al. 2011). Cdkn1c is expressed predominantly 
in the glycogen cells, spongiotrophoblast and giant cells of the mouse 
placenta (reviewed in (Tunster et al. 2013)). Tunster et al. (2011) 
demonstrated overgrowth of Cdkn1c deficient embryos from mid to late 
gestation, although there was no effect on pup weight at birth. This may be 
due to the significant placental abnormalities associated with loss of cdkn1c, 
in the context of intrauterine competition. Impaired vascularisation in these 
Cdkn1c deficient placentas has been attributed to excessive proliferation of 
labyrinth trophoblasts and spongiotrophoblast cells (Takahashi et al. 2000; 
Kanayama et al. 2002). In contrast, increasing Cdkn1c expression using a 
BAC transgene approach (modelling loss of imprinting) resulted in fetal and 
postnatal growth restriction (Andrews et al. 2007).  
CDKN1C is expressed in the human heart, lung, brain, kidney, 
pancreas, testis, skeletal muscle and placenta (Eggerman et al. 2014). 
Monoallelic expression from the maternal allele has been confirmed in the 
human placenta (Monk and Moore 2004). Mutations in CDKN1C have been 
reported in human cases of BWS (characterised by pre- and postnatal 
overgrowth) (Engel et al. 2000) and in a family displaying IUGR and short 
stature and type II diabetes in adulthood (Kerns et al. 2014).  
Few studies, often with conflicting results, have examined placental 
CDKN1C expression in relation to growth restriction. In a relatively small 
study (10 normal and 7 IUGR placentas) Diplas et al. (2009) reported no 
significant difference in CDKN1C expression in IUGR placentas. Similarly, 
Moore et al. (2015) found no significant association between placental 
CDKN1C expression and placental weight, birth weight or head 
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circumference in 81 participants (across a normal birth weight range). In 
contrast, McMinn et al. (2006) report a three-fold increase in CDKN1C 
expression in IUGR placentas. Rajaraman et al. (2010) found significantly 
reduced CDKN1C expression and protein in growth restricted placentas 
associated with placental insufficiency. Thus, further research is needed to 
fully clarify the relationship between fetal growth and human placental 
CDKN1C expression.  
Little is known about whether maternal lifestyle factors influence 
placental CDKN1C expression. Shukla et al. (2010) found increased 
placental Cdkn1c expression in response to ethanol exposure and calorie 
restriction in pregnant rat dams. In contrast no significant effect of maternal 
high fat – high sugar diet on placental Cdkn1c expression was observed in a 
mouse model (Sferruzi-Perri et al. 2013). Finally, human placental CDKN1C 
expression was demonstrated not to be significantly associated with maternal 
pre-pregnancy weight or smoking during pregnancy (Moore et al. 2015). 
Thus, further research is required into factors affecting human placental 
CDKN1C expression. 
 
1.6.2. PEG3 
The paternally expressed imprinted gene Peg3 (alternative names: Pw1, 
Znf904, Zscan24, Zkscan22) encodes the paternally expressed gene 3 
protein, which is thought to play a role in cell proliferation and p53-mediated 
apoptosis (reviewed in Coan et al. 2005). In humans, the PEG3 gene is 
located on chromosome 19q13.4 and in mice on proximal chromosome 7. 
Peg3 is imprinted in both the mouse (Wang et al. 2011) and human (Hiby et 
al. 2001) placenta with expression from the paternal allele only. 
Loss of function of Peg3 results in fetal growth restriction with Peg3 
mutants being 10% smaller than wild type littermates at birth. This suggests 
a role for Peg3 in the positive control of fetal growth (Li et al. 1999; Kim et al. 
2013). Furthermore, these Peg3 mutants become obese in adulthood, 
showing increased body fat despite reduced food intake (Curley et al. 2005). 
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Peg3 deficient placentas were significantly smaller and displayed significant 
changes in gene expression with differentially expressed genes including 
those involved in regulating cell proliferation, behaviour, and metabolism 
(Kim et al. 2013a). The Peg3 mutation was also demonstrated to affect the 
maternal reproductive organs and lactation (Li et al. 1999; Kim et al. 2013). 
Finally, the mouse model of Peg3 loss of function demonstrated a role for 
Peg3 in the induction of nurturing and nest building behaviour in rodents (Li 
et al. 1999; Curley et al. 2004; Champagne et al. 2009; Chiavegatto et al. 
2012) a role which is further described in section 1.9.3.  
Four previous studies have found no association between placental 
PEG3 expression and measures of fetal growth. Moore et al. (2015) found no 
significant correlation between placental PEG3 expression and placental 
weight, birth weight or head circumference, although it should be noted that 
all placentas were from normal birth weight deliveries. Similarly, McMinn et 
al. (2006), Diplas et al. (2009) and Kumar et al. (2012) reported no significant 
difference in PEG3 expression between SGA and AGA placentas. However, 
the largest of these studies examined only 15 SGA placentas and therefore 
the association between PEG3 and birth weight needs to be further explored 
in a larger cohort.  
A number of studies have analysed the effect of the maternal 
environment on mouse placental Peg3 expression. Broad and Keverne 
(2011) demonstrated a significant 35% decrease in Peg3 expression 
following maternal starvation for 24 hours. In contrast, Radford et al. (2012) 
reported increased Peg3 expression in response to maternal calorie 
restriction. Maternal high fat diet (Gallou-Kabani et al. 2010) and high fat – 
high sugar diet (Sferruzzi-Perri et al. 2013) during pregnancy do not result in 
altered placental Peg3 expression. In terms of human studies, Moore et al. 
(2015) found no significant correlation between placental PEG3 expression 
and maternal smoking or pre-pregnancy weight. Similarly, umbilical cord 
PEG3 expression is not significantly altered in obese mothers (Thakali et al. 
2014).  
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1.6.3. PEG10 
The paternally expressed imprinted gene Peg10 (alternative names: EDR, 
HB-1, Mar2, MEF3L, Mart2, RGAG3) encodes the retrosponson-derived 
protein PEG10 of unknown function (Coan et al. 2005). In humans, the 
PEG10 gene is located on chromosome 7q21 (Ono et al. 2001) and in mice 
on proximal chromosome 6 (Ono et al. 2006). Peg10 is imprinted in both the 
mouse (Ono et al. 2006) and human (Ono et al. 2001; Daelemans et al. 
2010) placenta with expression from the paternal allele only. 
Peg10 expression is extensive throughout the trophoblast lineage of 
the mouse placenta (Tunster et al. 2013). Loss of function of Peg10 results in 
embryonic lethality before E10.5, in association with growth retardation and 
an absent heart beat (Ono et al. 2006). Embryonic lethality was attributed to 
a severe placental defect with perturbed labyrinth development and an 
absence of spongiotrophoblast cells (Ono et al. 2006).  
PEG10 is expressed in the human testis, brain, lung and placenta 
(Smallwood et al. 2003). In the human placenta, PEG10 begins to increase 
around 11 weeks of gestation (coinciding with establishment of maternal 
blood supply to the placenta) and continues to increase till term (Smallwood 
et al. 2003). Dowregulation of PEG10 expression (by 85%) has been 
demonstrated in third trimester placentas from fetal deaths, although this was 
not analysed in relation to fetal growth restriction (Doria et al. 2012). Three 
studies have examined placental PEG10 expression in relation to fetal 
growth with conflicting results. Diplas et al. (2009) reported an almost three 
fold increase in PEG10 expression in placentas of IUGR pregnancies, with 
monoallelic expression maintained. In contrast, umbilical cord PEG10 
expression was reported to be significantly positively correlated with birth 
weight in a study of Chinese infants (Lim et al. 2012). In this study, PEG10 
expression was significantly decreased by 50% and PEG10 methylation 
significantly increased in LBW placentas (Lim et al. 2012). Finally, Moore et 
al. (2015) found no significant correlation between placental PEG10 
expression and birth weight, placental weight or head circumference in a 
cohort of 110 infants of normal birth weight range.  
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Few studies have examined the effect of maternal lifestyle on 
placental PEG10 expression. Placental Peg10 expression was not 
significantly altered in response to a maternal high fat diet in a mouse model 
(Gallou-Kabani et al. 2010). Similarly, there was no significant effect of 
maternal antibiotic use (Vidal et al. 2013) or parental obesity (Soubry et al. 
2013) on PEG10 methylation in umbilical cord blood. More research is 
needed to determine the association between placental PEG10 expression 
and fetal growth, and the possible influence of maternal lifestyle factors.  
 
1.7. Fetal overgrowth 
Given the role of imprinted genes in the control of fetal growth, it is possible 
that fetal overgrowth is associated with aberrant imprinted gene expression. 
Excessive growth of a fetus during pregnancy can result in the birth of 
a macrosomic (≥4,000g) and/or large for gestational age (LGA) infant (≥ 90th 
birth weight centile). In 2013, 11% and 11.8% of infants were born 
macrosomic in England and Wales respectively (Office for National Statistics 
2014).  
Fetal overgrowth is of clinical relevance due to the increased risk of 
adverse outcomes observed in these infants and their mothers (Zhang et al. 
2008; Larkin et al. 2011; Pasupathy et al. 2012). For example, mothers of 
LGA or macrosomic infants have an increased risk of prolonged labour, 
postpartum haemorrhage and birth trauma (such as third or fourth degree 
tearing) (Jolly et al. 2003; Henriksen 2008; Larkin et al. 2011; Pasupathy et 
al. 2012). In addition, these infants have reduced apgar scores at delivery 
and are more likely to be admitted to NICU (Pasupathy et al. 2012). Zhang et 
al. (2008) also reported an increased risk of perinatal mortality in infants born 
weighing ≥ 4,500g. Importantly, the association between fetal overgrowth 
and adverse birth outcomes is most pronounced in pregnancies where the 
infant is LGA by custom birth weight centiles, i.e., in which the infant has 
exceeded its genetic growth potential (Pasupathy et al. 2012).  
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Advanced maternal age and multiparity have both been demonstrated 
to be associated with macrosomia (Jolly et al. 2003; Orskou et al. 2003). In 
terms of modifiable risk factors, maternal pre-pregnancy BMI and weight, 
gestational weight gain and subcutaneous fat are associated with an 
increased risk of delivering an LGA or macrosomic infant (Jolly et al. 2003; 
Orskou et al. 2003; Voldner et al. 2008; Henriksen et al. 2008). Low physical 
activity (< 1 hr / week) has been demonstrated to increase LGA risk (Voldner 
et al. 2008). Finally, pregnancies complicated by gestational diabetes are 3 
times more likely to result in delivery of an LGA infant (Surkan et al. 2004).  
 Whilst the main focus of research on placental abnormalities has been 
in relation to fetal growth restriction, fetal overgrowth has also been 
associated with altered placental structure and function. Increased placental 
weight and volume are typically observed in LGA pregnancies with 
differences apparent from as early as the first trimester (Schwartz et al. 
2014). In terms of placental abnormalities, Evers et al. (2003) reported 
increased markers of chronic hypoxia in macrosomic placentas. There is also 
evidence to suggest that glucose transport by the placenta is altered in cases 
of fetal overgrowth (reviewed in (Desforges and Sibley 2010)).  
 Although a number of studies have examined the relationship between 
PHLDA2, CDKN1C, PEG3 and PEG10 expression and fetal growth (section 
1.5 and 1.6), no study to date has determined whether expression of these 
genes is altered in macrosomic or LGA placentas.   
 
1.8. Imprinted genes and placental hormone production 
During pregnancy, women undergo a number of physiological and hormonal 
adaptations required to support the optimal development of the fetus, many 
of which are driven by placental hormones (reviewed in Tan and Tan 2013). 
Imprinting has been proposed to have evolved and subsequently conserved 
due to a conflict between the maternal and paternal genome for allocation of 
maternal resources to the fetus (Moore and Haig 1991). It is therefore 
possible that imprinted genes regulate fetal growth through control of 
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mechanisms driving maternal adaptation to pregnancy (Haig 1993), such as 
placental hormone production (John 2013). The two related genes placental 
growth hormone (PGH) and human placental lactogen (hPL) encode 
placental hormones with established roles in maternal adaptation to 
pregnancy and control of fetal growth (Newbern and Freemark 2011).  
 
1.8.1. Placental growth hormone (PGH) 
The placental growth hormone gene (PGH/GH2/GH-V) is located within a 
growth hormone/placental lactogen gene cluster on human chromosome 
17q.22-24 (Baumann 2009). The gene encodes a 191 amino acid protein 
(placental growth hormone), which is highly related to pituitary growth 
hormone (GH) and binds to the same growth hormone receptor (Lacroix et 
al. 2002). PGH is expressed in the syncytiotrophoblast layer of the human 
placenta, the main site of placental growth hormone production (Scippo et al. 
1993) and in extravillous cytotrophoblast cells (Lacroix et al. 2002).  
 PGH is released in to the maternal circulation and between 10 – 20 
weeks of gestation replaces pituitary GH as the primary form of growth 
hormone (Lacroix et al. 2002). PGH levels in the maternal circulation 
continue to rise till term, peaking around 34-37 weeks gestation (Lacroix et 
al. 2002). Production of PGH is positively associated with placental size and 
maternal glucose levels (Newbern and Freemark 2011).  
 One maternal adaptation to pregnancy with consequences for fetal 
growth is changes to maternal metabolism that prioritise transfer of glucose 
to the developing fetus (Tan and Tan 2013). Insulin production is increased 
by approximately 60% resulting in increased fat accumulation in the second 
trimester (Newbern and Freemark 2011). Despite the increase in insulin 
production, in mid to late pregnancy peripheral insulin resistance develops 
with insulin sensitivity decreased by approximately 70% (Newbern and 
Freemark 2011).  
 The rise in PGH production around 20 weeks gestation coincides with 
the appearance of maternal insulin resistance (Newbern and Freemark 
 38	  
2011). PGH promotes fetal growth by acting as an insulin antagonist, 
preventing uptake of glucose by the maternal muscles (Newbern and 
Freemark 2011). In addition, PGH promotes maternal lipolysis in order to 
utilise the accumulated maternal fat as an energy source (Newbern and 
Freemark 2011). Finally, PGH stimulates glucose production by the liver 
(Newbern and Freemark, 2011). Thus, the actions of PGH (Figure 1.6) 
ensure that glucose present in the maternal circulation is preferentially 
transported to the developing fetus. Another growth promoting function of 
PGH is in the positive regulation of maternal serum levels of insulin-like 
growth factor -1 (IGF-1) (Mirlesse et al. 1993), which stimulates maternal 
tissue growth and transfer of nutrients and oxygen to the fetus (Newbern and 
Freemark 2011). Presence of growth hormone receptors in the developing 
placenta, further suggest a growth-promoting role of PGH on the placenta 
(Lacroix et al. 2002). Finally, PGH may be of importance in response to 
nutrient deficiency as hormone levels are negatively associated with 
maternal glucose levels; this has been suggested to reflect an adaptation by 
the placenta to ensure delivery of nutrients to the fetus in an adverse 
intrauterine environment (Newbern and Freemark 2011).   
 A number of studies have demonstrated decreased PGH levels and/or 
gene expression in growth restricted pregnancies. Mannik et al. 2010 
reported a significant correlation between term placental PGH expression 
and birth weight but not placental weight. However, PGH expression was 
only reduced by 10% in SGA compared with AGA placentas (Mannik et al. 
2010). Koutsaki et al. (2011) similarly demonstrated a modest reduction in 
placental PGH expression in FGR placentas. In another study, maternal 
serum PGH levels were significantly reduced by 44% in IUGR pregnancies 
(Mirlesse et al. 1993). Finally, McIntyre et al. (2000) found significantly 
reduced serum PGH levels in IUGR pregnancies at both 28 and 36 weeks 
gestation.  
 Thus, PGH promotes fetal growth through induction of peripheral 
insulin resistance in mid to late pregnancy as part of the normal adaptation of 
a mother’s body to pregnancy. The subsequent development of glucose 
intolerance is prevented by actions of human placental lactogen (section 
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1.8.2). However, in some women with genetic and/or environmental risk 
factors, gestational diabetes may develop as a result of inadequate 
adaptation to pregnancy (section 1.9.2).  
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Placental hormone control of fetal growth and adaptation of 
maternal metabolism to pregnancy. A possible role for imprinted genes in 
regulating placental hormone production is shown. GDM = gestational diabetes, 
GSIS = glucose stimulated insulin secretion. Adapted from Newbern and Freemark 
(2011).  
 
1.8.2 Human placental lactogen (hPL) 
Human placental lactogen (also known as human chorionic 
somatomammotropin hormone  (CSH)) is encoded by three genes hPL-A, 
hPL-B and hPL-L located within the growth hormone/placental lactogen gene 
cluster on human chromosome 17q.22-24. Although highly related and 
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structurally similar to GH, hPL is a lactogenic hormone that binds to the 
prolactin receptor (PRLR) and shares many similar functions with prolactin 
(Newbern and Freemark 2011).  
 hPL is expressed in the syncytiotrophobast of the human placenta 
(Newbern and Freemark 2011). hPL is secreted in to the maternal and fetal 
circulations, with levels rising during gestation and peaking at 32 – 35 weeks 
(Newbern and Freemark 2011). Around 13 weeks of gestation hPL replaces 
prolactin as the main lactogenic hormone (Newbern and Freemark 2011). As 
with PGH, serum hPL levels are positively associated with placental size 
(Newbern and Freemark 2011). Although maternal serum levels of hPL are 
associated with PGH levels, they are significantly higher (Fuglsang and 
Ovesen 2006). 
 Maternal secretion of insulin increases during pregnancy as a result of 
increased insulin production, proliferation of β-cells and glucose-stimulated 
insulin production (GSIS) an adaptation that is mediated by hPL (Newbern 
and Freemark 2011), Figure 1.6. Prolactin and placental lactogens stimulate 
pancreatic β-cell expansion and GSIS both in vivo and in vitro (Kim et al. 
2010; Arumugam et al. 2011). The action of placental lactogen on β-cell 
proliferation was demonstrated to be via effects on serotonin synthesis, 
which when blocked resulted in reduced β-cell expansion and glucose 
intolerance in pregnant mice (Kim et al. 2010). In addition, PRLR KO mice in 
which the actions of placental lactogens and PRL are inhibited, demonstrate 
a reduction in pancreatic islet density and size (Freemark et al. 2002). Insulin 
production was also reduced in the pancreas of these mice and GSIS was 
inhibited both in vivo and in isolated islets in vitro (Freemark et al. 2002). 
Adult PRLR KO mice also displayed symptoms of impaired glucose tolerance 
(Freemark et al. 2002). The effects of loss of function of PRLR were similar in 
pregnant mice (Huang et al. 2009). Thus, these studies support a role for 
hPL in the control of maternal insulin secretion, counteracting the effects of 
PGH in the regulation of fetal growth, Figure 1.6.  
 Mannik et al. (2010) found no significant difference in placental hPL 
expression between SGA and AGA pregnancies. In contrast, Dutton et al. 
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(2012) demonstrated significantly reduced maternal serum hPL levels (but 
not placental hPL expression) in pregnancies with a poor perinatal outcome 
including FGR. Roh et al. (2005) examined placental hPL expression in twin 
pregnancies where only one twin suffered from IUGR. hPL expression was 
significantly decreased by at least 50% in IUGR compared with control 
placentas (Roh et al. 2005).  
 Thus, hPL and PGH control fetal growth through opposing actions on 
maternal metabolism, such that preferential transfer of nutrients to the fetus 
occurs while maintaining maternal metabolic homeostasis. It is possible that 
inadequate maternal adaptation to pregnancy, due to aberrant placental 
hormone signalling, could result in fetal growth restriction as well as other 
complications of pregnancy (section 1.9).  
 
1.8.3 Imprinted gene control of placental hormone production 
 A number of imprinted genes have been demonstrated to regulate the 
endocrine lineage of the mouse placenta (the spongiotrophoblast cells of the 
junctional zone) thereby indirectly controlling production of placental 
hormones (reviewed in John 2013). For example, the junctional zone of the 
mouse placenta is increased in Phlda2 KO mice  (Frank et al. 2002). In 
contrast, two-fold expression of Phlda2 resulted in a significantly decreased 
junctional zone with a specific loss of spongiotrophoblast cells (Tunster et al. 
2010). In addition, there was a three-fold decrease in expression of the 
placental lactogen Prl8a8 (Tunster et al. 2010). Cdkn1c loss of function in a 
mouse model resulted in a reduction in spongiotrophoblast cells and 
decreased expression of the placental lactogens Prl8a8 and Prl3a1 (Tunster 
et al. 2011). Loss of function of Peg3 in the mouse placenta results in a 
myriad of gene changes in the placenta including a marked alterations in the 
expression of several mouse placental lactogens as gestation proceeds 
(Broad and Keverne 2011;Kim et al. 2013). Finally, Peg10 KO mice show a 
severe placental defect caused by an absence of spongiotrophoblast cells 
(Ono et al. 2006). Thus, these studies provide evidence for imprinted gene 
control of the endocrine lineage of the mouse placenta, in particular 
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production of placental lactogens. Perturbed imprinted gene expression 
could therefore, via changes in placental hormone production, result in 
inadequate maternal adaptation to pregnancy and subsequent fetal growth 
restriction (John 2013), Figure 1.6.  
The human placenta differs in many respects to the rodent placenta, 
not in the least with respect to the cell types and placental hormones that 
they manufacture (Carter 2012). Therefore, it is important to obtain evidence 
as to whether these observations on imprinted gene control of placental 
hormone production in a mouse model have relevance to humans. Thus far, 
no study has reported on the relationship between imprinted gene expression 
and hormone production by the human placenta.  
 
1.9. Imprinted genes and other complications of pregnancy 
Imprinted genes have been hypothesised to play a role in the control of 
maternal adaptations to pregnancy, as supported by evidence of imprinted 
gene regulation of the placental endocrine lineage (John 2013). It is therefore 
possible that aberrant imprinted gene expression is associated with other 
pregnancy complications characterised by inadequate maternal adaptation to 
pregnancy. In this study, placental imprinted gene expression was analysed 
in pregnancies complicated by preeclampsia, gestational diabetes and 
maternal mood disorders.  
 
1.9.1. Preeclampsia 
Preeclampsia (PE) is defined as hypertension during pregnancy developing 
after 20 weeks gestation (≥ 90 – 99 mm Hg diastolic blood pressure and ≥ 
140 – 149 mm Hg systolic blood pressure) in association with significant 
proteinuria (300 mg protein in 24 hr urine test) (NICE 2010) . Preeclampsia 
may precede development of eclampsia which is characterised by seizures 
(Hutcheon et al. 2011). Preeclampsia differs from pregnancy-induced 
hypertension (PIH), which is defined as new-onset hypertension during 
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pregnancy that is not associated with proteinuria (Hutcheon et al. 2011). 
There is debate as to whether PE and PIH are separate pregnancy 
complications resulting in similar symptoms or whether PIH is an earlier, 
milder form of PE (Villar et al. 2006).  
Preeclampsia is associated with maternal morbidity and mortality as 
well as adverse short and long-term outcomes for the infant. It is estimated 
that hypertensive disorders of pregnancy underlie 18% of maternal deaths 
worldwide (Abalos et al. 2013). Women with a previous PE pregnancy are 
also at increased risk of cardiovascular and metabolic disease in later life 
(Hutcheon et al. 2011). Importantly, PE pregnancies are associated with an 
increased risk of infant perinatal mortality, preterm birth and reduced 
measures of infant wellbeing at delivery (such as low apgar scores and NICU 
admission) (Villar et al. 2006; Hutcheon et al. 2011). These infants are also 
more likely to develop hypertension and cardiovascular disease in later life 
although it is not certain whether this is due to shared genetic or 
environmental risk factors (Hutcheon et al. 2011). 
 Estimates of PE prevalence vary but it is thought that approximately 
4.6% of pregnancies worldwide and 2.5% in the UK are affected by PE 
(Abalos et al. 2013). A previous PE pregnancy or a family history of PE is 
associated with an increased risk of developing PE (Duckitt and Harrington 
2005). Similarly, first-time mothers have a three fold increased risk of PE and 
mothers over the age of 40 have a two fold increased risk (irrespective of 
parity)(Duckitt and Harrington 2005).  In terms of maternal lifestyle factors, a 
raised maternal BMI is associated with PE (Duckitt and Harrington 2005). 
Several studies have examined the effect of micronutrient supplementation 
(e.g. calcium, vitamin C, folate) on reducing PE risk, with limited success 
(Sibai et al. 2005; Oken et al. 2007). Brantsaeter et al. (2009) found the risk 
of PE was increased in women with a high-energy diet rich in sugar and 
polyunsaturated fatty acids. In contrast, a diet rich in milk and vitamin D was 
associated with a reduced risk of PE (Brantsaeter et al. 2009).  
 Although the exact cause of preeclampsia is unknown, abnormal 
placentation is a characteristic feature of this pregnancy complication (Noris 
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et al. 2005). During placental development, extravillous cytotrophoblasts 
invade the maternal uterine spiral arteries inducing their remodelling 
(Huppertz 2008). This increases blood flow and reduces resistance in these 
vessels, thereby maximising placental perfusion (Gude et al. 2004). Poor 
trophoblast invasion and inadequate uterine spiral artery remodelling is a 
common feature of PE pregnancies and results in increased vessel 
resistance and a reduction in uteroplacental blood flow (Noris et al. 2005).  
 Examination of a role for imprinted genes in the pathogenesis of 
preeclampsia is suggested by two observations. Firstly, there is an increased 
prevalence of fetal growth restriction in PE pregnancies; Villar et al. (2006) 
estimated that IUGR occurred in 22% of women with PE and in 13% of 
women with PIH. Similarly, women with PE are up to 4 times more likely to 
deliver an SGA infant (Hutcheon et al. 2011). Given the established role of 
imprinted genes in the control of fetal growth, it is possible that the co-
morbidity between FGR and PE can be explained by aberrant imprinted gene 
expression.  
 Secondly, some studies suggest a role for the maternally expressed 
imprinted gene CDKN1C in preeclampsia. Loss of Cdkn1c expression in a 
mouse model resulted in preeclampsia-like symptoms including increased 
blood pressure and proteinuria during pregnancy (Kanayama et al. 2002). 
Importantly, preeclampsia-like symptoms were present in wild type mice 
carrying mutant pups suggesting a feto-placental cause (Kanayama et al. 
2002). Loss of function of Cdkn1c was associated with increased 
spongiotrophoblast and labyrinth trophoblast proliferation resulting in a 
narrowed intervillous space (Takashashi et al. 2000; Kanayama et al. 2002). 
It was suggested that a narrowed intervillous space could impede 
uteroplacental blood flow, which combined with the shallow trophoblast 
invasion observed, could contribute to the development of preeclampsia-like 
symptoms (Kanayama et al. 2002). Given the role of the imprinted genes 
Phlda2, Peg3 and Peg10 in the regulation of the spongiotrophoblast cell 
lineage (section 1.8.3), it is possible that these genes also play a role in 
preeclampsia.  
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  Few studies have examined imprinted gene expression in relation to 
preeclampsia in human pregnancies. As with the animal data, most studies 
thus far have focused on CDKN1C, with conflicting results. Women carrying 
infants with BWS due to a CDKN1C mutation have been reported to develop 
a severe form of preeclampsia known as HELLP (haemolysis, elevated liver 
enzymes and low platelets) (Romanelli et al. 2009). However, Bourque et al. 
(2010) found no significant difference in placental CDKN1C expression or 
methylation in PE pregnancies. In contrast, Enquobahrie et al. (2008) 
reported a significant 59% increase in CDKN1C expression in PE placentas. 
PHLDA2 expression has similarly been shown to be upregulated in PE 
placentas, although this was not statistically significant (McMinn et al. 2006). 
Lambertini et al. (2008) found LOI of PEG3 in 50% of the human 
preeclamptic placentas examined, although gene expression was not 
analysed. Finally, analysis of PEG10 expression in relation to preeclampsia 
have yielded conflicting results with Chen et al. (2012) reporting increased 
expression and Liang et al. (2014) decreased CDKN1C expression in PE 
placentas.  
 In summary, the role of imprinted genes in preeclampsia is intriguing 
but, as yet, not well established.  
 
1.9.2.  Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is defined as new-onset glucose 
intolerance during pregnancy (Buchanan et al. 2007; Hartling et al. 2014; 
Mitanchez et al. 2014). WHO criteria for the diagnosis of GDM is fasting 
glucose ≥ 6.1 mmol/L or ≥7.8 mmol/L at 2 hours following a 75g oral glucose 
tolerance test (GTT). In gestational diabetes, maternal β-cell function and 
therefore insulin secretion is reduced (Buchanan et al. 2007). As this occurs 
in conjunction with normal pregnancy-induced insulin resistance, 
hyperglycaemia results (Buchanan et al. 2007). GDM is typically managed 
with diet and exercise, however in up to 20% of cases metformin or insulin 
treatment is necessary (NICE 2008).  
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GDM has consequences for both the mother and her offspring. GDM 
is associated with increased risk of birth trauma, hypertension and 
depression in the mother (Hartling et al. 2014). In addition, GDM women are 
almost 6 times more likely to subsequently develop type II diabetes after 
pregnancy (Hartling et al. 2014). GDM is also associated with fetal 
overgrowth. This has been proposed to occur as maternal hyperglycaemia 
stimulates increased transfer of glucose to the fetus, fetal insulin production 
and therefore also increased fat accumulation (Mitanchez et al. 2014). 
Consistent with this hypothesis is the 2 fold increased risk for GDM mothers 
of delivering an LGA or macrosomic infant (Hartling et al. 2014). Catalano et 
al. (2003) also reported significantly increased neonatal body fat in infants of 
GDM mothers. Fetal overgrowth has consequences for the offspring, as 
discussed in section 1.7, and may underlie the 2 fold increased risk of 
shoulder dystocia during delivery of a GDM infant (Hartling et al. 2014). It is 
important to note that the association between GDM and adverse infant 
outcomes is strongest in obese women (Makgoba et al. 2012; Mitanchez et 
al. 2014). Long-term consequences of GDM on the offspring include an 
increased risk of obesity in childhood (Hartling et al. 2014) as well as 
symptoms of neurodevelopmental delay (Ornoy 2011).  
2 – 5% of pregnancies in England and Wales are complicated by 
maternal diabetes, of which 88% is gestational diabetes (NICE 2008). Some 
ethnicities, e.g. women of Asian origin, are at an increased risk of developing 
GDM (Teh et al. 2011). In addition, women who are overweight or obese 
before pregnancy are more likely to develop GDM, for example women with 
a BMI ≥ 35 are at a 6 fold increased risk (Teh et al. 2011). One study 
reported that raised maternal BMI accounted for 46% of GDM cases 
(Mitanchez et al. 2014). Maternal lifestyle factors affecting GDM risk are less 
well understood. Bowers et al. (2012) reported an increased risk of GDM in 
women consuming a diet rich in animal fat and cholesterol. In terms of GDM 
prevention, maternal exercise during pregnancy (up to 2 hours per week) 
was found to significantly reduce GDM risk (Dempsey et al. 2004).  
Placental abnormalities associated with GDM have recently been 
reviewed (Gauster et al. 2012). Oxygen supply to the fetus has been 
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demonstrated to be compromised in GDM pregnancies, possibly due to 
increased fetal aerobic metabolism in response to hyperinsulinemia (Gauster 
et al. 2012). The increased placental weight and enhanced villous branching 
(despite relative villous immaturity) observed in GDM placentas was 
therefore suggested to be an adaptation to fetal hypoxia (Gauster et al. 
2012). Genes differentially expressed in the GDM placentas include genes 
involved in apoptosis and inflammation (Radaelli et al. 2003; Enquobahrie et 
al. 2009; Magee et al. 2014).  
 A role for imprinted genes in the pathogenesis of GDM is suggested 
by two observations. Firstly, GDM pregnancies are typically associated with 
fetal overgrowth (Hartling et al. 2014). Given the established role of imprinted 
genes in the control of fetal growth, it is possible that the co-morbidity 
between GDM and fetal overgrowth can be explained by aberrant imprinted 
gene expression. Secondly, imprinted genes are known to control the 
endocrine lineage of the mouse placenta, particularly expression of placental 
lactogens known to prevent glucose intolerance in normal pregnancies 
(section 1.8). Indeed, maternal serum levels and placental gene expression 
of hPL and PGH have been found to be altered in pregnancies complicated 
by diabetes (Ursell et al. 1973; McIntyre et al. 2000; Mannik et al. 2012). 
While Mao et al. (2012) reported significantly increased risk of GDM in 
women inheriting a genetic variant of KCNQ1, the imprinting cluster in which 
PHLDA2 and CDKN1C are located, no study to date has examined placental 
PHLDA2, CDKN1C, PEG3 or PEG10 gene expression in GDM pregnancies.  
 
1.9.3.  Maternal mood disorders 
Women are particularly prone to developing symptoms of depression and 
anxiety during and after pregnancy, which may be a consequence of the 
numerous physiological and hormonal changes that are required to support 
the optimal development of the fetus and to prepare the mother for the 
postnatal care of her offspring (Tan and Tan 2013). A 2001 UK study 
reported depressive symptoms in 11.8% (second trimester) to 13.6% (third 
trimester) of the 12,059 women studied (Evans et al. 2001). Interestingly, 
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Evans et al. (2001) also reported that prenatal depression was in fact more 
frequent than postnatal depression. Prevalence of anxiety disorders during 
pregnancy is estimated to be around 6% (Andersson et al. 2004).  
Maternal symptoms of depression and anxiety, exposure to adverse 
life events and acute disasters are all associated with adverse long term 
consequences for the child including an increased risk of fetal growth 
restriction (Steer et al. 1992; Pritchard and Teo Mfphm 1994; Paarlberg et al. 
1999; Berkowitz et al. 2003; Khashan et al. 2008; Henrichs et al. 2010; Uguz 
et al. 2013), emotional and behavioural problems, learning difficulties, 
cognitive impairment and psychopathology in adulthood (reviewed in (Van 
den Bergh et al. 2005; Talge et al. 2007)). 
Maternal prenatal stress, anxiety and depression have previously 
been associated with altered placental function in both animal models 
(Mairesse et al. 2007; Jensen Pena et al. 2012) and in humans (O'Donnell et 
al. 2012; Blakeley et al. 2013). This has primarily been interpreted as an 
effect of maternal mood on placental function. However, the placenta is a 
significant source of hormones that act on the maternal brain priming the 
mother for pregnancy and postnatal care (Glynn and Sandman 2011). It is 
therefore possible that aberrant placental function may influence maternal 
mood (Glynn and Sandman 2011).   
The placenta produces large quantities of hPL (section 1.8.2), a 
lactogenic hormone that has been demonstrated to induce maternal 
behaviour in animal studies (Bridges et al. 1985; Bridges et al. 1990; Bridges 
and Freemark 1995; Bridges et al. 1997). hPL is closely related to the 
pituitary hormone prolactin which stimulates maternal neurogenesis (Bridges 
and Grattan 2003; Shingo et al. 2003; Walker et al. 2012). Prolactin also 
contributes to a suppression of anxiety related behaviours during pregnancy 
via binding to prolactin receptors, which also bind placental lactogens (Torner 
et al. 2001). Previous studies have demonstrated decreased serum prolactin 
levels in mothers with postnatal depression symptoms (Abou-Saleh et al. 
1998; Ingram et al. 2003; Groer and Morgan 2007) and increased levels in 
mothers with low anxiety scores during pregnancy (Asher et al. 1995).  
 49	  
Given that imprinted genes have been reported to functionally 
converge on the endocrine lineages of the murine placenta to regulate 
placental signalling (John 2013), particularly of placental lactogens, it is 
possible that imprinted genes play a role in the adaptation of maternal 
psychology to pregnancy.  
 
 
 
 
 
 
 
 
 
Figure 1.7: Placental signalling and maternal psychological adaptation to 
pregnancy. Animal studies have identified a role for placental hormones (e.g. 
placental lactogen) in inducing maternal behaviour during pregnancy (green arrow). 
It is therefore possible that aberrant placental signalling could contribute to 
inadequate adaptation of maternal psychology to pregnancy, manifesting as 
maternal mood disorders. In particular, loss of expression of the imprinted gene 
Peg3 has been associated with impaired maternal behaviour in a mouse model and 
is known to regulate placental hormone production. Aberrant hormonal signalling 
may also occur as a consequence of prenatal stress (yellow arrow) thereby 
establishing a cycle of aberrant placental gene expression, placental signalling and 
maternal stress. Impaired placental signalling may therefore underlie maternal mood 
disorders and associated outcomes in the offspring.  
 
Via a direct action on the maternal brain, the paternally expressed 
imprinted gene Peg3 has been demonstrated to be required for the induction 
of nurturing and nest building behaviour in primiparous rodent mothers (Li et 
al. 1999; Curley et al. 2004; Champagne et al. 2009; Chiavegatto et al. 
2012). It is also possible that Peg3 modulates maternal psychological 
adaptation to pregnancy via indirect actions on placental hormone 
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production, Figure 1.7. Indeed, loss of function of Peg3 in the mouse 
placenta results in marked alterations in the expression of several mouse 
placental lactogens as gestation proceeds (Broad and Keverne 2011; Kim et 
al. 2013a). Since loss of Peg3 in an animal model also results in offspring 
fetal growth restriction, later life obesity and abnormal behaviour (Li et al. 
1999; Curley et al. 2005; Champagne et al. 2009; Chiavegatto et al. 2012), 
aberrant placental Peg3 expression could potentially explain the co-
occurrence of inadequate adaptation of the maternal brain to pregnancy 
(manifesting as altered maternal mood), fetal growth restriction and poor 
outcomes (Figure 1.7).  
No maternal behaviour phenotypes have as yet been reported for 
aberrant Phlda2, Cdkn1c or Peg10 expression, but male mice carrying a 
Cdkn1c-BAC transgene display aberrant social behaviour (Thesis of G 
McNamara) and wild type female mice carrying Phlda2 mutant pups display 
altered maternal behaviours (RMJ lab, unpublished data). Given their role in 
the control of the endocrine lineage of the mouse placenta, particularly 
expression of placental lactogens, it is possible that imprinted genes 
contribute to maternal psychological adaptation to pregnancy. Finally, no 
study has examined human placental imprinted gene expression in relation 
to maternal behaviour or maternal mood disorders of pregnancy.  
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1.10. Study aims and hypotheses 
 
As discussed above, experimental data from both human and mouse studies 
suggest a role for the imprinted genes PHLDA2, CDKN1C, PEG3 and 
PEG10 in the control of fetal growth and other pregnancy complications. The 
aims of this study was to: 
1) Quantify target imprinted gene expression in the human placenta of 
growth restricted pregnancies 
2) Quantify target imprinted gene expression in the human placenta of 
pregnancies complicated by fetal overgrowth, preeclampsia, 
gestational diabetes and maternal mood disorders 
3) Identify environmental factors associated with reduced birth weight 
and altered target imprinted gene expression in the human placenta 
4) Identify environmental factors associated with altered imprinted gene 
expression in the mouse placenta 
 
The hypotheses to be tested were as follows: 
1) Growth restriction will be associated with increased expression of the 
maternal expressed imprinted genes (PHLDA2 and CDKN1C) and 
decreased expression of the paternally expressed imprinted genes 
(PEG3 and PEG10) in the human placenta.  
2) Fetal overgrowth will be associated with decreased expression of 
PHLDA2 and CDKN1C but increased expression of PEG3 and PEG10 
in the human placenta.  
3) Preeclampsia, gestational diabetes and maternal mood disorders will 
be associated with aberrant imprinted gene and placental hormone 
gene expression.  
4) Adverse maternal lifestyles (such as smoking, alcohol and poor diet) 
will be associated with aberrant target gene expression in the human 
and mouse placenta. 
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CHAPTER 2: MATERIALS AND METHODS 
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In order to examine placental imprinted gene expression in human fetal 
growth restriction (Chapter 3) and pregnancy complications such as 
preeclampsia, gestational diabetes and maternal mood disorders (Chapter 
4), the Wales Cohort was established (section 2.1). To provide further 
validation for findings from the Wales Cohort, placental gene expression was 
also analysed in the Manchester (section 2.2) and Imperial (section 2.3) 
Cohorts.  
The effect of maternal lifestyle factors on human placental target gene 
expression (Chapter 5) was also analysed in the Wales Cohort. These 
findings were further explored in a mouse model (section 2.4) to provide 
evidence for a cause or effect relationship between maternal lifestyle, fetal 
growth and placental gene expression (Chapter 6).  
 
 
2.1. Wales cohort 
 
2.1.1 Study design 
The Wales Cohort was established as part of this PhD with the aim of 
determining the association between placental target gene expression and 
complications of pregnancy such as fetal growth restriction, fetal overgrowth, 
preeclampsia and gestational diabetes.  
The study design is shown in Figure 2.1. The study was approved by 
the South East Wales Research Ethics Committee Panel B (REC number: 
10/WSE02/10) and by University Hospital Wales (UHW) and Royal Gwent 
Hospital (RGH) Research and Development.  
 
2.1.2. Participant recruitment 
A total of 271 participants were recruited for the study. Participants were 
recruited at two research sites: 176 at University Hospital Wales in Cardiff 
(Cardiff and Vale University Health Board) and 98 at the Royal Gwent 
Hospital in Newport (Aneurin Bevan Health Board). Recruitment was carried 
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out at these two sites based on anticipated differences in LBW prevalence 
and maternal lifestyle factors, as exemplified in Figure 1.3. At both sites, 
participants were recruited any time from 20 weeks gestation (for example 
during antenatal assessment) up till delivery (for example when admitted for 
elective caesarean section or induction of labour). Dr Richard Penketh at 
UHW, Dr Sajitha Parveen at RGH and trained midwives at both sites 
recruited participants.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Wales cohort study design. Retention rates are shown as 
percentages in red. LGA = large for gestational age, PIH = pregnancy induced 
hypertension. Growth restriction was defined as birth weight < 10th centile by custom 
birth weight centiles.  
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A participant information sheet (see Appendix 1) was used to explain the 
study to participants. Subsequently, written informed consent (see Appendix 
2) was obtained from otherwise healthy women with singleton pregnancies. 
Exclusion criteria included mothers with infectious diseases or those whose 
infants had known congenital or chromosomal abnormalities.  
 
2.1.3. Participant questionnaire 
A self-administered participant questionnaire (Appendix 3) was completed by 
216 participants representing approximately 80% of the study population. 
The questionnaire was designed to collect information on physical (maternal 
BMI, age, and birth weight) and socioeconomic characteristics (education, 
family income) of the mother and information about her pregnancy 
(gestational age, IVF or natural conception). The questionnaire was also 
designed to collect information on maternal lifestyle factors before and during 
pregnancy including smoking, alcohol, drugs, exercise and diet. Variables 
chosen for inclusion in the questionnaire were based on factors previously 
demonstrated to be associated with fetal growth restriction (section 1.2) 
and/or aberrant PHLDA2 gene expression (section 1.5.3). Questions on 
maternal lifestyle in the three months before conception were included as 
preconception maternal health is known to affect fetal development and 
growth (Ford 2011, Weisman et al. 2011). In addition, questions regarding 
maternal smoking and alcohol during pregnancy were divided into exposure 
in the first compared with the second and third trimesters combined. Finally, 
an important consideration in the questionnaire design was that it should be 
feasible to complete within a short period of time.  
 A food frequency questionnaire (FFQ) was chosen to assess maternal 
habitual diet before and during pregnancy as this method is easily self-
administered and is associated with high return rates (Cade et al. 2004; 
Crozier et al. 2008; Thompson and Subar 2008). A FFQ is comprised of a list 
of foods with which the participant indicates how frequently they consumed 
each food item over a specified period of time (Cade et al. 2004). FFQs are 
frequently used in the study of diet during pregnancy (Erkkola et al. 2001; 
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Rao et al. 2001; Moore et al. 2004; Baer et al. 2005; Mouratidou et al. 2006; 
Venter et al. 2006). However, no pre-existing FFQ was considered 
appropriate for use in this study due to issues of length, target population 
and/or diet components of interest and therefore a new FFQ was designed 
specifically for the purpose of the current study. The FFQ was designed 
based on food items previously demonstrated to be associated with fetal 
growth restriction (section 1.2.3) and the typical diet of the target population.  
 A Cardiff-based nutritionist, J Crovini with extensive practical 
experience of the typical diet of pregnant women living in Cardiff, evaluated 
the FFQ with the aim of ensuring that a sufficient range of food items was 
included on the basis of which diet quality could be simply assessed.  
 In addition, 10 women (of which 4 were pregnant and 6 had recently 
given birth) reviewed the draft questionnaire. The women chosen to review 
the questionnaire were of different ages (23-45), either primiparous or 
multiparous (up to 4 children) and included those with and without a scientific 
background. All women were UK based to exclude cultural differences in diet. 
The women were asked to comment on the following questions: 
1. Are there any questions that you feel that you would not have liked to 
answer? 
2. Are there any questions that you feel were not clear? 
3. Do you have any comments on the length of the questionnaire? 
4. Would reading through the questionnaire discourage you from taking 
part in the study?  
Based on the feedback from the questionnaire trial and the nutritionist, the 
final questionnaire (Appendix 3) was submitted to South East Wales 
Research Ethics Committee Panel B as a significant amendment to the 
study.  
 
2.1.4. Obstetric covariates 
Further information was obtained from the participant’s medical notes using a 
data collection proforma (see Appendix 4) to ensure consistency across 
study sites. N Savory, A Holmes and personnel from the National Institute for 
Social Care and Health Research Clinical Research Centre (NISCHR CRC) 
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at UHW and J Beasley at RGH carried out data collection. Obstetric history 
was noted with respect to parity, previous stillbirths and previous low birth 
weight or macrosomic pregnancies. Information was also obtained on the 
current pregnancy including prescribed medication, intrauterine infection or 
antepartum haemorrhage. Maternal smoking, alcohol consumption and drug 
use before and during pregnancy was recorded from participant’s medical 
notes and compared with self-report measures from the participant 
questionnaire. Information on birth outcomes was also obtained including 
mode of delivery (and indication), complications of delivery, birth weight, fetal 
sex and gestational age. Finally, measures of infant wellbeing such as Apgar 
scores, arterial cord blood pH and NICU admission were also recorded.  
 
2.1.5. Measures of fetal growth 
In addition to birth weight, a number of growth parameters were recorded 
from the participant’s medical notes including antenatal concern over fetal 
growth (such as static growth, SGA abdominal or head circumference 
measurements on scan and/or low fundal height), IUGR diagnosis, amniotic 
fluid index (AFI), Doppler anomalies and ultrasound growth centiles during 
pregnancy. Custom birth weight centiles were calculated based on maternal 
height, weight, parity and ethnicity as well as infant birth weight, gestational 
age and gender using the GROW bulk centile calculator (UK), version 6.7.5 
(Gardosi and Francis 2014).  
 
2.1.6. Gestational diabetes information 
Information on GDM was recorded from the participant’s medical notes 
including gestational age at which the first abnormal glucose tolerance test 
(GTT) was observed and when GDM was diagnosed. A previous GDM 
pregnancy was also noted. Finally, the form of GDM management (diet, 
exercise and/or medication) was recorded. At UHW and RGH, women are 
not routinely screened for GDM unless they have one or more risk factors 
such as previous history, family history of diabetes, or BMI ≥ 30. Therefore, in 
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addition to the GDM participants recruited, the study cohort included a 
number of control participants with a confirmed normal GTT (at ≥ 28 weeks).  
  
2.1.7.  Preeclampsia information 
A diagnosis of Preeclampsia and the gestational age at diagnosis was 
recorded from the participant’s medical notes. In addition, previous history of 
a PE pregnancy was noted. Gestational age at first occurrence of 
hypertension and proteinurea were recorded to distinguish between 
pregnancy induced hypertension (hypertension without proteinurea) and 
preeclampsia (presence of both hypertension and proteinurea). Finally, the 
treatment for preeclampsia e.g. labetalol was noted as well as the gestational 
age at which treatment began.  
 
2.1.8. Placental Dissection 
Placental dissection was carried out for 228 participants (approximately 84% 
of the study population) with 74% sampled by A Janssen and the remaining 
by trained midwives. The most frequent cause of failing to dissect a study 
participant’s placenta was complications during or immediately following 
delivery including infant distress and NICU admission, maternal post-partum 
haemorrhage and/or emergency C-section.  
Placentas were collected and dissection carried out within 2 hrs of 
delivery, as determined by protocol optimisation experiments (section 2.1.9). 
Placentas were weighed and both the fetal and maternal surfaces checked 
for gross abnormalities. Tissue was taken from the maternal side of the 
placenta (Figure 2.2) midway between the cord and distal edge. To exclude 
contamination of the sample with maternal decidual cells, the uppermost 
cotyledon surface was removed and the villous tissue underneath samples 
(Figure 2.2). To remove excess maternal blood and amniotic fluid, samples 
were washed in phosphate buffered saline, PBS (Life Technologies, Paisley, 
UK) and then stored in RNAlater (Sigma, Dorset, UK) at 4ºC overnight. 
Approximately 100mg of tissue was stored in each 1.5ml microcentrifuge 
tube containing 1 ml RNAlater (Sigma). This process was repeated for a total 
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of 5 sampling sites distributed evenly across the maternal surface of the 
placenta (Figure 2.2).  
Samples were subsequently removed from RNAlater and finely 
dissected in ice cold PBS (Life Technologies) to remove vessel parts. Finally, 
placental tissue was stored at -80ºC. Details of each placental dissection 
were recorded on the placenta proforma (see Appendix 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Placenta dissection protocol. (A) Maternal placental surface showing 
tissue sampling site. (B) Dissection of villous trophoblast tissue directly under the 
uppermost cotyledon surface. (C) Washing in phosphate buffered saline to remove 
maternal blood and amniotic fluid. (D) Process repeated for five evenly spaced sites 
across the placenta.  
 
 
2.1.9. Protocol optimisation 
In order to control for any effects of time to sampling on RNA concentration 
and quality as well as placental gene expression, for three participants 
placental tissue samples were taken at the same sampling site within 30 
minutes, 1 hour, 1.5 hours and 2 hours of delivery. RNA was extracted from 
all time points and RNA concentrations compared. In addition, qPCR analysis 
of housekeeping and target gene expression was carried out.  
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Possible differences in placental target gene expression depending on 
tissue sampling site were also analysed. Following the protocol of Wyatt et al. 
(2005) three samples (close to the cord insertion site, middle and distal edge) 
were taken from each of the fetal, middle and maternal layers of the placenta 
as shown in Figure 2.3. This was carried out for 3 placentas from elective C-
sections with normal birth weight infants.   
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Controlling for placental sampling site. For three participants, tissue 
samples were taken close to the cord insertion site (1 A – C), middle (2 A – C) and 
distal edge of the placenta (3 A – C). Adapted from Wyatt et al. (2005).  
 
In addition, placental gene expression was compared between early 
term (37 – 38 weeks), full term (39 – 40 weeks) and late term (≥ 40 weeks) 
gestational age groups for 19 control participants to determine the effect of 
gestational age on target gene expression. Importantly, all infants were 
delivered normal birth weight by elective caesarean section. In order to 
examine the effect of fetal sex on placental target gene expression, gene 
expression was also compared between 11 male and 11 female control 
placentas from normal birth weight, elective C-section deliveries. Finally, 
placental gene expression was compared between 29 participants delivering 
by elective C section (N = 21), emergency C section (N = 4) or vaginal 
delivery (N = 4) in order to examine the effect of labour or mode of delivery 
on placental target gene expression. All participants delivered normal birth 
weight infants and had no known complications of pregnancy.  
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2.1.10 RNA extraction and DNase treatment  
RNA was extracted using the Sigma GenElute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, Dorset, UK) according to the manufacturers 
instructions. Briefly, 40mg of placental tissue per sample was homogenized 
in 500µl of a 1:100 dilution of 2-mercaptoethanol and lysis solution. The 
resulting mix was added to a GenElute Filtration column and centrifuged at 
13,000 rpm for 2 minutes. The filtration column was subsequently discarded 
and 500µl 70% ethanol added to the filtered lysate. The lysate was 
thoroughly vortexed then added in 700µl aliquots to a GenElute Binding 
Column. The Binding column was centrifuged at 13,000 rpm for 15 seconds.  
The flow through was discarded and 250µl Wash Solution 1 added to 
the column before centrifuging at 13,000 rpm for 15 seconds. DNase 
treatment was subsequently carried out by adding 10µl DNase I and 70µl 
DNase Digest Buffer to the column and incubating at room temperature for 
15 minutes. 250µl of Wash Solution 1 was then added to the column, which 
was centrifuged at 13,000 rpm for 15 seconds before transfer to a clean 
collection tube.  
500µl Wash solution 2 was next added to the column before 
centrifugation at 13,000 rpm for 15 seconds. The flow through was discarded 
and another 500µl Wash solution 2 added to the column before centrifugation 
at 13,000 rpm for 2 minutes. After the resulting flow through had been 
discarded, the column was centrifuged for a further 1 minute at 13,000 rpm. 
Finally, the binding column was transferred to a new collection tube and 30µl 
Elution Solution added to the column which was centrifuged at 13,000 rpm 
for 1 minute. The flow through (containing the eluted RNA) was nanodropped 
using a Nanodrop ND-1000 spectrophotometer in order to determine RNA 
concentration and purity. The 260/280 ratio was used to assess RNA purity, 
with a ratio of 1.8 to 2.1 considered acceptable.  
 
2.1.11 Reverse transcription 
For each DNase treated RNA sample, approximately 5µg of RNA was added 
to 1µl (0.5µg/µl) random hexamers (Promega, Southampton, UK) and the 
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volume made up to 11µl with RNase free water (Ambion, Paisley, UK). 
Samples were incubated at 70°C for 10 minutes before transfer to ice. 8µl of 
master mix (Table 2.1) was added to each sample before incubation for 2 
minutes at 37 °C. 1µl MMULV (Promega) was subsequently added to each 
RT+ (but not RT-) reaction and the incubation continued at 37°C for a further 
2 hours.  The samples were then diluted 1:10 with 10mM Tris (pH 8) (Sigma) 
for use in PCR and 1:50 for qPCR. PCR was performed on all –RT samples 
to check for presence of genomic DNA (protocol described in section 2.1.13) 
with a lack of product in the RT – reactions confirming the absence of any 
genomic DNA contamination. 
 
Table 2.1: Master mix (1X) components for reverse transcription 
 
 
 
 
 
 
2.1.12. Primer design  
Sequences for target gene primers are shown in Table 2.2. Primers included 
those previously published (as detailed in Table 2.2) and those designed for 
the current study using Primer3 (Untergasser et al. 2012). Criteria for design 
of these primers were a product size between 100 – 250 bp, an approximate 
melting temperature (Tm) of 60 and that forward and reverse primers were 
either side of an exon-exon boundary (to prevent amplification of genomic 
DNA). A blast search of the NCBI database was also performed for all 
primers to avoid non-target amplification of a PCR product of a similar size.  
Reagent Volume (µl) 
5 X First strand synthesis buffer  4µl 
10mM dNTPs 1µl 
RNase free water 3µl 
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Table 2.2: Primers used for qPCR analysis of gene expression.  
Target 
gene Primer sequence 
Product 
size 
Reference 
    Human 
YWHAZ 
Forward:  
TTCTTGATCCCCAATGCTTC 
Reverse:  
AGTTAAGGGCCAGACCCAGT 
212bp Own design 
PHLDA2 
Forward:	  	  
GAGCGCACGGGCAAGTA 
Reverse:	  	  
CAGCGGAAGTCGATCTCCTT 
68bp  (Apostolidou et 
al. 2007) 
CDKN1C 
Forward: 
CCCATCTAGCTTGCAGTCTCTT  
Reverse: 
CAGACGGCTCAGGAACCATT 
106bp (Diplas et al. 
2009) 
PEG3 
Forward:  
CTCACAACACAATCCAGGAC 
Reverse: 
TAGACCTCGACTGGTGCTTG 
152bp Own design 
PEG10 
Forward: 
AAATTGCCTGACATGAAGAGGAGTCTA 
Reverse: 
AAGCCTAGTCACCACTTCAAAACACACTAAA 
158bp (Diplas et al. 
2009) 
hPL 
Forward:  
CATGACTCCCAGACCTCCTTC 
Reverse:  
TGCGGAGCAGCTCTAGATTG 
97bp (Dutton et al. 
2012) 
PGH 
Forward:  
GTTTGAAGAAGCCTATATCCTG 
Reverse:   
TCACCCTGTTGGAAGGTGTT 
107bp (Vakili et al. 
2013) 
     Mouse 
β-actin 
Forward: 
CCTGTATGCCTCTGGTCGTA 
Reverse: 
CCATCTCCTGCTCGAAGTCT 
260bp Designed by S 
Tunster 
Phlda2 
Forward: 
TCAGCGCTCTGAGTCTGAAA 
Reverse: 
TCCTGGGCTCCTGTCTGAT 
124bp Designed by S 
Tunster 
Cdkn1c 
Forward: 
AGAGAACTGCGCAGGAGAAC 
Reverse: 
TCTGGCCGTTAGCCTCTAAA 
141bp Designed by S 
Tunster 
Peg3 
Forward: 
AAAACTCACCACTCCGTTGG 
Reverse: 
GTCTCGAGGCTCCACATCTC 
190bp Designed by S 
Tunster 
Peg10 
Forward: 
GGGTAGATAATCATAAGTATTTTGGGC 
Reverse: 
CAACATTCTAAACTTTATTCCAGCAAC 
526bp (Ogawa et al. 
2009) 
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In addition, PCR was carried out (section 2.1.13) to ensure amplification of a 
single product at the expected product size. Melt curves produced during 
qPCR were also examined to confirm the presence of a single peak (section 
2.1.14).  
 
2.1.13. PCR 
24µl of PCR master mix (Table 2.3) was added to 1µl of template cDNA 
(diluted 1:10 with 10mM Tris (pH 8)). Primer combinations were made up by 
combining 25µl 100µM forward primer, 25µl 100µM reverse primer and 50µl 
10mM Tris (Sigma). PCR was carried out using thermocycler conditions: 
94°C for 3 minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds and finally 72°C for 3 minutes. PCR products were run 
on a 1% Tris-acetate EDTA (TAE) agarose gel containing 0.5µg/ml ethidium 
bromide (Sigma) and visualised under UV. Products were compared against 
a 100bp DNA ladder (Norgen Biotek, Lichfield, UK) to confirm correct product 
size for RT+ reactions.  
 
Table 2.3: Master mix (1X) components for PCR 
 
 
 
 
 
 
 
 
 
2.1.14 qPCR 
cDNA samples were diluted 1:50 with 10mM Tris (pH 8) (Sigma). Each 
sample was assayed in triplicate and duplicate plates run to confirm gene 
Reagent Volume (µl) 
10X Buffer (Sigma) 2.5µl 
25mM MgCl2 2µl 
10mM dNTPs  0.5µl 
Primer Combination  1µl 
RNase free water 17.84µl 
Taq (Fermentas) 1µl 
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expression results. 15µl qPCR master mix (Table 2.4) was added to 5µl 
cDNA in each well of a 96 well qPCR plate. Primer combinations were made 
up as described for PCR (section 2.1.13).  
 
Table 2.4: Master mix (1X) components for qPCR 
 
 
 
 
 
 
 
 
 
 
 
qPCR was performed using Chromo4 Continuous Fluorescence Detector 
mounted on a PTC 200 Thermocycler (MJ Research) and results analysed 
using Opticon 3 software. The thermocycler conditions were as follows: 94°C 
for 15 minutes, then 40 cycles of 94°C for 30 seconds, 60°C for 30 seconds 
and 72°C for 30 seconds followed by an anti dimer step at 75°C for 30 
seconds. Melt curves were produced by incubating at a further 70°C to 94°C 
and reading at every 0.5°C. Melt curves produced by qPCR were examined 
to confirm the presence of a single peak, suggesting no primer dimers or 
non-specific amplification.  
 Expression data is presented as the ΔCT (target gene expression 
relative to the housekeeping gene expression) and as the fold change in 
expression. The fold change was calculated using the 2 -ΔΔCT (Livak and 
Schmittgen 2001), where the ΔΔCT is the target gene expression relative to 
expression in a defined control group. To ease interpretation of gene 
Reagent Volume (µl) 
RNase free water 10.9µl 
10 X Buffer (Sigma) 2µl 
25mM MgCl2 1.6µl 
10mM dNTPs  0.4µl 
Primer Combination  0.8µl 
Taq (Fermentas) 0.13µl 
Sybr Green (Invitrogen) 0.16µl 
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expression data, ΔCT values were inverted (χ(-1)) such that lower ΔCT 
values represent decreasing expression.  
 
2.1.15 Statistical analysis 
All statistical analysis was carried out using IBM SPSS Statistics for Windows 
(version 20.0, 2011). All variables were analysed for outliers. P-P plots were 
generated and a Shapiro-Wilk test carried out to test for normal distribution of 
the data. Normally distributed data, either untransformed or following ln 
transformation, was analysed using appropriate parametric tests. Data that 
remained non-normally distributed after transformation was analysed using 
appropriate non-parametric tests. Chapter specific statistical analyses are 
further detailed in each individual chapter.  
 
2.2. Manchester cohort 
To provide further validation for results reported in the Wales Cohort with 
respect to fetal growth, gene expression was further analysed in placentas 
from the Manchester Cohort. Study design was as shown in Figure 2.4. 
Participants were recruited as part of a larger study investigating the 
association between reduced fetal movements, placental structure and 
function (Warrander et al. 2012) and infant outcomes (Dutton et al. 2012). 
Written informed consent was obtained from mothers and the study approved 
by Oldham and Greater Manchester North Research Ethics Committees 
(REC no. 08/1011/83 and 11/NW/0664). Villous trophoblast samples (n = 
110) were obtained from participants delivering within one week of clinical 
assessment for reduced fetal movements in the third trimester as previously 
described in (Dutton et al. 2012; Warrander et al. 2012). All placentas were 
dissected within 30 minutes of delivery. Placental sampling procedure was 
directly comparable to that carried out in the Wales Cohort study.  
 In addition to birth weight, a number of growth parameters were 
available for these participants. Firstly, antenatal assessment of fetal growth 
such as ultrasound measures of femur length, abdominal circumference and 
head circumference were documented. Umbilical Artery Doppler 
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measurements, mean placental diameter on scan and amniotic fluid levels 
were recorded, factors that are used to ascertain the presence and severity 
of growth restriction. As with the Wales Cohort, custom birth weight centiles 
were calculated using the GROW bulk centile calculator (UK), version 6.7.5 
(Gardosi and Francis 2014). Information on infant outcomes around the time 
of delivery, such as apgar scores, NICU admission and umbilical artery cord 
blood pH was also available. Finally, information on maternal lifestyle during 
pregnancy and a diagnosis of depression during pregnancy (including any 
treatment prescribed) was recorded from the participant’s medical notes. 
 Following transfer to Cardiff University, samples were processed for 
qPCR analysis as described in section 2.1.10 – 2.1.15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Study design for Manchester cohort. CTG = cardiotocograph, HC = 
head circumference, AC = abdominal circumference, FL = femur length, AGA = 
average for gestational age, SGA = small for gestational age, LGA = large for 
gestational age. Adapted from Dutton et al. (2012).  
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2.3. Imperial cohort 
 
2.3.1. Study design  
 
In order to analyse target imprinted gene expression in relation to maternal 
mood during pregnancy, gene expression was further analysed in placentas 
of the Imperial Cohort. Study design was as shown in Figure 2.5.  
 
 
Figure 2.5: Study design for Imperial cohort. EPDS = Edinburgh Postnatal 
Depression Scale. STAI = Spielberger Trait Anxiety Inventory. Adapted from 
O’Donnell et al. (2012) and Blakeley et al. (2013).  
 
 
Healthy women with singleton pregnancies were recruited one day prior to 
their elective caesarean sections at Queen Charlotte’s and Chelsea Hospital, 
Hammersmith (London) as described in O'Donnell et al. (2012) and Blakeley 
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et al. (2013). Written informed consent was obtained and the study was 
approved by the Ethics Committee of Hammersmith and Queen Charlotte’s 
Hospital, London (REC no. 08/H0708/126). All participants were recruited by 
V. Glover’s research group at Imperial College London as part of a larger 
cohort study (N=65) examining the effects of prenatal stress on the placenta. 
40 placenta samples from this cohort were available for analysis of placental 
hormone and imprinted gene expression. 
 
2.3.2. Participant psychometric assessment  
Maternal anxiety was measured using the Spielberger Trait Anxiety Inventory 
(STAI), see Appendix 6. The STAI is a comprehensively validated self-report 
questionnaire which assesses how the participant “generally feels”. The 
questionnaire is comprised of twenty 4-point questions with total scores 
ranging from 20 (low anxiety) to 80 (high anxiety), with higher scores 
indicating higher levels of anxiety. An anxiety disorder is indicated by an 
STAI score ≥ 40 (Grant et al. 2008). Participants were divided into those 15 
with lowest STAI scores and those 15 with highest STAI scores.  
Maternal depression was measured using the Edinburgh Postnatal 
Depression Scale (EPDS), see Appendix 7. The EPDS has been validated 
for use during pregnancy (Cox et al. 1996) and is a self-report questionnaire 
comprised of ten questions. Total EPDS scores range from 0 (low 
depression) to 30 (high depression). Depression is indicated by an EPDS 
score of ≥13 (Cox et al. 1987). Participants were divided into those 15 with 
lowest EPDS scores and those 15 with highest EPDS scores.  
In addition, maternal demographics including prescribed medication, 
occupation, household income, education and lifestyle during pregnancy (e.g. 
alcohol and smoking) were recorded using a self-report questionnaire. Birth 
outcomes including gestational age, fetal sex, birth weight and apgar scores 
were recorded from the participant’s medical notes.  
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2.3.3. Placental sample processing 
Placental dissection was carried out as described in O'Donnell et al. (2012) 
and Blakeley et al. (2013). Placental sampling procedure was directly 
comparable to that carried out in the Wales Cohort study. Briefly, a villous 
trophoblast tissue sample was taken from the central part of the placenta 
(just underneath the maternal surface) within one hour of delivery. Samples 
were washed in PBS before overnight storage in RNAlater at 4°C. RNAlater 
was then removed and the placental sample stored at -80°C until RNA 
extraction was carried out. RNA was extracted by A Janssen and P Blakeley 
(Imperial College London) using RNeasy Mini Kits (Qiagen, Crawley, UK) 
and according to the manufacturer’s instructions. Subsequently, RNA 
integrity was determined using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Stockport, UK) and samples with a RIN ≥ 5 used for gene 
expression analysis. Finally, 2 µg of RNA was reverse transcribed using 
Superscript III first strand cDNA synthesis system (Invitrogen, Paisley, UK), 
according to manufacturer’s instructions. Following transfer of cDNA samples 
to Cardiff University, gene expression was analysed by qPCR as described in 
section 2.1.14.  
 
2.4. Animal model 
In order to investigate the effects of maternal pre-conception and prenatal 
diet on allelic expression of imprinted genes within the distal chromosome 7 
region, Mus mus domesticus C57BL/6 mice carrying the Mus spretus region 
of distal chromosome 7 were used. Cdkn1c-RFLP mice were originally 
generated by crossing a M.m spretus male with a C57BL/6J female and 
selecting for the Cdkn1c Aval RFLP for > 8 generations. To generate 
placental and fetal material exposed to a variety of maternal diets, wildtype 
C57BL/6 female mice (aged 7 – 10 weeks) were mated with Cdkn1c-RFLP 
males. RFLP analysis of the Cdkn1c Aval polymorphism was used to 
determine which fetuses inherited the Spretus allele. In this way, RFLP 
analysis was used to determine the parent of origin of imprinted gene 
expression.  
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Animals were housed following Home Office Regulations and under 
the project licence 30/2600 (until November 2013) and 30/3134 (from 
November 2013). Females were checked daily for the presence of a vaginal 
plug, indicating a successful mating.  The day on which a vaginal plug was 
observed was designated as embryonic day 0.5 (E0.5), and females were 
subsequently re-housed singly. Generation of and care for experimental mice 
was carried out by G. McNamara and S. Tunster.  
 
2.4.1. Maternal diet 
For the first experiment, the effect of maternal low protein or high fat diet 
during pregnancy was examined. Control females were fed a basal diet (diet 
energy from; protein 18.3%, fat 22.1%, carbohydrate 59.6%) (Test Diet, St. 
Louis, MO) before and during pregnancy. Both low protein and high fat diet 
females were similarly fed a basal diet before pregnancy. However, from 
E0.5 low protein diet females were placed on a low protein diet (diet energy 
from; protein 8.1%, fat 21.8%, carbohydrate 70.1%) (Test Diet, St. Louis, 
MO) whereas high fat diet females were placed on a high fat diet (diet energy 
from; protein 18.1%, fat 46.1%, carbohydrate 35.8%) (Test Diet, St. Louis, 
MO).  
The second experiment design is shown in Figure 2.6. Before 
pregnancy females were placed on a basal (15% sugar content and diet 
energy from; protein 17.7%, fat 10%, carbohydrate 61%) (Test Diet, St. 
Louis, MO) or high fat - high sugar (HFHS) diet (34% sugar content and diet 
energy from; protein 17.8%, fat 20.0%, Carbohydrate 49.9%) (Test Diet, St. 
Louis, MO). Females were on the pre-pregnancy diet for 12 weeks and 
weighed every week to assess pre-pregnancy weight gain. At week 12 
females were mated and from E0.5 till E18.5 females were fed either the 
basal or HFHS diet during pregnancy, as shown in Figure 2.6.  Control-HFHS 
females were used to model effects of over nutrition specific to pregnancy. In 
addition, comparison of the HFHS-Control with the HFHS-HFHS females was 
used to model effectiveness of an intervention to improve maternal diet 
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during pregnancy. Mice were weighed at E0.5 and E18.5 to determine 
maternal weight gain during pregnancy.  
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Study design for a mouse model of maternal high fat-high sugar  
diet before and during pregnancy. HFHS = high fat-high sugar diet. E = 
embryonic day.  
 
 
Of note was the relative difficulty in achieving and maintaining 
pregnancy in the HFHS-Control and HFHS-HFHS females. 75% of control-
control females and 57% of control-HFHS females mated produced a litter at 
E18.5. In contrast, although all 6 females in the HFHS-control group plugged, 
only 2 successfully delivered a litter (33% success rate), of which one 
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included three reabsorptions. Similarly, of the 5 females on the HFHS-HFHS 
diet that were mated, only 2 became pregnant (40% success rate) with both 
delivering litters including 2-3 reabsorptions. This contributed to significantly 
lower numbers of placentas for analysis in these two groups.  
 
2.4.2. Dissection 
Dissection was carried out at E13.5 and E18.5 for the low protein diet 
experiment in order to examine time specific effects of maternal protein 
restriction. For all other mice, dissection was carried out at E18.5. Females 
were killed by cervical dislocation at E18.5 by G McNamara and S Tunster. 
The uterus was placed in ice cold PBS and the embryos killed under 
schedule 1 by separation from the yolk sac (ASPA 1986). Dissection was 
carried out by A Janssen and G McNamara. The embryos and placentas 
were weighed. Embryo and placental weight was adjusted to account for 
differences in litter size using the following formula:  
Mean weight for diet   x     individual weight 
Mean weight for litter 
 
The kidneys were dissected out of the embryos and stored at - 80°C. The 
placentas were then frozen immediately at - 80°C until processing for qPCR 
(as described in section 2.1.10 – 2.1.15). Yolk sacs were stored at -20°C for 
RFLP and sex typing (Section 2.4.3).  
 
2.4.3. RFLP and sex typing 
RFLP analysis was performed by G McNamara and R John. Yolk sacs were 
digested in 300µl lysis buffer (0.1M Tris.HCl pH 8.5, 0.005 M EDTA pH 8.0, 
0.02% SDS, 0.2M NaCl, 100 µg/ml Proteinase K (Promega, UK)) at 55-60°C 
overnight. Samples were then vortexed and centrifuged at 13,000 rpm for 14 
minutes before transfer of the supernatant to a new 1.5ml Eppendorf.  A 1X 
volume of isopropanol was added and the samples mixed thoroughly before 
incubation at 4°C for 30 minutes. After vortexing briefly, samples were 
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centrifuged at 13,000 rpm for 12 minutes with the gDNA forming a pellet. The 
supernatant was discarded and the resulting pellet air dried at room 
temperature for 10 minutes. The pellet was then resuspended in 80 µl TE 
buffer (10mM Tris pH8, 0.1mM EDTA pH8). PCR was carried out using 1µl of 
the resulting solution as the PCR template.   	  
Table 2.5: Master mix (1X) PCR components for RFLP and sex typing 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 shows the master mix volumes for PCR. For sex typing, 
PCR conditions were as follows; 94°C for 15 minutes, 94°C for 45 seconds, 
61°C for 45 seconds, 72°C for 45 seconds, repeat 35 times then 72°C for 5 
minutes. Primer sequences for sex typing were Ssty forward: 5’-CT 
GGAGCTCTACAGTGATGA-3’ and Ssty reverse: 5’-CAGTTAC 
CAATCAACACATCAC-3’, Om1a forward: 5’-TTACGTCCATCGTGGAC 
AGCAT-3’ and Om1a reverse: 5’-TGGGCTGGGTGTTAGTCTTAT-3’. PCR 
products were run on a 1% TAE agarose gel with ethidium bromide and 
visualised under UV. Products were compared against a DNA ladder to 
confirm correct product size. Primers used for sex typing amplified an 
autosomal linked gene (Om1a) and a Y linked gene (Ssty), with the presence 
of two bands indicating male sex and a single band female sex.  
For the RFLP analysis, PCR conditions were as described above 
(Table 2.5) for Phlda2 and Cdkn1c with Tm of 58°C and 64.5°C, respectively. 
Primers for Cdkn1c RFLP were 5’-GGCTTCAGATCTGACCTCAG-3’ and 5’-
AGAGAGGCTGGTCCTTCAGC-3’. For the Phlda2 RFLP, Primer E36 was 5’-
Reagent Volume (µl) 
Buffer 10X with 15 mM MgCl2 (Qiagen) 2.5 
MgCl2 (25 mM) 2 
dNTPs (4 mM) 2 
Forward (25 µM) and Reverse (25 µM) Primers 1 
HotStart Taq (Qiagen) 0.25 
Template DNA 1 
dH20 16.25 µl 
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TCAGCGCTCTGAGTCTGAAA-3’ and primer R647 was 5’-
TCCTGGGCTCCTGTCTGAT-3’ (Figure 2.7).  Samples amplified by PCR 
from either genomic DNA or cDNA were digested to show the presence of 
the different alleles. For the Cdkn1c digest, 10 µl Cdkn1c PCR product was 
added to 3 µl 10X Buffer 4, 0.5 µl AvaI enzyme (NEB) and 16.5 µl H₂0. The 
samples were then digested for at least 8 hours at 37 °C. The RFLP for 
Cdkn1c is further described in Li et al. (2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Phlda2 RFLP. (A) Phlda2 genomic locus. Arrows indicate position of 
primers EG36 and R647 used to in PCR and boxes indicate exons. Taul restriction 
enzyme cut sites are also shown. (B) Validation of Phlda2 RFLP using genomic 
DNA with predicted band sizes shown on the right. (C) RFLP analysis using cDNA 
with predicted band sizes shown on the right. Red box indicates position of 
predicted bands on gel image.  
 
 
 For the Phlda2 digest, 10 µl Phlda2 PCR product was added to 3 µl 
10X Buffer B (ThermoScientific 10X Buffer B with BSA), 0.5 µl TauI enzyme 
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(ThermoScientific TauI enzyme 3U/µl) and 16.5 µl H₂0. The samples were 
then digested for 8 hours at 55 °C. A sample of genomic DNA was used as a 
control in both cases and to validate the Phlda2 RFLP (Figure 2.7). The 
products were analysed by gel electrophoresis as described in section 
2.1.13. The Taul restriction enzyme recognises a sequence on the C57BL/6 
Phlda2 allele and cuts the cDNA, resulting in the presence of two bands on 
the gel approximately 100bp and 50bp in length respectively (Figure 2.7). In 
contrast, a polymorphism in the Spretus sequence means that the Taul 
enzyme cannot recognise the Taul cut sites, resulting in the presence of a 
larger (undigested) band of 150bp in length (Figure 2.7). 
In this way, it is possible to identify the parental origin of the Phlda2 
allele; because Phlda2 is a maternally expressed imprinted gene, inheritance 
of the maternal Spretus allele by the F1 offspring will result in the presence of 
one larger undigested band of 150bp in length. In contrast, inheritance of the 
paternal Spretus allele by the F1 offspring (which when imprinted is not 
expressed) will result in the presence of two (digested) bands of 100bp and 
50bp in length. Thus, loss of imprinting (resulting in both maternal and 
paternal expression of Phlda2) will be indicated by the presence of two bands 
at 150bp and 100bp in length as shown in Figure 2.7.  
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CHAPTER 3: IMPRINTED GENES AND FETAL 
GROWTH 
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3.1. Introduction 
Fetal growth restriction (FGR) is the failure of a fetus to achieve its optimal 
growth potential during gestation (Ergaz et al. 2005), and is associated with 
an increased risk of adverse infant outcomes around the time of delivery as 
well as diseases such as type II diabetes and cardiovascular disease in 
adulthood (Godfrey and Barker 2001). Further understanding of the causes 
of growth restriction is therefore essential for the prevention of adverse short 
and long term effects on offspring health. It is possible that imprinted genes 
have a causative role in fetal growth restriction, given their well-established 
functions in the control of fetal growth. Thus, the main aim of this chapter was 
to explore a possible association between aberrant placental imprinted gene 
expression and FGR.  
 In particular, a number of animal and human studies have investigated 
the role of the maternally expressed imprinted gene PHLDA2 in fetal growth 
restriction (reviewed in Jensen et al. 2014). Two fold over expression of 
Phlda2 in a mouse model resulted in stunted placental growth combined with 
asymmetric fetal growth restriction in late gestation (Tunster et al. 2010; 
Tunster et al. 2014). Increased placental PHLDA2 expression has similarly 
been reported in human growth restricted pregnancies (McMinn et al. 2006; 
Diplas et al. 2009; Kumar et al. 2012), with an estimated 25% of the IUGR 
placentas analysed displaying aberrant PHLDA2 expression (McMinn et al. 
2006). However, a relatively small number of placentas were examined in 
these studies, with the largest study analysing only 38 IUGR placentas 
(Diplas et al. 2009). Thus, larger cohort studies are required to fully 
determine whether aberrant placental PHLDA2 expression plays a role in 
fetal growth restriction.  In addition, previous studies have not distinguished 
between asymmetric and symmetric growth restriction. Tunster et al. (2014) 
observed asymmetric growth restriction as a result of Phlda2 over expression 
in a mouse model, however it is not certain whether placental PHLDA2 
expression is similarly associated with asymmetric growth restriction in 
human pregnancies. Finally, no study to date has analysed placental 
PHLDA2 expression in relation to birth outcomes. This would determine 
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whether placental PHLDA2 expression could serve as a biomarker to identify 
at risk infants (Jensen et al. 2014).  
 The imprinted genes Cdkn1c, Peg3 and Peg10 have also been 
demonstrated to regulate fetal growth in an animal model. Overexpression of 
the maternally expressed imprinted gene Cdkn1c was associated with pre- 
and postnatal growth restriction (Andrews et al. 2007). Loss of function of the 
paternally expressed imprinted gene Peg3 was also associated with fetal 
growth restriction and impaired placental growth (Li et al. 1999; Kim et al. 
2013). Finally, loss of function of the paternally expressed imprinted gene 
Peg10 resulted in embryonic lethality attributed to a severe placental defect 
(Ono et al. 2006). Despite convincing data in an animal model, the 
expression of CDKN1C, PEG3 and PEG10 in the placenta of human growth 
restricted pregnancies has been less extensively researched and with 
conflicting results. Both increased (McMinn et al. 2006), decreased 
(Rajaraman et al. 2010) and unaltered (Diplas et al. 2009) CDKN1C 
expression has been reported in IUGR placentas. Placental PEG3 
expression was not significantly altered in growth restricted pregnancies in 
three small studies (McMinn et al. 2006; Diplas et al. 2009; Kumar et al. 
2011). Finally, placental PEG10 expression was significantly increased in 
IUGR placentas (Diplas et al. 2009). Thus, further research is required as to 
the role of aberrant placental CDKN1C, PEG3 and PEG10 expression in 
human FGR pregnancies.  
 Importantly, differences in placental dissection protocol may account 
for the conflicting results reported in previous studies, particularly of human 
placental CDKN1C expression in relation to fetal growth. A considerable 
number of factors have been reported to affect placental gene expression 
such as time to sampling, sampling site, fetal sex and mode of delivery 
(Burton et al. 2014). Increased time between delivery and sampling of the 
placenta has previously been demonstrated to result in increased RNA 
degradation and subsequent effects on placental gene expression (Avila et 
al. 2010). In terms of sampling site, a number of studies have demonstrated 
significant intraplacental variation in gene expression (Hempstock et al. 2003; 
Pidoux et al. 2004; Wyatt et al. 2005; Sood et al. 2006) and thus consistency 
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in placental sampling is of key importance. Fetal sex is another important 
consideration in study design, given the sexual dimorphism observed in 
placental gene expression, particularly of genes related to fetal growth, both 
under normal conditions (Buckberry et al. 2014) and in response to an 
adverse intrauterine environment (Clifton 2010). Mode of delivery represents 
another potential confounding factor in analysis of placental gene expression. 
Decreased placental blood supply during contractions, exposure to hormones 
associated with labour as well as differences in pain relief (Burton et al. 2014) 
may account for differences in gene expression observed between labouring 
and non labouring placentas (Cindrova-Davies et al. 2007; Sitras et al. 2008; 
Lee et al. 2010; Peng et al. 2011; Kim et al. 2013b). Gestational age 
differences in infant morbidity and mortality exist within term pregnancies 
(Crump et al. 2013) and the incidence and type of placental pathologies has 
also been demonstrated to vary between different term gestational ages 
(Stanek 2014). Therefore, although not previously examined, it is possible 
that gestational age differences, even within term pregnancies, may affect 
placental gene expression. While no previous study has examined placental 
imprinted gene expression in relation to these potential confounding factors, 
this is likely to be of relevance in the design of future studies.    
It has been proposed that imprinted genes, such as PHLDA2, may 
regulate fetal growth through control of mechanisms driving maternal 
adaptation to pregnancy (Haig 1993), such as placental hormone production 
(John 2013). Indeed, the imprinted genes Phlda2, Cdkn1c, Peg3 and Peg10 
have been demonstrated to regulate the endocrine lineage of the mouse 
placenta, thereby indirectly controlling production of placental hormones such 
as placental lactogens (reviewed in John 2013). The human placenta differs 
in several ways from the rodent placenta (Carter 2012) and therefore it is 
important to investigate whether the observations of imprinted gene control of 
placental hormone production in a mouse model has relevance to humans. In 
humans, the placental hormones hPL and PGH control fetal growth by driving 
maternal metabolic adaptations to pregnancy such that preferential transfer 
of nutrients to the fetus occurs while maintaining maternal homeostasis 
(Newbern and Freemark 2011). It is therefore possible that aberrant 
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imprinted gene expression could result in FGR via negative effects on 
placental production of hormones such as hPL and PGH. No previous study 
has analysed the relationship between placental imprinted gene expression 
and expression of the placental hormones hPL and PGH, in the context of 
growth restriction.  
 Fetal overgrowth, resulting in delivery of an LGA or macrosomic infant, 
is also of clinical relevance given the increased risk of adverse outcomes in 
these infants around the time of delivery, as well as the increased risk of 
associated birth traumas for the mothers (Zhang et al. 2008; Larkin et al. 
2011; Pasupathy et al. 2012). As imprinted genes have a well-established 
role in the control of fetal growth, it is possible that aberrant placental 
imprinted gene expression also underlies cases of fetal overgrowth. As 
discussed above, previous studies of placental imprinted gene expression in 
relation to fetal growth have focussed on FGR and therefore no study to date 
has examined placental imprinted gene expression in macrosomic or LGA 
placentas.  
 In summary, while results from previous animal and human studies 
suggest a role for placental imprinted gene expression in the control of 
human fetal growth, further research is warranted in larger cohorts to confirm 
these findings. This chapter therefore aimed to examine placental imprinted 
gene and placental hormone gene expression in pregnancies complicated by 
growth restriction or fetal overgrowth.  
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3.2. Chapter specific methods 
Methods were as described in Chapter 2. For ease of interpretation of the 
results presented in this chapter, methods related to the study of placental 
target gene expression in pregnancies complicated by FGR and fetal 
overgrowth are summarised below. In this Chapter, gene expression was 
analysed in placentas from two cohorts, the Wales and Manchester Cohorts.  
 
3.2.1. Placental dissection protocol optimisation 
To control for any effect of time to sampling on RNA concentration and 
placental target gene expression, placental samples were taken at 30 
minutes, 1 hour, 1.5 hours and 2 hours after delivery for three participants 
delivering AGA infants by elective C-section. RNA was extracted from 
placental samples taken at all time points and RNA concentrations 
compared. In addition, placental target gene expression was compared 
between time points.  
 In order to analyse intraplacental variation in target gene expression, 
three samples (close to the cord insertion site, middle and distal edge) were 
taken from each of the fetal, middle and maternal layers of the placenta as 
described in Wyatt et al. (2005). This was carried out for 3 placentas from 
elective C-sections.   
 Placental target gene expression was also compared between early 
term (37 – 38 weeks), full term (39 – 40 weeks) and late term (≥ 40 weeks) 
gestational age groups for 19 control participants to determine the effect of 
gestational age on gene expression. In order to examine the effect of fetal 
sex on placental target gene expression, gene expression was also 
compared between 11 male and 11 female control placentas from normal 
birth weight, elective C-section deliveries. Finally, placental gene expression 
was compared between 29 participants delivering by elective C section (N = 
21), emergency C section (N = 4) or vaginal delivery (N = 4) in order to 
examine the effect of labour or mode of delivery on placental target gene 
expression. 
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3.2.2. Statistical analysis 
All statistical analysis was carried out using IBM SPSS statistics for Windows 
(version 20.0, 2011) with a p value <0.05 considered statistically significant. 
Normal distribution was assessed using P-P plots and a Shapiro-Wilk test. 
For normally distributed data, associations between placental gene 
expression and measures of fetal growth were assessed using a Pearson 
correlation test while differences in placental gene expression were analysed 
using an independent samples T tests (to compare e.g. control and IUGR 
pregnancies) or one-way ANOVA with a Tukey post hoc test (to compare e.g. 
AGA, symmetric SGA and asymmetric SGA pregnancies). Any significant 
associations with gene expression were confirmed with and without the 
addition of preterm deliveries. Linear regression analysis was used to 
determine the proportion of variation in fetal growth measures accounted for 
by differences in target gene expression. A Bonferroni correction was also 
used to control for multiple comparisons in target gene expression between 
SGA and AGA placentas (α/6 = 0.008).  
Only placental PHLDA2 expression in the Manchester cohort 
remained non-normally distributed (also after ln transformation); In this 
cohort, a Spearman rank order correlation test was used to determine the 
association between placental PHLDA2 gene expression and measures of 
fetal growth while differences in PHLDA2 expression between groups was 
analysed using a Mann Whitney U test.  
For all protocol optimisation experiments, a small number of matched 
control participants delivering normal birth weight infants were chosen for 
gene expression analysis to control for variation due to differences in 
maternal demographics or birth outcomes. In order to examine intraplacental 
variation in target gene expression, gene expression was first analysed 
relative to sampling site 1A (on the basal surface close to the cord insertion 
site) to determine the variation in gene expression across all sampling sites 
as described in Wyatt et al. (2005). Subsequently, gene expression was 
compared between different regions of the placenta (basal versus chorionic 
sampling sites and cord versus distal sampling sites).  
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3.3. Results 
 
3.3.1. Protocol optimisation 
3.3.1.1. Time to sampling 
For three control participants, placental tissue samples were taken at the 
same sampling site at four time points; 30 minutes, 1 hour, 1.5 hours and 2 
hours after delivery in order to determine the effect of time to sampling on 
RNA concentration and placental target gene expression.  
 
Figure 3.1: Effect of time to sampling on (A) RNA concentration and (B) 
YWHAZ expression. (A) There was no significant effect of time to sampling on RNA 
concentration as determined by one-way ANOVA. (B) PCR analysis revealed RNA 
of sufficient quality at all sampling time points as indicated by consistently high 
expression of the housekeeping gene YWHAZ. Error bars represent SD.  
 
There was no significant effect of time to sampling on placental RNA 
concentration as determined by a one-way ANOVA (F(3,8) = 0.46, p = 0.72), 
Figure 3.1. There was also no significant correlation between expression of 
the housekeeping gene YWHAZ and time to sampling (r = 0.43, p = 0.16, n = 
12), as confirmed by PCR analysis demonstrating sufficient quality RNA for 
gene expression analysis from placental samples taken at all time points 
(Figure 3.1). Finally, there was no significant effect of time to sampling on 
placental PHLDA2 (F(3,8) = 0.65, p = 0.61), CDKN1C (F(3,8) = 0.94, p = 
0.47), PEG3 (F(3,8) = 0.74, p = 0.56), PEG10 (F(3,8) = 0.53, p = 0.68), hPL 
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(F(3,8) = 0.02, p = 0.99) or PGH (F(3,8) = 0.05, p = 0.98) expression as 
determined by qPCR. These results therefore suggest that gene expression 
analysis can be carried out for samples taken up to 2 hours after delivery 
without a significant effect on RNA concentration or target gene expression.  
 
3.3.1.2.  Intraplacental variation in gene expression 
For three AGA participants, tissue samples were taken at different sites 
across the placenta and gene expression compared to determine the effect 
of sampling site on target gene expression. Variation in target gene 
expression with sampling site is shown in Figure 3.2, relative to sampling site 
1A (close to the cord insertion and on the basal surface of the placenta).  
As shown in Figure 3.2, placental PHLDA2 expression was 
significantly increased by 59% in samples taken at distal sites (3 A – C) 
compared with sites close to the cord insertion (1 A – C) (p = 0.048, n = 18). 
In contrast no significant difference in placental PHLDA2 gene expression 
was seen between basal (1 – 3 A) and chorionic sites (1 – 3 C) (p = 0.52, n = 
18).  No significant difference was observed in placental CDKN1C, PEG3 or 
PEG10 expression relative to sampling site 1A (Figure 3.2). Similarly, there 
was no significant difference in expression at distal sites compared with sites 
close to the cord insertion or between basal and chorionic sites. There was a 
significant 52% increase in placental hPL expression at site 3B (distal, middle 
layer) compared with site 1A (cord insertion site, basal layer) (p = 0.002, n = 
18) Figure 3.2. However, there was no significant difference in placental hPL 
expression between site 1A and any other sampling site, or between distal 
sites compared with sites close to the cord insertion or between basal and 
chorionic sites. Finally, no significant difference in placental PGH expression 
was observed relative to sampling site 1A (see Figure 3.2) and expression 
did not differ significantly between distal sites and sites close to the cord 
insertion or between basal and chorionic sites. 
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Figure 3.2: Effect of sampling site on placental target gene expression.  Samples were taken from the cord insertion site to distal edge (1-
3) and from the basal to chorionic surface (A – C). Graphs show mean fold gene expression, relative to sampling site 1A (Cord, Basal). Tables 
summarize differences in gene expression between basal and chorionic sites and between cord and distal sites. * p ≤0.05, ** p ≤0.001. 
B) 
C) 
D) 
E) 
F) 
A) 
B) 
C) 
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3.3.1.3. Effect of gestational age on placental gene expression 
Placental gene expression was compared between gestational age groups for 
19 controls participants. Birth outcomes for early term (37 – 38 weeks), full 
term (39 – 40 weeks) and late term (≥ 40 weeks) deliveries are shown in 
Table 3.1. Aside from gestational age, there was no significant difference in 
any other birth outcome between these groups.  
There was no significant correlation between gestational age at 
delivery and placental PHLDA2 (r = 0.24, p = 0.33, n = 19), CDKN1C (r = 
0.21, p = 0.39, n = 19), PEG3 (r = 0.35, p = 0.14, n = 19) or PEG10 
expression (r = 0.34, p = 0.15, n = 19). Similarly, there was no significant 
difference in expression between early term, full term and late term deliveries 
as determined by a one-way ANOVA (Figure 3.3). PHLDA2 and PEG3 
expression was greatly increased in the late term placentas examined but due 
to the small number of participants and the large variation in gene expression 
in this group, these differences were not statistically significant.  
 
Table 3.1: Birth Outcomes of early, full and late term participants used for 
methods optimisation. Mean (SD)/Range or Number (%) is shown. Groups were 
compared with early term deliveries using a one-way ANOVA or Chi squared test as 
appropriate. *** p < 0.001.  
 
 Early Term  
(37 – 38 
weeks) 
Full Term 
(39 – 40 
weeks) 
Late Term  
(>40 weeks) 
P value 
Gestational Age 
(days) 
266 (4.6) 
/ 259 - 272 
279 (4.6)  
/ 273 - 285 
290 (3.6)  
/ 287-294 
 
< 0.001 *** 
Birth Weight 
(g) 
3398 (112) 
/ 3020 - 3920 
3488 (159) 
/ 3180 - 3740 
3823(284) 
/ 3500 - 4030 
 
0.10 
Placental Weight 
(g) 
651(112) 
/510 – 835 
760 (159) 
/531 - 970 
666 (135) 
/580 - 822 
 
0.40 
Fetal Sex 
          Male 
Female 
 
4 (44%) 
5 (56%) 
 
4 (57%) 
3 (53%) 
 
1 (57%) 
2 (53%) 
 
0.76 
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Figure 3.3: Effect of gestational age on target gene expression. Fold gene 
expression is shown relative to early term deliveries. Differences in fold gene 
expression were analysed using a one-way ANOVA and Tukey Post hoc test. ** p < 
0.01. Error bars represent SEM. 
 
There was no significant correlation between gestational age at delivery and 
placental hPL expression (r = - 0.32, p = 0.18, n = 19) and no significant 
difference in gene expression between gestational age groups (Figure 3.3). 
However, there was a significant positive correlation between gestational age 
at delivery and placental PGH expression (r = 0.70, p = 0.001, n = 19). 
Placental PGH was also significantly different between gestational age groups 
(F (2,16) = 8.41, p = 0.003, n = 19); a Tukey post hoc test revealed a 
significant increase in PGH expression in late term compared with early term 
deliveries (Figure 3.3).  
 
3.3.1.4. Effect of fetal sex on placental gene expression 
Placental gene expression was compared between 11 male and 11 female 
AGA infants to determine the effect of fetal sex on target gene expression. 
There was no significant difference in birth outcomes as shown in Table 3.2. 
Placental target gene expression did not differ significantly between male and 
female placentas as shown in Figure 3.4. 
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Table 3.2: Birth outcomes of male and female infants used for methods 
optimisation. Mean (SD)/Range is shown. Birth outcomes for female infants were 
compared with those for male infants using an independent samples T-test with 
resulting P values shown.  
 
Figure 3.4: Sex differences in placental target gene expression. Fold gene 
expression is shown relative to expression in male placentas. Error bars represent 
SEM. Differences in gene expression were not statistically significant using a t-test. 
 
3.3.1.5. Effect of mode of delivery on placental gene expression 
Placental gene expression was compared between 29 participants delivering 
by elective C section (ELCS), emergency C section (EMCS) or vaginal 
delivery (SVD) to determine the effect of mode of delivery on target gene 
 Male  
(N = 11) 
Female  
(N = 11) 
P value 
Gestational Age 
(days) 
274 (8.2) 
/ 263 - 289 
274 (11.4)  
/ 259 - 274 
 
0.85 
Birth Weight 
(g) 
3380 (215) 
/ 3100 - 3780 
3600 (305) 
/ 3020 - 4030 
 
0.07 
Placental Weight (g) 663 (114) 
/531 – 859 
742 (143) 
/510 - 970 
 
0.17 
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expression. There was no significant difference in birth outcomes between 
different modes of delivery, as shown in Table 3.3.   
 
Table 3.3: Birth outcomes by mode of delivery. Mean (SD)/Range or Number (%) 
is shown. Groups were compared using a one-way ANOVA or Chi squared test as 
appropriate.  
 
Figure 3.5: Effect of mode of delivery on target gene expression. Fold gene 
expression is shown relative to elective c section deliveries. Differences in fold gene 
expression were analysed using a one-way ANOVA and Tukey Post hoc test. ** p < 
0.01. Error bars represent SEM.  
 Elective       
C-section  
(N = 21) 
Emergency       
C-section  
(N = 4) 
Vaginal 
Delivery 
(N = 4) 
P value 
Gestational Age 
(days) 
273 (9.5) 
/ 259 - 294 
280 (13.5)  
/ 266 – 296 
273 (8.5)  
/ 266-285 
 
0.91 
Birth Weight 
(g) 
3469 (269) 
/ 3020 - 4030 
3532 (381) 
/ 3160 - 3940 
3502 (284) 
/ 3290- 3850 
 
0.42 
Placental Weight 
(g) 
707 (134) 
/510 – 970 
657 (98) 
/552 - 744 
633 (149) 
/434 - 788 
 
0.51 
Fetal Sex 
          Male 
Female 
 
11 (52%) 
10 (48%) 
 
1 (25%) 
3 (75%) 
 
2 (50%) 
2 (50%) 
 
0.60 
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As shown in Figure 3.5, there was no significant difference in placental 
PHLDA2 (p = 0.32, n = 29), PEG3 (p = 0.79, n = 29), PEG10 (p = 0.77, n = 
29), hPL (p = 0.96, n = 29) or PGH (p = 0.69, n = 29) expression between 
varying modes of delivery. However, CDKN1C expression was significantly 
2.9 fold higher in placentas of women delivering by EMCS and 2.5 fold higher 
in women delivering by SVD (Figure 3.5). 
 
3.3.1.6. Methods optimisation summary 
A summary of the changes in target gene expression according to time to 
sampling, sampling site, gestational age, fetal sex and mode of delivery is 
shown in table 3.4. There was no significant effect of time to sampling or fetal 
sex on expression of any target gene. There was however a significant effect 
of sampling site on PHLDA2 expression, a significant positive association 
between PGH expression and gestational age and a significant increase in 
CDKN1C expression in emergency caesarean and vaginal delivery placentas.  
 
Table 3.4. Summary of methods optimisation results. Percentage change in 
expression is shown relative to controls. EMCS = emergency caesarean section, 
SVD = spontaneous vertex delivery (vaginal delivery).  
Gene Time to 
Sampling 
Sampling 
site 
Gestational 
age 
Fetal sex Mode of 
delivery 
PHLDA2 - ↑ 59% at 
distal sites 
- - - 
CDKN1C - - - - ↑ 190% in 
EMCS,  
↑ 150% in 
SVD 
PEG3 - - - - - 
hPL - - - - - 
PGH - - Positive 
association 
- - 
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3.3.2. Fetal growth restriction: Wales cohort 
3.3.2.1. SGA participant demographics 
The characteristics of the Wales Cohort participants (N=219) are shown in 
Table 3.5. The cohort included 67 participants delivering SGA infants (with no 
other pregnancy complication) of which 34 were also LBW infants (< 2,500g). 
 Participants delivering SGA infants did not differ significantly in terms of 
ethnicity (p = 0.40, n = 158) compared with controls, with 90% and 96% of 
participants, respectively, being Caucasian. There was also no significant 
difference in maternal age between groups (p = 0.27, n = 158). 
 Maternal BMI at booking was significantly reduced in participants with 
SGA infants (24.5 v. 26.7, p = 0.02, n = 219). This reduction was significant 
for both maternal weight (64.1 kg v. 71.4 kg, p = 0.003, n = 138) and height 
(1.61m v. 1.64 m, p = 0.01, n = 115) independently. Similarly, the participants 
own birth weight (self-reported) was significantly lower for SGA participants 
(3.03kg v. 3.29kg, p = 0.02, n = 83).  
 Birth outcomes for SGA and AGA participants are shown in Table 3.6. 
Due to sampling bias, a significantly smaller number of SGA participants 
delivered by elective c-section highlighting the need to control for mode of 
delivery in target gene expression analysis. In addition to the hypothesised 
differences in birth weight, placental weight and head circumference, 
gestational age was also significantly reduced in SGA participants (Table 3.6). 
This likely reflects the early delivery of severe IUGR cases. Finally, the 
number of infants admitted to NICU on delivery was significantly higher for 
SGA participants compared with controls (Table 3.6).  
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 Mean (SD)/Range or 
Number (%) 
 Mean (SD)/Range or 
Number (%) 
Birth Outcomes 
 
Fetal Sex 
Male 
Female 
 
Gestational age (weeks) 
 
Birth weight (g) 
Custom birth weight centile  
Placental Weight (g) 
Apgar Scores (1 min) 
Apgar Scores (5 min) 
 
Birth weigh Classification  
AGA only 
SGA only 
LGA only 
 
NICU Admission 
Yes 
No 
 
Mode of Delivery 
SVD 
ELCS 
EMCS 
Instrumental 
 
 
 
115 (52.5%) 
104 (47.5%) 
 
39 (1.40) / 29 – 42 
 
3214 (678) / 730 - 4990 
41 (32) / 0 - 100 
632 (160) / 226 – 1064  
9 (1.37) / 0 - 10  
10 (0.81) / 3 – 10  
 
 
91 (42%) 
67 (31%) 
23 (11%) 
 
 
7(3%) 
212 (97%) 
 
 
45 (20%) 
113 (61%) 
24 (11%) 
17 (8%) 
Maternal characteristics  
 
Ethnicity 
Caucasian 
African/Afro-Caribbean 
Indian/Pakistani/Bangladeshi 
Middle Eastern 
Other 
 
Age (years) 
Maternal BMI  
Parity  
 
Smoking during Pregnancy 
Yes 
No 
Not reported 
 
Alcohol consumption  
None 
1-5 units / week 
Not reported 
  
Obstetric complications of Pregnancy 
 
Preeclampsia/PIH 
Gestational diabetes 
 
 
 
 
207 (94.5%) 
 2 (1%) 
6 (2.7%) 
1 (0.5%) 
3 (1.3%) 
 
30 (5.5) / 17 – 43 
27 (6.06) / 17 – 49  
1 (1.02) / 0 – 6 
 
 
52 (24%) 
153 (70%)  
14 (6%) 
 
 
140 (64%) 
69 (32%) 
10 (4%) 
 
 
 
22 (7%) 
16 (10%) 
 
Table 3.5: Characteristics of Wales cohort participants (N=219). Mean (SD)/Range or Number (%) is shown.  
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Table 3.6: Comparison of birth outcomes between AGA and SGA participants. 
Mean (SD)/Range or Number (%) is shown. Differences were analysed using an 
independent samples T test or Chi – square test where appropriate.  
 
 
 
3.3.2.2 Prenatal growth restriction and PHLDA2 expression 
Prenatal growth information was available for 136 AGA or SGA participants. 
Placental PHLDA2 expression was significantly increased by 60% in 
participants where concern over fetal growth had been documented 
prenatally, including static growth, SGA centiles and/or low fundal height 
(Figure 3.6). However, there was no significant correlation between placental 
PHLDA2 expression and week of first documented concern over fetal growth 
(r = 0.06, p = 0.67, n = 45).  
 Placental PHLDA2 expression was also significantly increased in 
those participants where infants measured SGA by abdominal and head 
circumference on ultrasound scan (< 10th centile), Figure 3.6. However, there 
 AGA 
Participants  
(N = 91) 
SGA participants  
(N = 67) 
P Value 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Custom birth weight centile 
Head circumference (cm) 
Gestational age (weeks) 
Placental weight (g) 
 
Gender 
Male 
Female 
Apgar score (1 min) 
Apgar score (5 min) 
Arterial cord blood pH 
 
NICU admission 
No 
Yes 
Fetal distress during delivery 
No 
Yes 
 
 
7 (8%) 
78 (86%) 
4 (4%) 
2 (2%) 
3480 (277)/ 
2830 - 4190 
53 (22) / 10 - 89 
35 (1) / 32 - 39 
39 (1) / 37 - 42 
703 (124) / 309 
- 905 
 
44 (48%) 
47 (52%) 
9 (1) / 4 - 10 
10 (0.6) / 7 – 10 
7.3 (0.07) / 7.1 
– 7.4 
 
91 (100%) 
0 (0%) 
 
77 (85%) 
4 (4%) 
 
 
28 (42%) 
22 (33%) 
8 (12%) 
9 (13%) 
2448 (446)/ 730 - 
3250 
7 (7)/ 0 - 10 
33 (2) / 28 - 35 
38 (2) / 29 - 41 
500 (110) / 226 - 
832 
 
32 (48%) 
35 (52%) 
8 (2) / 0 - 10 
9 (1)/ 3 - 10 
7.3 (0.08) / 7.1 – 
7.5 
 
63 (94%) 
4 (6%) 
 
49 (73%) 
4 (8%) 
 
 
 
 
 
P < 0.001*** 
 
P < 0.001*** 
P < 0.001*** 
P < 0.001*** 
P < 0.001*** 
 
P < 0.001*** 
 
 
P = 0.80 
P = 0.07 
P = 0.16 
P = 0.36 
 
 
P = 0.01** 
 
 
 
P = 0.32 
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was no significant correlation between placental PHLDA2 expression and 
week of first reported SGA abdominal (r = - 0.08, p = 0.60, n = 48) or head (r 
= - 0.16, p = 0.28, n = 48) centile.  
 
Figure 3.6: Placental PHLDA2 expression and prenatal growth restriction. 
Placental PHLDA2 expression was significantly increased in participants with 
prenatal growth concerns (A) and in infants measuring SGA by abdominal and head 
circumference on scan (B). Gene expression was not significantly altered in 
participants with low or high AFI (C). ** p < 0.01. AFI = amniotic fluid index. Error 
bars represent SEM.  
 
 
 Another prenatal indicator of fetal growth restriction is a reduction in 
amniotic fluid. Placental PHLDA2 expression was increased in participants 
with a low AFI (amniotic fluid index) during pregnancy, however this 
difference was not statistically significant (Figure 3.6). Finally, ultrasound 
assessment of umbilical artery blood flow can also used to ascertain the 
presence and severity of growth restriction. Only one participant exhibited 
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Doppler abnormalities (reversed end diastolic flow) and therefore differences 
in placental target gene expression could not be analysed.  
 
3.3.2.3. Fetal growth restriction and PHLDA2 expression 
The Wales Cohort included seven participants with infants delivered preterm. 
These participants had a prenatal IUGR diagnosis and indications for early 
delivery included IUGR, placental abruption, reduced fetal movements and 
fetal distress. Given that there was no significant correlation between 
placental PHLDA2 expression and gestational age (r = - 0.11, p = 0.16, n = 
181) and no significant difference in expression between term and preterm 
placentas (p = 0.31, n = 181), participants with preterm deliveries were 
included in the overall cohort analysis. Any significant associations with 
target gene expression were confirmed with and without the addition of these 
participants.  
 With the exclusion of any participants with complications of pregnancy 
(PE or GDM, see Chapter 4), there was a significant inverse correlation 
between placental PHLDA2 expression and birth weight (r = - 0.25, p = 
0.001, n = 181) and custom birth weight centiles (r = - 0.28, p <0.001, n = 
181), Figure 3.7. Linear regression analysis indicated that placental PHLDA2 
expression accounted for 6% of variance in birth weight (F = 12.3, p = 0.001, 
n = 181) and 8% of variance in custom birth weight centiles (F = 13.96, p 
<0.001, n = 181). For every 1 CT increase in PHLDA2 expression 
(corresponding to a doubling of gene expression) there was a 180g reduction 
in birth weight and a 9 centile reduction in custom birth weight centiles. 
 Placental PHLDA2 expression was on average 2 fold higher in 
participants with SGA compared with AGA infants (Figure 3.7). 18 SGA 
placentas demonstrated ≥ 2 fold higher expression compared with controls, 
suggesting aberrant PHLDA2 expression in 27% of the SGA participants. 
Interestingly, PHLDA2 expression was also 2 fold higher than the AGA mean 
for 7 AGA placentas; this included one participant with a normal birth weight 
but a custom birth weight centile of 10.5. There was no obvious 
distinguishing feature of the other high PHLDA2 expressing AGA cases.
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Figure 3.7: Placental PHLDA2 expression and fetal growth. PHLDA2 expression is shown in relation to birth weight (A), SGA (B) and IUGR 
(C) pregnancies, head circumference (D), asymmetric and symmetric growth restriction (E) and placental weight (F). Error bars represent SEM. 
* P <0.05, ** p < 0.01, *** p < 0.001.  
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PHLDA2 Expression was also significantly 62% higher in placentas of women 
delivering IUGR term infants (Figure 3.7) although there was no significant 
correlation between placental PHLDA2 expression and week of IUGR 
diagnosis (r = - 0.08, p = 0.68,n = 29). In contrast, PHLDA2 expression was 
not significantly altered in placentas of LBW infants (p = 52, n = 181), possibly 
as a result of the few number of participants (N=32) delivering LBW infants.  
 Head circumference at delivery was significantly inversely associated 
with placental PHLDA2 expression (r = - 0.32, p < 0.001, n = 125), Figure 3.7. 
Linear regression analysis indicated that placental PHLDA2 expression 
accounted for 1% of variance in head circumference (F = 13.83, p < 0.001, n 
= 125) with every 1 CT increase in PHLDA2 expression associated with a 
0.6cm reduction in head circumference. 
 There was also a significant inverse correlation between PHLDA2 
expression and placental weight (r = - 0.15, p = 0.04, n = 180). Linear 
regression analysis indicated that placental PHLDA2 expression accounted 
for 2% of variance in placental weight (F = 4.34, p = 0.04, n = 180) with every 
1 CT increase in PHLDA2 expression associated with a 25g reduction in 
placental weight.  
 In order to determine whether there was any difference in placental 
gene expression between symmetric and asymmetrically growth restricted 
infants, prenatal ultrasound head (HC) and abdominal (AC) circumferences 
were analysed with an SGA abdominal circumference but not head 
circumference being indicative of brain sparing. A one-way ANOVA revealed 
a significant difference in PHLDA2 expression between groups (F(2,142) = 
6.73, p = 0.002) however expression was only significantly increased in SGA 
(symmetric) and not SGA (asymmetric) placentas compared with controls, 
Figure 3.7.    
 Finally, previous obstetric history was available for 46 of the 67 
participants delivering SGA infants with 17% of participants having previously 
delivered a LBW infant. There was no significant difference in placental 
PHLDA2 expression between these participants and those previously 
delivering a normal birth weight infant (p = 0.50, n = 46).  
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3.3.2.4.  Poor perinatal outcomes and PHLDA2 expression 
In the overall cohort, 7 infants were admitted to NICU at delivery for 
respiratory distress. While placental PHLDA2 expression was almost three 
fold higher in these placentas, there was a large variation in the NICU 
expression group and the difference was found not to be statistically 
significant (Figure 3.8). Similarly, PHLDA2 expression was not significantly 
altered in infants exhibiting fetal distress during delivery (Figure 3.8).  
There was no significant correlation between placental PHLDA2 
expression and arterial cord blood pH (r = 0.05, p = 0.62, n = 103). There was 
also no significant association between placental PHLDA2 expression and 
apgar scores at 1 minute (r  = - 0.06, p = 0.44, n = 163) or at 5 minutes (r = - 
0.03, p = 0.74, n = 163).  
Figure 3.8: Placental PHLDA2 expression and infant outcomes. Placental 
PHLDA2 expression was not significantly altered in infants admitted to NICU 
following delivery (A) or those exhibiting fetal distress during delivery (B). Error bars 
represent SEM 
  
3.3.2.5. Fetal growth restriction and CDKN1C 
When analysed as a group, without accounting for mode of delivery, placental 
CDKN1C expression was significantly inversely correlated with birth weight (r 
= - 0.20, p = 0.01, n = 181) and custom birth weight centiles (r = - 0.25, p = 
0.001, n = 181) but not placental weight (r = - 0.11, p = 0.16, n = 180), Figure 
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3.9. However, when the results were split according to labour status, there 
was no significant correlation between CDKN1C and birth weight in either 
labouring or non-labouring groups independently. Given the previous finding 
of increased CDKN1C expression in women delivering by EMCS or SVD 
(labouring placentas) (section 3.3.1.5), the correlation observed in the overall 
cohort was likely a result of differences in mode of delivery. Similarly, 
CDKN1C expression was not significantly altered in SGA placentas when 
results were split by labour status (Figure 3.9).  
 
Figure 3.9: Placental CDKN1C expression and fetal growth. Although placental 
CDKN1C expression was significantly inversely correlated with birth weight (A), this 
association was not significant when results were analysed according to labour 
status (B). ** p < 0.01, *** p < 0.001. Error bars represent SEM.  
 
Finally, placental CDKN1C expression was not significantly altered in 
placentas of infants admitted to NICU at delivery (p = 0.43, n = 219) and there 
was no significant correlation between CDKN1C expression and apgar scores 
or arterial cord blood pH (results not shown). 	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Figure 3.10: Fetal growth and placental PEG3 and PEG10 expression. There was no significant correlation between PEG3 or 
PEG10 and birth weight (A and C) although both genes showed a trend for a positive correlation with placental weight (B and D). 
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3.3.2.6. Fetal growth restriction and PEG3 and PEG10 expression 
Placental PEG3 (r = - 0.09, p = 0.90, n = 174) and PEG10 expression (r = 
0.02, p = 0.82, n = 174) was not significantly associated with birth weight 
(Figure 3.10). Similarly, placental PEG3 (r = - 0.01, p = 0.99, n = 174) and 
PEG10 expression (r = 0.01, p = 0.88, n = 174) was not significantly 
associated with custom birth weight centiles. Placental PEG3 (p = 0.43, n = 
158) and PEG10 (p = 0.56, n = 158) expression was also not significantly 
altered in SGA placentas. Finally, there was no significant correlation 
between placental weight and PEG3 (r = 0.13, p = 0.09, n = 174) and PEG10 
(r = 0.14, p = 0.07, n = 174) expression, Figure 3.10.  
Placental PEG3 (p = 0.86, n = 219) and PEG10 (p = 0.85, n = 219) 
expression was not significantly altered in placentas of infants admitted to 
NICU at delivery and there was no significant correlation between expression 
and apgar scores (at 1 minute and 5 minutes) or arterial cord blood pH 
(results not shown).  
 
3.3.2.7. Fetal growth restriction and hPL gene expression 
Placental hPL expression was significantly decreased in participants with 
antenatal growth concerns (p = 0.02, n = 195), although there was no 
significant correlation with week of first documented concern over fetal 
growth (r = - 0.12, p = 0.41, n = 45). Expression was also significantly 
decreased in placentas of infants with a prenatal SGA abdominal and head 
circumference (results not shown).  
 Placental hPL expression was significantly positively correlated with 
birth weight (r = 0.17, p = 0.03, n = 174) and custom birth weight centiles (r = 
0.17, p = 0.03, n = 174). There was also a significant positive correlation 
between hPL expression and placental weight (r = 0.16, p = 0.03, n = 180). 
However, hPL expression was not significantly altered in SGA (Figure 3.11), 
LBW (p = 0.39, n = 164) or IUGR placentas (p = 0.24, n = 158).  
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Placental hPL expression was not significantly altered (p = 0.38, n = 164) in 
placentas of term infants admitted to NICU at delivery (Figure 3.11). There 
was also no significant correlation between hPL expression and apgar scores 
at 1 minute (r = 0.08, p = 0.34, n = 163) or at 5 minutes (r = 0.10, p = 0.23, n 
= 163). Placental hPL expression was however significantly correlated with 
arterial cord blood pH (r = 0.20, p = 0.04, n = 103), Figure 3.11. 
 
Figure 3.11: Placental hPL expression and fetal growth. Placental hPL 
expression was significantly positively associated with birth weight (A) but was not 
significantly altered in SGA placentas (B). There was no significant difference in hPL 
expression in placentas of infants admitted to NICU (C) although expression was 
positively associated with arterial cord blood pH (D). Error bars represent SEM. * P 
<0.05.  
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3.3.2.8. Fetal growth restriction and PGH expression 
While initial analysis suggested placental PGH expression was significantly 
positively correlated with birth weight (r = 0.16, p = 0.03, n = 181), this 
association was not significant in a partial correlation controlling for 
gestational age (partial r = 0.06, p = 0.40, n = 181)(Figure 3.13). This likely 
reflects the significant association between PGH expression and gestational 
age observed in section 3.2.3. Similarly, there was no significant difference in 
PGH expression between AGA and SGA (term only) placentas, Figure 3.12.  
Figure 3.12: Placental PGH expression and fetal growth. Placental PGH 
expression was not significantly correlated with birth weight in a partial correlation 
controlling for gestational age (A) and was not significantly altered in SGA placentas 
(B). PGH expression was significantly decreased in placentas of infants admitted to 
NICU (C) and expression was positively associated with arterial cord blood pH (D). * 
P <0.05. Error bars represent SEM.  
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Placental PGH expression was significantly decreased (p = 0.04, n = 164) in 
placentas of term infants admitted to NICU (Figure 3.12). PGH expression 
was not significantly correlated with apgar scores at 1 minute (r = 0.02, p = 
0.83, n = 163) or at 5 minutes (r = 0.04, p = 0.60, n = 163). Placental PGH 
expression was however significantly correlated with arterial cord blood pH (r 
= 0.24, p = 0.02, n = 103), Figure 3.12. Results remained significant in a 
partial correlation controlling for gestational age (partial r = 0.24, p = 0.02, n = 
103).  
 
Table 3.7: Relationship between imprinted gene expression and placental hPL 
and PGH expression. Results were analysed using Pearson correlation test. ** p < 
0.01 *** p < 0.001  
 
 
 
 
 
 
 
 
3.3.2.9. Placental hormone and imprinted gene expression 
In the overall cohort, there was a significant inverse association between 
placental PHLDA2 and hPL expression (r = - 0.27, p < 0.001, n = 219), 
Figure 3.13. There was also a significant inverse correlation between 
placental CDKN1C expression and hPL expression (Table 3.7), which 
remained significant after controlling for mode of delivery (r = - 0.20, p = 
0.002, n = 216).  
 
 Placental hPL 
expression 
Placental PGH 
expression 
Placental PHLDA2 
expression 
r = - 0.27*** 
p < 0.001 
n = 219 
r = 0.02 
p = 0.84 
n = 219 
Placental CDKN1C 
expression  
r = - 0.20** 
p = 0.002 
n = 216 
r = 0.04 
p = 0.58 
n =219 
Placental PEG3 
expression 
r = - 0.01 
p = 0.93 
n = 219 
r = - 0.09 
p = 0.25 
n = 219 
Placental PEG10 
expression 
r = 0.04 
p = 0.62 
n = 219 
r = - 0.07 
p = 0.38 
n = 219 
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Figure 3.13: Placental PHLDA2 and hPL expression. Placental gene expression 
was significantly correlated as determined by Pearson correlation analysis. *** p < 
0.001  
 
Table 3.8: Summary of target gene expression changes in SGA placentas. Fold 
gene expression is shown relative to AGA participants. Results highlighted in bold 
were statistically significant using an independent samples T test. ** p ≤ 0.01. 
 
3.3.2.10. Wales Cohort Summary  
A summary of the changes in target gene expression in SGA compared with 
AGA placentas is shown in Table 3.8. Only placental PHLDA2 expression 
Gene AGA Participants  
(N = 91) 
SGA participants  
(N = 67) 
P Value 
PHLDA2 1.00 2.01 P = 0.004** 
CDKN1C 1.00 1.25 P = 0.88 
PEG3 1.00 1.06 P = 0.43 
PEG10 1.00 1.28 P = 0.56 
hPL 1.00 0.94 P = 0.36 
PGH 1.00 1.01 P = 0.89 
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was significantly increased in SGA participants. The increase observed in 
placental PHLDA2 expression remained significant after controlling for 
multiple comparisons using a Bonferroni correction (p = 0.01).  
 
3.3.3. Fetal growth restriction: Manchester Cohort 
In order to replicate the finding of a significant inverse correlation between 
placental PHLDA2 expression and birth weight demonstrated in the Wales 
Cohort, target gene expression was analysed in a second independent 
cohort.  
 
3.3.3.1. Participant demographics 
The characteristics of the Manchester cohort (N=110) are shown in Table 
3.9. All participants (N=110) experienced reduced fetal movements during 
pregnancy. The cohort included 21 participants delivering infants that were 
SGA by custom growth centiles of which ten infants were also born LBW.  
 
3.3.3.2. Prenatal fetal growth restriction and placental PHLDA2 
There was no significant correlation between placental PHLDA2 expression 
and any prenatal measure of fetal growth (Table 3.10), although a trend for 
an inverse correlation with head circumference on scan was shown (r(s) = - 
0.16, p = 0.09, n = 110). 14 participants were identified during prenatal 
scanning to be carrying a growth restricted fetus (defined as estimated fetal 
weight <10th centile). Although placental PHLDA2 expression was increased 
in pregnancies identified as growth restricted prenatally, this did not reach 
statistical significance (p = 0.16, n = 110), Figure 3.14.  
Another prenatal indicator of fetal growth restriction is a reduction in 
amniotic fluid. In this cohort there was no significant correlation between 
placental PHLDA2 expression and amniotic fluid volume (r (s) = - 0.02, p = 
0.81, n = 105) and no significant difference in gene expression between 
participants with a low AFI during pregnancy and controls (p = 0.90, n = 108). 
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Table 3.9: Characteristics of Manchester Cohort Participants (N=110). Mean (SD)/Range or Number (%) are shown.	  
 Mean (SD)/Range or 
Number (%) 
 Mean (SD)/Range or 
Number (%) 
Birth Outcomes 
 
Fetal Sex 
Male 
Female 
 
Gestational age (weeks) 
 
Birth weight (g) 
Custom birth weight centile  
Placental Weight (g) 
Apgar Scores (1 min) 
Apgar Scores (5 min) 
 
Birth weight Classification 
AGA 
SGA 
LGA 
 
NICU Admission 
Yes 
No 
 
Mode of Delivery 
SVD 
ELCS 
EMCS 
Instrumental 
 
 
 
55 (50%) 
55 (50%) 
 
39 (1.90) / 30 – 42 
 
3304 (595) / 850 - 4680 
40 (29) / 0 - 100 
587 (127) / 353 – 854 
9 (1.44) / 0 - 10  
10 (1.01) / 0 – 10  
 
 
81 (74%) 
21 (19%) 
8 (7%) 
 
 
6 (5.5%) 
104 (94.5%) 
 
 
60 (54%) 
10 (9%) 
14 (13%) 
26 (24%) 
Maternal characteristics  
 
Ethnicity 
Caucasian 
African/Afro-Caribbean 
Indian/Pakistani/Bangladeshi 
Middle Eastern 
Other 
 
Age (years) 
Maternal BMI  
Parity  
 
Smoking during Pregnancy 
Yes 
No 
 
Alcohol consumption  
None 
1-5 units / week 
  
Obstetric complications of Pregnancy 
 
Preeclampsia/PIH 
PV bleed 
Oligohydramnios 
Prenatal Suboptimal growth 
Reduced Fetal Movements only 
 
 
 
72 (65%) 
 10 (9%) 
22 (20%) 
3 (3%) 
3 (3%) 
 
29 (5.81) / 17 – 46 
26.01 (5.34) / 17 – 46  
1 (1.22) / 0 – 7  
 
 
17 (15.5%) 
93 (84.5%)  
 
 
109 (99%) 
1 (1%) 
 
 
 
5 (4.5%) 
1 (1%) 
1 (1%) 
3 (2.5%) 
100 (91%) 
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Ultrasound assessment of the placenta and umbilical artery blood flow are 
also used to ascertain the presence and severity of growth restriction. There 
was no significant correlation between placental PHLDA2 expression and 
mean placental diameter on scan (r(s) = - 0.02, p = 0.84, n = 104) or umbilical 
artery pulsatility index (r (s) = - 0.08, p = 0.40, n = 106).  
 
Table 3.10: Relationship between placental PHLDA2 expression and prenatal 
measures of fetal growth. No significant correlation was observed, as determined 
using Spearman rank order correlation test. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Placental PHLDA2 expression and prenatal growth restriction. 
Prenatal growth restriction was determined by a custom growth centile <10th during 
prenatal scans. Differences in PHLDA2 expression were not statistically significant 
using a Mann Whitney U test. Error bars represent SEM	  
 Placental PHLDA2 expression  
Estimated fetal weight (g) r(s) = - 0.03 
p = 0.73 
n = 110 
Estimated growth centile  r(s) = - 0.07 
p = 0.47 
n = 110 
Abdominal circumference (mm) r(s) = - 0.07 
p = 0.46 
n = 110 
Head circumference (mm) r(s) = - 0.16 
p = 0.09 
n = 110 
Femur length (mm) r(s) = 0.01 
p = 0.95 
n = 110 
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Figure 3.15: Placental PHLDA2 expression and fetal growth. PHLDA2 expression is shown in relation to birth weight (A) and custom birth 
weight centiles (B) and in SGA (C) and LBW (D) pregnancies. SGA = small for gestational age, LBW = Low birth weight. Error bars represent 
SEM. * P <0.05.  
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3.3.3.3. Fetal growth restriction and placental PHLDA2 
In this cohort, 6 participants delivered an infant preterm and low birth weight. 
As there was no significant correlation between placental PHLDA2 
expression and gestational age (r (s) = 0.01, p = 0.89, n = 110) and no 
significant difference in gene expression between preterm and term 
pregnancies (p = 0.25, n = 110), these participants were included in the 
overall cohort for analysis of PHLDA2 expression and measures of fetal 
growth.  
Placental PHLDA2 expression was not significantly correlated with birth 
weight (r(s) = - 0.14, p = 0.15, n = 110) in the overall cohort, Figure 3.15. 
However, there was a statistically significant inverse correlation between 
placental PHLDA2 expression and custom birth weight centiles (r (s) = - 0.20, 
p = 0.04, n = 110), Figure 3.15. Interestingly, both birth weight (r(s) = - 0.21, 
p = 0.03, n = 104) and custom birth weight centiles (r(s) = - 0.24, p = 0.02, n 
= 104) were significantly inversely associated with PHLDA2 expression when 
only term placentas were analysed. There was also a significant inverse 
correlation between placental PHLDA2 expression and placental weight (r (s) 
= -0.4, p = 0.03, n = 31).   
 
  
 
 
 
 
Figure 3.16: Placental PHLDA2 expression and asymmetric versus symmetric 
fetal growth restriction. Fold PHLDA2 expression is shown relative to AGA 
expression. Asymmetric or symmetric growth restriction was determined using the 
HC:AC ratio. AGA = average for gestational age, SGA = small for gestational age. 
Error bars represent SEM. 
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There was a trend for increased placental PHLDA2 expression in 
placentas of SGA compared with control (either AGA or LGA) pregnancies (p 
= 0.06, n = 110), Figure 3.15, and in placentas of low birth weight compared 
with normal birth weight infants (p = 0.06, n = 110) Figure 3.15.   
In order to determine whether there was any difference in placental 
gene expression between symmetric and asymmetrically growth restricted 
infants, prenatal ultrasound head (HC) and abdominal (AC) circumferences 
were analysed with an elevated HC:AC ratio being indicative of asymmetric 
growth restriction. There was no significant correlation between placental 
PHLDA2 expression and HC:AC ratio (r (s) = 0.08, p = 0.47, n = 98) and no 
significant difference in gene expression between infants born AGA, SGA 
(symmetric) or SGA (asymmetric), Figure 3.16.  
 
3.3.3.4. Poor perinatal outcomes and PHLDA2 expression 
There was a significant 2.27 fold increase in placental PHLDA2 expression in 
participants with a poor perinatal outcome (including preterm labour, fetal 
growth restriction, NICU admission), as shown in Figure 3.17.  
  
 
 
 
 
 
Figure 3.17: Placental PHLDA2 expression and poor perinatal outcome. Poor 
Perinatal outcome included preterm birth (< 37 weeks), SGA (birth weight centile < 
10th) or term NICU admission. PHLDA2 expression was significantly reduced using 
a Mann Whitney U test.  * p≤ 0.05. Error bars represent SEM.  
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The relationship between placental PHLDA2 expression and birth 
outcomes in the overall cohort is shown in Table 3.11. Results did not differ 
when SGA cases were analysed independently. Finally, placental PHLDA2 
expression did not differ significantly in infants admitted to NICU at delivery 
(Figure 3.18).  
 
Table 3.11: Relationship between placental PHLDA2 expression and birth 
outcomes. Placental PHLDA2 expression was not significantly correlated with any 
birth outcome as determined using Spearman rank order correlation test.  
 
 
 
 
 
 
 
 
 
Figure 3.18: Placental PHLDA2 expression and NICU admission at birth. 
PHLDA2 expression was not significantly altered as determined by a Mann Whitney 
U test.  Error bars represent SEM.  
 
 
 Placental PHLDA2 expression  
Arterial Cord Blood pH r(s) = - 0.07 
p = 0.57 
n = 78 
Venous Cord Blood pH r(s) = - 0.05 
p = 0.69 
n = 85 
 Apgar Score at 1min  r(s) = 0.14 
p = 0.14 
n = 106 
Apgar Score at 5min r(s) = 0.05 
p = 0.61 
n = 105 
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3.3.3.5. Fetal growth and CDKN1C expression 
There was no significant correlation placental CDKN1C expression and any 
prenatal measure of fetal growth (results not shown). CDKN1C expression 
was also not significantly altered in placentas of participants identified during 
prenatal scanning to be carrying a growth-restricted fetus, see Figure 3.19. 
 Birth weight was not significantly correlated with placental CDKN1C 
expression (r = - 0.07, p = 0.48, n = 110) and expression did not differ 
significantly between SGA and AGA pregnancies, see Figure 3.19. Placental 
CDKN1C expression was also not significantly correlated with custom birth 
weight centiles (r = - 0.10, p = 0.30, n = 110) or placental weight (r = - 0.07, p 
= 0.72, n = 31).  
Figure 3.19: Placental CDKN1C expression and fetal growth. CDKN1C 
expression was not significantly altered in participants with prenatal growth 
restriction (A) and there was no correlation between expression and birth weight (B). 
CDKN1C expression was not significantly altered in SGA infants (C) or those with a 
poor perinatal outcome (D). Error bars represent SEM.  
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Finally, placental CDKN1C expression was not significantly altered in 
participants with a poor perinatal outcome, as shown in Figure 3.19. There 
was also no significant correlation between CDKN1C expression and any 
other birth outcome measure and expression was not significantly altered in 
placentas of infants admitted to NICU at delivery (p = 0.97, n = 110).  
 
3.3.3.6. Fetal growth and PEG3 expression 
Placental PEG3 expression was not significantly correlated with any prenatal 
measure of fetal growth (results not shown) and expression was not 
significantly altered in placentas of participants identified during prenatal 
scanning to be carrying a growth-restricted fetus (Figure 3.20). 
There was no significant correlation between placental PEG3 
expression and birth weight (r = 0.05, p = 0.59, n = 110), custom birth weight 
centile (r = 0.08, p = 0.44, n = 110) or placental weight (r = - 0.14, p = 0.46, n 
= 31) and expression did not differ significantly between SGA and AGA 
pregnancies (Figure 3.20).  
Finally, placental PEG3 expression was not significantly altered in 
participants with a poor perinatal outcome, as shown in Figure 3.20. 
Similarly, PEG3 expression was not significantly correlated with any birth 
outcome measure and was not significantly altered in placentas of infants 
admitted to NICU at delivery (p = 0.58, n = 110).  
 
3.3.3.7. Fetal growth and PEG10 expression 
There was a significant positive correlation between placental PEG10 
expression and prenatal abdominal circumference (r = 0.26, p = 0.01, n = 
110) and femur length (r = 0.21, p = 0.03, n = 110) as well as a trend for a 
positive correlation with estimated fetal weight on ultrasound scan (r = 0.17, p 
= 0.07, n = 110). However, placental PEG10 expression was not significantly 
altered in participants with a prenatally identified growth-restricted fetus, see 
Figure 3.21. 
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Figure 3.20: Placental PEG3 expression and fetal growth. PEG3 expression was 
not significantly altered in participants with prenatal growth restriction (A) and there 
was no correlation between expression and birth weight (B). PEG3 expression was 
not significantly altered in SGA infants (C) or those with a poor perinatal outcome 
(D). Error bars represent SEM.  
 
 Placental PEG10 expression was also significantly positively 
correlated with birth weight (r = 0.25, p = 0.01, n = 110) but not with custom 
birth weight centile (r = 0.15, p = 0.12, n = 110), Figure 3.21. PEG10 
expression was significantly decreased in placentas of SGA compared with 
AGA pregnancies (p = 0.046, n = 110) and in LBW compared with normal 
birth weight pregnancies (p = 0.03, n = 110), Figure 3.21. Analysis of the HC: 
AC ratio was used to distinguish between symmetric and asymmetric growth 
restriction. Interestingly, there was no significant difference in PEG10 
expression between AGA and SGA (symmetric) placentas (p = 0.26) 
however a trend was seen for a 60% reduction in expression in SGA 
(asymmetric) placentas (p = 0.09).  
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Figure 3.21: Placental PEG10 expression and fetal growth. PEG10 expression 
was not significantly altered in participants with prenatal growth restriction (A) 
although there was a significant positive correlation between expression and birth 
weight (B). PEG10 expression was significantly reduced in SGA infants (C) and in 
those with a poor perinatal outcome (D). Error bars represent SEM. * P <0.05, ** p < 
0.01.   
 
Placental PEG10 expression was significantly decreased by 32% in 
infants with a poor perinatal outcome (Figure 3.21) and expression was 
significantly positively correlated with Apgar scores at 1 minute (r = 0.28, p = 
0.004, n = 106) and at 5 minutes (r = 0.30, p = 0.002, n = 105). Finally, 
PEG10 expression was not significantly altered in infants admitted to NICU at 
delivery (p = 0.22, n = 110). 
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3.3.3.8. Fetal growth restriction and placental hormone gene expression 
In terms of prenatal indicators of fetal growth restriction, there was a 
significant positive correlation between placental hPL expression and femur 
length (r = 0.23, p = 0.01, n = 109). There was also a significant positive 
correlation between placental PGH expression and head circumference (r = 
0.25, p = 0.01, n = 98). Although placental hPL (p = 0.21, n = 110) and PGH 
expression (p = 0.21, n = 110) were decreased in pregnancies identified as 
growth restricted prenatally, these differences were not statistically 
significant. 
 
Figure 3.22: Placental hPL and PGH expression and fetal growth. There was a 
trend for a postive correlation between custom birth weight centiles and hPL (A) and 
PGH  (B) expression. Gene expression was not significantly altered in SGA infants 
(C) or in those with a poor perinatal outcome (D). PPO = poor perinatal outcome. 
Error bars represent SEM.  
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There was a trend for a positive correlation between custom birth 
weight centile and placental hPL (r = 0.17, p = 0.08, n = 110), and PGH (r = 
0.18, p = 0.06, n = 110) expression as shown in Figure 3.22. However, there 
was no significant correlation with birth weight or placental weight (results not 
shown). Finally, placental hPL and PGH expression was not significantly 
altered in placentas of SGA pregnancies (Figure 3.22).  
In terms of birth outcomes, there was also no significant difference in 
placental hPL and PGH expression in participants with a poor perinatal 
outcome (Figure 3.22). Finally, there was no significant correlation between 
placental hPL or PGH expression and any other birth outcome examined 
(results not shown).  
 
3.3.3.9. Imprinted gene and placental hormones 
As can be seen in Table 3.12, there was no significant correlation between 
any of the imprinted genes examined and placental hPL and PGH 
expression. Only a trend was observed for a positive correlation between 
placental PEG3 and hPL expression. 
 
Table 3.12: Relationship between imprinted gene expression and placental 
hPL and PGH expression. No significant correlation was found using Spearman 
rank order or Pearson correlation test. 
 
 
 
 
 
 
 
 
 
 Placental hPL 
expression 
Placental PGH 
expression 
Placental PHLDA2 
expression 
r(s) = 0.09 
p = 0.33 
n = 110 
r(s) = - 0.14 
p = 0.16 
n = 110 
Placental CDKN1C 
expression  
r(p) = - 0.10 
p = 0.30 
n = 110 
r(p) = - 0.10 
p = 0.29 
n = 110 
Placental PEG3 
expression 
r(p) = 0.17 
p = 0.07 
n = 110 
r(p) = 0.15 
p = 0.12 
n = 110 
Placental PEG10 
expression 
r(p) = 0.13 
p = 0.17 
n = 110 
r(p) = 0.12 
p = 0.21 
n = 110 
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Table 3.13: Summary of target gene expression changes in SGA placentas. 
Fold gene expression is shown relative to AGA participants. Results highlighted in 
bold were statistically significant using an independent samples T test. * p ≤ 0.05. 
 
3.3.3.10. Manchester cohort summary  
A summary of the changes in target gene expression in SGA compared with 
AGA placentas is shown in Table 3.13. Only a trend for increased PHLDA2 
expression was observed in this cohort, although placental PHLDA2 
expression was significantly inversely correlated with birth weight and custom 
birth weight centiles. In addition, placental PEG10 expression was 
significantly reduced in SGA placentas. 
 
3.3.4. Fetal overgrowth   
Given the well established role of imprinted genes in fetal growth and the 
associations observed in the Wales and Manchester Cohorts between birth 
weight and expression of a number of the target genes examined (section 
3.3), it is possible that imprinted genes and placental hormones also play a 
role in fetal overgrowth resulting in delivery of an LGA (large for gestational 
age) or macrosomic (≥4,000g) infant.  
 
Gene AGA Participants  
(N = 81) 
SGA participants  
(N = 21) 
P Value 
PHLDA2 1.00 2.33 P = 0.09 
CDKN1C 1.00 1.02 P = 0.86 
PEG3 1.00 0.98 P = 0.84 
PEG10 1.00 0.72 P = 0.046* 
hPL 1.00 0.87 P = 0.29 
PGH 1.00 0.89 P = 0.42 
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Table 3.14: Comparison of birth outcomes between AGA and LGA 
participants. Mean (SD)/Range or Number (%) is shown. Differences were 
analysed using an independent samples T test or Chi – square test where 
appropriate. AGA = average for gestational age, LGA = large for gestational age.  * 
P <0.05, *** p < 0.001.  
 
3.3.4.1. Fetal overgrowth: Wales cohort 
The Wales Cohort included 23 participants delivering LGA infants of which 
19 were also macrosomic (≥ 4,000g). A comparison of maternal 
characteristics and birth outcomes between AGA and LGA groups is shown 
in Table 3.14. Only birth weight, placental weight and head circumference 
were significantly different between AGA and LGA participants.  
There was no significant difference in placental PHLDA2, CDKN1C or 
PEG3 expression between LGA and SGA placentas, as shown in Figure 
3.23.  
 AGA 
Participants  
(N = 91) 
LGA 
participants  
(N = 67) 
P Value 
Maternal characteristic 
Maternal BMI (kg/m2) 
Maternal age (years) 
 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Head circumference (cm) 
Gestational age (weeks) 
Placental weight (g) 
Gender 
Male 
Female 
Apgar score (1 min) 
Apgar score (5 min) 
Arterial cord blood pH 
 
27 (6) / 17 - 42 
31 (5) / 19 - 41 
 
 
 
7 (8%) 
78 (86%) 
4 (4%) 
2 (2%) 
3480 (277)/ 
2830 - 4190 
35 (1) / 32 - 39 
39 (1) / 37 - 42 
703 (124) / 309 
- 905 
44 (48%) 
47 (52%) 
9 (1) / 4 - 10 
10 (0.6) / 7 – 10 
7.3 (0.07) / 7.1 
– 7.4 
 
 
29 (6) / 22 - 43 
32 (7) / 20 - 44 
 
 
 
2 (9%) 
17 (74%) 
2 (9%) 
2 (9%) 
4206 (314) / 
3820 - 4990 
36 (1) / 33 - 38 
39 (1) / 38 - 42 
850 (113) / 637 
- 1064 
13 (57%) 
10 (43%) 
9 (1) / 5 - 10 
10 (1) / 7 - 10 
7.3 (0.05) / 7.2 
– 7.3 
 
P = 0.07 
P = 0.75 
 
 
 
 
 
 
P = 0.17 
 
P < 0.001*** 
P = 0.03* 
P = 0.21  
 
P < 0.001*** 
 
P = 0.48 
P = 0.25 
P = 0.34 
 
P = 0.93 
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Figure 3.23: Imprinted gene expression and LGA. Placental PHLDA2, CDKN1C 
and PEG3 expression was not significantly altered in placentas of LGA infants as 
determined by an independent samples T test. AGA = average for gestational age, 
LGA = large for gestational age. Error bars represent SEM.  
Figure 3.24: PEG10 expression and fetal overgrowth. Placental PEG10 
expression was significantly increased in placentas of LGA (A) and macrosomic (B) 
infants as determined by an independent samples T test. AGA = average for 
gestational age, LGA = large for gestational age. * P <0.05, ** p < 0.01. Error bars 
represent SEM.   
 
In contrast, placental PEG10 expression was significantly increased 
by 34% in LGA placentas and by 23% in macrosomic placentas (Figure 
3.24). Placental PEG10 expression was also significantly increased in infants 
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measuring LGA prenatally by abdominal centiles (p = 0.02, n = 107) and 
head centiles (p = 0.04, n = 107). However, there was no significant 
correlation between PEG10 expression and head circumference at delivery (r 
= 0.08, p = 0.49, n = 82). Interestingly, placental PEG10 expression was not 
significantly altered in participants with a previous macrosomic delivery 
compared with those previously delivering normal birth weight infants (p = 
0.58, n = 144). In terms of placental hormone gene expression, there was no 
significant difference in placental hPL or PGH expression between LGA and 
SGA placentas, as shown in Figure 3.25.  
 
 
 
 
 
 
Figure 3.25: Fetal overgrowth and placental hormone gene expression. 
Placental hPL and PGH expression was not significantly altered in placentas of LGA 
infants as determined by an independent samples T test. AGA = average for 
gestational age, LGA = large for gestational age. Error bars represent SEM.  
 
3.3.4.2. Fetal overgrowth: Manchester Cohort 
The Manchester cohort included eight participants delivering an LGA infant. 
Only PHLDA2 expression was significantly decreased in placentas of LGA 
infants (Figure 3.26). Placental PHLDA2 expression was also decreased in 
placentas of macrosomic infants (p = 0.02, n = 90). No other imprinted gene 
examined showed significantly altered expression (Figure 3.26).  
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Figure 3.26: Target gene expression in LGA placentas. Only placental PHLDA2 
expression was significantly decreased in LGA placentas as determined by a Mann 
Whitney U test.  AGA = average for gestational age, LGA = large for gestational 
age.  
 
3.3.4.3. Fetal overgrowth summary 
A summary of the changes in target gene expression in LGA compared with 
AGA placentas is shown in Table 3.15. In the Wales Cohort, only PEG10 
expression was significantly increased in LGA placentas whereas in the 
Manchester Cohort only PHLDA2 expression was significantly decreased in 
LGA placentas.  
 
Table 3.15: Summary of target gene expression changes in LGA placentas in 
Wales and Manchester Cohorts Percentage change in expression relative to 
controls is shown. 
 
 
 
 
 
Gene LGA placentas 
Wales Cohort  
LGA placentas 
Manchester Cohort 
PHLDA2 - ↓ 25%  
CDKN1C - - 
PEG3 - - 
PEG10 ↑ 34%  - 
hPL - - 
PGH - - 
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3.4. Discussion  
This chapter examined a role for aberrant placental imprinted gene 
expression in pregnancies complicated by fetal growth restriction and fetal 
overgrowth. A summary of imprinted gene expression alterations in SGA and 
LGA placentas is shown in Table 3.16. These results suggest a role for 
placental PHLDA2 in the negative regulation of fetal growth and a role for 
placental PEG10 in the positive regulation of fetal growth.  
 
Table 3.16: Summary of target gene expression changes in SGA and LGA 
placentas from the Wales and Manchester Cohorts. Percentage change in 
expression is shown relative to AGA controls.   
 
3.4.1. Protocol Optimisation 
Time between delivery and placental dissection did not significantly affect 
placental RNA concentrations or expression of the housekeeping gene 
YWHAZ. YWHAZ gene expression can be used as a marker of RNA integrity 
with significantly decreased YWHAZ expression associated with increased 
RNA degradation (Huang et al. 2013). Thus, these results suggest that 
placental samples taken up to two hours after delivery are of sufficient quality 
for gene expression analysis. Similarly, time to sampling was not significantly 
associated with changes in placental target gene expression. These results 
are consistent with those of Fajardy et al. (2009) who reported stable 
placental RNA integrity and gene expression up to 96hrs after delivery, 
Gene SGA  
Wales 
Cohort 
SGA  
Manchester 
Cohort 
LGA  
Wales 
Cohort 
LGA  
Manchester 
Cohort 
PHLDA2 ↑ 101%  - - ↓ 25%  
CDKN1C - - - - 
PEG3 - - - - 
PEG10 - ↓ 25%  ↑ 34%  - 
hPL - - - - 
PGH - - - - 
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provided samples were stored in RNAlater. Similarly, although Avila et al. 
(2010) observed significant mRNA degradation of target genes with 
increasing processing time up to 24hrs, the greatest reduction in target gene 
expression was observed between 2 and 3 hrs post-delivery suggesting that 
samples taken within 2 hours of delivery were of sufficient quality for qPCR.  
Therefore, only samples obtained within 2 hours of delivery were used in the 
current study.   
 Placental PHLDA2 expression differed significantly with sampling site, 
with increased expression at distal sampling sites compared with sites close 
to the umbilical cord. Although no previous study has examined placental 
PHLDA2 expression in relation to sampling site, a number of studies have 
similarly reported significant intraplacental variation in gene expression 
(Hempstock et al. 2003; Pidoux et al. 2004; Wyatt et al. 2005; Sood et al. 
2006; Tzschoppe et al. 2010). Given that PHLDA2 expression is altered in 
response to hypoxia (Roh et al. 2005; Kim et al. 2007; Tomlinson et al. 
2010), it is possible that differences in perfusion between distal sites and 
sites close to the umbilical cord (Hempstock et al. 2003; Wyatt et al. 2005) 
could underlie the differences observed in placental PHLDA2 expression. No 
significant difference was observed in placental CDKN1C, PEG3, PEG10, 
PGH or hPL expression between sampling sites. The observation of 
intraplacental variation in PHLDA2 expression is novel and has implications 
for future studies with consistency in placental sampling of key importance; 
based on these results all placental samples for the current study were 
consistently taken from site 2B (middle layer, mid way between cord insertion 
and distal edge).   
 Only placental PGH expression was significantly positively correlated 
with gestational age, with 2.5 fold increased expression between early term 
and late term placentas. This result is consistent with observations of 
increasing maternal serum PGH as gestation progresses  (Lacroix et al. 
2002). There was no significant correlation between gestational age and 
expression of any other target gene. However, it should be noted that 
placental PHLDA2 and PEG3 expression was greatly increased in late term 
placentas but due to large standard deviations and a small sample size this 
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was not statistically significant. Thus, gestational age was controlled for in all 
analyses of placental PGH, PHLDA2 and PEG3 expression.  
 There was no significant difference in target gene expression between 
male and female control placentas. Moore et al. (2015) similarly report no 
significant effect of fetal sex on placental PHLDA2, CDKN1C, PEG3 or 
PEG10 expression. Mannik et al. (2010) also observed no significant 
differences in hPL or PGH expression between male and female placentas 
despite reports of increased maternal serum hPL and PGH in mothers of 
female fetuses (Fuglsang and Ovesen 2006). However, it should be noted 
that sexual dimorphism exists in the fetal response to an adverse 
environment (Clifton 2010) and therefore although no difference in placental 
target gene expression was observed in the control placentas analysed, it is 
possible that gene expression may be altered to different extents in male and 
female placentas by complications of pregnancy such as FGR.  
 Placental CDKN1C expression was significantly increased by almost 
three fold in labouring compared with non-labouring placentas. Although no 
previous study has examined placental CDKN1C expression in response to 
labour, significant differential gene expression has previously been reported 
between labouring and non-labouring placentas (Lee et al. 2010; Peng et al. 
2011; Cindrova-Davies et al. 2007). This result is novel and has implications 
for interpretation of results in future studies. In addition, it could explain the 
conflicting results reported regarding CDKN1C and human fetal growth 
restriction. For example, Rajamaran et al. 2010 analysed CDKN1C 
expression in placentas from both vaginal and elective C-section deliveries, 
which could confound the results reported. Therefore, in the current study 
mode of delivery was controlled for in any analysis of CDKN1C expression.   
 In conclusion, placental samples taken up to two hours after delivery 
are of sufficient quality for gene expression analysis. In addition, consistency 
in placental sampling is necessary to ensure comparable gene expression 
data. Finally, both gestational age and mode of delivery must be fully 
described in all studies and should be accounted for in analyses of placental 
gene expression.  
 128	  
3.4.2. PHLDA2 and FGR 
In the Wales Cohort, placental PHLDA2 expression was significantly 
increased by 60% in participants with prenatal concern over fetal growth 
including those with fetus’ measuring SGA by head or abdominal 
circumference on ultrasound. Placental PHLDA2 expression was also 
increased (by 150%) in participants with prenatal growth restriction in the 
Manchester cohort, although this difference was not statistically significant 
due to the large variation in PHLDA2 expression in infants with prenatal 
growth concern. There was no significant association between placental 
PHLDA2 expression and time of fetal growth restriction onset, amniotic fluid 
levels, umbilical artery pulsatility index or placental diameter on scan. No 
previous study has reported on placental PHLDA2 expression and prenatal 
growth restriction or time of onset (McMinn et al. 2006; Diplas et al. 2009; 
Kumar et al. 2012). This is therefore the first evidence that increased 
placental PHLDA2 expression is associated with fetal growth restriction that 
becomes evident during pregnancy, although gene expression was not 
significantly associated with time of onset or other factors used to ascertain 
the presence and severity of growth restriction.  
In both the Manchester and Wales Cohorts, placental PHLDA2 
expression was significantly inversely associated with birth weight and 
custom birth weight centiles. In the Wales Cohort PHLDA2 expression 
accounted for 6% of variance in birth weight and 8% of variance in custom 
birth weight centiles. Apostolidou et al. (2007) and Lim et al. (2012) similarly 
reported an inverse association between PHLDA2 expression and birth 
weight. However, these results contrast those of Lambertini et al. (2012), 
Lewis et al. (2012) and Demetriou et al. (2014) which observed no significant 
association between placental PHLDA2 expression and birth weight. These 
conflicting results could be due to differences in study methodology and 
population. For example, Demetriou et al. (2014) analysed placental 
PHLDA2 expression from first trimester chorionic villus samples, suggesting 
that the role of PHLDA2 in the control of fetal growth is specific to late 
pregnancy. It is also possible that no association between placental PHLDA2 
expression and birth weight was detected in the studies by Lambertini et al. 
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(2012) and Lewis et al. (2012) because of the relatively small number of 
placentas analysed (106 and 102 respectively) compared with the current 
study (181 and 110 in the Wales and Manchester Cohorts).  
A two fold increase in PHLDA2 expression was observed in SGA 
placentas of the Wales Cohort. A similar two fold increase in PHLDA2 
expression was observed in the Manchester cohort although this difference 
did not reach statistical significance (p = 0.09) possibly due to the smaller 
number of SGA placentas in this cohort (21 compared with 67). A two fold 
increase in placental PHLDA2 expression is slightly less than the three fold 
increase in gene expression observed in IUGR placentas by Diplas et al. 
(2009). This may result from differences in the definition of growth restriction; 
while the current study defined SGA as birth weight < 10th centile, Diplas et 
al. (2009) used a more stringent cut off, with IUGR defined as birth weight 
<3rd centile.   
In the Wales Cohort, 27% of SGA placentas displayed aberrant 
placental PHLDA2 expression (defined as ≥ 2 fold expression compared with 
controls). This is consistent with 25% of placentas examined by McMinn et 
al. (2006) demonstrating increased PHLDA2 expression. Interestingly, 
aberrant PHLDA2 expression was also observed in a number of AGA 
placentas in the Wales Cohort, including one participant with a custom birth 
weight centile close to the SGA cut off. This result is novel and suggests it is 
possible that PHLDA2 expression could be used to identify growth restriction 
in utero not resulting in LBW or SGA.  Although no obvious clinical feature 
linked these cases, further studies are needed to fully characterise these 
infants and their growth during pregnancy.  
In the Manchester Cohort, no significant difference was observed in 
placental PHLDA2 expression between AGA infants and either symmetric or 
asymmetric SGA infants possibly due to the small number of each (17 and 4 
respectively). However, in the Wales Cohort, placental PHLDA2 expression 
was increased in both symmetric and asymmetric SGA pregnancies relative 
to AGA controls, although this difference was only statistically significant for 
symmetric SGA infants. Tunster et al. (2014) observed asymmetric growth 
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restriction, with evidence of head sparing, in the mouse model of Phlda2 over 
expression. No previous studies have analysed human placental PHLDA2 
expression in symmetric and asymmetric SGA cases independently. The 
results of the current study therefore provide the first evidence that PHLDA2 
may also play a role in symmetric growth restriction. It should also be noted 
that given the non-significant, almost 2 fold increase in PHLDA2 expression 
observed in asymmetric SGA placentas, this study does not discount a role 
for PHLDA2 in asymmetric growth restriction in human pregnancies which 
may become apparent in further studies with larger sample sizes.    
In terms of other definitions of growth restriction, there was no 
significant difference in PHLDA2 expression in LBW placentas in either 
cohort, likely reflecting the heterogeneous causes of being born LBW 
including pathological growth restriction and constitutional smallness. Only 
43% of SGA pregnancies in the Wales Cohort were diagnosed as IUGR 
prenatally. Placental PHLDA2 expression was significantly increased in 
IUGR pregnancies although there was no significant correlation between 
gene expression and time of onset. Diplas et al. (2009) and McMinn et al. 
(2006) similarly demonstrated increased PHLDA2 expression in cases of 
clinically diagnosed IUGR although neither study reported on time of onset.  
Placental PHLDA2 expression was also significantly inversely 
associated with head circumference at birth in the Wales Cohort, although 
PHLDA2 expression only accounted for 1% of variance in head 
circumference. Previous studies (Apostolidou et al. 2007; Lewis et al. 2012; 
Lambertini et al. 2012) reported no significant association between placental 
PHLDA2 expression and head circumference. These conflicting results may 
be due to the relatively small number of pregnancies analysed (Lambertini et 
al. 2012) and/or that only normal birth weight infants were examined 
(Apostolidou et al. 2007; Lewis et al. 2012). Therefore, these results provide 
the first evidence that human placental PHLDA2 expression is negatively 
associated with head circumference. Importantly, this is consistent with the 
increased placental PHLDA2 expression observed in symmetric SGA cases 
in the current study, suggesting that in cases of fetal growth restriction 
characterised by aberrant placental PHLDA2 expression, head sparing (the 
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typical fetal adaptation to an adverse intrauterine environment), may be 
impaired.   
Finally, PHLDA2 expression was inversely correlated with placental 
weight in both the Wales and Manchester Cohorts with PHLDA2 expression 
accounting for 2% of variance in placental weight. Although human studies 
have previously reported no significant association between placental 
PHLDA2 expression and placental weight (Apostolidou et al. 2006; Lewis et 
al. 2011), as with head circumference, this may be due to the cohorts 
examined including only normal birth weight infants. However, the results of 
the current study are consistent with the impaired placental growth observed 
in the mouse model of Phlda2 over expression (Tunster et al. 2010). The 
novel results of the current study therefore suggest a role for PHLDA2 in the 
control of placental growth in human pregnancies.  
 
3.4.3. PHLDA2 and poor perinatal outcomes 
In the Manchester Cohort, placental PHLDA2 expression was 
significantly increased (by 130%) in infants with a poor perinatal outcome, 
defined as preterm birth, SGA or term NICU admission. However, there was 
no significant difference in placental PHLDA2 expression in infants admitted 
to NICU in this cohort and no significant correlation between gene expression 
and gestational age. This suggests that the difference observed in infants 
with poor perinatal outcome is due to the relationship between PHLDA2 
expression and fetal growth restriction alone. Similarly, in the Wales Cohort, 
although placental PHLDA2 expression was three fold higher in infants 
admitted to NICU this difference was not statistically significant. This is likely 
due to the large variation seen in PHLDA2 expression in the NICU group 
reflecting the heterogeneous group of infants admitted to NICU.  
 Finally, placental PHLDA2 expression was not significantly associated 
with measures of adverse infant outcomes such as fetal distress during 
delivery, umbilical cord blood pH or apgar scores. No previous study has 
examined placental PHLDA2 expression in relation to poor perinatal 
outcomes. Therefore, this study is the first to suggest that aberrant placental 
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PHLDA2 expression does not identify infants at high risk of poor perinatal 
outcomes at birth. However, it should be noted that few infants in either 
cohort suffered extreme adverse outcomes at delivery and therefore larger 
studies are needed to fully determine the role of PHLDA2 expression in 
predicting adverse outcomes.   
 
3.4.4. CDKN1C and FGR 
Although initial analysis of the Wales Cohort suggested an inverse 
correlation between placental CKN1C expression, birth weight and custom 
birth weight centiles, this association was subsequently demonstrated not to 
be significant when results were analysed according to labour status. 
Similarly, placental CDKN1C expression was not significantly associated with 
any measure of fetal growth in the Manchester Cohort. There was also no 
significant difference in CDKN1C expression between SGA and AGA 
placentas in either cohort. Few previous studies, with conflicting results, have 
examined placental CDKN1C expression in relation to growth restriction. Our 
results are consistent with those of Diplas et al. (2009) demonstrating no 
significant difference in CDKN1C expression in IUGR placentas. In contrast, 
McMinn et al. (2006) reported significantly increased and Rajaraman et al. 
(2010) significantly decreased placental CDKN1C expression in growth 
restricted pregnancies. These conflicting results may have arisen from a 
failure to control for mode of delivery, for example Rajaraman et al. (2010) 
analysed CDKN1C expression in vaginal and elective c-section placentas 
combined whereas the labour status of the placentas examined by McMinn 
et al. (2006) was not determined. Thus, the results of the current study do not 
support a role for placental CDKN1C expression in human FGR and highlight 
the need to thoroughly control for mode of delivery in future studies.  
 Finally, there was no significant difference in placental CDKN1C 
expression in infants admitted to NICU at delivery and no significant 
correlation between CDKN1C expression and measures of adverse infant 
outcomes such as umbilical cord blood pH or apgar scores in either cohort. 
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These  results suggest that aberrant placental CDKN1C expression does not 
identify infants at high risk of poor perinatal outcomes at birth.  
 
3.4.5. PEG3 and FGR 
Placental PEG3 expression was not significantly correlated with birth weight 
or custom birth weight centiles in either cohort. Similarly, PEG3 expression 
was not significantly altered in SGA placentas. This is consistent with results 
from four previous studies (McMinn et al. 2006; Diplas et al. 2009; Kumar et 
al. 2011 and Moore et al. 2015) reporting no association between placental 
PEG3 expression and measures of fetal growth. Similarly, placental PEG3 
expression was not significantly associated with placental weight in the 
Wales or Manchester Cohort. Moore et al. (2015) also reported no significant 
association between PEG3 expression and placental weight. Thus, 
consistent with previous studies, the findings of the current study do not 
support a role for PEG3 in human fetal growth restriction. It is possible that 
the 10% decrease in weight of Peg3 mutants at birth (Li et al. 1999; Kim et 
al. 2013) represents a mouse-specific response or that the relatively small 
effect of Peg3 loss of function on fetal growth cannot be detected in a cohort 
of this size. Finally, there was no significant difference in placental PEG3 
expression in infants admitted to NICU at delivery and no significant 
correlation between PEG3 expression and umbilical cord blood pH or apgar 
scores in either cohort, suggesting that aberrant placental PEG3 expression 
does not identify infants at high risk of poor perinatal outcomes at birth. 
 
3.4.6. PEG10 and FGR 
In the Wales Cohort, placental PEG10 expression was not significantly 
associated with birth weight or custom birth weight centiles and expression 
did not differ significantly between AGA and SGA pregnancies. In contrast, a 
significant positive association was observed between placental PEG10 
expression and prenatal abdominal circumference and femur length on scan, 
as well as birth weight, in the Manchester Cohort. Placental PEG10 
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expression was also significantly decreased in SGA compared with AGA 
placentas. The greatest reduction in placental PEG10 expression was 
observed in the asymmetric SGA placentas, although this difference did not 
reach statistical significance (p = 0.09). This is consistent with the positive 
correlation between placental PEG10 expression, abdominal circumference 
and femur length, (but not head circumference), suggesting a role for PEG10 
in asymmetric fetal growth restriction characterised by reduced length and 
abdominal circumferences but relative sparing of the head. Similarly, 
placental PEG10 expression was not significantly associated with head 
circumference at delivery. These results contrast those of Diplas et al. (2009) 
demonstrating increased placental PEG10 expression in IUGR placentas and 
those of Moore et al. (2015) demonstrating no significant association with 
birth weight. Lim et al. (2012) however, have previously demonstrated a 
significant positive association between birth weight and umbilical cord 
PEG10 expression. This is therefore the first evidence of an association 
between human placental PEG10 expression and fetal growth, with a specific 
correlation with abdominal and femur growth during pregnancy.  
Furthermore, placental PEG10 expression was significantly reduced in 
infants with poor perinatal outcome. PEG10 expression was not altered in 
infants admitted to NICU after delivery, suggesting that the association with 
poor perinatal outcome was due to fetal growth restriction cases alone. 
Placental PEG10 expression was significantly positively associated with 
apgar scores at 1 minute and 5 minutes after delivery. No previous study has 
examined placental PEG10 expression in relation to infant outcomes at 
delivery. Therefore this is the first evidence that placental PEG10 expression 
may predict apgar scores at delivery. Further research is required to 
determine whether placental PEG10 expression can be used to identify 
infants at increased risk of adverse outcomes at delivery.  
 
3.4.7. hPL and FGR 
In the Wales Cohort, placental hPL expression was significantly decreased in 
pregnancies with prenatal growth concerns, including those with SGA 
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abdominal and head circumferences on scan. A significant positive 
correlation between placental hPL expression and femur length was also 
observed in the Manchester Cohort, which may underlie prenatal growth 
restriction.   
Placental hPL expression was significantly positively correlated with 
birth weight, custom birth weight centiles and placental weight in the Wales 
Cohort. In contrast, only a trend was observed for a positive correlation 
between placental hPL expression and custom birth weight centiles in the 
Manchester Cohort (p = 0.08), possibly as a result of the smaller number of 
placentas examined. Despite the association observed between placental 
hPL expression and birth weight in the Wales Cohort, expression was not 
significantly altered in SGA, LBW or IUGR pregnancies in either cohort. 
These findings are consistent with those reported by Mannik et al. (2010) of 
no significant difference in hPL expression between SGA and AGA 
placentas. It is possible that placental hPL expression plays a role in the 
control of fetal growth but that perturbations in this pathway do not underlie 
FGR. Further research is required to fully determine the role of hPL in human 
growth restricted pregnancies.  
Finally, as reported by Dutton et al. (2012), placental hPL expression 
was not significantly altered in infants with poor perinatal outcomes, NICU 
admission at delivery or low apgar scores. However, placental hPL 
expression was significantly associated with arterial cord blood pH in the 
Wales Cohort. It is possible that this association reflects the inverse 
association reported between placental hPL expression and hypoxia (Roh et 
al. 2005), suggesting placental hPL expression as a potential biomarker of 
hypoxia during delivery.  
 
3.4.8. PGH and FGR 
There was no significant correlation between placental PGH expression and 
birth weight, custom birth weight centiles or placental weight in either cohort, 
after controlling for gestational age. Similarly, placental PGH expression was 
not significantly altered in SGA compared with AGA pregnancies. These 
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results contrast those of Mannik et al. (2010) reporting a significant 
association between placental PGH expression and birth weight. However 
previous studies have noted only a modest reduction in placental PGH 
expression (approximately 10%) in SGA compared with AGA infants (Mannik 
et al. 2010; Koutsaki et al. 2011), which may not have been detectable in our 
cohorts. Furthermore, given the significant correlation between placental 
PGH expression and gestational age observed in the current study, 
conflicting result may be explained by failure of previous studies to control for 
gestational age (Koutsaki et al. 2011). The findings of the current study 
therefore do not support a role for aberrant placental PGH expression in fetal 
growth restriction.  
Finally, placental PGH expression was not significantly altered in 
infants with poor perinatal outcomes in the Manchester Cohort. However, in 
the Wales Cohort placental PGH expression was significantly reduced in 
infants admitted to NICU at delivery. In addition, placental PGH expression 
was significantly positively correlated with arterial cord blood pH after 
controlling for gestational age. This contrasts results by Trollmann et al. 
(2007) of no significant difference in placental PGH expression in response 
to acute birth asphyxia characterised by reduced umbilical artery pH. Thus, 
this is the first report of aberrant placental PGH expression in infants 
admitted to NICU and in association with reduced umbilical artery pH. Larger 
studies of infant birth outcomes are needed to determine the significance of 
these findings.  
 
3.4.9. Imprinted genes and placental hormones 
Placental PHLDA2 expression was significantly inversely associated with 
hPL but not PGH expression in the Wales Cohort. A similar correlation was 
not observed in the Manchester Cohort, possible as a result of the fewer 
numbers of placentas examined (110 compared with 219). An inverse 
association between placental PHLDA2 and hPL expression in the Wales 
Cohort is consistent with findings of decreased placental lactogen expression 
and loss of spongiotrophoblast cells (the endocrine lineage of the placenta) 
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in the mouse model of Phlda2 over expression (Tunster et al. 2010). No 
previous study has examined the relationship between imprinted gene 
expression and hormone production in the human placenta. Therefore, the 
results of the current study provide the first evidence for an association 
between human placental PHLDA2 and hPL expression with the mouse 
model of Phlda2 over expression suggesting that this relationship is causal, 
with PHLDA2 expression negatively regulating hPL expression.  
 An inverse correlation between placental CDKN1C and hPL but not 
PGH expression was also observed in the Wales Cohort, after controlling for 
mode of delivery. An inverse association between placental CDKN1C and 
hPL expression in the Wales Cohort is consistent with findings of decreased 
placental lactogen expression and loss of spongiotrophoblast cells (the 
endocrine lineage of the placenta) in the mouse model of Cdkn1c over 
expression (Tunster et al. 2011). No previous study has examined the 
relationship between imprinted gene expression and hormone production in 
the human placenta. Therefore, the results of the current study provide the 
first evidence for an association between human placental CDKN1C and hPL 
expression with the mouse model of Cdkn1c over expression suggesting that 
this relationship is causal with CDKN1C expression negatively regulating hPL 
expression. 
 Neither placental PEG3 nor PEG10 expression was significantly 
associated with hPL or PGH expression in the Wales or Manchester Cohorts. 
A trend was observed for a positive correlation between placental PEG3 and 
hPL expression (p = 0.07) in the Manchester Cohort. Given the effect of loss 
of function of Peg3 on placental lactogen expression in a mouse model 
(Broad and Keverne 2011; Kim et al. 2013), it is possible that PEG3 
positively regulates placental hPL expression in the human placenta however 
this needs to be confirmed in future studies.  
 
3.4.10. Fetal overgrowth 
In the Wales Cohort, placental PHLDA2, CDKN1C and PEG3 expression 
was not significantly altered in LGA or macrosomic pregnancies. However, 
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placental PHLDA2 was significantly decreased in LGA and macrosomic 
pregnancies in the Manchester Cohort. Given the significant correlation 
between placental PHLDA2 and birth weight in both cohorts, it is possible 
that PHLDA2 expression is altered in cases of fetal overgrowth. However, 
given the discrepancies between the two cohorts, this remains to be 
confirmed in future studies.  
 Placental PEG10 expression was significantly increased by 34% in 
LGA pregnancies and by 23% in macrosomic pregnancies of the Wales 
Cohort. There was no significant difference in PEG10 expression in LGA 
placentas of the Manchester Cohort, possibly due to the smaller number of 
LGA placentas examined. However, results are consistent with the positive 
correlation observed between placental PEG10 expression and birth weight 
in the Manchester Cohort. Although no study has previously examined 
placental PEG10 in relation to LGA, these results are consistent with the role 
of PEG10 in the positive regulation of fetal growth as suggested by both 
human (Lim et al. 2012) and animal studies (Ono et al. 2006). In addition, the 
results of the current study uniquely suggest a role for aberrant placental 
PEG10 expression in pregnancies complicated by fetal overgrowth.  
Finally, there was no significant change in placental hPL or PGH 
expression in LGA or macrosomic pregnancies of either cohort.   
 
3.4.11. Summary 
In summary, the results presented in this chapter support a role for placental 
PHLDA2 in the negative regulation of fetal growth with abnormally increased 
expression observed in pregnancies complicated by fetal growth restriction. 
A role for placental PEG10 expression in the positive regulation of fetal 
growth was also suggested. These results therefore support the first and 
second study hypotheses of aberrant placental imprinted gene expression in 
pregnancies complicated by growth restriction and fetal overgrowth. Further 
research will be required to elucidate the mechanisms by which aberrant 
placental imprinted gene expression drives growth restriction.   
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CHAPTER 4: IMPRINTED GENES AND OTHER 
COMPLICATIONS OF PREGNANCY 
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4.1. Introduction  
Results from Chapter 3 support a role for placental imprinted gene 
expression, particularly PHLDA2 and PEG10, in the control of fetal growth. 
Abnormal fetal growth is known to occur in a number of pregnancy 
complications, such as preeclampsia, gestational diabetes and maternal 
depression and/or anxiety, prompting investigation of placental imprinted 
gene expression in these pregnancies. In addition, results from chapter 3 
provide evidence for an association between imprinted gene expression and 
expression of the placental hormone hPL, which has an established role in 
maternal adaptation to pregnancy (Newbern and Freemark 2011). Pregnancy 
complications such as gestational diabetes are suggested to result from 
inadequate maternal adaptation to pregnancy (Newbern and Freemark 
2011), further supporting investigation of placental imprinted gene and 
placental hormone gene expression in study participants suffering from these 
complications. Thus, the main aim of this chapter was to explore a possible 
association between aberrant placental imprinted gene expression and 
development of the pregnancy complications preeclampsia, gestational 
diabetes and maternal mood disorders.  
 Preeclampsia (PE) is defined as new onset hypertension and 
proteinuria during pregnancy (NICE 2010), differing from pregnancy induced 
hypertension (PIH) in which proteinuria is absent. PE is associated with an 
estimated four fold increased risk of FGR (Villar et al. 2006; Hutcheon et al. 
2011), highlighting the abnormal fetal growth phenotype associated with this 
pregnancy complication. Given the role of imprinted genes in the control of 
fetal growth, it is possible aberrant placental expression of these genes 
underlies the co-morbidity of PE and FGR.  In addition, the mouse model of 
Cdkn1c loss of function supports a role for imprinted genes in the 
pathogenesis of preeclampsia. Preeclampsia-like symptoms develop in wild 
type mice carrying mutant Cdkn1c pups an effect that was attributed to 
shallow trophoblast invasion and increased spongiotrophoblast proliferation 
in the placenta (Kanayama et al. 2002). As the imprinted genes Phlda2, 
Peg3 and Peg10 are also known to regulate the spongiotrophoblast cell 
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lineage of the mouse placenta (reviewed in John 2013), it is possible that 
these genes also play a role in preeclampsia. However, previous studies of 
imprinted gene expression in human PE placentas have yielded conflicting 
results. A severe form of preeclampsia (HELLP) has been reported to occur 
in pregnancies in which the infant suffers from BWS as a result of a CDKN1C 
mutation (Romanelli et al. 2009) whereas another study demonstrated 
increased CDKN1C expression PE placentas (Enquobahrie et al. 2008). In 
contrast, placental PHLDA2 expression has previously been demonstrated 
not to be significantly altered in a small number of PE placentas (McMinn et 
al. 2006). While no previous study has examined placental PEG3 expression 
in PE pregnancies, Lambertini et al. (2008) demonstrated LOI of PEG3 in 
50% of the PE placentas examined. Finally, both increased (Chen et al. 
2012) and decreased (Liang et al. 2014) placental PEG10 expression has 
been reported in PE pregnancies.  
 Gestational diabetes (GDM) is defined as new onset glucose 
intolerance during pregnancy (Buchanan 2007; Hartling et al. 2013; 
Mitanchez et al. 2014). Pregnancies complicated by GDM are twice as likely 
to result in delivery of an LGA or macrosomic infant (Hartlingt et al. 2013), 
possibly as a result of increased neonatal body fat (Catalano et al. 2003). 
Given the role of imprinted genes in the control of fetal growth, it is possible 
aberrant placental expression of these genes underlies the co-morbidity of 
GDM and fetal overgrowth. The association between placental imprinted 
gene expression and hPL expression demonstrated in Chapter 3 further 
suggests a role for imprinted genes in the pathogenesis of GDM. The 
placental hormone hPL is known to prevent maternal glucose intolerance as 
a consequence of metabolic adaptation to pregnancy (reviewed in Fuglsang 
and Ovesen 2006; Newbern and Freemark 2011). This is supported by 
reports of altered maternal hPL serum levels in diabetic pregnancies (Ursell 
et al. 1973; McIntyre et al. 2000; Mannik et al. 2012). No previous study has 
examined placental PHLDA2, CDKN1C, PEG3 or PEG10 expression in GDM 
pregnancies, although an increased risk of GDM has been reported in 
women inheriting a genetic variant of KCNQ1 (the imprinting cluster in which 
PHLDA2 and CDKN1C are located) (Mao et al. 2012).  
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It is thought that women are particularly prone to developing 
symptoms of depression and anxiety during and after pregnancy, which may 
be due to the numerous physiological and hormonal changes that occur 
during pregnancy (Tan and Tan 2013). The placenta is a key source of 
hormones that act on the maternal brain, priming the mother for pregnancy 
and postnatal care (Glynn and Sandman 2011) and thereby inducing 
maternal psychological adaptation to pregnancy. In particular, hPL produced 
by the placenta has been demonstrated to induce maternal behaviour in 
animal studies (Bridges et al. 1985; Bridges et al. 1990; Bridges and 
Freeman 1995; Bridges et al. 1997) and to be reduced in the serum of 
human mothers with postnatal depression (Abou-Saleh et al. 1998; Ingram et 
al. 2003; Groer and Morgan 2007). It has therefore been suggested that 
aberrant placental function may influence maternal mood (Glynn and 
Sandman 2011). Based on the association between placental imprinted gene 
expression and hPL expression reported in Chapter 3, it was proposed that 
imprinted genes could contribute to maternal psychological adaptation to 
pregnancy via control of placental hormone production, with inadequate 
adaptation manifesting as symptoms of anxiety and/or depression during 
pregnancy. In support of this hypothesis, Peg3 has previously been 
demonstrated to be necessary for the induction of nurturing and nest building 
behaviour in rodents (Li et al. 1999; Curley et al. 2004; Champagne et al. 
2009; Chiavegatto et al. 2012). Investigation of placental imprinted gene 
expression in pregnancies complicated by maternal mood disorders is also 
warranted based on the established association between maternal anxiety 
and depression during pregnancy and fetal growth restriction (Khashan et al. 
2008; Berkowitz et al. 2003; Pritchard and Teo 1994; Paarlberg et al. 1999; 
Steer et al. 1992; Henrichs et al. 2010; Uguz et al. 2013). Given the role of 
placental imprinted genes in the control of fetal growth, it is possible that 
aberrant gene expression could explain the co-occurrence of maternal mood 
disorders and fetal growth restriction.  
Thus, this chapter aimed to examine placental imprinted gene and 
placental hormone gene expression in pregnancies complicated by 
preeclampsia, gestational diabetes and maternal mood disorders. 
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4.2. Chapter specific methods 
Methods were as described in Chapter 2. For ease of interpretation of the 
results presented in this chapter, methods related to the study of placental 
target gene expression in pregnancies complicated by PE, GDM and 
maternal mood disorders are summarised below. 
 
4.2.1. Methods: preeclampsia 
Target gene expression was analysed in 22 placentas from PE or PIH 
pregnancies in the Wales Cohort. In this study, preeclampsia was defined as 
diastolic blood pressure ≥ 90 – 99 mm Hg and systolic blood pressure ≥ 140 
– 149 mm Hg in association with ≥ 300mg protein in a 24hr urine test. A 
diagnosis of PE and the gestational age at diagnosis, was recorded from the 
participant’s medical notes. Gestational age at first occurrence of 
hypertension and proteinurea were recorded to distinguish between 
pregnancy induced hypertension (hypertension without proteinurea) and 
preeclampsia (presence of both hypertension and proteinurea). Finally, the 
treatment for preeclampsia was noted as well as the gestation age at which 
treatment began.  
 
4.2.2. Methods: gestational diabetes  
Target gene expression was analysed in 16 placentas from GDM 
pregnancies in the Wales Cohort. In this study, GDM was defined as fasting 
glucose ≥ 6.1mmol/L or ≥ 7.8mmol/L at 2 hours following a 75g oral GTT. 
Gestational age at first abnormal GTT and GDM diagnosis was recorded 
from the participants’ medical notes. A previous GDM pregnancy was also 
noted. Finally, the form of GDM management (diet, exercise and/or 
medication) was recorded. The Wales Cohort also included a number of 
women with a confirmed normal GTT (at ≥ 28 weeks) who had been tested 
for GDM because of risk factors such as previous history, family history of 
diabetes, LGA infant, and/or BMI ≥ 30.  
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4.2.3. Methods: Maternal mood disorders  
Target gene expression was analysed with respect to maternal depression in 
the Imperial and Manchester Cohorts. In the Imperial Cohort, symptoms of 
depression were assessed using the Edinburgh Postnatal Depression Scale 
(EPDS) with higher scores indicating higher levels of depression. A median 
split of the cohort by maternal EPDS scores was carried out for the purpose 
of analysing the effects of maternal depression on placental gene 
expression. In addition, placental target expression was compared between 
participants with an EPDS score ≥13 (indicative of clinical depression) and 
those with EPDS scores < 13. In the Manchester Cohort, a diagnosis of 
depression during pregnancy (including any treatment prescribed) was 
recorded from the participant’s medical notes. 
Target gene expression was analysed with respect to maternal anxiety 
in the Imperial Cohort. Maternal anxiety was measured using the Spielberger 
Trait Anxiety Inventory (STAI), a self-administered psychometric 
questionnaire with higher scores indicating higher levels of anxiety. A median 
split of the cohort by maternal STAI scores was carried out for the purpose of 
analysing the effects of maternal depression on placental gene expression. 
This median split also divided participants into those with a STAI score ≥ 40 
(indicative of clinical anxiety) and those with a STAI score < 40.  
 
4.2.4. Statistical analysis 
All statistical analysis was carried out using IBM SPSS statistics for Windows 
(version 20.0, 2011) with a p value <0.05 considered statistically significant. 
Normal distribution was assessed using P-P plots and a Shapiro-Wilk 
test. All data was normally distributed and therefore parametric statistical 
tests used. Associations between placental gene expression and measures 
of maternal mood (e.g. EPDS scores) were assessed using a Pearson 
correlation test. Differences in placental gene expression between control 
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and complicated pregnancies were analysed using an independent samples 
T tests or one-way ANOVA with a Tukey post hoc test where appropriate.  
Given the differences in placental CDKN1C expression according to 
mode of delivery as demonstrated in Chapter 3, multiple linear regression 
analysis was also carried out to determine whether labour status and 
preeclampsia independently predicted placental CDKN1C expression. 
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4.3. Results 
 
4.3.1. Maternal preeclampsia  
4.3.1.1. Participant demographics 
22 Caucasian participants were diagnosed with preeclampsia or pregnancy 
induced hypertension during pregnancy. Of these 22 participants, five were 
diagnosed with PIH and 17 with PE. There was no significant difference in 
any maternal lifestyle factor examined between PE/PIH and control 
participants as shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Maternal lifestyle and PIH/PE. There was no significant difference in 
maternal age (A), BMI at booking (B) or lifestyle factors (C) between PIH/PE and 
control participants as determined by an independent samples t-test or chi-squared 
test where appropriate. PIH = pregnancy induced hypertension, PE = preeclampsia. 
Error bars represent SEM.  
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4.3.1.2. Preeclampsia and birth weight 
Birth outcomes for PE/PIH and control participants are shown in Table 4.1. A 
significantly smaller number of PIH/PET participants delivered by elective c-
section highlighting the need to control for mode of delivery in target gene 
expression analysis. 
 
Table 4.1: Comparison of birth outcomes between control and PIH/PE 
participants. Mean (SD)/Range or Number (%) is shown. Differences were 
analysed using an independent samples T test or Chi – square test where 
appropriate. PE = preeclampsia, PIH = pregnancy induced hypertension.  
 
 Birth weight was significantly reduced by 360g in infants born to 
PE/PIH participants compared with controls (p = 0.01, n = 113, Table 4.1). A 
one-way ANOVA revealed significant differences in birth weight when 
participants were divided into those with PIH or PE (p <0.001, n = 113) 
Figure 4.2. A Tukey post hoc test further revealed decreased birth weights 
for PE (p < 0.001, n = 108) but not PIH participants (p = 0.44, n = 96). Due to 
the differing effects on birth weight, placental target gene expression was 
examined in the PE and PIH participants combined and independently.  
 As with birth weight, custom growth centiles were significantly reduced 
in PIH/PE participants compared with controls (p = 0.001, n = 113). Further 
 Control 
Participants  
(N = 91) 
PE/PIH 
participants  
(N = 22) 
P Value 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Custom birth weight centile 
Head circumference (cm) 
Gestational age (weeks) 
Placental weight (g) 
 
Gender 
Male 
Female 
 
 
7 (8%) 
78 (86%) 
4 (4%) 
2 (2%) 
3480 (277)/ 
2830 - 4190 
53 (22) / 11 - 89 
35 (1) / 32 - 39 
39 (1) / 37 - 42 
703 (124) / 309 
– 905 
 
44 (48%) 
47 (52%) 
 
 
6 (27%) 
6 (27%) 
6 (27%) 
4 (18%) 
3123 (560)/ 
1830 - 3910 
33 (26) / 0 - 86 
35 (1) / 33 - 38 
39 (1) / 35 - 42 
591(120) / 367– 
820 
 
15 (68%) 
7 (32%) 
 
 
 
 
 
P < 0.001*** 
 
P = 0.007** 
P = 0.001*** 
P = 0.04* 
P = 0.24 
 
P = 0.10 
 
 
P = 0.08 
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analysis revealed that custom growth centiles were significantly reduced only 
in PE (p = 0.001, n = 108) but not PIH participants (p = 0.58, n = 96), Figure 
4.2. Finally, a trend was observed for decreased placental weight in PE/PIH 
participants compared with controls (p = 0.10, n = 113). 
 Only one participant was diagnosed with early onset preeclampsia (≤ 
34 weeks) and therefore fetal growth and placental gene expression could 
not be compared between severity groups.  
 
 
 
 
Figure 4.2: Birth weight and preeclampsia.  Birth weight (A) and custom birth 
weight centiles (B) were significantly reduced in PE but not PIH participants 
compared with controls, as determined by a one-way ANOVA and Tukey post-hoc 
test. PIH = pregnancy induced hypertension, PE = preeclampsia. *** p < 0.001.  
Error bars represent SD.  
 
 
4.3.1.3. Preeclampsia and placental PHLDA2 expression 
Placental PHLDA2 expression was significantly increased by 63% in PIH/PE 
placentas compared with controls, Figure 4.3. A one-way ANOVA revealed 
significant differences in placental PHLDA2 expression when participants 
were divided into those with PIH or PE (p = 0.02, n = 113, Figure 4.3). A 
Tukey post hoc test further demonstrated increased placental PHLDA2 
expression for PE (p = 0.01, n = 108) but not PIH participants (p = 0.96, n = 
96). Results remained significant with the exclusion of one preterm 
participant delivered at 36 weeks (+5 days) (results not shown).  
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Figure 4.3: Placental PHLDA2 expression and preeclampsia. PHLDA2 
expression was significantly increased in PIH/PE placentas (A) as determined by an 
independent samples t-test. Increased expression was significant only in PE 
placentas (B). Differences in expression were not significant when participants were 
divided according to AGA/SGA status (C) as determined by one-way ANOVA and 
Tukey post-hoc test. PIH = pregnancy induced hypertension, PE = preeclampsia. 
 
 To determine whether the increase observed in placental PHLDA2 
expression was associated with the growth restriction reported in 38% of the 
PIH/PE participants, expression was compared between controls and PIH/PE 
participants with or without the presence of SGA. There was a significant 
difference in placental PHLDA2 expression between groups as determined 
by a one-way ANOVA (p = 0.04, n = 113). However, although increased 
expression compared with controls was observed for both PIH/PE (SGA) and 
PIH/PE (AGA) groups respectively these differences were not statistically 
significant (Figure 4.3).  
 
4.3.1.4. Preeclampsia and CDKN1C, PEG3 and PEG10 expression 
Placental CDKN1C expression was significantly increased by 45% in 
participants with PIH/PE compared with controls, Figure 4.4. A one-way 
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ANOVA revealed a trend for differences in placental CDKN1C expression 
when participants were divided into those with PIH or PE (p = 0.07, n = 113) 
with increased CDKN1C expression in the PE group only (Figure 4.4). 
However, there was no significant difference in placental CDKN1C 
expression when PIH/PE participants were divided into those with or without 
SGA (p = 0.12, n = 113) although expression was increased in both groups 
compared with controls (results not shown).  
   
 
 
 
 
 
 
 
Figure 4.4: Placental CDKN1C expression and preeclampsia. CDKN1C 
expression was significantly increased in PIH/PE placentas (A) as determined by an 
independent samples t-test. Expression was increased in both PIH and PE 
placentas (B) although differences were not significant as determined by one-way 
ANOVA. When divided according to labour status, CDKN1C expression was only 
significantly increased in response to labour (C). PIH = pregnancy induced 
hypertension, PE = preeclampsia. 
 
 Given the significant increase in CDKN1C expression in labouring 
placentas (section 3.3.1.5) and the significant difference in mode of delivery 
between PIH/PE and control participants (Table 4.1), CDKN1C expression in 
PIH/PE placentas was further analysed according to labour status. As shown 
in Figure 4.4, CDKN1C expression was only increased between control 
labouring and non-labouring placentas, as determined by a one-way ANOVA 
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and Tukey post hoc test. Multiple linear regression analysis was also carried 
out to determine whether labour status and preeclampsia independently 
predicted placental CDKN1C expression. This model significantly predicted 
placental CDKN1C expression (F(2, 110) = 3.71, p = 0.03, R2 = 0.06), 
however only labour status (p = 0.02) and not preeclampsia (p = 0.37) 
significantly predicted placental CDKN1C expression. 
 There was no significant difference in placental PEG3 or PEG10 
expression between control and PIH/PE participants (Figure 4.5). Results 
remained non-significant when participants were divided into those with PIH 
or PE, and into those with or without SGA (results not shown).  
 
 
 
 
 
 
 
 
Figure 4.5: Placental PEG3 and PEG10 expression and preeclampsia. There 
was no significant difference in expression between PIH/PE placentas and controls 
as determined by an independent samples T-test. PIH = pregnancy induced 
hypertension, PE = preeclampsia. Error bars represent SEM.  
 
 
4.3.1.5. Preeclampsia and placental hormone gene expression 
 
Placental hPL and PGH expression was not significantly altered in PIH/PE 
participants compared with controls (Figure 4.6). Results remained non-
significant when participants were divided into those with PIH or PE and into 
those with or without SGA (results not shown).  
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Figure 4.6: Placental hPL and PGH expression and preeclampsia. There was no 
significant difference in expression between PIH/PE placentas and controls as 
determined by an independent samples T-test. PIH = pregnancy induced 
hypertension, PE = preeclampsia. Error bars represent SEM.  
 
4.3.1.6. Preeclampsia Summary 
A summary of the changes in target gene expression in PIH/PE placentas is 
shown in Table 4.2. Placental PHLDA2 expression was significantly 
increased in placentas of PIH/PE participants. While CDKN1C expression 
was also altered in these placentas, this was demonstrated to be due to 
differences in labour status.  
Table 4.2. Summary of placental gene expression changes associated with 
preeclampsia. Fold gene expression is shown relative to control participants. 
Results highlighted were statistically significant using an independent samples T 
test. ** p ≤ 0.01. (a) p value after controlling for labour using multilinear regression.  
Gene Control Participants 
 (N=91) 
PE/PIH participants 
(N=22) 
P Value 
PHLDA2 1.00 1.63 P = 0.01 ** 
CDKN1C 1.00 1.45 P = 0.37 (a) 
PEG3 1.00 1.44 P = 0.24 
PEG10 1.00 1.32 P = 0.24 
hPL 1.00 0.92 P = 0.44 
PGH 1.00 0.97 P = 0.82 
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4.3.2. Maternal Gestational Diabetes Mellitus (GDM) 
4.3.2.1. Participant demographics 
16 Caucasian participants were diagnosed with GDM during their pregnancy. 
A comparison of maternal lifestyle factors between GDM and control 
participants is shown in Figure 4.7.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Maternal lifestyle and GDM. Maternal BMI was significantly higher in 
GDM compared with control participants (A) although weight gain during pregnancy 
was significantly less (B). Fruit or vegetable consumption was significantly higher in 
GDM participants (C) but there was no significant difference in any other lifestyle 
factors determined by an independent samples t-test or chi-squared test where 
appropriate. GDM = gestational diabetes mellitus. Error bars represent SEM.  
 
 Maternal BMI was significantly higher in GDM compared with control 
participants (p = 0.04, n = 107), Figure 4.7. Therefore, for the purposes of 
analysing the association between target gene expression and GDM, 
placental expression was compared with all controls (no known GTT status) 
and with normal or high BMI controls (known negative GTT test) respectively.  
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 In contrast, maternal weight gain was significantly lower in GDM 
compared with control participants (Figure 4.7) possibly as a result of 75% of 
the GDM participants receiving weekly nutrition advice and weight 
management. Similarly, maternal fruit and vegetable consumption was 
significantly higher in GDM participants (Figure 4.7). There was no significant 
difference in any other maternal lifestyle factor examined between GDM and 
control participants as shown in Figure 4.7.  	  
4.3.2.2. Maternal GDM and birth weight 
Birth outcomes for the gestational diabetes (GDM) and control participants 
are compared in Table 4.3.  
 
Table 4.3: Comparison of birth outcomes between control and GDM 
participants. Mean (SD)/Range or Number (%) is shown. Differences were 
analysed using an independent samples T test or Chi – square test where 
appropriate. GDM = Gestational Diabetes Mellitus.   
 
There was no significant difference in birth weight (p = 0.15, n = 107) or 
placental weight (p = 0.37) between control and GDM participants. Similarly, 
differences remained non significant when participants were divided into 
those with a normal BMI and high BMI (overweight/obese), Figure 4.8. There 
 Control 
Participants  
(N = 91) 
GDM 
participants  
(N = 16) 
P Value 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Custom birth weight centile 
Head circumference (cm) 
Gestational age (weeks) 
Placental weight (g) 
 
Gender 
Male 
Female 
 
 
7 (8%) 
78 (86%) 
4 (4%) 
2 (2%) 
3480 (277)/ 
2830 - 4190 
53 (22) / 11 - 89 
35 (1) / 32 - 39 
39 (1) / 37 - 42 
703 (124) / 309 
– 905 
 
44 (48%) 
47 (52%) 
 
 
2 (13%) 
11 (69%) 
3 (19%) 
0 (0%) 
3543 (426)/ 
2710 - 4160 
64 (26) / 13 - 95 
35 (1) / 33 - 38 
39 (1) / 37 - 40 
718 (144) / 451– 
1050 
 
11 (69%) 
5 (31%) 
 
 
 
 
 
P = 0.18 
 
P = 0.15 
P = 0.11 
P = 0.80 
P = 0.22 
 
P = 0.37 
 
 
P = 0.22 
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was also no significant correlation between time of onset and placental (r = 
0.11, p = 0.73, n = 16) or birth weight (r = 0.18, p = 0.57, n = 16). Finally, 
there was no significant difference in birth weight or placental weight 
between participants requiring metformin or insulin treatment for GDM and 
those with diet and/or exercise management, Figure 4.8. 
 
 
 
 
 
 
 
Figure 4.8: Birth weight and GDM.  Birth weight was not significantly different 
when GDM participants were compared with BMI matched controls (A) or when 
divided according to management type (B) as determined by a one-way ANOVA 
and independent samples t-test respectively. GDM = gestational diabetes mellitus.  
 
 Of the 16 GDM participants, 3 delivered LGA infants and 13 AGA 
infants (determined by custom birth weight centiles). Therefore, placental 
gene expression was also compared between control (AGA) and GDM 
(AGA) participants and control (LGA) and GDM (LGA) participants 
respectively.   
 
4.3.2.3. Maternal GDM and placental PHLDA2 expression 
Placental PHLDA2 expression was approximately two fold higher in GDM 
pregnancies (Figure 4.9), however this difference was not statistically 
significant due to the large variation in PHLDA2 expression in the GDM 
placentas. When results were analysed according to BMI category, placental 
PHLDA2 expression was decreased in placentas of normal BMI GDM 
participants in comparison to normal BMI controls whereas expression was 
increased in high BMI GDM participants in comparison to high BMI controls 
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(Figure 4.9) suggesting an effect of BMI on the association between GDM 
and placental PHLDA2 expression. However, these differences were not 
statistically significant. Finally, there was no significant difference in placental 
PHLDA2 expression when participants were divided into those delivering 
AGA or LGA infants, Figure 4.9.  
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Placental PHLDA2 expression and GDM. PHLDA2 expression was 
not significantly altered in GDM placentas (A). Results remained non-significant 
when participants were compared with BMI matched controls (B) and according to 
AGA or LGA status (C). GDM = gestational diabetes mellitus.  
 
4.3.2.4. Maternal GDM and CDKN1C, PEG3 and PEG10 expression 
There was no significant difference in placental CDKN1C, PEG3 or PEG10 
expression between control and GDM participants, Figure 4.10. Results 
remained non-significant when gene expression was compared with BMI 
matched controls and when participants were divided into those delivering 
AGA or LGA infants (results not shown).  
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Figure 4.10: Placental CDKN1C, PEG3 and PEG10 expression and GDM. There 
was no significant difference in expression between GDM placentas and controls as 
determined by an independent samples T-test. GDM = gestational diabetes mellitus.  
 
 
4.3.2.5. Maternal GDM and placental hormone gene expression 
Placental hPL and PGH expression was not significantly altered in GDM 
participants (Figure 4.11). Results remained non significant when hPL 
expression was compared with BMI matched controls, see (Figure 4.11). 
There was however, a significant 36% increase in PGH expression in high 
BMI GDM placentas compared with matched controls (Figure 4.11). This was 
in contrast to a non-significant 19% decrease in normal BMI GDM placentas. 
Finally, there was no significant difference in placental hPL or PGH 
expression when participants were divided into those delivering AGA or LGA 
infants (results not shown). 
 
4.3.2.6. Gestational diabetes summary 
A summary of the changes in target gene expression in GDM placentas is 
shown in Table 4.4. Target gene expression was not significantly altered in 
placentas of GDM participants compared with controls.  
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Figure 4.11: Placental hPL and PGH expression and GDM. Gene expression 
was not significantly altered in GDM placentas (A). There was also no significant 
difference in hPL expression (B) when GDM participants were compared to BMI 
matched controls. In contrast, placental PGH expression was significantly increased 
in high BMI GDM participants compared with high BMI controls (C). Error bars 
represent SEM.  
 
Table 4.4. Summary of placental gene expression changes associated with 
maternal gestational diabetes. Fold gene expression is shown relative to control 
participants. Differences were not statistically significant using an independent 
samples T test.  
 
Gene Control Participants 
 (N=91) 
GDM participants 
(N=16) 
P Value 
PHLDA2 1.00 1.94 P = 0.25 
CDKN1C 1.00 1.26 P = 0.32 
PEG3 1.00 1.15 P = 0.58 
PEG10 1.00 1.14 P = 0.43 
hPL 1.00 1.34 P = 0.18 
PGH 1.00 1.14 P = 0.31 
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4.3.3. Maternal prenatal depression: Imperial cohort 
4.3.3.1. Participant demographics 
Placentas from the Imperial Cohort (N=30) were sampled following delivery 
by elective caesarean section and all infants were normal birth weight.  A 
median split of the cohort by maternal EPDS scores was carried out for the 
purpose of analysing association between maternal depression and placental 
gene expression. Gene expression was compared between participants with 
low EPDS scores (mean EPDS score 4.5) and high EPDS scores (mean 
EPDS score 14.5). Importantly, participants did not differ significantly in 
terms of any other maternal characteristic or birth outcome (Table 4.5).  
 
Table 4.5: Comparison of maternal characteristics and birth outcomes 
between high and low EPDS scorers. Mean (SD)/Range or Number (%) is shown. 
Differences were analysed using an independent samples T test or Chi – square 
test where appropriate. *** p < 0.001.  
 
Placental gene expression was also compared between participants with an 
EPDS score ≥ 13 (N = 9), (participants at risk of developing a depressive 
 Low EPDS 
scorers 
(N = 15) 
High EPDS 
scorers 
(N = 15) 
P Value 
Maternal Characteristic 
Total EPDS score 
Maternal age 
Maternal BMI (kg / m2) 
Parity 
Currently Smoking: 
No 
Yes 
Drinking Alcohol: 
No 
Yes 
Birth Outcome 
Birth weight (g) 
 
Gestational age (weeks) 
Placental weight (g) 
 
Gender 
Male 
Female 
 
4.5 (2) / 1 - 8 
36 (4) / 29 - 41 
25 (4) / 20 - 35 
2 (2) / 0 -11 
 
14 (93%) 
1 (7%) 
 
14 (93%) 
1 (7%) 
 
3501 (525) / 
2930 - 4700 
39 (0.5) / 38 - 40 
622 (163) / 387 - 
932 
 
6 (40%) 
9 (60%) 
 
14.5 (4) / 11 - 25 
35 (5) / 27 - 41 
25 (5) / 20 - 38 
2 (2) / 0 - 5 
 
13 (87%) 
2 (13%) 
 
11 (73%) 
4 (27%) 
 
3441 (402) / 
2640 - 4140 
39 (0.7) / 38 - 41 
644 (125) / 460 - 
851 
 
9 (60%) 
6 (40%) 
 
P < 0.001*** 
P = 0.83 
P = 0.78 
P = 0.87 
 
 
P = 0.60 
 
 
P = 0.14 
 
 
P = 0.73 
P = 0.75 
 
P = 0.68 
 
 
P = 0.27 
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disorder), and participants with an EPDS score <13 (N = 21). Notably, no 
participant had a prenatal diagnosis of depression and none were currently 
taking antidepressants. 
 
4.3.3.2. Maternal depression and birth weight 
There was no significant correlation between maternal prenatal EPDS scores 
and birth weight (r = - 0.24, p = 0.21, n = 30). Although birth weight was 
reduced in participants with the highest EPDS scores compared with the 
lowest scores (3501g v. 3441g, p = 0.73 n = 30) this difference was not 
statistically significant (Figure 4.12). Similarly there was no significant 
difference in birth weight when participants were divided into those with 
EPDS scores < 13 and ≥ 13 (cut off for clinical depression), Figure 4.12.  
 As with birth weight, no significant association was observed between 
placental weight and maternal EPDS or when participants were divided into 
low and high EPDS scorers (results not shown). 
 
Figure 4.12. Maternal depression and birth weight. (A) No significant difference 
in mean birth weight between 15 participants with lowest and highest EPDS scores. 
(B) No significant difference in mean birth weights between participants with EPDS 
scores < or ≥ 13.  Error bars represent SEM.  
 
4.3.3.3. Maternal depression and PHLDA2 and CDKN1C expression 
There was no significant association between placental PHLDA2 expression 
and maternal EPDS scores (r = 0.15, p = 0.42, n = 30) in the overall cohort.  
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Although placental PHLDA2 expression was increased in the highest EPDS 
scorers, this difference was not statistically significant (p = 0.33, n = 30), see 
Figure 4.13. Similarly, there was no significant difference in PHLDA2 
expression between participants with EPDS scores < 13 and ≥ 13 (p = 0.44, 
n = 30). 
 
 
 
 
 
 
Figure 4.13: Maternal depression and placental PHLDA2 (A) and CDKN1C (B) 
expression. (A) No significant difference in PHLDA2 expression between 15 
participants with lowest and highest EPDS scores. (B) No significant difference in 
CDKN1C expression between 15 participants with lowest and highest EPDS scores.  	  
There was no significant correlation between placental CDKN1C expression 
and maternal EPDS scores (r = - 0.20, p = 0.31, n = 30).  Similarly, no 
significant difference was seen in CDKN1C expression between the low and 
high EPDS scorers (Figure 4.13) or when comparing those participants with 
EPDS scores < 13 and  ≥ 13 (p = 0.30, n = 30). 
 
4.3.3.4. Maternal depression and PEG3 expression 
There was a significant inverse association between placental PEG3 
expression and maternal EPDS scores (r = - 0.36, p < 0.05, n = 30), Figure 
4.14. There was also a significant 15% decrease in placental PEG3 
expression in the high EPDS scorers (Figure 4.14).  
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Figure 4.14: Maternal depression and placental PEG3 expression. (A) A significant inverse correlation between placental PEG3 expression 
and maternal EPDS scores. B) A significant decrease in PEG3 expression between 15 participants with lowest and highest EPDS scores. (B) A 
trend for decreased PEG3 expression between participants with EPDS scores <13 and ≥ 13. Error bars represent SEM. * P <0.05.  
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  Placental PEG3 expression was also decreased in participants with 
EPDS scores ≥ 13 compared with those scoring <13, although this difference 
did not reach statistical significance (p = 0.08, n = 30), Figure 4.14.  
 
4.3.3.5. Maternal depression and hPL expression 
There was a trend for an inverse correlation between placental hPL 
expression and maternal EPDS scores (r = - 0.33, p = 0.08, n = 30), Figure 
4.15. A significant 31% decrease in placental hPL expression was observed 
in the 15 participants with the highest EPDS scores compared with the 15 
participants with the lowest EPDS scores (Figure 4.15).  
 
  
 
 
 
Figure 4.15: Maternal depression and placental hPL expression. (A) A trend for 
an inverse association between hPL expression and maternal EPDS scores. (B) A 
significant decrease in hPL expression between 15 participants with lowest and 
highest EPDS scores. Error bars represent SEM. * P <0.05.  
 
 However when participants were divided into those with EPDS score < 
13 and ≥ 13 expression was not significantly different, perhaps as a result of 
the few number of participants with an EPDS score ≥13 (p = 0.77, n = 30).  
There was no significant correlation between placental PEG3 and hPL 
expression (r = 0.04 p = 0.85, n = 30). Similarly, placental hPL expression 
was not significantly correlated with PHLDA2 (r = 0.12, p = 0.53, n = 30) or 
CDKN1C expression (r = 0.28, p = 0.14, n = 30).  
 164	  
4.3.3.6. Maternal depression and PGH expression 
Placental PGH expression was significantly inversely correlated with 
maternal EPDS scores (r = -0.38, p = 0.04, n = 30). However, no significant 
difference in PGH expression was seen between the 15 participants with the 
lowest and highest EPDS scores (p = 0.10, n = 30) or when comparing those 
participants with EPDS scores < 13 and ≥ 13 (p = 0.14, n = 30).  
There was no significant correlation between placental PGH 
expression and PHLDA2 (r = -0.07, p = 0.72, n = 30), CDKN1C (r = 0.14, p = 
0.45, n = 30) or PEG3 (r = 0.20, p = 0.30, n = 30) gene expression.  
 
Table 4.6. Summary of placental gene expression changes associated with 
maternal prenatal depression in the Imperial depression cohort. Fold gene 
expression is shown relative to low depression scorers. Results highlighted in bold 
were statistically significant using an independent samples T test. * p ≤ 0.05.   
 
 
 
4.3.3.7. Maternal depression summary 
A summary of the changes in placental gene expression in association with 
maternal prenatal depression in the Imperial Cohort is shown in Table 4.6. 
Only placental PEG3 and hPL expression were significantly reduced in 
placentas of participants with high total EPDS scores.  
 
Gene Low Depression 
scores (N=15) 
High Depression 
scores (N=15) 
P Value 
PHLDA2 1.00 1.29 P = 0.33 
CDKN1C 1.00 0.75 P = 0.10 
PEG3 1.00 0.85 P = 0.03* 
hPL 1.00 0.69 P = 0.03* 
PGH 1.00 0.68 P = 0.10 
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4.3.4. Maternal depression: Manchester cohort 
In order to replicate the findings of a significant inverse association between 
placental PEG3 and hPL expression and maternal depression, gene 
expression was analysed in a second independent cohort.  
 
4.3.4.1. Participant demographics 
Characteristics of the overall Manchester cohort are shown in Table 3.9 
(Section 3.3.3). This cohort did not have EPDS scores, but included a subset 
of women (N = 7) with diagnosed depression during pregnancy. Placental 
gene expression was compared with control participants (N=70) with no 
previous history of mood disorders or other maternal complication (e.g. 
asthma, epilepsy). Maternal characteristics and birth outcomes did not differ 
significantly between depressed participants and controls (Table 4.7). 
 
4.3.4.2. Maternal depression and birth weight 
As with the Imperial Cohort, infants of mothers with depression during 
pregnancy were lighter than control infants (3296g v. 3092g, p = 0.41 n = 77) 
although this difference was not statistically significant (Table 4.7). For this 
cohort, custom growth centiles were available; there was a non-significant 
decrease in mean growth centile of infants born to depressed mothers 
compared with control infants (Table 4.7).  
 
4.3.4.3. Maternal depression and imprinted gene expression 
For this cohort, placental PEG10 expression was also analysed due to the 
larger amounts of cDNA available for gene expression analysis. There was 
no significant difference in placental PHLDA2, CDKN1C or PEG10 
expression between depressed and control participants (Figure 4.16). 
However, as with the Imperial Cohort, maternal prenatal depression was 
associated with a significant decrease in placental PEG3 expression (Figure 
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4.16). Compared with the 15% decrease in PEG3 expression observed with 
maternal depression in the Imperial Cohort, in the Manchester cohort 
maternal depression was associated with a 40% decrease in gene 
expression (p = 0.02, n = 77). 
 
Table 4.7: Comparison of maternal characteristics and birth outcomes 
between control and depressed participants. Mean (SD)/Range or Number (%) 
is shown. Differences were analysed using an independent samples T test or Chi – 
square test where appropriate.  
 
 Control 
Participants  
(N = 70) 
Depressed 
participants  
(N = 7) 
P Value 
Maternal Characteristic 
Maternal age 
Maternal BMI (kg / m2) 
Parity 
Currently Smoking: 
No 
Yes 
Drinking Alcohol: 
No 
Yes 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Custom birth weight centile 
Gestational age (weeks) 
Gender 
Male 
Female 
 
28 (5) / 17 - 42 
26 (4) / 19 - 38 
3 (2) / 1 - 9 
 
64 (86%) 
10 (14%) 
 
73 (99%) 
1 (1%) 
 
 
38 (51%) 
4 (5%) 
9 (12%) 
23 (31%) 
3331 (619) / 850 - 
4680 
42 (30) / 0 – 99 
39 (2) / 30 - 42 
 
35 (47%) 
39 (53%) 
 
29 (7) / 19 - 35 
24 (4) / 20 – 30  
4 (3) / 1 - 9 
 
5 (83%) 
1 (17%) 
 
7 (100%) 
0 (0%) 
 
 
4 (67%) 
1 (17%) 
0 (0%) 
1 (17%) 
3092 (507) / 
2440 - 3720 
28 (25) / 2 - 61 
39 (2)/ 36 - 41 
 
3 (50%) 
3 (50%) 
 
P = 0.86 
P = 0.53 
P = 0.11 
 
 
P = 1.00 
 
 
P = 0.75 
 
 
 
 
 
P = 0.11 
 
P = 0.41 
P = 0.30 
P = 0.49 
 
 
P = 0.72 
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Figure 4.16: Maternal clinical depression and placental imprinted gene 
expression. Only placental PEG3 expression was significantly altered in mothers 
with clinical depression during pregnancy. * p ≤ 0.05.  Error bars represent SEM.  
 
4.3.4.4. Maternal depression and placental hormones 
Placental hPL expression was significantly decreased by 44% in mothers 
with diagnosed depression in pregnancy compared with controls (p = 0.02, n 
= 77)(Figure 4.17), replicating results from the Imperial cohort (section 4.3.3).  
Maternal serum hPL levels were measured for 54 participants in the 
Manchester Cohort. Serum hPL was reduced in mothers with prenatal 
diagnosed depression (Figure 4.17), however due to the small number of 
depressed participants (N=2) with serum hPL measures this difference could 
not be statistically analysed.  
In the Manchester Cohort, placental PEG3 and hPL expression were 
significantly correlated (r = 0.28, p = 0.01, n = 77) as shown in Figure 4.17. 
However, there was no significant correlation between maternal serum hPL 
levels and placental PEG3 (r = - 0.05, p = 0.75, n = 54) or hPL expression (r 
= -0.07, p = 0.61, n = 54), as shown in Figure 4.17. 
 In addition, placental PGH expression was significantly decreased by 
43% in mothers with diagnosed depression (p = 0.03, n = 77) (Figure 4.17).
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Figure 4.17: Maternal depression and placental hormones. (A) Placental hPL and PGH expression were significantly reduced in 
depressed participants. (B) Serum hPL levels were also decreased although this could not be analysed statistically due to the small 
sample size. Placental PEG3 expression was significantly positively associated with hPL expression (C) but not serum hPL levels 
(D). 	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4.3.4.5. Maternal depression medication and placental gene expression 
Of the seven participants with diagnosed prenatal depression, four 
participants were taking prescribed medication for the treatment of 
depression (most commonly selective serotonin reuptake inhibitors, SSRIs). 
There was no significant difference in placental target gene expression 
between depressed participants on prescribed SSRIs during pregnancy and 
those not on prescribed medication for depression (Figure 4.18). Given the 
small numbers of participants in this analysis, these results must be 
interpreted with caution. However, they do suggest that the difference in 
placental PEG3, hPL and PGH expression in clinically depressed participants 
may not be a result of medication differences.  
 
 
 
 
 
 
Figure 4.18: Maternal prescribed medication for clinical depression and 
placental target gene expression. There was no significant difference in target 
gene expression between depressed participants prescribed SSRIs and those not 
prescribed medication during pregnancy as determined by an independent samples 
T test. SSRI = selective serotonin reuptake inhibitor. Error bars represent SEM.  
 
4.3.4.6. Manchester depression cohort summary 
A summary of the changes in placental gene expression in association with 
maternal clinical depression in the Manchester Cohort is shown in Table 4.6. 
Replicating the results from the Imperial Cohort (see section 4.3.3) placental 
PEG3 and hPL expression were significantly reduced in placentas of 
participants with clinical depression. In addition, placental PGH was also 
significantly reduced in depression participants.   
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Table 4.8. Summary of placental gene expression changes associated with 
maternal clinical depression in the Manchester cohort. Fold gene expression is 
shown relative to controls. Results highlighted in bold were statistically significant 
using an independent samples T test. * p ≤ 0.05.  
 
 
 
4.3.5. Maternal prenatal anxiety 
Maternal anxiety and depression are often co-morbid and indeed within the 
Imperial Cohort maternal EPDS and STAI scores were significantly 
correlated (r = 0.81**, p<0.001, n= 30), Figure 4.19. However, it has also 
previously been demonstrated that anxiety and depression are independently 
associated with altered placental gene expression (O’Donnell et al. 2012; 
Blakeley et al. 2013). Therefore, placental imprinted and hormone gene 
expression was also analysed in relation to maternal prenatal trait anxiety in 
the Imperial Anxiety Cohort.  
Gene Controls                   
(N = 70) 
Clinical Depression   
(N = 7) 
P Value 
PHLDA2 1.00 0.86 P = 0.87 
CDKN1C 1.00 1.13 P = 0.49 
PEG3 1.00 0.60 P = 0.02* 
PEG10 1.00 0.82 P = 0.49 
hPL 1.00 0.56 P = 0.02* 
PGH 1.00 0.57 P = 0.03* 
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Figure 4.19: Maternal depression and trait anxiety scores. Maternal trait anxiety 
was measured using the Spielberger Trait Anxiety Inventory (STAI). Maternal 
depression was measured using the Edinburgh Postnatal Depression Scale. ** p < 
0.001.  
 
Table 4.9: Comparison of maternal characteristics and birth outcomes 
between high and low STAI scorers. Mean (SD)/Range or Number (%) is shown. 
Differences were analysed using an independent samples T test or Chi – square 
test where appropriate.  
 STAI score < 40 
(N = 15) 
STAI score ≥40 
(N = 15) 
P Value 
Maternal Characteristic 
Total STAI score 
Maternal age 
Maternal BMI (kg / m2) 
Parity 
Currently Smoking: 
No 
Yes 
Drinking Alcohol: 
No 
Yes 
Birth Outcome 
Birth weight (g) 
 
Gestational age (weeks) 
Placental weight (g) 
 
Gender 
Male 
Female 
 
27 (4) / 20 - 32 
36 (4) / 27 - 42 
25 (5) / 19 - 35 
2 (3) / 0 -11 
 
14 (93%) 
1 (7%) 
 
14 (93%) 
1 (7%) 
 
3448 (426) / 2930 
– 4700  
39 (0.5) / 38 - 39 
629 (143) / 422 - 
932 
 
8 (53%) 
7 (47%) 
 
50 (7) / 41 - 66 
36 (5) / 26 - 41 
24 (5) / 20 - 38 
2 (2) / 1 - 6 
 
14 (93%) 
1 (7%) 
 
8 (53%) 
7 (47%) 
 
3360 (382) / 2640 
- 4140 
39 (0.6) / 38 - 41 
585 (93) / 422 - 
762 
 
8 (53%) 
7 (47%) 
 
P < 0.001*** 
P = 0.85 
P = 0.69 
P = 0.87 
 
 
P = 0.37 
 
 
P = 0.01** 
 
P = 0.56 
P = 0.75 
P = 0.33 
 
 
P = 1.00 
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4.3.5.1. Participant demographics 
 
All placentas (N=30) were sampled following delivery by elective caesarean 
section and all infants were normal birth weight. 
 The mean maternal STAI score was 38.2, with 15 women scoring ≥ 
40, highlighting them as at risk of developing an anxiety disorder. Placental 
gene expression was compared between participants with a low STAI score 
<40 (N=15) and those with a high STAI score ≥ 40 (N=15). This also 
represented a median split of the Imperial Anxiety Cohort. Notably, no 
participant had a prenatal diagnosis of or was receiving treatment for an 
anxiety disorder. Participant characteristics and birth outcomes are compared 
in Table 4.9. Maternal alcohol consumption during pregnancy was 
significantly more frequent in participants with an STAI score ≥ 40 (table 4.9). 
Participants did not differ significantly in any other maternal characteristic of 
birth outcome examined.   
Figure 4.20. Effects of maternal anxiety on birth weight (A) and placental 
weight (B). No significant difference in mean birth or placental weight between 
participants with STAI scores < or ≥ 40. Error bars represent SD.  
 
4.3.5.2. Maternal anxiety and birth weight  
No significant correlation was observed between birth weight and maternal 
prenatal STAI scores (r = - 0.13, p = 0.50, n = 30). Similarly, placenta and 
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birth weight were not significantly altered in participants with STAI scores ≥40 
(Figure 4.20)  
 
4.3.5.3. Maternal anxiety and imprinted gene expression 
There was no significant association between maternal STAI scores and 
placental PHLDA2 (r = 0.12, p = 0.58, n = 30), CDKN1C (r = - 0.10, p = 0.60, 
n = 30) or PEG3 (r = - 0.24, p = 0.20, n = 30) gene expression. Furthermore, 
no significant difference was seen in placental imprinted gene expression 
when participants were divided into those with STAI scores < 40 or ≥40 
(Figure 4.21). 
Figure 4.21. Maternal Anxiety and placental imprinted gene expression. There 
was no significant difference in PHLDA2, CDKN1C or PEG3 expression between 
participants with STAI scores < or ≥ 40. Error bars represent SEM.  
 
In contrast to the significant decrease in placental PEG3 expression with 
maternal depression, only a trend was observed for maternal STAI scores ≥ 
40 (p = 0.09, n = 30).  
 
4.3.5.4. Maternal anxiety and placental hormone gene expression 
A trend was observed for an inverse association between maternal STAI 
scores and placental hPL expression (r = - 0.35, p = 0.07, n = 30). Similarly, 
although a decrease was seen in hPL expression in placentas of mothers 
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with an STAI score ≥40, this did not reach statistical significance (p = 0.09, n 
= 30), Figure 4.22. Placental PGH expression was significantly inversely 
associated with maternal STAI scores (r = - 0.39, p = 0.04, n = 30). However, 
there was no significant difference in PGH expression between mothers with 
STAI score ≥40 and <40 (p = 0.09, n = 30), Figure 4.22.  
 
 
 
 
 
 
Figure 4.22. Maternal Anxiety and placental hormone gene expression. No 
significant difference in hPL or PGH expression between participants with STAI 
scores < or ≥ 40. Error bars represent SEM.  
 
Table 4.10. Summary of placental gene expression changes associated with 
maternal prenatal trait anxiety (STAI). Fold gene expression is shown relative to 
participants with STAI score < 40. Results were not statistically significant using an 
independent samples T test.  
 
Gene Low Anxiety,  
STAI < 40 (N=15) 
High Anxiety,  
STAI ≥ 40 (N=15) 
P Value 
PHLDA2 1.00 1.16 P = 0.56 
CDKN1C 1.00 0.89 P = 0.29 
PEG3 1.00 0.86 P = 0.09 
hPL 1.00 0.76 P = 0.09 
PGH 1.00 0.66 P = 0.09 
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A summary of the changes in placental gene expression in association with 
maternal prenatal trait anxiety is shown in Table 4.10. Trait anxiety is a 
measure of how the participant “generally feels”. Maternal SSAI scores, 
measuring how the participant felt “at that moment” (day before elective 
Caesarean section) were also available for the Imperial Anxiety Cohort. 
There was no significant association between maternal SSAI scores and 
placental PHLDA2, CDKN1C, PEG3, hPL or PGH expression (results not 
shown), suggesting a specific effect of trait anxiety.  
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4.4. Discussion 
This chapter examined a role for placental imprinted gene expression in the 
pregnancy complications preeclampsia, gestational diabetes and maternal 
mood disorders. A summary of imprinted gene expression alterations in 
these pregnancy complications is shown in Table 4.11. These results 
suggest a role for placental PHLDA2 in the pathogenesis of preeclampsia 
and a role for PEG3 and placental hormones in maternal mood disorders 
during pregnancy.  
 
 Table 4.11. Summary of target gene expression changes following 
complications of pregnancy. Percentage change in expression relative to controls 
is shown. PIH = pregnancy induced hypertension, PE = preeclampsia, GDM = 
gestational diabetes mellitus.  
 
Gene PIH/PE GDM Depression 
(Imperial 
Cohort) 
Depression 
(Manchester 
cohort) 
Trait 
Anxiety 
PHLDA2 ↑ 63% - - - - 
CDKN1C - - - - - 
PEG3 - - ↓ 15% ↓ 40% - 
PEG10 - - - - - 
hPL - - ↓ 31% ↓ 44% - 
PGH - - - ↓ 43% - 
 
4.4.1. Preeclampsia 
Birth weight and custom birth weight centiles were significantly reduced in PE 
but not PIH pregnancies compared with controls. Head circumference was 
similarly reduced in PIH/PE pregnancies. Although placental weight was also 
decreased in PIH/PE pregnancies, this difference did not reach statistical 
 177	  
significance. This is consistent with previous studies reporting increased 
prevalence of FGR in PIH/PE pregnancies (Villar et al. 2006; Hutcheon et al. 
2011). Villar et al. (2006) estimated that IUGR occurred in 22% of women 
with PE and in 13% of women with PIH; indeed SGA was observed in 38% of 
the PIH/PE pregnancies in the current study.  
 Placental PHLDA2 expression was significantly increased by 63% in 
PIH/PE pregnancies. Furthermore, this increase was found to be specific to 
PE pregnancies. Given the increased prevalence of SGA in these 
pregnancies, it is possible the increased PHLDA2 expression observed in 
PIH/PE placentas reflects the association between placental PHLDA2 and 
fetal growth observed in the current study (Chapter 3), rather than a specific 
association with preeclampsia. However, placental PHLDA2 expression was 
increased by over 50% in PIH/PE pregnancies with or without the presence 
of SGA. Unfortunately, these differences were not statistically significant, 
possibly as a result of the relatively small number of PIH/PE pregnancies in 
each group (16 AGA and 6 SGA with PIH/PE). These results are consistent 
with those of McMinn et al. (2006) reporting a non-significant increase in 
PHLDA2 expression in PE placentas. Uniquely, the results of the current 
study also suggest a role for increased placental PHLDA2 expression in the 
pathogenesis of preeclampsia, independent of any associated effect on fetal 
growth. 
  PIH/PE was also associated with a 45% increase in placental 
CDKN1C expression. However, multiple linear regression analysis revealed 
that preeclampsia did not independently predict placental CDKN1C 
expression after controlling for labour status. Previous studies examining 
placental CDKN1C expression in human preeclamptic pregnancies have 
yielded conflicting results. Enquobahrie et al. (2008) and Unek et al. (2014) 
reported increased CDKN1C expression in preeclamptic placentas while 
Kawasaki et al. (2015) reported significantly reduced placental CDKN1C 
expression. Given the association between labour and placental CDKN1C 
expression demonstrated in chapter 3, it is possible that these conflicting 
results result from a failure to control for labour status. For example, the 
caesarean delivery rate differed between control and PE pregnancies in the 
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study by Enquobahrie et al. (2008) whereas in the study by Unek et al. 
(2014), labour status was not described. 
Placental PEG3 and PEG10 expression was not significantly altered in 
PIH/PE pregnancies. Lambertini et al. (2008) reported LOI of PEG3 in 50% of 
PE placentas examined although gene expression was not analysed. Studies 
of placental PEG10 expression in relation to PE have yielded conflicting 
results; Chen et al. (2012) reported increased expression and Liang et al. 
(2014) decreased expression of PEG10 in PE placentas. In comparison, it is 
possible that the current study did not detect any differences in PEG10 
expression due to cohort differences. For example, Chen et al. (2012) 
analysed severe cases of preeclampsia (onset before 34 weeks) and Liang 
et al. (2014) excluded cases of PIH. In summary the results of the current 
study do not support a role for placental PEG3 or PEG10 in the pathogenesis 
of preeclampsia.  
Finally, placental hPL and PGH expression was not significantly 
altered in PIH/PE pregnancies. Although Mannik et al. (2012) demonstrated 
significantly reduced hPL and PGH expression in PE placentas, the majority 
of pregnancies were complicated by severe preeclampsia. It is therefore 
possible that the current study did not detect any association preeclampsia 
and hPL or PGH expression due to differences in disease severity. Thus, the 
results of the current study do not support a role for placental hPL or PGH in 
preeclampsia. 
 
4.4.2. Gestational diabetes 
Maternal BMI was significantly higher in GDM compared with control 
pregnancies. Therefore, placental gene expression analysis was split by BMI 
category. Results are consistent with reports of raised BMI increasing GDM 
risk (Teh et al. 2011; Mitanchez et al. 2014). In contrast, maternal weight gain 
during pregnancy was significantly lower in GDM participants, possible as a 
result of diet and exercise management of GDM. Similarly, Hartlington et al. 
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(2013) observed significantly reduced maternal weight gain in GDM 
pregnancies.  
 Birth weight, custom birth weight centiles and placental weight were 
not significantly altered in GDM pregnancies. This contrasts reports by 
Hartlington et al. (2013) of an almost two fold increased risk of LGA in GDM 
pregnancies. However, this meta-analysis included studies of up to 34,000 
participants. It is therefore possible, that an effect of GDM on birth weight 
was not observed in the current study due to the relatively small number of 
GDM participants recruited.  
 Placental PHLDA2 expression was almost two fold higher in GDM 
pregnancies, although this difference failed to reach statistical significance 
due to the large variation in PHLDA2 expression in the GDM group and small 
sample sizes. Aberrant placental PHLDA2 expression (≥ 2 fold) was 
demonstrated in 19% of GDM participants. When results were split by 
maternal BMI, placental PHLDA2 expression was only increased in high BMI 
GDM participants compared with high BMI controls (although again this result 
was not statistically significant). This suggests an effect of BMI on the 
association between GDM and placental PHLDA2 expression. No previous 
study has examined placental PHLDA2 expression in relation to GDM. 
Therefore, these novel preliminary results, although not significant, prompt 
additional research as to the role of placental PHLDA2 in GDM pregnancies.  
 In contrast, placental CDKN1C, PEG3 and PEG10 expression were 
not significantly altered in GDM pregnancies. No previous study has 
examined placental CDKN1C, PEG3 or PEG10 expression in relation to 
GDM. The results of the current study do not support a role for CDKN1C, 
PEG3 or PEG10 in the pathogenesis of GDM.  
 Placental hPL expression was not significantly altered in GDM 
pregnancies (independent of maternal BMI). Mannik et al. (2010) similarly 
reported no significant difference in hPL expression in GDM placentas. This 
is surprising given the key role of hPL in preventing glucose intolerance 
during pregnancy (Newbern and Freemark 2011) and the increase in 
placental PHLDA2 expression observed in GDM placentas (which was 
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demonstrated to be inversely correlated with placental hPL expression). 
Studies of larger GDM cohorts are required to fully determine the role of 
placental PHLDA2 in GDM and the possible role of hPL in mediating this 
association.  
Finally, placental PGH expression was significantly increased in high 
BMI GDM pregnancies compared with high BMI controls. This was in 
contrast to a non-significant decrease in normal BMI GDM placentas. Mannik 
et al. (2012) similarly reported increased PGH expression in placentas of 
GDM women delivering LGA infants. The results of the current study are also 
consistent with the known role of PGH in promoting fetal growth through 
induction of peripheral insulin resistance during pregnancy (Newbern and 
Freemark 2011). The effect of maternal BMI on the association between 
placental PGH expression and GDM is intriguing. A similar effect of maternal 
obesity on the association between GDM and adverse infant outcomes has 
been noted (Makgoba et al. 2012; Mitanchez et al. 2014). Thus, the findings 
of the current study support a role for placental PGH in GDM and uniquely 
suggest that maternal BMI mediates this association.  
 
4.4.3. Maternal depression 
Maternal prenatal depression was associated with decreased placental 
PEG3 expression in both the Imperial and Manchester Cohorts. In the 
Imperial Cohort, placental PEG3 expression was significantly decreased by 
15% in mothers with the highest EPDS scores compared with those with the 
lowest EPDS scores. While the change in gene expression was modest, this 
finding was replicated in a second independent cohort. In the Manchester 
Cohort, placental PEG3 expression was decreased by 40% in participants 
with diagnosed depression during pregnancy. The role of Peg3 in regulating 
rodent maternal behaviour via a direct action in the brain is well established 
(Li et al. 1999; Curley et al. 2004; Champagne et al. 2009; Chiavegatto et al. 
2012), however this is the first report that placental PEG3 is associated with 
maternal mood in humans.  
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Peg3 in the rodent placenta is known to be responsive to 
environmental stimuli, such as maternal diet (Broad and Keverne 2011; 
Radford et al. 2012). It is therefore possible that human placental PEG3 is 
responsive to maternal prenatal stress, or alterations in maternal lifestyles 
associated with prenatal stress. However, the association between maternal 
mood and placental expression of PEG3 also raises the possibility that this 
gene may modulate maternal psychological adaptation to pregnancy 
indirectly via the placenta.  
Maternal prenatal depression was also associated with decreased 
placental hPL expression in both the Imperial and Manchester Cohorts. In the 
Imperial Cohort, placental hPL expression was significantly decreased by 
31% in mothers with the highest EPDS scores compared with those with the 
lowest EPDS scores. Similarly, maternal diagnosed depression during 
pregnancy was associated with a 44% decrease in placental hPL expression 
in the Manchester Cohort. Maternal serum hPL levels were only available for 
two participants with diagnosed depression in the Manchester Cohort; 
although hPL levels were decreased compared with controls this could not be 
statistically analysed.  
hPL is a key placental lactogenic hormone, closely related to the 
pituitary hormone prolactin, which has been demonstrated to induce maternal 
behaviour in animal studies (Bridges et al. 1985; Bridges et al. 1990; Bridges 
and Freemark 1995; Bridges et al. 1997). Previous studies have 
demonstrated decreased serum prolactin levels in mothers with postnatal 
depression symptoms (Abou-Saleh et al. 1998; Ingram et al. 2003; Groer and 
Morgan 2007). This study is the first to report that perturbed hPL expression 
in the human placenta is associated with abnormal maternal mood. Further 
research is required both in a larger study cohort and one in which maternal 
serum levels of hPL can be measured to determine whether reduced 
placental hPL expression in the term placenta manifests as reduced hormone 
serum level during pregnancy. This is of clinical relevance since it may be 
possible to use maternal serum hPL levels as a biomarker in combination 
with self-report questionnaires to identify mothers at high risk of maternal 
depression.  
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There was no significant association between PEG3 and hPL 
expression (p = 0.59) in the Imperial cohort. However, placental PEG3 
expression was significantly positively associated with hPL expression in the 
Manchester cohort (p = 0.03), perhaps reflecting the larger sample size. A 
relationship between PEG3 and hPL expression is consistent with the finding 
that loss of function of Peg3 in the mouse placenta results in a marked 
alteration in the expression of several mouse placental lactogens as 
gestation proceeds (Broad and Keverne 2011; Kim et al. 2013a).  
There was no significant association between maternal prenatal 
depression and placental PHLDA2 expression in either cohort. In an animal 
model, female mice carrying Phlda2 mutant pups display altered maternal 
behaviours (RMJ lab, unpublished data). It is therefore possible that placental 
PHLDA2 expression is associated with other aspects of maternal 
psychological adaptation to pregnancy, such as mother-infant bonding which 
requires investigation in future studies.  
 Finally, placental PGH expression was significantly decreased by 43% 
in mothers with diagnosed depression during pregnancy. PGH promotes fetal 
growth through induction of peripheral insulin resistance in the mother 
resulting in preferential transfer of glucose to the fetus (Newbern and 
Freemark 2011). The novel finding of decreased placental PGH expression in 
mothers with diagnosed depression may underlie the reported association 
between depression during pregnancy and fetal growth restriction (Steer et 
al. 1992; Henrichs et al. 2010; Uguz et al. 2013). This remains to be 
confirmed in a larger study where maternal serum PGH levels can be 
measured.  
 
4.4.4. Maternal anxiety  
Although anxiety and depression are co-morbid, placental PEG3 and hPL 
expression was not significantly altered in mothers with the highest STAI 
scores compared with those with the lowest STAI scores. However, a trend 
for reduced placental expression of PEG3 and hPL in mothers with higher 
symptoms of trait anxiety (p = 0.09) was observed. Blakeley et al. (2013) and 
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O’Donnell et al. (2012) similarly reported different effects of maternal prenatal 
anxiety and depression on placental gene expression. The differential 
associations, if any, of placental PEG3 and hPL expression with depression 
and anxiety, remain to be determined in a larger cohort.  
 
4.4.5. Summary 
In summary, the results presented in this chapter suggest a role for aberrant 
placental PHLDA2 in preeclampsia. Placental PHLDA2 expression was 
significantly increased in PE pregnancies, independent of any associated 
effect on fetal growth. In contrast, the results of the current study do not 
support a role for aberrant imprinted gene expression in gestational diabetes, 
although further studies on larger GDM cohorts are needed to confirm this 
result. Finally, this study demonstrated decreased placental PEG3 and hPL 
expression in pregnancies complicated by maternal mood disorders. These 
novel results provide the first evidence to support the hypothesis that 
aberrant placental function may influence maternal mood during pregnancy. 
In conclusion, this chapter supports the third study hypothesis of aberrant 
placental imprinted gene expression in pregnancies complicated by PE and 
maternal mood disorders and therefore highlights a role for placental 
imprinted genes in maternal adaptation to pregnancy, an observation which 
warrants further research.  
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CHAPTER 5: HUMAN PLACENTAL IMPRINTED GENE 
EXPRESSION AND MATERNAL LIFESTYLE 
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5.1. Introduction  
Results from Chapters 3 and 4 support a role for aberrant imprinted gene 
expression in fetal growth restriction and other complications of pregnancy 
such as preeclampsia and maternal mood disorders. Therefore, identifying 
factors responsible for altered imprinted gene expression is of paramount 
importance. Of particular interest are maternal lifestyle factors, as these may 
be most amenable to intervention.  
 A number of studies have examined the relationship between maternal 
lifestyle factors and fetal growth. Smoking during pregnancy in particular has 
been associated with a two fold increased risk of LBW (Pollack et al. 2000; 
Figueras et al. 2008; Rasmussen and Irgens 2006) and has been estimated 
to account for 11% of LBW pregnancies (Pollack et al. 2000). Although 
current NICE guidelines recommend cessation of smoking during pregnancy 
(NICE 2010), an estimated 16% of mothers in Wales continue smoking 
during pregnancy (Health and Social Care information Centre 2012). Despite 
the well established association between smoking and growth restriction, the 
mechanisms underlying this relationship are unclear. Proposed mechanisms 
include restriction of placental oxygen supply, transfer of toxic compounds to 
the fetus and/or direct effects on placental development and function (Pollack 
et al. 2000; Zdravkovi et al. 2006).  
 Although light, recreational exercise is considered safe during 
pregnancy (in the absence of any medical complications) (RCOG 2006), a 
number of studies have reported significantly decreased birth weight in 
women carrying out strenuous exercise during pregnancy (Clapp 2003; Bell 
et al. 1995). This has been proposed to be due to an exercise-induced 
reduction in placental blood flow and growth (Clapp 2003; Juhl et al. 2010).  
 Heavy alcohol consumption during pregnancy (> one drink/day) has 
also been demonstrated to negatively affect birth weight, although it is 
unclear whether light to moderate drinking has any effect on fetal growth 
(Patra et al. 2011; Henderson et al. 2007). NICE guidelines recommend that 
pregnant women should not consume alcohol in the first trimester and those 
choosing to drink alcohol during pregnancy should consume no more than 1 
to 2 units a week (NICE 2008). However, approximately 39% of women in 
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Wales are estimated to continue drinking alcohol during pregnancy (Infant 
Feeding Survey 2010). In addition, illegal drug use during pregnancy has 
been associated with a significantly increased risk of growth restriction (Pinto 
et al. 2010).  
 Both extremes of maternal BMI have been associated with fetal 
growth restriction. Low pre-pregnancy BMI, short stature and poor weight 
gain during pregnancy significantly increase the risk of delivering a LBW 
infant (Valero de Bernabe et al. 2004). In contrast, although maternal obesity 
is generally thought to be protective against growth restriction, Gardosi 
(2009) demonstrated that in fact the risk of SGA is also increased in obese 
mothers. NICE guidelines recommend weight loss in obese women before 
pregnancy in order to minimise associated risks for mother and fetus during 
pregnancy (NICE 2010b). Given that 58% of people in Wales are overweight 
and 23% obese (Health and Social Care information Centre 2012), it is likely 
that a substantial number of women are obese during pregnancy.  
 Finally, a number of studies have analysed maternal diet with respect 
to effects on fetal growth. Indeed, the importance of a healthy diet during 
pregnancy is recognised in clinical practice with current NICE guidelines 
recommending that pregnant women receive information on diet and nutrition 
at their booking appointment (NICE 2008). Fruit and vegetable consumption 
in particular have been demonstrated to be positively associated with birth 
weight (Mikkelsen et al. 2006; Rao et al. 2001; Thompson et al. 2010; 
Matthews et al. 1999). However, it is estimated that only 33% of people in 
Wales consume the minimum five portions of fruits or vegetables a day 
(Health and Social Care information Centre 2012) that is recommended (FSA 
2007). Dairy consumption during pregnancy is similarly positively associated 
with birth weight (Ford 2011; Xue et al. 2008; Olsen et al. 2007; Ludvigsson 
and Ludvigsson 2004). It is recommended that a healthy daily diet include 
moderate amounts of dairy (FSA 2007) and that this should be increased 
during pregnancy (Ortega 2001).  
 Studies have yielded conflicting results regarding the relationship 
between maternal carbohydrate consumption and fetal growth with some 
reporting a positive association (Mitchell et al. 2004; Thompson et al. 2010) 
and others a negative association (Godfrey et al. 1996; Moore et al. 2004). It 
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is currently recommended that as part of a healthy diet, 50% of food energy 
should come from total carbohydrates (FSA 2007) but that this should not be 
increased during pregnancy (Williamson et al. 2006). Conflicting results have 
also been reported regarding the relationship between maternal protein 
consumption during pregnancy and fetal growth with some studies reporting 
a positive association (Godfrey et al. 1996; Ford 2011; Thompson et al. 2010; 
Moore et al. 2004) and others a negative association (Knudsen et al. 2008; 
Campbell et al. 1996; Ricci et al. 2010). It is recommended that a healthy 
daily diet contain protein-rich foods (such as meat, fish or meat alternatives) 
(FSA 2007) with some studies suggesting that this should be increased 
during pregnancy (Ortega 2001; Williamson 2006). Fish is one source of 
protein in particular, which has been positively associated with birth weight 
(Makrides et al. 2009; Ricci et al. 2010; Rogers et al. 2004). Indeed, it is 
recommended that at least two portions of fish are consumed a week as part 
of a healthy diet (FSA 2007).  
 Maternal caffeine consumption has also been demonstrated to be 
negatively associated with fetal growth (Santos et al. 1998; Xue et al. 2008; 
Vik et al. 2003) and as such it is recommended that pregnant women 
consume no more than 200mg of caffeine a day, which equates to 
approximately two mugs of instant coffee (FSA 2007). Finally, micronutrients 
in the form of maternal folate and iron supplementation are positively 
associated with birth weight (Godfrey et al. 1996; Mitchell et al. 2004), 
although only daily folate supplementation is routinely recommended to all 
pregnant women (NICE 2008).  
 Importantly, with respect to analysing the effect of maternal diet on 
fetal growth, it has been suggested that analysis of diet patterns (rather than 
individual food items or groups as described above) provides more 
information on the interacting effects of food items and is of greater relevance 
in the design of future healthy eating interventions (Crozier et al. 2008). In 
particular, analysis of diet patterns during pregnancy has previously revealed 
two contrasting diets; the “Western Diet” or “Junk Food Diet” pattern 
characterised by frequent consumption of high fat and high sugar food items 
and the “Prudent Diet” or “Healthy Diet” pattern characterised by frequent 
consumption of fruit, vegetables, fish and dairy products (Hu 2002; Crozier et 
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al. 2006; Thompson et al. 2010). A prudent or healthy diet has been 
demonstrated to be associated with a significantly reduced risk of delivering 
an SGA infant (Thompson et al. 2010).  
 Thus, a number of studies highlight the effect of maternal lifestyle on 
fetal growth. However, the mechanisms underlying these associations are 
not well understood. The growth regulating functions of the placenta are 
vulnerable to changes in the maternal environment, providing a possible 
mechanism by which an adverse maternal lifestyle could result in fetal growth 
restriction (Fowden et al. 2011). For example, imprinted gene expression in 
the placenta is known to be responsive to environmental signals (Fowden et 
al. 2011), although the majority of these studies have focussed on maternal 
diet alterations in an animal model. It is therefore possible that aberrant 
placental imprinted gene expression may underlie the association between 
adverse maternal lifestyles and FGR, although this requires further 
investigation in human pregnancies.  
 Human placental PHLDA2 expression has been demonstrated to be 
significantly increased in mothers carrying out strenuous exercise during 
pregnancy (Lewis et al. 2011). Bruchova et al. (2010) also reported increased 
placental PHLDA2 expression in women smoking during pregnancy, although 
a subsequent study by Moore et al. (2015) failed to replicate this finding. 
While aberrant placental Phlda2 expression has been demonstrated in 
response to ethanol consumption and calorie restriction in pregnant rat dams 
(Shukla et al. 2011), the effects of maternal diet and alcohol consumption on 
human placental PHLDA2 expression remain to be determined. Similarly, 
placental CDKN1C expression was not significantly altered in mothers who 
continued smoking during pregnancy (Moore et al. 2015). In an animal 
model, placental Cdkn1c expression was increased in response to maternal 
ethanol consumption and calorie restriction (Shukla et al. 2011), but not 
significantly altered by a high fat – high sugar diet (Sferruzi-Perri et al. 2013). 
PEG3 expression was not significantly altered in placentas of smokers 
(Moore et al. 2015) or in the umbilical cord of obese mothers (Keshari et al. 
2014).  However, placental Peg3 expression was significantly decreased as a 
result of transient maternal starvation (Broad and Keverne 2011) and 
increased due to calorie restriction in a mouse model (Radford et al. 2012). In 
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contrast, no significant effect of maternal high fat or high fat- high sugar diet 
was observed on mouse placental Peg3 expression (Gallou-Kabani et al. 
2010; Sferruzzi-Perri et al. 2013). Finally, placental Peg10 expression has 
been demonstrated not to be significantly altered in response to a maternal 
high fat diet in a mouse model (Gallou-Kabani et al. 2010) or in response to 
human maternal obesity (Soubry et al. 2013) or antibiotic use during 
pregnancy (Vidal et al. 2014).  
 In summary, few studies have examined human placental expression 
of the imprinted genes PHLDA2, CDKN1C, PEG3 and PEG10 in response to 
maternal lifestyle during pregnancy. Given the evidence presented in 
Chapters 3 and 4 supporting a role for aberrant imprinted gene expression in 
fetal growth restriction and other complications of pregnancy such as 
preeclampsia and maternal mood disorders, identifying maternal lifestyle 
factors associated with aberrant placental imprinted gene expression was a 
key aim of this chapter. In addition, in light of the association reported 
between placental imprinted gene (PHLDA2 and CDKN1C) and hormone 
gene expression (hPL) in Chapter 3, the effects of maternal lifestyle on 
placental hormone gene expression were also analysed.  
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5.2.  Chapter specific methods 
5.2.1. Study participants  
The effects of maternal lifestyle on fetal growth and placental imprinted gene 
expression were examined in Caucasian control participants and (where 
relevant) in SGA participants of the Wales Cohort. Control participants were 
defined as those delivering AGA infants and with no documented 
complication of pregnancy or medical disorder. Otherwise healthy 
participants, with singleton pregnancies, were recruited antenatally at two 
research sites: UHW (Cardiff) and RGH (Newport). Only control placentas 
were used to determine maternal lifestyle effects on placental imprinted gene 
expression such that any effect observed was not due to the underlying 
association between imprinted gene expression and fetal growth.  
 
5.2.2. Maternal lifestyle measures 
A self-administered participant questionnaire was used to assess maternal 
BMI, smoking, alcohol consumption and illegal drug use before and during 
pregnancy. This data was compared with that recorded in the participant’s 
medical notes to ensure consistency in self-report measures. In addition, 
information on the number of cigarettes smoked and alcohol units consumed 
were recorded from the medical notes. 
The participant questionnaire also included a food frequency 
questionnaire (FFQ), with which the participant indicated how frequently they 
consumed each food item during their pregnancy. This FFQ (Appendix 3) 
was designed and trialled by A Janssen and J Crovini (Cardiff based 
nutritionist) as previous FFQs used in the study of diet during pregnancy 
were not suitable due to length, target population and/or diet components of 
interest. Although a basic, non-quantitative method for the assessment of 
diet, the FFQ was chosen in order to assess habitual diet during pregnancy 
in a format easily self-administered as part of the recruitment process.   
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5.2.3. Statistical analysis 
All statistical analysis was carried out using IBM SPSS statistics for Windows 
(version 20.0, 2011) with a p value <0.05 considered statistically significant. 
P-P plots were generated and a Shapiro-Wilk test carried out to test for 
normal distribution of the data. All variables in this chapter, including 
placental target gene expression, were normally distributed and therefore 
parametric tests were used in data analysis. Pearson correlation tests or 
partial correlations (when controlling for a potential confounding variable) 
were used to analyse associations between variables.  Differences between 
two groups or more were analysed using a T-test or one-way ANOVA (with a 
Tukey post-hoc test) respectively.  
In addition, specific to this chapter, principle component analysis 
(PCA) was used to analyse maternal diet patterns. PCA is a multivariate 
statistical method used in dietary research to group food items based on how 
strongly the frequency of their consumption is correlated, with the aim of 
identifying food patterns that explain the greatest proportion of variance in 
FFQ data (Hu 2002). In this study, PCA of reported consumption of 17 food 
items was carried out in SPSS. Firstly, a scree plot was generated to 
determine the number of components (or diet patterns) present in the data as 
well as the proportion of variance in FFQ data explained by each component. 
A correlation matrix was further used to determine the degree of correlation 
between each food item within a component or diet pattern. Within each diet 
pattern, positive and negative coefficients were generated for each food item. 
PCA coefficients explain the degree to which each food item is consumed 
more or less frequently as part of the diet pattern, with coefficients ≤ - 0.15 or 
≥ 0.15 considered a characteristic food item. The PCA coefficients for each 
food item were then multiplied by the frequency of consumption reported by 
the participant to generate a food item score. A diet pattern score was 
subsequently calculated (the sum of the food item scores) with higher scores 
indicating a diet more closely matching the diet pattern described.  
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5.3. Results 
 
The Wales Cohort included 91 control participants (delivering AGA infants 
with no known complications of pregnancy) of which 96% were Caucasian. 
Furthermore, 78% of control participants were Welsh and 70% described 
their baby’s father as Caucasian-Welsh. Due to the known differences in birth 
weight between ethnic groups and differences in culture, which may impact 
on maternal lifestyle during pregnancy, only Caucasian control participants 
(N = 87) were included in the analysis of lifestyle effects on birth weight and 
target gene expression. Maternal characteristics and birth outcomes for these 
participants are summarised in table 5.1.  
 One factor of relevance when analysing maternal lifestyle during 
pregnancy is that of maternal education and family income. Low maternal 
educational attainment and/or low family income have been demonstrated to 
be associated with adverse lifestyle during pregnancy and low birth weight 
(Collingwood Bakeo and Clarke 2006). In the overall cohort 49% of 
participants reported GCSE/O levels as their highest level of education and 
17% reported a combined family income (before deductions) of < £18,000. 
There was a trend for an increased proportion of participants reporting a 
family income < £18,000 at the RGH site (20%) (p = 0.09, n = 216) but there 
was no significant difference in maternal education between sites (p = 0.37, n 
= 216).  
 
 
5.3.1. Pre-pregnancy smoking 
In the overall cohort (n = 219), 31% of participants reported smoking in the 
three months before pregnancy. The majority of smokers reported daily 
smoking (83%) in contrast to occasional smoking (17%) with a mean of 7 
cigarettes smoked per day. The proportion of pre-pregnancy smokers was 
highest at the RGH site (38%) compared with UHW (27%) although this 
difference did not reach statistical significance (p = 0.08). The participants’ 
reported smoking in the study questionnaire and that recorded in the medical 
notes was significantly positively correlated (r = 0.79, p <0.001, n = 188).  
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Table 5.1: Maternal characteristics and birth outcomes for control participants 
included in analysis of lifestyle effects on placental gene expression. Mean 
(SD)/Range or Number (%) is shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Control Caucasian Participants  
(N = 87) 
Maternal Lifestyle 
Maternal age 
Parity 
 
 
Smoking during pregnancy: 
No 
Yes 
Not known 
 
Strenuous exercise: 
No 
Yes 
Not known 
 
Drinking Alcohol during pregnancy: 
No 
Yes 
Not known 
 
Maternal BMI (kg / m2) 
Underweight 
Normal weight  
Overweight 
Obese 
Not known 
 
Birth Outcome 
Mode of Delivery: 
Vaginal 
Elective C section 
Emergency C section 
Instrumental 
Birth weight (g) 
 
Custom birth weight centile 
Gestational age (weeks) 
Gender 
Male 
Female 
 
30 (5) / 19 – 41 
2 (1) / 0 – 7 
 
 
 
63 (72%) 
17 (20%) 
7 (8%) 
 
 
57 (66%) 
9 (10%) 
21 (24%) 
 
 
53 (61%) 
32 (37%) 
2 (2%) 
 
27 (6) / 19 – 42 
0 (0%) 
41 (47%) 
17 (20%) 
25 (29%) 
4 (4%) 
 
 
 
6 (7%) 
76 (87%) 
4 (5%) 
1 (1%) 
3485 (280) / 2830 – 4190 
 
53 (22) / 11 – 89 
39 (1) / 37 - 42 
 
42 (48%) 
45 (52%) 
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 Pre-pregnancy smoking information was available for 85 control 
(Caucasian) participants with 28% reporting pre-pregnancy smoking. There 
was no significant difference in birth weight or custom birth weight centiles 
between pre-pregnancy smokers and non-smokers (Figure 5.1). Similarly, 
placental weight was not significantly altered in smokers (p = 0.29, n = 85).  
 As shown in Figure 5.1, there was no significant difference in placental 
expression of the imprinted genes and placental hormones examined. 
Differences in birth weight and gene expression remained non-significant 
when participants were divided into those reporting daily or occasional 
smoking (results not shown). Finally, there was no significant association 
between the number of cigarettes smoked and birth weight (r = 0.01, p = 
0.96, n = 74) or placental PHLDA2 (r = 0.16, p = 0.19, n = 74), CDKN1C (r = 
0.15, p = 0.19, n = 74), PEG3 (r = - 0.07, p = 0.54, n = 74), PEG10 (r = - 
0.04, p = 0.72, n = 74), hPL (r = - 0.13, p = 0.27, n = 74) or PGH (r = 0.08, p 
= 0.53, n = 74) expression.  
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Effects of pre-pregnancy smoking on birth weight and placental 
target gene expression. There was no significant effect of maternal pre-pregnancy 
smoking on birth weight (A), custom birth weight centiles (B) or placental target gene 
expression (C). Error bars represent SEM.  
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5.3.2. Smoking during pregnancy 
In the overall cohort (n = 219), 25% of participants reported smoking during 
pregnancy. 25% of participants reported smoking during the first trimester 
and 22% in the second and third trimesters combined, with a mean of 10 
cigarettes smoked per day. As with pre-pregnancy smoking, the proportion of 
participants smoking during pregnancy was highest at the RGH site (33%) 
compared with UHW (22%) although this difference did not reach statistical 
significance (p = 0.06). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Effects of smoking during pregnancy on birth weight and placental 
target gene expression. There was no significant effect of maternal smoking during 
pregnancy on birth weight (A), custom birth weight centiles (B) or placental target 
gene expression (C). Error bars represent SEM.  
 
Pregnancy smoking information was available for 80 control 
(Caucasian) participants with 21% reporting smoking during pregnancy. 
There was no significant difference in birth weight or custom birth weight 
centiles between smokers and non-smokers (Figure 5.2). Similarly, placental 
weight was not significantly altered in smokers (p = 0.19, n = 80). However, 
the proportion of smokers was significantly higher in SGA compared with 
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AGA participants (p = 0.01). In addition, smokers were 2 times more likely to 
deliver an SGA infant than non-smokers as determined by logistic regression 
analysis (OR = 2.26 (1.09, 4.67); p = 0.03; n = 158), further suggesting a role 
for smoking in fetal growth.  
As shown in Figure 5.2, there was no significant difference in placental 
expression of the imprinted genes and placental hormones examined. 
Differences in birth weight and gene expression remained non-significant 
when participants were divided into those reporting daily or occasional 
smoking (results not shown). Similarly, there was no significant association 
between the number of cigarettes smoked and birth weight (r = 0.03, p = 
0.79, n = 79) or placental PHLDA2 (r = 0.07, p = 0.57, n = 79), CDKN1C (r = 
0.06, p = 0.58, n = 79), PEG3 (r = - 0.14, p = 0.21, n = 79), PEG10 (r = - 
0.07, p = 0.53, n = 79), hPL (r = 0.06, p = 0.62, n = 79) or PGH (r = - 0.12, p 
= 0.30, n = 79) expression.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Effects of smoking during pregnancy on SGA placentas. Birth 
weight  (A) and custom birth weight centiles (B) were significantly reduced in SGA 
participants smoking during pregnancy but there was no change in placental target 
gene expression (C). Error bars represent SEM. * P <0.05.  
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Birth weight and custom birth weight centiles were significantly lower in SGA 
participants reporting smoking during pregnancy compared with non-smokers 
(Figure 5.3). However, there was no significant difference in placental 
imprinted gene or placental hormone gene expression between smokers and 
non-smokers delivering SGA infants (Figure 5.3).  
 
5.3.3. Strenuous exercise 
15% of participants in the overall cohort (n = 216) reported undertaking 
strenuous exercise (defined as exercise at least 30 minutes in duration, at 
least once a week). There was no significant difference in the proportion of 
participants undertaking strenuous exercise between the RGH (10%) and 
UHW (16%) sites (p = 0.81).  
 
 
 
 
 
 
 
 
Figure 5.4: Effects of strenuous exercise during pregnancy. There was no 
significant effect of strenuous exercise on birth weight  (A) or placental target gene 
expression (B). Error bars represent SEM.  
 
  
Exercise information was available for 66 of the Caucasian control 
participants of which 14% were exercising during pregnancy. There was no 
significant difference in birth weight (Figure 5.4), custom birth weight centiles 
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(p = 0.12, n = 66) or placental weight (p = 0.63, n = 66) between exercisers 
and non-exercisers. Similarly, there was no significant difference in the 
proportion of participants undertaking strenuous exercise between AGA, 
SGA or LGA groups (p = 0.81, n = 66). There was no significant difference in 
placental expression of any of the imprinted genes or placental hormones 
examined (Figure 5.4). Results remained non-significant when the overall 
cohort was analysed. 
 
 
5.3.4.  Pre-pregnancy alcohol consumption 
 
Alcohol consumption in the three months before pregnancy was reported in 
59% of the overall cohort with a mean of 1.7 units per week consumed. 
Maternal pre-pregnancy alcohol consumption was significantly increased at 
UHW (65%) compared with RGH (47%) sites (p = 0.02). Participant self-
reported alcohol consumption in the study questionnaire was significantly 
positively correlated with that recorded in the medical notes (r = 0.31, p 
<0.001, n = 149).  
Pre-pregnancy alcohol consumption information was available for 85 
of the Caucasian control participants of which 62% were consuming alcohol 
during the three months before their pregnancy. Birth weight, custom birth 
weight centiles (Figure 5.5) and placental weight (p = 0.84, n = 85) were not 
significantly reduced in participants consuming alcohol before pregnancy. 
Similarly, there was no significant difference in the proportion of participants 
consuming alcohol before pregnancy between AGA and SGA groups (p = 
0.62, n = 85). 
There was no significant difference in placental expression of any of 
the imprinted genes or placental hormones examined (Figure 5.5), although a 
trend was shown for increased placental hPL (p = 0.06, n = 85) and PGH (p 
= 0.07, n = 85) expression in participants consuming alcohol. Results 
remained non-significant when the overall cohort was analysed. Finally, there 
was no significant correlation between the number of units consumed per 
week and birth weight (r = 0.10, p = 0.40, n = 73) or placental PHLDA2 (r = 
0.05, p = 0.65, n = 73), CDKN1C (r = 0.06, p = 0.60, n = 73), PEG3 (r = - 
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0.02, p = 0.98, n = 73), PEG10 (r = - 0.06, p = 0.61, n = 73), hPL (r = 0.14, p 
= 0.23, n = 73) or PGH (r = 0.09, p = 0.47, n = 73) expression. 
 
   
 
 
 
 
 
 
 
 
 
Figure 5.5: Effects of pre-pregnancy alcohol consumption. There was no 
significant effect of alcohol consumption on birth weight  (A), custom birth weight 
centiles (B) or placental target gene expression (C). Error bars represent SEM.  
 
 
5.3.5.  Alcohol consumption during pregnancy 
 
In the overall cohort 33% of participants reported consuming alcohol during 
their pregnancy with a mean of 1.1 units consumed per week. In contrast to 
pre-pregnancy alcohol consumption, there was no significant difference in the 
proportion of participants consuming alcohol during pregnancy between RGH 
(27%) and UHW (36%) sites. Interestingly, alcohol consumption was less 
frequent in the first trimester (24%) compared with the second and third 
trimesters (27%). There was also a significant positive correlation between 
alcohol consumption before and during pregnancy (r = 0.55, p <0.001, n = 
197).  
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 Information on alcohol consumption during pregnancy was available 
for 85 of the Caucasian control participants of which 38% were consuming 
alcohol during pregnancy. Birth weight, custom birth weight centiles (Figure 
5.6) and placental weight (p = 0.21, n = 85) were not significantly reduced in 
participants consuming alcohol during pregnancy. Similarly, there was no 
significant difference in the proportion of participants consuming alcohol 
during pregnancy between AGA and SGA groups (p = 0.55, n = 85).  
 There was no significant difference in placental expression of the 
imprinted genes or placental hormones examined (Figure 5.6), although as 
with pre-pregnancy alcohol consumption, a trend was observed for increased 
hPL expression in mothers consuming alcohol during pregnancy (p = 0.06).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Effects of alcohol consumption during pregnancy. There was no 
significant effect of alcohol consumption on birth weight  (A), custom birth weight 
centiles (B) or placental target gene expression (C). Error bars represent SEM.  
 
There was also no significant correlation between the number of units 
consumed per week and birth weight (r = 0.08, p = 0.41, n = 73) or placental 
PHLDA2 (r = 0.05, p = 0.65, n = 73), CDKN1C (r = 0.06, p = 0.60, n = 73), 
PEG3 (r = - 0.02, p = 0.98, n = 73), PEG10 (r = - 0.06, p = 0.61, n = 73), hPL 
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(r = 0.14, p = 0.23, n = 73) or PGH (r = 0.09, p = 0.47, n = 73) expression. 
Finally, there was no significant difference in birth weight (p = 0.66, n =55) or 
custom birth weight centiles (p = 0.19, n = 55) in SGA participants reporting 
consuming alcohol during pregnancy. Similarly, placental imprinted gene or 
placental hormone gene expression was not significantly altered (results not 
shown).  
 
5.3.6.  Illegal drug use 
In the overall cohort (n = 219), only 3 participants (1 AGA and 2 SGA 
participants) had a record of pre-pregnancy illegal drug use with none 
continuing throughout pregnancy.  
 
 
 
 
 
 
 
 
Figure 5.7: Effects of pre-pregnancy illegal drug use. Birth weight  (A) and 
custom birth weight centiles (B) were significantly reduced in participants with pre-
pregnancy illegal drug use, however there was no significant effect on placental 
target gene expression (C). Error bars represent SEM. * P <0.05, *** p < 0.001.   
 
Birth weight and custom birth weight centiles were significantly 
reduced in these participants compared with controls with no documented 
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illegal drug use (Figure 5.7). Although placental weight was also reduced by 
89g, this difference was not statistically significant (p = 0.91, n = 93). There 
was no significant difference in placental expression of the imprinted genes 
or placental hormones examined (Figure 5.7). 
 
5.3.7. Maternal BMI  
In the overall cohort (n = 219), 1% of participants were underweight, 47% 
were a healthy BMI, 24% were overweight and 28% were obese at booking. 
There was no significant difference in the proportion of BMI categories 
between RGH and UHW sites (p = 0.51, n = 219). Importantly, maternal self-
report of BMI was significantly positively correlated with that recorded in the 
medical notes (r = 0.94, p < 0.001, n = 147).  
  
 
 
 
 
 
 
Figure 5.8: Effects of maternal BMI. There was no significant effect of maternal 
BMI at booking on birth weight  (A), custom birth weight centiles (B) or placental 
target gene expression (C). Error bars represent SEM.  
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Maternal BMI information was available for 83 of the Caucasian 
control participants of which 51% were overweight or obese at booking. Of 
the obese participants, 36% were classified as Class 1 Obese (BMI 30.0 – 
34.9), 52% as Class 2 Obese (BMI 35 – 39.9) and 12% as Class 3 Obese 
(BMI ≥ 40). Maternal BMI was not significantly correlated with birth weight (r 
= 0.06, p = 0.59, n = 83), custom birth weight centiles (r = - 0.15, p = 0.21, n 
= 83) or placental weight (r = 0.06, p = 0.62, n = 83). Similarly, there was no 
significant difference in birth weight (p = 0.49, n = 83), custom birth weight 
centiles (p = 0.64, n = 83) or placental weight (p = 0.88, n = 83) between 
normal BMI, overweight and obese participants as determined by a one-way 
ANOVA (Figure 5.8).  
 As shown in Figure 5.8, there was no significant difference in placental 
expression of the imprinted genes or placental hormones examined, although 
a trend was observed for increased CDKN1C (p = 0.08) expression in obese 
participants. When participants were divided into those with a healthy BMI 
compared with overweight or obese participants, placental CDKN1C 
expression was significantly increased by 54% in overweight or obese 
participants (p = 0.03, n = 83). Given that there was no significant difference 
in mode of delivery between participants of different BMI categories (p = 
0.15, n = 83), this suggests that the observed increase in CDKN1C 
expression in overweight/obese participant placentas is independent of any 
effects of labour on CDKN1C expression. Placental PHLDA2 expression was 
also increased by 33% in overweight/obese participants, although this 
difference failed to reach statistical significance (p = 0.06, n = 83). Finally, 
there was no significant correlation between maternal BMI at booking and 
placental PHLDA2 (r = 0.17, p = 0.14, n = 83), CDKN1C (r = 0.17, p = 0.12, n 
= 83), PEG3 (r = 0.11, p = 0.34, n = 83), PEG10 (r = - 0.01, p = 0.93, n = 83), 
hPL (r = - 0.04, p = 0.71, n = 83) or PGH expression (r = 0.08, p = 0.45, n = 
83). Results remained non-significant when maternal height and weight data 
were analysed independently (results not shown).  
 In the overall cohort the mean maternal weight gain during pregnancy 
was 12kg with no significant correlation between maternal BMI at booking 
and weight gain (r = - 0.17, p = 0.17, n = 68). As maternal weight gain during 
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pregnancy is not routinely assessed at either research site, maternal weight 
gain information was only available for 25 Control Caucasian participants. 
There was no significant correlation between maternal weight gain and 
placental PHLDA2 (r = 0.10, p = 0.65, n = 25), CDKN1C (r = - 0.10, p = 0.65, 
n = 25), PEG3 (r = 0.20, p = 0.20, n = 25), PEG10 (r = 0.02, p = 0.91, n = 
25), hPL (r = 0.14, p = 0.50, n = 25) or PGH expression (r = - 0.14, p = 0.51, 
n = 25). 
 
5.3.8. Fruit and vegetable consumption 
In the overall cohort, 50% of participants reported consuming fresh fruit, fresh 
vegetables or dried fruit more than once a day during pregnancy, with 30% of 
participants reporting increased consumption compared with before 
pregnancy. There was no significant difference in fruit and vegetable 
consumption between UHW (51%) and RGH (50%) sites (p = 0.93).  
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Effects of maternal fruit and vegetable consumption during 
pregnancy. There was no significant effect of fruit and veg consumption on birth 
weight  (A) or custom birth weight centiles (B). Placental hPL and PGH expression 
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was significantly decreased in participants with low fruit and veg consumption (C). 
Error bars represent SEM. * P <0.05.  
 Information on maternal fruit and vegetable consumption was 
available for 64 Caucasian control participants of which 38% reported 
consuming fresh fruit, fresh vegetables or dried fruit more than once a day 
during pregnancy. Birth weight (p = 0.22, n = 64), custom birth weight 
centiles (p = 0.89, n = 64) and placental weight (p = 0.95, n = 64) were not 
significantly altered in participants consuming fruit and vegetables once a day 
or less (Figure 5.9), i.e. less than government recommendations.  
Placental hPL and PGH expression was significantly reduced in 
participants reporting consuming fruit or vegetables ≤ once a day during 
pregnancy (Figure 5.9). There was also a significant positive correlation 
between placental hPL expression and frequency of vegetable consumption 
during pregnancy (r = 0.30, p = 0.02, n = 64) and between placental PGH 
expression and dried fruit consumption (r = 0.28, p = 0.03, n = 63) 
respectively. Placental PHLDA2, CDKN1C, PEG3 and PEG10 expression 
was not significantly altered in participants reporting consuming fruit or 
vegetables ≤ once a day during pregnancy (Figure 5.9). Results remained 
non-significant when gene expression was analysed in relation to fruit and 
vegetable consumption in the overall cohort.  
 
5.3.9. Dairy consumption 
In the overall cohort 58% of participants reported consuming dairy products 
(such as milk, cheese or yoghurt) at least once a day during pregnancy, with 
26% of participants reporting increased consumption compared with before 
pregnancy. There was no significant difference in dairy consumption between 
UHW (54%) and RGH (67%) sites (p = 0.09).  
Information on maternal dairy consumption was available for 64 
Caucasian control participants of which 66% reported consuming dairy 
products at least once a day during pregnancy. Birth weight (p = 0.65, n = 
64), custom birth weight centiles (p = 0.56, n = 64) and placental weight (p = 
0.08, n = 64) was not significantly altered in participants consuming dairy less 
than once a day (Figure 5.10).  
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There was a trend for decreased placental PEG3 (p = 0.08, n = 64) 
and PEG10 (p = 0.06, n = 64) expression in participants consuming dairy 
products less than once a day (Figure 5.10). However, there was no 
significant difference in placental PHLDA2, CDKN1C, hPL or PGH 
expression (Figure 5.10).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Effects of maternal dairy consumption during pregnancy. There 
was no significant effect of dairy consumption on birth weight  (A), custom birth 
weight centiles (B) or placental target gene expression (C). Error bar represent 
SEM. 
 
 
5.3.10 Carbohydrate consumption  
In the overall cohort 52% of participants reported consuming carbohydrate 
rich foods (such as bread, potatoes and pasta) more than once a day during 
pregnancy, with 23% of participants reporting increased consumption 
compared with before pregnancy. There was no significant difference in 
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carbohydrate consumption between UHW (51%) and RGH (54%) sites (p = 
0.52).  
Information on maternal carbohydrate consumption was available for 
63 Caucasian control participants of which 56% reported consuming 
carbohydrate rich foods more than once a day during pregnancy. There was 
no significant difference in birth weight (p = 0.28, n = 63) or placental weight 
(p = 0.96, n = 63) in these participants (Figure 5.11). However, there was a 
trend for higher custom birth weight centiles in these participants (p = 0.09, n 
= 63), and frequency of maternal carbohydrate consumption was significantly 
positively associated with custom birth weight centiles (r = 0.27, p = 0.04, n = 
63).  
Placental PEG10 (p = 0.04, n = 63) and hPL (p = 0.04, n = 63) 
expression was significantly increased in participants consuming 
carbohydrate rich foods more than once a day (Figure 5.11). There was no 
significant difference in placental PHLDA2, CDKN1C, PEG3 or PGH 
expression (Figure 5.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Effects of maternal carbohydrate consumption during pregnancy. 
There was no significant effect of dairy consumption on birth weight  (A) or custom 
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birth weight centiles (B). Placental PEG10 and hPL expression was significantly 
increased in participants with a carbohydrate rich diet (C). Error bars represent 
SEM. * P <0.05 
5.3.11. Protein consumption  
In the overall cohort 52% of participants reported consuming protein rich 
foods (meat, fish and meat alternatives) less than once a day during 
pregnancy. There was no significant difference in protein consumption 
between UHW (52%) and RGH (39%) sites (p = 0.11).  
Information on maternal protein consumption was available for 65 
Caucasian control participants of which 55% reported consuming protein rich 
foods less than once a day during pregnancy. Birth weight (p = 0.90, n = 65), 
custom birth weight centiles (p = 0.64, n = 65) and placental weight (p = 0.88, 
n = 65) was not significantly reduced in these participants (Figure 5.12). 
There was also no significant difference in placental expression of the 
imprinted genes or placental hormones examined (Figure 5.12). Results 
remained non-significant when gene expression was analysed in relation to 
protein consumption in the overall cohort. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Effects of maternal protein consumption during pregnancy. There 
was no significant effect of protein consumption on birth weight (A), custom birth 
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weight centiles (B) or placental target gene expression (C). Error bars represent 
SEM.  
 
Maternal fish consumption in particular has previously been positively 
associated with birth weight. However, in this cohort there was no significant 
difference in birth weight (p= 0.91, n = 62), custom birth weight centiles (p = 
0.51, n = 62) or placental weight (p = 0.19) in participants consuming fish 
less than the recommended 2 times a week. Similarly, placental target gene 
expression was not significantly altered in these participants (Figure 5.13).  
 
 
 
 
 
 
Figure 5.13: Effects of maternal fish consumption during pregnancy. There 
was no significant effect of fish consumption on placental target gene expression.  
 
5.3.12. High sugar snacks 
In the overall cohort 45% of participants reported consuming a high sugar 
snack (chocolate, cake, biscuits and soft drinks) more than once a day during 
pregnancy. This did not differ significantly between UHW (43%) and RGH 
(49%) sites (p = 0.41).  
Information on high sugar snack consumption was available for 65 
Caucasian control participants of which 46% reported consuming a sugary 
snack more than once a day during pregnancy. Birth weight (p = 0.32, n = 
65), custom birth weight centiles (p = 0.19, n = 65) and placental weight (p = 
0.98, n = 65) were not significantly altered in these participants (Figure 5.14). 
Similarly, placental target gene expression was not significantly altered 
(Figure 5.14). In terms of individual sugar rich snacks, only maternal soft 
drink consumption was significantly positively associated with placental 
PEG3 expression (r = 0.26, p = 0.04, n = 64).  
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Figure 5.14: Effects of maternal high sugar snack consumption during 
pregnancy. There was no significant effect of high sugar snack consumption on 
birth weight (A), custom birth weight centiles (B) or placental target gene expression 
(C). Error bars represent SEM.  
 
 
5.3.13. Caffeine consumption 
30% of participants in the overall cohort reported consuming caffeinated 
drinks (tea, coffee, power drinks) more than once a day during pregnancy 
with 27% of participants reporting decreased consumption compared with 
before pregnancy. This did not differ significantly between UHW (26%) and 
RGH (38%) sites (p = 0.09). 
Information on caffeine consumption was available for 64 Caucasian 
control participants of which 30% reported consuming a caffeinated drink 
more than once a day during pregnancy. Although birth weights and custom 
growth centiles were reduced for these participants, these differences were 
not statistically significant (Figure 5.15). Similarly, there was no significant 
difference in placental weight (p = 0.45, n = 64). There was also no 
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significant difference in placental target gene expression in mothers 
consuming caffeinated drinks more than once a day during pregnancy, 
although placental PGH expression was significantly inversely correlated with 
frequency of caffeine consumption (r = - 0.24, p < 0.05, n = 64).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Effects of maternal caffeinated drink consumption during 
pregnancy. There was no significant effect of caffeine consumption on birth weight 
(A), custom birth weight centiles (B) or placental target gene expression (C).  
 
 
Interestingly, for participants delivering SGA infants placental PHLDA2 
expression was significantly increased in participants consuming caffeinated 
drinks more than once a day (Figure 5.16).  These participants also 
demonstrated decreased birth weights, custom birth weight centiles and 
placental weights, although these differences did not reach statistical 
significance (Figure 5.16).  
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Figure 5.16: Effects of maternal caffeinated drink consumption during 
pregnancy on SGA placentas. Birth weight  (A) and custom birth weight centiles 
(B) were not significantly altered in SGA participants with high caffeine consumption 
but placental PHLDA2 expression was significantly increased (C). Error bars 
represent SEM. * P <0.05.  
 
5.3.14. Supplement use 
59% of participants in the overall cohort reported taking supplements (iron, 
folate and/or vitamin) at least once a day during pregnancy with 28% of 
participants reporting increased use compared with before pregnancy. This 
did not differ significantly between UHW (52%) and RGH (39%) sites (p = 
0.17). 
Information on maternal supplement use was available for 65 
Caucasian control participants of which 59% reported taking supplements at 
least once a day during pregnancy. There was no significant difference in 
birth weight (p = 0.58, n = 65) or custom birth weight centiles (p = 0.41, n = 
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65) between these participants and those taking supplements less than once 
a day (Figure 5.17). Similarly, there was no significant in placental expression 
of the imprinted genes and placental hormones examined (Figure 5.17).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17: Effects of maternal supplement use during pregnancy. There was 
no significant effect of supplement use on birth weight  (A), custom birth weight 
centiles (B) or placental target gene expression (C). Error bars represent SEM.  
 
 
5.3.15. Maternal diet patterns 
Principle component analysis of reported consumption of 17 food items was 
carried out to examine participant diet patterns and associated effects on 
fetal growth and placental target gene expression. Examining diet patterns, in 
contrast to individual diet components may provide more information on the 
interacting effects of food items and has been suggested to be of greater 
relevance for designing healthy eating interventions (Crozier et al. 2008).  
PCA identified two diet components accounting for 19% and 9% of 
variation in maternal diet information respectively. Component 1 was 
characterised by frequent consumption of high fat and high sugar snacks 
 214	  
(such as chips, crisps, chocolate and cake), processed meat and soft drinks, 
and a low intake of fruit, vegetables and supplements (Table 5.2). 
Component 1 therefore displayed many similarities with the “Western diet” 
pattern observed in similar studies (Crozier et al. 2006; Thompson et al. 
2010; Hu 2002).  A western diet score was calculated for each participant 
based on the component coefficients and reported consumption of each food 
item, with higher scores indicating a more Western diet. 
 
Table 5.2: Principle component analysis coefficients. Positive and negative 
coefficients are shown for food items that are consumed more or less frequently as 
part of the diet pattern. The Western diet and Healthy diet patterns explained 19% 
and 9% of variance in maternal diet data. Coefficients ≥ 0.15 are highlighted in bold.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Food item or group Component 1 
(Western Diet) 
Component 2 
(Healthy Diet) 
Chips and Crisps 
Chocolate 
Takeaway meals 
Cakes, biscuits, ice 
cream 
Processed meat 
Dried Fruit 
Soft drinks 
Cheese and Yoghurt 
Bread, cereals, rice 
and pasta 
Vegetables or Salad 
Milk  
Fruit 
Unprocessed meat 
Fish and shellfish 
Supplements 
Caffeine 
Meat alternatives 
0.80 
0.65 
0.64 
0.60 
 
0.59 
- 0.53 
0.49 
- 0.003 
- 0.05 
 
- 0.39 
0.09 
- 0.39 
0.03 
- 0.06 
- 0.30 
0.09 
0.02 
- 0.15 
0.04 
0.06 
0.12 
 
0.35 
0.004 
- 0.01 
- 0.30 
- 0.27 
 
0.27 
- 0.42 
0.17 
0.56 
0.42 
- 0.20 
- 0.42 
0.40 
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In the Caucasian control participants, there was no significant correlation 
between maternal western diet scores and birth weight (r = 0.14, p = 0.27, n 
= 65), custom birth weight centiles (r = 0.06, p = 0.65, n = 65) or placental 
weight (r = - 0.13, p = 0.32, n = 65). Similarly, there was no significant 
correlation between maternal western diet scores and placental PHLDA2 (r = 
0.04, p = 0.75, n = 65), CDKN1C (r = - 0.07, p = 0.54, n = 65), PEG3 (r = 
0.04, p = 0.72, n = 65), PEG10 (r = 0.20, p = 0.09, n = 65), PGH (r = - 0.01, p 
= 0.90, n = 65) or hPL expression (r = 0.05, p = 0.69,n = 65).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18: Effects of a maternal western diet during pregnancy in SGA 
participants. In SGA participants, maternal western diet scores were significantly 
inversely correlated with custom birth weight centiles (A) and positively correlated 
with placental PHLDA2 expression. * P <0.05 
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However, in participants delivering SGA infants there was a significant 
inverse correlation between maternal western diet scores and birth weight (r 
= - 0.29, p = 0.04, n = 47) and custom birth weight centiles (r = - 0.48, p = 
0.01, n = 47), Figure 5.18. Maternal western diet scores were also 
significantly positively associated with placental PHLDA2 expression (r = 
0.34, p = 0.02, n = 47), Figure 5.18, but not with any other imprinted gene or 
placental hormone examined.  
PCA Component 2 was characterised by high intake of fruit and 
vegetables, unprocessed meat, fish and meat alternatives and a low intake of 
caffeine, dairy products and carbohydrates (Table 5.2). Component 2 
therefore displayed similarities with the “Prudent” or “healthy diet” pattern 
observed in similar studies (Crozier et al. 2006; Thompson et al. 2010; Hu 
2002).  A healthy diet score was calculated for each participant based on the 
component coefficients and reported consumption of each food item, with 
higher scores indicating a more healthy diet. 
In the Caucasian control participants, there was no significant 
correlation between maternal healthy diet scores and birth weight (r = - 0.03, 
p = 0.83, n = 65), custom birth weight centiles (r = 0.12, p = 0.36, n = 65) or 
placental weight (r = - 0.08, p = 0.52, n = 65). Similarly, there was no 
significant correlation between maternal healthy diet scores and placental 
PHLDA2 (r = 0.07, p = 0.58, n = 65), CDKN1C (r = 0.17, p = 0.19, n = 65), 
PEG3 (r = - 0.02, p = 0.86, n = 65), PEG10 (r = 0.03, p = 0.81, n = 65), hPL (r 
= 0.20, p = 0.12, n = 65) or PGH expression (r = 0.09, p = 0.51, n = 65). 
Results remained non-significant when analysed in SGA placentas 
independently.  
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5.4. Discussion 
This chapter examined the possible influence of maternal lifestyle on 
placental imprinted gene and placental hormone gene expression. A 
summary of target gene expression changes is shown in Table 5.3. These 
results suggest that imprinted gene expression in the human placenta may 
be responsive to maternal lifestyle factors during pregnancy. Similarly, 
expression of placental hormones hPL and PGH was also altered in 
response to maternal lifestyle.  
 
Table 5.3. Summary of significant changes in target gene expression in 
association with maternal lifestyle factors. Percentage change in expression 
relative to controls is shown.  
 
Maternal 
lifestyle factor 
 
PHLDA2 CDKN1C PEG3 PEG10 hPL PGH 
Smoking - - - - - - 
Exercise - - - - - - 
Alcohol - - - - - - 
Illegal drug use - - - - - - 
Overweight or 
Obese 
- ↑ 54%  - - - - 
Low fruit intake - - - - ↓ 20% ↓ 22% 
Dairy intake - - - - - - 
High carb 
intake 
- - - ↑ 27% ↑ 22% - 
Protein intake - - - - - - 
Sugary snacks - - - - - - 
Caffeine ↑ 150% 
(SGA only) 
- - - - - 
Supplement 
use 
- - - - - - 
Western diet 
pattern 
+ ve 
association 
(SGA only) 
- - - - - 
Healthy diet 
pattern 
- - - - - - 
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5.4.1. Maternal smoking 
28% of control participants reported smoking before pregnancy. Pre-
pregnancy smoking was not significantly associated with any measure of 
fetal growth and target gene expression was not significantly altered between 
smokers and non-smokers. Smoking during pregnancy (21% prevalence), 
was also not significantly associated with birth weight, custom birth weight 
centiles or target gene expression in control participants. However, women 
smoking during pregnancy were twice as likely as non-smokers to deliver an 
SGA infant. This is consistent with previous reports of a two fold increased 
risk of LBW in smokers (Pollack et al. 2000; Figueras et al. 2008; Rasmussen 
and Irgens 2006). Although birth weight was significantly lower in SGA 
infants born to smokers compared to SGA infants born to non-smokers, there 
was no associated effect on placental target gene expression. Bruchova et 
al. (2010) reported increased placental PHLDA2 expression in pregnant 
smokers in a small microarray study, with results not subsequently validated 
by qPCR. However, results of the current study are consistent with those of 
Moore et al. (2015) demonstrating no significant association between 
maternal smoking and placental PHLDA2, CDKN1C, PEG3 or PEG10 
expression. Thus, these results do not provide evidence for an effect of 
maternal smoking on placental imprinted gene expression.  
 
5.4.2. Maternal exercise 
Only 15% of participants reported carrying out strenuous exercise during 
pregnancy, defined as exercise at least 30 minutes in duration at least once a 
week (Statistics for Wales 2013). Maternal exercise was not significantly 
associated with birth weight, custom birth weight centiles or placental weight. 
A number of studies have previously demonstrated decreased birth weight in 
response to maternal exercise (Juhl et al. 2010; Clapp 2003; Bell et al. 1995; 
Hopkins et al. 2010). However, the study of effects of exercise on fetal 
growth are complicated by issues of pre-pregnancy exercise levels, time of 
exposure, duration of exercise as well as effects of interacting maternal 
lifestyle factors. The results of the current study are consistent with those of 
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Hegaard et al. (2010) and Kramer and McDonald (2006) reporting no 
significant association between exercise and measures of fetal growth. 
Finally, there was no significant effect of maternal exercise during pregnancy 
on placental target gene expression. Only placental PHLDA2 expression has 
previously been suggested to be altered in response to strenuous exercise 
(Lewis et al. 2012). As with birth weight, it is possible that no difference in 
placental PHLDA2 expression was observed in the current study due to 
differences in exercise intensity or duration.   
 
5.4.3. Alcohol consumption 
62% of control participants reported consuming alcohol in the three months 
before pregnancy. There was no effect of maternal pre-pregnancy alcohol 
consumption on any measure of fetal growth or placental target gene 
expression. 38% of participants reported consuming alcohol (of any quantity) 
during pregnancy, with a mean of 1 unit consumed per week. As with pre-
pregnancy alcohol consumption, drinking alcohol during pregnancy had no 
significant effect on birth weight or placental target gene expression. 
Although maternal alcohol consumption has previously been reported to be 
associated with fetal growth restriction (Patra et al. 2011; Henderson et al. 
2007), the risk of LBW was demonstrated to increase only above 1 – 1.5 
drinks / day. It is unclear whether light to moderate drinking has any effect on 
fetal growth (Patra et al. 2011; Henderson et al. 2007). It is therefore possible 
that no effect of alcohol consumption was observed in the current study in 
which a mean of 1 units per week was consumed. Similarly, the study by 
Shukla et al. (2011) demonstrating increased placental Phlda2 and Cdkn1c 
expression in response to an ethanol-containing diet was proposed to model 
effects of moderate alcohol consumption. In conclusion, the results of the 
current study do not provide evidence for an effect of maternal alcohol 
consumption on placental imprinted gene expression. 
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5.4.4. Pre-pregnancy illegal drug use 
Three participants (1 AGA and 2 SGA participants) had a record of pre-
pregnancy illegal drug use with none continuing throughout pregnancy. Birth 
weight was significantly reduced by 858g in these participants compared with 
controls. Pinto et al. (2010) similarly estimated an almost four fold increased 
risk of LBW and IUGR in UK women using drugs during pregnancy. 
Furthermore, placental target gene expression was not significantly altered in 
response to maternal pre-pregnancy illegal drug use. However, given the 
small number of participants reporting illegal drug use, this study also does 
not discount a role for placental imprinted genes in mediating the association 
between illegal drug use and fetal growth restriction. 
 
5.4.5. Maternal BMI 
51% of control participants were overweight or obese at booking. There was 
no significant correlation between maternal BMI and birth weight, custom 
birth weight centiles or placental weight. Although birth weight was similar 
between normal BMI, overweight and obese participants, there was a non-
significant gradual reduction in custom birth weight centiles consistent with 
the observation that the use of custom birth weight centiles identifies a 
significantly higher number of SGA infants in obese mothers compared with 
controls (Gardosi 2009). Placental CDKN1C expression was significantly 
increased by 54% in overweight or obese participants compared with 
controls. Moore et al. (2015) previously reported no significant association 
between maternal pre-pregnancy weight and placental CDKN1C expression 
in a similar sample size, although placental CDKN1C expression was not 
analysed in relation to maternal BMI or maternal BMI categories. Thus, the 
results of the current study provide the first evidence of an effect of maternal 
high BMI (overweight or obese) on placental CDKN1C expression.  
 Placental PHLDA2 expression was also increased by 33% in 
overweight or obese participants, however this failed to reach statistical 
significance (p = 0.06). Similarly, Moore et al. (2015) observed a trend 
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(p=0.099) for a positive association between maternal weight and placental 
PHLDA2 expression. Thus, these findings suggest a possible effect of 
maternal BMI on placental PHLDA2 expression, which must be confirmed in 
a larger cohort of obese participants.   
 
5.4.6. Fruit and vegetables consumption 
38% of control participants reported consuming fruit or vegetables more than 
once a day. Fruit and vegetable consumption was not significantly associated 
with birth weight, custom birth weight centiles or placental weight. Previous 
studies have reported a positive association between maternal fruit and 
vegetable consumption and birth weight (Mikkelsen et al. 2006; Rao et al. 
2001; Thompson et al. 2010). However, these studies have generally 
involved analysis of large cohorts, for example Mikkelsen et al. (2006) 
analysed maternal diet in 43,000 women. In addition, it is possible that 
maternal fruit and vegetable consumption as part of a diet pattern, rather 
than the individual components alone, affect fetal growth as suggested by 
Thompson et al. (2010). Placental hPL and PGH expression was significantly 
reduced by 20% and 22% respectively in participants consuming fruit and 
vegetables once a day or less. In particular, placental hPL expression was 
positively associated with frequency of vegetable consumption and PGH 
expression with frequency of dried fruit consumption. These novel results 
require further investigation in a larger study using a FFQ specifically 
designed to analyse maternal fruit and vegetable consumption. There was no 
significant effect of maternal fruit and vegetable consumption on placental 
PHLDA2, CDKN1C, PEG3 or PEG10 expression. Thus, the findings of the 
current study do not support an effect of maternal fruit and vegetable 
consumption on placental imprinted gene expression.  
 
5.4.7. Dairy consumption 
66% of participants consumed dairy products at least once a day during 
pregnancy. There was no significant association between maternal dairy 
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consumption and birth weight, custom birth weight centiles or placental 
weight. Previous studies reporting a significant positive correlation between 
dairy consumption during pregnancy and birth weight were of large national 
cohorts with diet analysed in up to 50,000 women (Ludvigsson and 
Ludvigsson 2004; Olsen et al. 2007; Xue et al. 2008). It is therefore possible 
that no effect of maternal dairy consumption was shown in the current study 
due to the comparatively smaller sample size. In terms of placental gene 
expression, decreased PEG3 (p = 0.08) and PEG10 (p = 0.06) were 
observed in participants consuming dairy products less than once a day, 
however these differences did not reach statistical significance. These novel 
results, although not significant, could underlie the positive correlation 
between dairy consumption and birth weight reported in previous studies 
(Ludvigsson and Ludvigsson 2004; Olsen et al. 2007; Xue et al. 2008; Ford 
2011). Examining placental imprinted gene expression in a larger cohort 
using a FFQ specifically designed to analyse consumption of dairy products, 
will determine the relevance of these findings.  
 
5.4.8.  Carbohydrate consumption 
56% of participants consumed carbohydrate rich foods more than once a 
day. Birth weight and placental weight were not significantly altered in these 
participants although there was a trend (p = 0.09) for increased custom birth 
weight centiles. Similarly, frequency of maternal carbohydrate consumption 
was significantly associated with custom birth weight centiles. This is 
consistent with the previously reported positive association between a diet 
rich in carbohydrates and birth weight (Mitchell et al. 2004; Thompson et al. 
2010). Placental hPL expression was increased by 22% in participants 
consuming carbohydrate rich foods more than once a day during pregnancy. 
Given the established role of hPL in the control of maternal insulin 
production, these results are consistent with the positive effect of 
carbohydrate consumption on blood glucose levels and insulin production 
(Sheard et al. 2004). Placental PEG10 expression was also significantly 
increased by 27% in participants consuming carbohydrate rich foods more 
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than once a day. As placental PEG10 plays a role in the positive control of 
fetal growth (chapter 3), it is possible that the association between maternal 
carbohydrate consumption and birth weight is mediated by an increase in 
placental PEG10 expression. This novel result requires replication in a larger 
cohort using a FFQ specifically designed to assess maternal consumption of 
carbohydrate rich foods including quantity and glycemic load.   
 
5.4.9. Protein consumption 
55% of participants reported consuming protein rich foods less than once a 
day. Maternal protein consumption during pregnancy was not significantly 
associated with birth weight, custom birth weight centiles or placental weight. 
Similarly, placental target gene expression was not significantly altered in 
women consuming protein rich foods less than once a day. Results remained 
non-significant when maternal fish consumption was analysed independently. 
Previous studies have reported conflicting results with respect to the 
relationship between maternal protein consumption and birth weight (Godfrey 
et al. 1996; Ford 2011; Thompson et al. 2010; Moore et al. 2004; Knudsen et 
al. 2008; Campbell et al. 1996; Ricci et al. 2010). This may be due to 
differences in study methodology or population, sources of protein and/or the 
interacting effects of other diet components. For example, in the study by 
Thompson et al. (2010), diet patterns were assessed, with a diet rich in 
protein and fruit and vegetables being positively associated with birth weight. 
Therefore, the effects of protein consumption alone were not analysed. 
Although studies in animal models suggest an effect of low protein diet or 
calorie restriction on imprinted gene expression, this is the first study to 
analyse human placental imprinted expression in response to maternal diet. 
The results of the current study do not provide evidence for an effect of 
maternal low protein diet on placental imprinted gene expression although 
further studies are needed to confirm these findings.  
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5.4.10. Maternal high sugar consumption  
46% of control participants reported consuming a high sugar snack more 
than once a day. Consumption of high sugar snacks during pregnancy was 
not significantly associated with birth weight, custom birth weight centiles or 
placental weight. Similarly, placental target gene expression was not 
significantly altered in women consuming a high sugar snack more than once 
a day during pregnancy. This is consistent with findings in animal studies, 
which demonstrated no significant effect of a high fat- high sugar diet on 
placental Phlda2, Cdkn1c or Peg3 expression (Sferruzzi-Perri et al. 2013). 
However, this study is the first to examine human placental imprinted gene 
expression in response to increased sugar consumption. Although these 
results do not provide evidence for an effect of maternal high sugar snack 
consumption on placental imprinted gene expression, they do not discount a 
role for a maternal high fat – high sugar diet pattern with interacting effects of 
other diet components.  
 
5.4.11. Caffeine consumption 
30% of control participants consumed caffeinated drinks more than once per 
day during pregnancy. Frequency of maternal caffeine consumption was not 
significantly associated with birth weight, custom birth weight centiles or 
placental weight in control participants. Previous studies have demonstrated 
a significant negative effect of maternal caffeine consumption on fetal growth 
(Santos et al. 1998; Xue et al. 2008; Vik et al. 2003). It is possible that no 
effect of caffeine consumption was detected in the current study because of 
differences in methodology; for example, Vik et al. 2003 used food records to 
quantitatively assess caffeine intake. In addition, previous studies have 
highlighted differential effects of distinct sources of caffeine, with e.g. coffee 
having the greatest effect. Given the non-quantitative FFQ used in the 
current study, as well as grouping of caffeinated drinks, it is possible that 
more subtle effects on birth weight could not be detected in this relatively 
small population. In control participants, placental target gene expression 
 225	  
was not significantly altered in women consuming caffeinated drinks more 
than once a day.  
 Interestingly, placental PHLDA2 expression was significantly 2.5 fold 
higher in SGA participants consuming caffeinated drinks more than once a 
day. Birth weight was also reduced by 206g in these participants, although 
this difference was not statistically significant (p = 0.17). Two possible 
explanations could underlie these novel findings. Firstly, PHLDA2 may drive 
fetal growth restriction caused by environmental factors (such as increased 
caffeine consumption). In contrast, it is possible that increased caffeine 
consumption exacerbates fetal growth restriction in already compromised 
pregnancies, through alterations in PHLDA2 expression. Animal models will 
aid in determining the mechanisms underlying the association between 
maternal caffeine consumption, fetal growth and PHLDA2 expression. For 
example, fetal growth restriction in response to maternal caffeine 
consumption in a mouse model, associated with increased PHLDA2 
expression, would lend support to the first hypothesis. Alternatively, if fetal 
growth restriction is observed only in compromised pregnancies (such as in 
the mouse model of Phlda2 over expression), this would support the latter 
hypothesis.  
 
5.4.12. Supplement use 
59% of control participants reported taking supplements (e.g. folate, iron or 
vitamins) at least once a day during pregnancy. Maternal supplement use 
was not significantly associated with birth weight, custom birth weight centiles 
or placental weight. Similarly, placental target gene expression was not 
significantly altered in women taking supplements less than once a day 
during pregnancy. Importantly, the current study did not quantitatively assess 
maternal levels of folate, iron or vitamins. Therefore, although these findings 
do provide evidence of an effect of maternal supplement use on fetal growth 
or target gene expression, this remains to be confirmed in larger quantitative 
studies of maternal supplement use during pregnancy.  
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5.4.13. Maternal diet patterns 
Principle component analysis revealed 2 diet patterns accounting for 19% 
and 9% of variation in maternal diet data respectively. This diet pattern was 
characterised by increased consumption of high fat and high sugar snacks 
(chips, crisps, chocolate and cake), processed meat and soft drinks and a 
low intake of fruit, vegetables and supplements. The first diet pattern 
therefore displayed many similarities with the “western diet pattern” observed 
in similar studies (Crozier et al. 2006; Crozier et al. 2008; Crozier et al. 2009; 
Thompson et al. 2010).  Maternal western diet scores were not significantly 
associated with birth weight, custom birth weight centiles or placental target 
gene expression in control participants.  
 However, as with caffeine consumption, in participants delivering SGA 
infants maternal western diet scores were significantly inversely correlated 
with birth weight and custom birth weight centiles. In addition, maternal 
western diet scores were positively correlated with placental PHLDA2 
expression, i.e. a more western diet was associated with increased placental 
PHLDA2 expression. As increased caffeine consumption was not 
characteristic of the western diet, this suggests that the effect of maternal 
western diet on birth weight and placental PHLDA2 expression was 
independent of caffeine consumption.  
 No previous study has examined human placental PHLDA2 
expression in relation to maternal diet. Sferruzzi-Perri et al. (2013) 
demonstrated no significant effect of a maternal high fat – high sugar diet on 
placental Phlda2 expression in a mouse model. However, the western diet 
described in the current study involves other aspects of diet in addition to 
high fat – high sugar foods (such as fruit and vegetable consumption and 
supplement use); it is therefore possible that it is the interaction between the 
individual food items of the maternal western diet rather than the isolated 
effect of maternal high fat – high sugar snack consumption which are 
associated with decreased fetal growth and increased placental PHLDA2 
expression. As described previously, these novel findings may be explained 
by PHLDA2 expression driving fetal growth restriction caused by 
environmental factors (such as maternal western diet) or maternal western 
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diet exacerbating fetal growth restriction in already compromised 
pregnancies, through alterations in PHLDA2 expression.  
 Finally, the second diet pattern identified by PCA was characterised by 
a high intake of fruit and vegetables, unprocessed meat, fish and meat 
alternatives and a low intake of caffeine, dairy products and carbohydrates. 
This diet pattern therefore displayed similarities with the “Prudent” or “healthy 
diet” pattern observed in similar studies (Crozier et al. 2006; Crozier et al. 
2008; Crozier et al. 2010; Thompson et al. 2010). Maternal health diet scores 
were not significantly associated with birth weight, custom birth weight 
centiles or placental target gene expression in control participants. Results 
remained non-significant in SGA pregnancies. These novel results therefore 
do not provide evidence of a protective effect of a healthy maternal diet on 
aberrant placental imprinted gene expression.  
 
5.4.14. Summary 
In summary, the results presented in this chapter suggest an effect of 
maternal lifestyle on imprinted gene and placental hormone gene expression 
in the human placenta. Placental PHLDA2 expression was significantly 
increased in response to maternal caffeine consumption and a western diet 
pattern, an effect that was specific to SGA pregnancies. Placental CDKN1C 
expression was increased in overweight or obese participants. In contrast, 
placental PEG3 expression however was not significantly altered in response 
to maternal lifestyle. Placental PEG10 expression was significantly increased 
in response to a carbohydrate rich diet. In terms of placental hormone gene 
expression, placental hPL expression was increased in response to a 
carbohydrate rich diet and both hPL and PGH expression was decreased in 
association with low fruit intake. These novel results provide the first 
evidence to suggest an effect of maternal lifestyle, particularly maternal diet, 
on human placental imprinted gene expression and therefore support the 
fourth study hypothesis of aberrant placental imprinted gene expression in 
response to an adverse maternal lifestyle. Given the role of aberrant 
placental imprinted gene expression in fetal growth restriction and other 
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complications of pregnancy as demonstrated in chapters 3 and 4 
respectively, these results could be of relevance in the design of future 
maternal lifestyle interventions.  
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CHAPTER 6: IMPRINTED GENES AND MATERNAL 
DIET IN AN ANIMAL MODEL 
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6.1. Introduction  
In this chapter, a mouse model was used to further explore whether placental 
imprinted gene expression is responsive to environmental stimuli, in 
particular maternal diet during pregnancy.   
Animal models of maternal low protein diet during pregnancy are 
commonly used in the study of fetal programming as offspring are born 
growth restricted and develop symptoms of hypertension, obesity and 
glucose intolerance in later life (reviewed in (Bertram and Hanson 2001; 
Martin-Gronert and Ozanne 2007)). Given that a two fold change in imprinted 
gene expression in the placenta can have a knock-on effect on fetal growth, 
such as in the case of Phlda2 (Tunster et al. 2010), it is possible that 
alterations in placental imprinted gene expression underlie the growth 
restriction observed as a result of a maternal low protein diet. No previous 
study, however, has examined placental Phlda2, Cdkn1c, Peg3 or Peg10 
expression in response to a low protein diet. Lillycrop et al. (2010) 
demonstrated no significant effect of low protein diet during pregnancy on 
Phlda2 expression in the offspring liver but placental expression was not 
analysed. Similarly, while Cdkn1c expression in the offspring brain was 
shown to be significantly increased in response to a maternal low protein 
diet, expression was not analysed in the placenta (Vucetic et al. 2010). 
Placental Peg3 and Peg10 expression have not been examined in a mouse 
model of low protein diet during pregnancy. Related models of under -
nutrition during pregnancy (such as calorie restriction or transient starvation) 
have however demonstrated perturbed placental Phlda2, Cdkn1c and Peg3 
expression (Shukla et al. 2011; Broad and Keverne 2011; Radford et al. 
2012).  
No significant association was observed between human placental 
imprinted gene expression and maternal protein consumption in Chapter 5. 
However, this may be due to only a small number of participants exhibiting 
sufficient severity of protein restriction to result in FGR and aberrant target 
gene expression, or that the presence of an association is obscured by 
confounding maternal lifestyle factors. Therefore, placental Phlda2, Cdkn1c, 
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Peg3 and Peg10 expression was analysed in a mouse model of low protein 
diet during pregnancy to fully determine whether protein restriction results in 
altered placental imprinted gene expression.  
It could be argued that animal models of over-nutrition are more 
relevant to western society. Effects of a maternal high fat diet during 
pregnancy have yielded conflicting results in mice, with some studies 
reporting growth restricted offspring and others increased fetal weight 
(reviewed in (Williams et al. 2014)), likely reflecting differences in study 
methodology. A number of studies have also demonstrated that offspring 
exposed to a high fat diet during pregnancy develop symptoms of 
hypertension, obesity and glucose intolerance in adulthood (Williams et al. 
2014).  
In Chapter 5, placental PHLDA2 expression was demonstrated to be 
significantly associated with a maternal diet pattern characterised by 
increased consumption of high-fat and high-sugar food items, processed 
meat and soft drinks and a low intake of fruit, vegetables and supplements. 
Thus, placental Phlda2, Cdkn1c, Peg3 and Peg10 expression was also 
analysed in two mouse models of over-nutrition: a high fat diet during 
pregnancy and a high fat – high sugar diet before and/or during pregnancy. 
Placental Phlda2, Cdkn1c and Peg3 have previously been suggested not to 
be significantly altered in response to a high fat – high sugar diet during 
pregnancy (Sferruzi-Perri et al. 2013), although the effect of pre-pregnancy 
diet was not examined. Similarly, placental Peg3 and Peg10 expression were 
not significantly altered in a mouse model of a maternal high fat diet during 
pregnancy (Gallou-Kabani et al. 2012). However, this study examined 
placental gene expression at an earlier time point (E15.5) suggesting that the 
period of exposure to a high fat diet may not have been sufficiently long to 
result in aberrant imprinted gene expression.  
No significant sex differences were observed in human placental 
target gene expression in control pregnancies or in response to different 
maternal lifestyles (Chapter 5). However, previous studies in the mouse have 
demonstrated differential imprinted gene expression between male and 
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female placentas both under normal conditions (Faisal et al. 2014) and in 
response to maternal diet alteration (Radford et al. 2012) in the mouse. Thus 
results were further analysed for sex-specific responses to maternal low 
protein, high fat or high fat-high sugar diet in the mouse model. 
In Chapter 3, an association was observed between imprinted gene 
expression and placental hormone gene expression in the human placenta. 
Similarly, a decrease in mouse placental spongiotrophoblast cells (and 
expression of placental prolactins) in response to aberrant Phlda2, Cdkn1c, 
Peg3 and Peg10 expression has been demonstrated in previous animal 
studies. Therefore, in the current study, placental expression of the 
spongiotrophoblast markers Prl3b1 and Prl8a8 was also analysed in 
response to maternal diet alteration to determine whether any aberrant 
placental imprinted gene expression observed was associated with a 
concurrent effect on placental spongiotrophoblast cells.  
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6.2. Chapter specific methods 
 
Methods were as described in Chapter 2. For ease of interpretation of the 
results presented in this chapter, methods related to the study of placental 
target gene expression in a mouse model are summarised below. 
 
6.2.1. Animals and maternal diet 
Mus mus domesticus C57BL/6 mice carrying the Mus spretus region of distal 
chromosome 7 were used, as described in section 2.4. All females in the first 
experiment were fed a basal diet before pregnancy (diet energy from; protein 
18.3%, fat 22.1%, carbohydrate 59.6%) (Test Diet) before pregnancy. On the 
day at which a vaginal plug was first detected (designated as E0.5), females 
were either fed a basal diet (control mice), a low protein diet (diet energy 
from; protein 8.1%, fat 21.8%, carbohydrate 70.1%) (Test Diet) or a high fat 
diet (diet energy from; protein 18.1%, fat 46.1%, carbohydrate 35.8%) (Test 
Diet) until E18.5.  
Females in the second experiment were fed either a basal diet (15% 
sugar content and diet energy from; protein 17.7%, fat 10%, carbohydrate 
61%) or a high fat – high sugar (HFHS) diet (34% sugar content and diet 
energy from; protein 17.8%, fat 20.0%, Carbohydrate 49.9%) for 12 weeks 
before mating. Mice were weighed every week to assess pre-pregnancy 
weight gain. At E0.5 females were placed on a control or HFHS diet for the 
remainder of pregnancy. Thus the following groups of mice were generated: 
Control-Control mice (fed basal diet before and during pregnancy), Control-
HFHS mice (fed a HFHS diet in pregnancy only), HFHS-Control (fed a HFHS 
diet before pregnancy only) and HFHS-HFHS mice (fed a HFHS diet both 
before and during pregnancy). Control-HFHS females were used to model 
effects of poor diet specific to pregnancy. In addition, comparison of the 
HFHS-Control with the HFHS-HFHS females was used to model 
effectiveness of an intervention to improve maternal diet during pregnancy. 
Mice were weighed at E0.5 and E18.5 to determine maternal pregnancy 
weight gain.  
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Dissection was carried out at E13.5 and E18.5 for the low protein diet 
experiment in order to examine time specific effects of maternal protein 
restriction. For all other mice, dissection was carried out at E18.5. Processing 
of placentas for qPCR analysis of gene expression was as described in 
Chapter 2. Embryos and placentas were weighed at dissection.  
 
6.2.2. Phlda2 RFLP analysis 
Phlda2 RFLP analysis was carried out as detailed in section 2.4.3. Briefly, 
cDNA samples amplified by PCR with the Phlda2 RFLP primers were 
digested with the Taul restriction enzyme and the products analysed by gel 
electrophoresis to show the presence of the different alleles. The Taul 
restriction enzyme recognises a sequence on the C57BL/6 Phlda2 allele and 
cuts the cDNA, resulting in the presence of two bands on the gel 
approximately 100bp and 50bp in length respectively. In contrast, a 
polymorphism in the Spretus sequence means that the Taul enzyme cannot 
recognise the Taul cut sites, resulting in the presence of a larger (undigested) 
band of 150bp in length. In this way, it is possible to identify the parental 
origin of the Phlda2 allele; because Phlda2 is a maternally expressed 
imprinted gene, inheritance of the maternal Spretus allele by the F1 offspring 
will result in the presence of one larger undigested band of 150bp in length. 
In contrast, inheritance of the paternal Spretus allele by the F1 offspring 
(which when imprinted is not expressed) will result in the presence of two 
(digested) bands of 100bp and 50bp in length. Thus, loss of imprinting 
(resulting in both maternal and paternal expression of Phlda2) will be 
indicated by the presence of two bands at 150bp and 100bp in length.  
 
6.2.3. Statistical analysis 
Embryo and placental weight was adjusted to account for differences in litter 
size using the following formula:  
Mean weight for diet   x     individual weight 
Mean weight for litter 
 235	  
All statistical analysis was carried out using IBM SPSS statistics for Windows 
(version 20.0, 2011) with a p value <0.05 considered statistically significant. 
Normal distribution was assessed using P-P plots and a Shapiro-Wilk 
test. All data was normally distributed and therefore parametric statistical 
tests used. Differences in placental gene expression between diet groups 
was analysed using an independent samples T tests or one-way ANOVA with 
a Tukey post hoc test where appropriate. A Bonferroni correction was also 
used to control for multiple comparisons in placental gene expression 
between maternal diet groups (α/6 = 0.008). Finally, in order to examine 
sexual dimorphism in the placental response to maternal diet changes results 
were analysed in the overall diet group and split by sex.  
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6.3. Results 
6.3.1. Sex differences in basal gene expression 
Previous studies have suggested sex differences in expression of some 
imprinted genes expression under normal conditions (Faisal et al. 2014). As 
shown in Figure 6.1, there was no significant difference in placental Phlda2 
(p = 0.51, n = 6), Cdkn1c (p = 0.41, n = 6), Peg3 (p = 0.90) or Peg10 (p = 
0.54, n = 6) imprinted gene expression between male and female control 
placentas. Similarly, there was no significant sex difference in placental gene 
expression of the spongiotrophoblast markers Prl3b1 (p = 0.63, n = 6) or 
Prl8a8 (p = 0.72, n = 6), Figure 6.1.  
Figure 6.1: Sex differences in placental target gene expression at E18.5. Gene 
expression is shown relative to expression in male placentas. Error bars represent 
Standard Error. Differences in gene expression were not statistically significant 
using a t-test. 
 
6.3.2. Maternal low protein diet  
There was no significant effect of maternal low protein diet on fetal (1.06 g ± 
0.11 v. 1.06 g ± 0.97, n = 61, p = 0.88) or placental weights (83.67 mg ± 7.66 
v. 85.71 mg ± 9.08, n = 61, p = 0.52) at E18.5, as shown in Figure 6.2 A and 
B. Similarly, no significant differences were seen in fetal weight when results 
were split by embryo sex (Figure 6.2 C and D).  
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Figure 6.2: Effects of maternal low protein diet on fetal and placental weights. 
Mean embryonic (A) and placental (B) weights are shown at E18.5. Mean embryonic 
weights are also shown split by sex; male (C) and female (D). Error bars represent 
standard deviation. The relative embryonic and placental weights of low protein diet 
offspring are shown as a percentage of the control values. Differences in weight 
were not statistically significant using an independent samples t-test. 
 
There was a significant 2.09 fold higher Phlda2 expression in placentas from 
low protein diet pregnancies compared with controls (p = 0.003, n =12), 
Figure 6.3 A. This difference was sex specific with increased Phlda2 
expression statistically significant in female placentas (p = 0.02, n = 6). In the 
male placentas, the elevated expression did not reach statistical significance 
(p=0.09, n = 6), Figure 6.3 B.  
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Figure 6.3: Effects of maternal low protein diet on placental Phlda2 
expression. Phlda2 expression was significantly increased following low protein diet 
using an independent samples T test (A); this difference was significant in female 
but not male placentas (B). *** p < 0.001. Error bars represent SEM.  
 
 
In contrast there was no significant effect of low protein diet on 
placental Cdkn1c expression (p = 0.21, n = 12). Results remained non-
significant when split by fetal sex.  
In terms of the paternally expressed imprinted genes, placental Peg3 
expression was significantly increased by 24% in low protein compared with 
control pregnancies (p = 0.01, n = 12), Figure 6.4. This difference was sex 
specific with increased expression statistically significant only in male (p = 
0.02, n = 6) but not female (p = 0.19, n = 6) placentas, Figure 6.4.  
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Figure 6.4: Effects of maternal low protein diet on placental Peg3 expression. 
Peg3 expression was significantly increased following low protein diet (A); this 
difference was significant in male but not female placentas (B). * p ≤ 0.05, ** p ≤ 
0.01. Error bars represent SEM.  
 
 In contrast, placental Peg10 expression was significantly decreased 
by 33% in low protein compared with control pregnancies (p = 0.02, n = 12), 
Figure 6.5. Although a decrease in expression was observed in both male 
and female placentas, this difference was only significant in female (p = 0.02, 
n = 6) and not male placentas (p = 0.41, n = 6).  
A summary of the changes in placental imprinted gene expression 
following maternal low protein diet is shown in Table 6.1. Note only the 
increase in Phlda2 expression and Peg3 expression remained significant 
after controlling for multiple comparisons using a Bonferroni correction (P = 
0.01).  
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Figure 6.5: Effects of maternal low protein diet on placental Peg10 expression. 
Peg10 expression was significantly increased following low protein diet (A); this 
difference was significant in female but not male placentas (B). * p ≤ 0.05. Error bars 
represent SEM.  
 
Table 6.1. Summary of placental imprinted gene expression changes following 
maternal low protein diet at E18.5. Fold gene expression is shown relative to 
basal gene expression. Results highlighted in bold were statistically significant using 
an independent samples T test. * p ≤ 0.05, ** p ≤ 0.01. LPD = Low protein Diet.  
Gene Active Allele Basal fold 
expression 
LPD fold 
expression 
P Value 
Phlda2 M 1.00 2.09 P = 0.003** 
Cdkn1c M 1.00 1.21 P = 0.21 
Peg3 P 1.00 1.24 P = 0.01** 
Peg10 P 1.00 0.67 P = 0.02* 
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 Phlda2 is known to negatively regulate the spongiotrophoblast lineage 
of the mouse placenta (reviewed in John 2013). Increased Phlda2 expression 
following maternal low protein diet might therefore result in a reduced 
spongiotrophoblast lineage in this model. To explore this possibility, 
expression of the spongiotrophoblast markers Prl3b1 and Prl8a8 was 
examined. As shown in Figure 6.6, there was no significant effect of maternal 
low protein diet on placental Prl3b1 (p = 0.86, n = 12) or Prl8a8  (p = 0.31, n 
= 12) expression. Results remained non-significant when analysed according 
to fetal sex.  
Figure 6.6: Effect of maternal low protein diet on spongiotrophoblast marker 
gene expression. There was no significant effect of low protein diet on placental 
Prl3b1 or Prl8a8 gene expression. Error bars represent SEM.   
 
 
 
Furthermore, to determine whether the increase observed in placental 
Phlda2 expression following low protein diet was organ specific, Phlda2 
expression was also examined in the kidney at E18.5. As can be seen in 
Figure 6.7, Phlda2 expression in the kidney was not significantly altered 
following low protein diet in contrast to the increased placental expression 
observed (section 6.4.2), suggesting a placental specific response to 
maternal diet. There was no significant difference in Phlda2 (p = 0.42, n = 6) 
expression between male and female control kidneys and no sex effect on 
the association between low protein diet and Phlda2 expression (results not 
shown).   
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Figure 6.7: Effects of maternal low protein diet on kidney Phlda2 gene 
expression. There was no significant effect of low protein diet on Phlda2 gene 
expression in the kidney. Error bars represent standard error.  
 
 
 
 
 
 
Figure 6.8: Effects of maternal low protein diet on E13.5 placental Phlda2 gene 
expression. Phlda2 expression was significantly increased using an independent 
samples T-test. Error bars represent standard error. ** p ≤ 0.01. 
 
Finally, to determine whether the changes observed in placental Phlda2 gene 
expression in response to maternal low protein diet were time specific, 
imprinted gene expression was also analysed at the earlier time point of 
E13.5. Phlda2 expression was significantly increased at E13.5 following low 
protein diet (p=0.01, n = 8), Figure 6.8. However, the increase in Phlda2 
expression at E13.5 (74%) was less than that seen at E18.5 (109%). There 
was no significant effect of maternal low protein diet on E13.5 placental 
expression of any other imprinted gene examined (results not shown). 
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Unaltered placental Peg3 expression at E13.5 (p=0.48, n = 12) suggested 
that the increase observed in E18.5 Peg3 placental expression was time 
specific.  
 
6.3.3. Maternal high fat diet 
 
Figure 6.9: Effects of maternal high fat diet on fetal and placental weights. 
Mean embryonic (A) and placental (B) weights are shown at E18.5. Mean embryonic 
weights are also shown split by sex; male (C) and female (D). Error bars represent 
Standard Deviation. The relative embryonic and placental weights of high fat diet 
offspring are shown as a percentage of the control values. Differences in weight 
were not statistically significant using a t-test.  
 
Given the responsiveness of a number of the imprinted genes examined 
(particularly Phlda2) to maternal low protein diet, other dietary alterations 
were explored. A maternal high fat diet was chosen as it has been suggested 
that animal models of over nutrition are currently more relevant to western 
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society. There was no significant effect of maternal high fat diet on fetal (1.06 
g ± 0.11 v. 1.06 g ± 0.97, n = 61, p = 0.88) or placental weights (83.67 mg ± 
7.66 v. 85.71 mg ± 9.08, n = 61, p = 0.52), Figure 6.9 A and B. Results 
remained non-significant when split by fetal sex (Figure 6.9 C and D).  
   
 
 
 
 
 
 
 
 
Figure 6.10: Effects of maternal high fat diet on placental Phlda2 expression. 
Phlda2 expression was significantly increased following high fat diet using an 
independent samples T test (A); this difference was significant in female but not 
male placentas (B). ** p ≤ 0.01. 
 
There was a significant 53% increase in placental Phlda2 expression in the 
maternal high fat compared with control pregnancies (p = 0.01, n = 12), 
Figure 6.10. This difference was sex specific with increased Phlda2 
expression significant in only female (p = 0.004, n = 6) and not male 
placentas (p=0.29, n = 6), Figure 6.10. 
 
 As shown in Figure 6.11, there was no significant effect of high fat diet 
on placental Cdkn1c (p = 0.20, n = 12) or Peg3 (p = 0.98, n = 12) gene 
expression. Results remained non-significant when split by embryo sex. A 
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trend was seen for decreased placental Peg10 expression in response to 
maternal high fat diet (p=0.07) (Figure 6.11), however this failed to reach 
statistical significance in either male (p = 0.48, n = 12) or female placentas (p 
= 0.07, n = 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: Effects of maternal high fat diet on placental imprinted gene 
expression. Gene expression was not significantly altered as a result of maternal 
high fat diet using an independent samples T test. Error bars represent SEM.  
 
Table 6.2. Summary of placental imprinted gene expression changes following 
maternal high fat diet at E18.5. Fold gene expression is shown relative to basal 
gene expression. Results highlighted in bold were statistically significant using an 
independent samples T test.  ** p ≤ 0.01. HFD = high fat diet.   
 
A summary of the changes in placental imprinted gene expression following 
maternal high fat diet is shown in Table 6.2. Only placental Phlda2 
expression was significantly increased in response to a maternal high fat diet. 
Gene Active Allele Basal fold 
expression 
HFD fold 
expression 
P Value 
Phlda2 M 1.00 1.53 P = 0.01** 
Cdkn1c M 1.00 1.30 P = 0.20 
Peg3 P 1.00 1.00 P = 0.98 
Peg10 P 1.00 0.87 P = 0.07 
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This increase in Phlda2 expression remained significant after controlling for 
multiple comparisons using a Bonferroni correction (P = 0.01). 
Figure 6.12: Effects of maternal high fat diet on spongiotrophoblast marker 
gene expression. There was no significant effect of high fat diet on placental Prl3b1 
or Prl8a8 gene expression. Error bars represent standard error.  
 
 
 
 
 
 
 
 
Figure 6.13: Effects of maternal high fat diet on kidney Phlda2 gene 
expression. There was no significant effect of high fat diet on Phlda2 gene 
expression in the kidney. Error bars represent standard error.  
 
Given the significant increase in placental Phlda2 gene expression resulting 
from a maternal high fat diet, expression of the spongiotrophoblast markers 
Prl8a8 and Prl3b1 was also examined. There was no significant effect of 
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maternal high fat diet on placental Prl3b1 (p = 0.48, n = 12) or Prl8a8 (p = 
0.79, n = 12) expression, as shown in Figure 6.12.  
Finally, to determine whether the effect of maternal high fat diet on 
placental Phlda2 expression was organ specific, expression of Phlda2 in the 
kidney was also analysed. As can be seen in Figure 6.13, maternal high fat 
diet did not significantly alter Phlda2 (p = 0.84, n = 11) expression in the 
kidney. Differences remained non-significant for both male and female 
kidney.  
 
6.3.4. Maternal high fat – high sugar diet 
Females were on a control or high fat – high sugar (HFHS) diet 12 weeks 
before pregnancy and were weighed every week to examine pre-pregnancy 
weight gain. As can be seen in Figure 6.14, females on a HFHS diet were 
significantly heavier than control females after 2 weeks and on average 42% 
heavier by week 12 (at mating). 
In addition, maternal weight gain during pregnancy was assessed 
between E0.5 and E18.5 (Figure 6.15). Females on a HFHS-HFHS diet 
gained significantly more weight than Control-Control females (1.33 g v. 2.44 
g, n = 5, p = 0.02). However, there was no significant difference in weight 
gain during pregnancy between Control-Control females and Control-HFHS 
(1.33 g v. 1.78 g, n = 7, p = 0.42) or HFHS-Control females (1.33 g v. 1.07 g, 
n = 5, p = 0.28).  
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Figure 6.14: Effects of maternal pre-pregnancy diet on maternal body weight. 
Mean body weights are shown, error bars represent Standard Deviation. The 
relative body weight of HFHS mice compared with controls (basal diet) are shown in 
percentages at week 12. HFHS mice were significantly heavier than basal mice from 
week 2. ** p ≤ 0.01, *** p ≤ 0.001.  
 
 
 
 
 
 
 
 
Figure 6.15: Effects of maternal diet on pregnancy weight gain. Mean 
pregnancy weight gain between E0.5 and E18.5 is shown for each diet condition. 
Error bars represent Standard Deviation. * p ≤ 0.05.  Maternal Weight gain was 
normalised to litter size.  
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There was a significant difference in fetal weight between maternal diet 
groups as determined by one-way ANOVA (F (3,48) = 10.46, p ≤ 0.001), see 
Figure 6.16 A. A Tukey post-hoc test revealed significantly increased embryo 
weight in offspring of mothers fed a HFHS-Control diet compared with a 
Control-Control diet (1.11 ± 0.17 v. 1.35 g ± 0.05, n = 27, p = 0.001) and a 
Control-HFHS diet (1.03 ± 0.12 v. 1.35 g ± 0.05, n = 27, p < 0.001).  
 
Figure 6.16: Effects of maternal diet on embryonic and placental weights. 
Mean embryonic (A) and placental (B) weights are shown at E18.5. Error bars 
represent Standard Deviation. Relative embryonic and placental weights compared 
with control-control are shown in percentages. HFHS = high fat – high sugar. *** p ≤ 
0.001. 
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There was also a significant difference in mean placental weights 
between maternal diet groups as determined by one-way ANOVA (F (3,48) = 
2.9, p = 0.04), see Figure 6.16 B. However, a Tukey post-hoc test revealed 
only a trend for increased placental weight for mothers fed a HFHS-HFSH 
diet compared with a Control-Control diet (91.83 mg ± 3.44 v. 125.71 mg ± 
1.44, n = 24, p = 0.10).  
There was no significant difference in placental Phlda2 expression 
between maternal diet groups as determined by a one-way ANOVA (F(3,18) 
= 1.90, p = 0.17).  Results remained non-significant when split by embryo 
sex. Similarly, there was no significant difference in placental Cdkn1c (F 
(3,18) = 1.67, p = 0.21) expression between maternal diet groups (Figure 
6.17).  
There was however a significant difference in placental Peg3 
expression between maternal diet groups as determined by one-way ANOVA 
(F (3,18) = 5.01, p = 0.01), as shown in Figure 6.17. A Tukey post-hoc test 
revealed a significant 50% increase in Peg3 expression in placentas of 
mothers fed a HFHS-Control diet as compared with a Control-Control diet (n 
= 12, p = 0.01). There was no significant difference in placental Peg3 
expression between any other diet groups as determined by a Tukey post-
hoc test.  
There was also a significant difference in placental Peg10 expression 
between maternal diet groups as determined by one-way ANOVA (F (3,18) = 
3.5, p = 0.04) (Figure 6.17). Although placental Peg10 expression was 
increased in all diet groups compared with the Control-Control offspring, A 
Tukey post-hoc test revealed only a significant 54% increase in Peg10 
expression in placentas of mothers fed a Control-HFHS diet as compared 
with a Control-Control diet (n = 12, p = 0.03).   
A summary of the changes in placental imprinted gene expression in 
response to maternal HFHS diet is shown in Table 6.3. The increase in 
placental Peg3 expression remained significant after controlling for multiple 
comparisons using a Bonferroni correction (P = 0.01). 
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Figure 6.17: Effects of maternal high fat – high sugar (HFHS) diet on placental imprinted gene expression Error bars represent 
standard error. * p ≤ 0.05, ** p ≤ 0.01. 
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Table 6.3. Summary of placental imprinted gene expression changes following 
maternal high fat – high sugar diet. Fold gene expression is shown relative to 
controls. Results highlighted in bold were statistically significant using an 
independent samples T test. * p ≤ 0.05, ** p ≤ 0.01. C = control diet, F = High fat – 
high sugar diet.   
Gene Active 
Allele 
C-C fold 
expression 
C-F fold 
expression 
F-C fold 
expression 
F-F fold 
expression 
Phlda2 M 1.00 
 
0.85 
(P = 0.80) 
0.96 
(P = 0.99) 
0.6 
(P = 0.15) 
Cdkn1c M 1.00 1.14 
(P = 0.76) 
0.83 
(P = 0.61) 
0.96 
(P = 0.99) 
Peg3 P 1.00 1.17 
(P = 0.60) 
1.5 
(P = 0.01)** 
1.18 
(P = 0.61) 
Peg10 P 1.00 1.54  
(P = 0.03)* 
1.31 
(P = 0.32) 
1.46  
(P = 0.13) 
 
In line with the absence of an effect of maternal HFHS diet on placental 
Phlda2 expression, placental expression of the spongiotrophoblast markers 
Prl3b1 and Prl8a8 was not significantly altered, Figure 6.18.  
 
Figure 6.18: Effects of maternal high fat – high sugar (HFHS) diet on 
spongiotrophoblast marker gene expression. There was no significant effect of 
HFHS diet on placental Prl3b1 or Prl8a8 gene expression. Error bars represent 
standard error.  
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6.3.5. RFLP analysis 
Gene expression analysis demonstrated significantly increased placental 
Phlda2 expression in response to a maternal low protein diet (at both E13.5 
and E18.5) and high fat diet (at E18.5) during pregnancy. Increased placental 
Phlda2 expression may result from either increased expression from the 
maternal Phlda2 allele or loss of imprinting at the paternal Phlda2 allele. In 
order to determine the allelic origin of Phlda2 expression in placentas from 
the mouse model of low protein and high fat diet, RFLP analysis was carried 
out. As Phlda2 is a maternally expressed imprinted gene it was expected that 
basal samples would only have the maternal 100bp band. Loss of imprinting 
would therefore be predicted to result in the presence of both the paternal 
150bp band and the maternal 100bp band.  
 
 
 
 
 
 
 
 
 
 
Figure 6.19: RFLP analysis. Results are shown for basal, high fat diet and low 
protein diet at E18.5 and for basal and low protein diet at E13.5. Expression from 
the maternal Phlda2 allele is indicated by the presence of a 100bp band, and 
expression from the paternal allele by presence of a 150bp band. Thus loss of 
imprinting is suggested in samples where both bands are present. HFD = high fat 
diet, LPD = low protein diet, LOI = loss of imprinting, C = control sample, L = ladder.   
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As can be seen in Figure 6.19, at E18.5 all samples (basal, high fat diet and 
low protein diet) had the paternal band present, suggesting a relaxation of 
imprinting at E18.5 under normal conditions which may obscure any effect of 
maternal diet on placental Phlda2 expression from the paternal allele. In 
contrast at E13.5, basal samples did not have the paternal band, suggesting 
that imprinting is maintained at this time point. Interestingly, two out of the 
five low protein diet samples at E13.5 had the paternal Phlda2 allele 
indicating loss of imprinting in these samples. These results suggest that loss 
of imprinting of the paternal Phlda2 allele occurs in response to low protein 
diet exposure during pregnancy (at E13.5), an effect which is obscured at a 
later time point (E18.5) as imprinting relaxes towards the end of gestation. 
However, this previously unreported result requires further investigation.  
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6.4. Discussion  
This chapter further explored the effect of maternal diet before and during 
pregnancy on placental imprinted gene expression in a mouse model. A 
summary of imprinted gene expression changes resulting from maternal diet 
alteration is shown in Table 6.4. These results suggest that placental Phlda2, 
Peg3 and Peg10 expression, but not Cdkn1c expression, is responsive to the 
maternal environment.  
 
6.4.1. Sex differences in imprinted gene expression 
Previous studies have suggested differential imprinted gene expression 
between male and female placentas both under normal conditions (Faisal et 
al. 2014) and in response to maternal diet alteration (Radford et al. 2012). 
This study demonstrated no significant difference in placental target gene 
expression between male and female placentas under basal conditions.  
However, an even number of male and female embryos were subsequently 
analysed for each condition (where possible), to determine sexual 
dimorphism in the placental response to maternal diet alterations.  
Table 6.4. Summary of placental imprinted gene expression changes following 
maternal diet alteration. Percentage change in expression relative to controls is 
shown. HFHS = high fat – high sugar.  
 
Gene Active 
Allele 
Low 
Protein 
Diet 
High Fat 
Diet 
HFHS – 
Control 
diet  
Control 
- HFHS 
diet 
HFHS -
HFHS 
diet 
Phlda2 M ↑ 109% ↑ 53% - - - 
Cdkn1c M - - - - - 
Peg3 P ↑ 24% - - ↑ 50% - 
Peg10 P ↓ 33% - -  ↑ 54% - 
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6.4.2. Maternal low protein diet and Phlda2 
Maternal low protein diet had no significant effect on embryo or placental 
weights at E18.5, as previously reported by Vucetic et al. (2010). Two fold 
increased Phlda2 expression was demonstrated in placentas of low protein 
diet pregnancies. Furthermore, although placental Phlda2 expression was 
increased in both male and female low protein diet placentas, this was only 
statistically significant in females. No previous study has analysed placental 
Phlda2 expression in response to maternal low protein diet, however these 
results are consistent with those of Shukla et al. (2011) demonstrating 
increased placental Phlda2 expression in a rat model of maternal under 
nutrition (in the form of calorie-restriction) during pregnancy.  
 Moreover, Phlda2 expression in the kidney was not significantly 
altered as a result of low protein diet, suggesting a placental specific 
response to maternal diet. Placental Phlda2 expression was however 
significantly increased at E13.5 suggesting that the effect of maternal diet on 
gene expression was not time specific. It should be noted that the increase in 
placental Phlda2 expression at E13.5 (174%) was more modest than that 
seen at E18.5 (209%), possibly as a result of the shorter exposure time to 
the low protein diet.  
Phlda2 has a known role in the negative regulation of the endocrine 
lineage of the placenta (reviewed in John 2013) with the mouse model of 
Phlda2 over expression demonstrating a specific loss of spongiotrophoblast 
cells (Tunster et al. 2010). Thus, given the two fold increase in placental 
Phlda2 expression observed in response to maternal low protein diet, 
expression of the spongiotrophoblast markers Prl8a8 and Prl3b1 was 
subsequently examined. Placental Prl8a8 and Prl3b1 expression was not 
significantly altered as a result of maternal low protein diet, suggesting no 
concurrent effect of maternal low protein diet on spongiotrophoblast cells of 
the placenta.  
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6.4.3. Maternal low protein diet and other imprinted genes 
Placental Peg3 expression was also increased in response to maternal low 
protein diet, although the effect observed was more modest (24% increase). 
In addition, this effect was sex specific with increased expression statistically 
significant in male but not female placentas. Radford et al. (2012) similarly 
reported an approximate 30% increase in placental Peg3 expression in 
response to maternal undernutrition during pregnancy.  As in the current 
study, this effect was sex-specific with Peg3 expression increased 
significantly in male placentas only (Radford et al. 2012). Increased placental 
Peg3 expression in response to maternal undernutrition was proposed to 
reflect a fetal adaptation, stimulating maternal food intake, in response to an 
adverse environment (Radford et al. 2012).  
 Maternal low protein diet also resulted in a significant 33% decrease in 
placental Peg10 expression. Furthermore, although placental Peg10 
expression was decreased in both male and female low protein diet 
placentas, this was only statistically significant in females. No previous study 
has analysed placental Phlda2 expression in response to maternal low 
protein diet, therefore these novel results provide the first evidence of an 
effect of maternal low protein diet on placental Peg10 expression.  
 
6.5.4. Maternal high fat diet  
Maternal high fat diet had no significant effect on embryo or placental 
weights at E18.5. Gallou-Kabani et al. (2010) similarly demonstrated no 
significant effect of maternal high fat diet on embryo weights at E15.5 
although placental weight was significantly reduced in response to high fat 
diet. However given that the number of mice studied by Gallou-Kabani et al. 
(2010) in each experimental group (209 v 184) was much higher than in the 
current study, it is possible that an effect of a high fat diet on placental weight 
could not be determined in a study of this size.  
 Placental Phlda2 expression was significantly increased by 53% in 
placentas of high fat diet pregnancies. As with low protein diet, this difference 
 258	  
was statistically significant in female placentas only. No previous study has 
analysed placental Phlda2 expression in response to maternal high fat diet, 
although Sferruzzi-Perri et al. (2013) did demonstrate a non-significant 
increase in placental Phlda2 expression in response to maternal high fat – 
high sugar diet. Thus, these novel results provide the first evidence of an 
effect of maternal high fat diet on placental Phlda2 expression. Furthermore, 
Phlda2 expression in the kidney was not significantly altered as a result of 
maternal high fat diet, suggesting a placental specific response to maternal 
high fat diet. Finally, no concurrent change in expression of the 
spongiotrophoblast markers Prl3b1 or Prl8a8 was observed.  
No significant difference was observed in expression of any other 
imprinted gene examined in response to maternal high fat diet.  
 
6.4.5. Maternal high fat – high sugar diet 
There was no significant effect of a maternal HFHS diet during pregnancy on 
embryo weight, as reported by Sferruzzi-Perri et al. (2013). However, embryo 
weight was increased in response to a HFHS before pregnancy, highlighting 
the importance of pre-conception diet on fetal growth. No associated effects 
on placental weight were observed.  
 There was no significant effect of maternal HFHS diet on placental 
Phlda2 expression when exposure occurred pre-pregnancy, during 
pregnancy or both. In addition, no associated effect on spongiotrophoblast 
marker expression was observed. Sferruzzi-Perri et al. (2013) similarly 
demonstrated no significant difference in placental Phlda2 expression in 
response to maternal high fat – high sugar diet. It should be noted for the 
current study that pregnancy was difficult to achieve and maintain in the 
HFHS-control and HFHS-HFHS mice and therefore results are based on 
placental gene expression in one litter. Analysis in an increased number of 
placentas from different litters will confirm the relationship, if any, between 
maternal HFHS diet and placental Phlda2 expression.  
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 Placental Peg3 expression was increased in all maternal HFHS diet 
groups compared with controls, however this difference was only statistically 
significant for HFHS-Control pregnancies. Sferruzi-Perri et al. (2013) 
previously demonstrated no significant effect of maternal HFHS diet on 
placental Peg3 expression, however in this study diet exposure was limited 
to pregnancy. Given the role of Peg3 in positively regulating fetal growth in 
the mouse, it is possible that the increased placental Peg3 expression 
observed underlies the increased embryo weights of the HFHS-control 
group.  
Finally, placental Peg10 expression was increased in all maternal 
HFHS diet groups compared with controls, although this difference was only 
statistically significant for control-HFHS mice. No previous study has 
examined placental Peg10 expression in relation to a HFHS diet. However, 
given that expression data form the control-HFHS group is derived from a 
single litter, the effect of a HFHS diet during pregnancy remain to be 
confirmed in an increased number of placentas from different litters.  
 
6.4.6. RFLP analysis 
Bands indicating expression of Phlda2 from the paternal allele were present 
in all E18.5 samples, including those where mothers were fed a basal diet 
during pregnancy. This suggests that a relaxation of imprinting of Phlda2 has 
occurred by E18.5. Previous studies of Phlda2 imprinting in the mouse have 
examined placentas only up to E14.5 (Qian et al. 1997; Frank et al. 1999; 
Frank et al. 2002). Thus, this novel result is the first evidence to support a 
relaxation of placental Phlda2 imprinting towards the end of gestation in the 
mouse.  
 Imprinting was maintained in basal samples at E13.5 with only 
maternal Phlda2 allelic expression observed. A proportion of the low protein 
diet samples (40%) demonstrated the presence of a paternal Phlda2 allele 
suggesting that loss of imprinting occurs in response to a maternal low 
protein diet, an effect which may be obscured at a later time point (E18.5) as 
imprinting relaxes towards the end of gestation.  Further work will involve 
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pyrosequencing of DNA methylation at the imprinted loci to fully determine 
whether loss of imprinting is responsible for the aberrant placental imprinted 
gene expression observed as a result maternal diet alteration.  
 
6.4.7. Summary  
In summary, the results presented in this chapter provide evidence to 
suggest that placental Phlda2, Peg3 and Peg10, but not Cdkn1c, expression 
is responsive to the maternal environment. Placental Phlda2 expression was 
increased at E18.5 as a result of maternal low protein diet and high fat diet 
during pregnancy. This study also demonstrated that placental Phlda2 
expression was increased due to a low protein diet at an earlier time point 
(E13.5) suggesting that the effect of low protein diet on placental Phlda2 
expression is not time specific. Furthermore, the absence of an effect of 
maternal low protein or high fat diet on placental Phlda2 expression in the 
kidney, suggests a placental specific response to maternal diet alteration. 
RFLP analysis suggested that the increased placental Phlda2 expression 
observed at E13.5 in response to maternal low protein diet was due to loss of 
imprinting but that this effect was obscured at E18.5 due to a relaxation of 
imprinting. Placental Peg3 expression was also significantly increased as a 
result of maternal low protein diet and high fat high sugar diet during 
pregnancy. In contrast, placental Peg10 expression was significantly 
decreased in the mouse model of low protein diet exposure but increased in 
response to a high fat – high sugar diet during pregnancy.  Finally, placental 
Cdkn1c expression was unchanged following maternal low protein, high fat 
or high fat – high sugar diet, suggesting that placental expression of this 
gene is not responsive to the maternal environment.  
 
 
 
 
 261	  
CHAPTER 7: DISCUSSION 
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7.1. Main findings 
 
Fetal growth restriction (FGR) is known to negatively impact on offspring 
health in the perinatal period and in adulthood, as well as long-term maternal 
health. A further understanding of the causes of growth restriction is 
therefore of paramount importance. This thesis examined expression of the 
imprinted genes PHLDA2, CDKN1C, PEG3 and PEG10 in relation to FGR 
and in relation to maternal lifestyles during pregnancy. Imprinted gene 
expression was also examined in relation to other complications of 
pregnancy that may result from inadequate maternal adaptation to pregnancy 
such as preeclampsia, gestational diabetes and maternal prenatal 
depression. This last premise was based on our understanding, from 
experimental animal models, that imprinted genes regulate the placental 
signals to the mother that induce adaptations required for a successful 
pregnancy.  
 
7.1.1. PHLDA2 
Placental PHLDA2 expression was significantly inversely associated with 
birth weight and custom birth weight centiles in two independent cohorts. 
Apostolidou et al. (2007) have previously demonstrated a negative 
correlation between birth weight and placental PHLDA2 expression. The 
results of the current study expand on these findings, demonstrating that the 
association between placental PHLDA2 and birth weight remains significant 
in a larger cohort including both AGA and SGA pregnancies. Furthermore, 
this study quantified the effect of placental PHLDA2 expression on fetal 
growth, demonstrating that expression accounted for 6% of variance in birth 
weight.  
 A significant two fold increase in placental PHLDA2 expression was 
also demonstrated in SGA pregnancies. These results are consistent with the 
increase in PHLDA2 expression previously observed in IUGR placentas 
(McMinn et al. 2006; Diplas et al. 2009; Kumar et al. 2012). Two fold Phlda2 
expression in a mouse model has been demonstrated to result in reduced 
fetal weights due to a gradual decrease in growth velocity during late 
gestation (Tunster et al. 2010). These data suggest that the aberrant 
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PHLDA2 expression observed in SGA placentas of the current study is the 
cause of fetal growth restriction rather than a consequence of an abnormal 
intrauterine environment. Furthermore, aberrant placental PHLDA2 
expression was observed in 27% of SGA placentas in this current study. 
McMinn et al. (2007) similarly reported a 25% prevalence of increased 
PHLDA2 expression. This suggests that as many as a quarter of all SGA 
births may be due to elevated PHLDA2 expression. Relating this finding to 
the number of term SGA pregnancies in the UK (approximately 53,000 in 
2012), aberrant placental PHLDA2 expression may underlie up to 14,000 
SGA pregnancies in the UK per annum (Office for National Statistics 2014).   
Aberrant placental PHLDA2 expression was also observed in a small 
proportion of AGA pregnancies in the current study. This might suggest that 
these infants, which would not normally be considered growth restricted, may 
have failed to reach their genetic growth potential. This novel finding 
suggests that placental PHLDA2 expression could be used to identify cases 
of in utero growth restriction not resulting in SGA or LBW. Full clinical 
characterisation of these infants, their growth patterns during pregnancy and 
their placentas will aid in determining the significance of these findings.  
Phlda2 over expression in a mouse model is specifically associated 
with asymmetric fetal growth restriction (Tunster et al. 2014). This study 
provides the first evidence that placental PHLDA2 expression may also play 
a role in symmetric growth restriction. Placental PHLDA2 expression was 
significantly increased in symmetric SGA pregnancies and was negatively 
associated with head circumference at delivery. These novel results suggest 
that in cases of FGR characterised by perturbed PHLDA2 expression, head 
sparing (the typical fetal adaptation to an adverse intrauterine environment) 
may be impaired. Importantly, this study does not discount a role for PHLDA2 
in human asymmetric growth restriction with a non-significant two fold 
increase in expression also observed in these pregnancies.  
In addition, placental PHLDA2 was significantly inversely associated 
with placental weight in two independent cohorts. This is consistent with the 
stunted placental growth observed in the mouse model of Phlda2 
overexpression (Tunster et al. 2010). However, previous studies have failed 
to replicate these findings in the human placenta (Apostolidou et al. 2007; 
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Lewis et al. 2012). Thus, this is the first evidence of a role for PHLDA2 in 
regulating human placental growth. In addition, these results provide support 
for the hypothesis that aberrant PHLDA2 expression results in FGR via a 
negative impact on placental growth (Jensen et al. 2014).  
Given the role of PHLDA2 in the control of fetal growth, it has been 
suggested that aberrant placental PHLDA2 expression could serve as a 
biomarker to identify infants at risk of poor perinatal outcomes (Jensen et al. 
2014). This is the first study to report on the relationship between placental 
PHLDA2 expression and measures of infant wellbeing at delivery. No 
significant association was demonstrated between placental PHLDA2 
expression and fetal distress during delivery, umbilical cord blood pH or 
apgar scores. Similarly, although placental PHLDA2 expression was almost 
three fold higher in infants admitted to NICU this difference was not 
statistically significant. Thus, the findings of the current study do not support 
the use of placental PHLDA2 as a biomarker to identify at risk infants.  
Based on the inverse association observed between placental 
PHLDA2 expression and measures of fetal growth, it was further 
hypothesised that decreased expression was associated with cases of fetal 
overgrowth resulting in the birth of an LGA or macrosomic infant. Indeed, 
placental PHLDA2 expression was significantly reduced in LGA pregnancies 
of the Manchester Cohort. This novel result suggests that alterations in 
PHLDA2 expression may underlie complications of pregnancy associated 
with both extremes of birth weight.  
Placental PHLDA2 expression was also hypothesised to be altered in 
preeclamptic pregnancies based on the increased prevalence of FGR in 
these pregnancies and the development of preeclampsia-like symptoms as a 
result of loss of function of Cdkn1c (in the same imprinting cluster) in a 
mouse model (Takahashi et al. 2000; Kanayama et al. 2002). The current 
study demonstrated significantly increased PHLDA2 in preeclamptic 
placentas, supporting previous reports by McMinn et al. (2006). In addition, 
these previous findings were expanded upon, with increased placental 
PHLDA2 expression demonstrated in preeclamptic pregnancies with and 
without the presence of SGA. These novel results are the first to suggest that 
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placental PHLDA2 may be involved in the pathogenesis of preeclampsia, 
independent of any effects on fetal growth.  
It has been proposed that imprinted genes, such as PHLDA2, regulate 
fetal growth through control of mechanisms driving maternal adaptations to 
pregnancy (Haig 1993), such as placental hormone production (John 2013). 
Indeed, Phlda2 is known to regulate the endocrine lineage of the mouse 
placenta (Tunster et al. 2010), specifically the placental lactogens. This study 
provides the first evidence of an inverse relationship between placental 
expression of PHLDA2 and the placental lactogen hPL, a hormone known to 
control fetal growth through alterations to maternal metabolism during 
pregnancy. Consistent with this finding, placental hPL expression was 
significantly positively correlated with birth weight.  
Inadequate adaptation of maternal metabolism to pregnancy may 
result in gestational diabetes, defined as glucose intolerance arising during 
pregnancy (Newbern and Freemark 2011). As placental PHLDA2 expression 
was demonstrated to be inversely associated with hPL expression, a 
hormone known to prevent glucose intolerance during pregnancy, gene 
expression was analysed in a small set of GDM placentas. A non-significant 
two fold increase in placental PHLDA2 expression in GDM pregnancies was 
demonstrated, specific to women with a high BMI. No concurrent change in 
placental hPL expression was observed. As GDM participants were 
compared with BMI matched controls, this suggests that the increased 
placental PHLDA2 expression observed in GDM placentas was not due to 
any association with maternal BMI. Further research is required to confirm 
these interesting but preliminary findings of aberrant placental PHLDA2 
expression in GDM placentas.   
 Thus, the current study provided new evidence of aberrant placental 
PHLDA2 expression in pregnancies complicated by FGR and PE as well as 
preliminary support for a possible alteration in GDM pregnancies.  Therefore, 
identifying environmental factors responsible for altered placental PHLDA2 
expression is of chief importance as these may be amenable to intervention. 
This study uniquely investigated the effect of maternal lifestyle factors such 
as smoking, alcohol consumption, exercise and diet on human placental 
PHLDA2 expression. Two maternal lifestyle factors were demonstrated to 
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increase PHLDA2 expression, caffeine and a Western diet. Although, no 
effect of maternal caffeine consumption was observed in AGA pregnancies, 
placental PHLDA2 expression was significantly increased in response to 
caffeine consumption in SGA pregnancies. Interestingly, these infants were 
also 206g smaller than SGA infants born to mother with lower caffeine 
consumption, although this difference was not statistically significant.  
Principle component analysis revealed a Western diet pattern 
characterised by consumption of high fat snacks, high sugar snacks, 
processed meat and soft drinks and low intake of fruit, vegetables and 
supplements. As with caffeine, there was no effect of a maternal western diet 
on placental PHLDA2 expression in AGA pregnancies. However, placental 
PHLDA2 expression was significantly increased in response to a maternal 
Western diet in SGA pregnancies. In these pregnancies, birth weight was 
also significantly inversely associated with maternal western diet scores. 
Similarly, Knudsen et al. (2008) have previously demonstrated an increased 
risk of SGA in mothers consuming a high fat Western diet during pregnancy. 
Two potential explanations were proposed to interpret the novel findings of 
the current study. Firstly, it is possible that placental PHLDA2 expression 
drives fetal growth restriction caused by environmental factors (such as 
increased caffeine consumption or a western diet). It is also possible that an 
adverse maternal environment exacerbates fetal growth restriction, via an 
increase in placental PHLDA2 expression, in already compromised 
pregnancies. Importantly with respect to possible interventions, a maternal 
diet characterised by high intake of fruit and vegetables, unprocessed meat, 
fish and meat alternatives and a low intake of caffeine, dairy products and 
carbohydrates (the healthy diet pattern) was not significantly associated with 
birth weight or placental PHLDA2 expression. This suggests that the healthy 
diet pattern was not protective of aberrant placental PHLDA2 expression and 
fetal growth restriction. In summary, these novel results are the first to 
suggest that human placental PHLDA2 expression may be altered by 
maternal caffeine consumption or a western diet pattern. Animal models will 
be essential in determining the mechanisms underlying these associations. 
Finally, a mouse model was used to examine the effects of maternal 
diet on fetal growth and imprinted gene expression, independent of other 
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lifestyle factors. Maternal low protein diet resulted in significantly increased 
placental Phlda2 expression at two time points (E13.5 and E18.5) although 
no effect on fetal or placental weights was observed. Interestingly, this effect 
was significant only in female placentas. To the author’s knowledge, no 
previous study has analysed placental Phlda2 expression in response to a 
low protein diet. These results are therefore the first to show that low protein 
diet may alter placental Phlda2 expression. As Phlda2 expression in the 
kidney was not significantly altered this suggests a placental specific 
response to a maternal diet. Human placental PHLDA2 expression was 
increased in mothers reporting consuming protein rich foods less than once a 
day, however this increase was modest and non-significant. Further research 
using a FFQ specifically designed to assess protein intake, will aid in 
determining the relevance to humans, of the observed increase in mouse 
placental Phlda2 expression in response to a low protein diet.   
Maternal high fat diet in a mouse model also resulted in significantly 
increased placental Phlda2 expression, although no associated effects on 
fetal or placental weight was observed. In contrast, there was no significant 
effect of maternal high fat – high sugar diet on placental Phlda2 expression, 
suggesting a specific effect of increased fat consumption. This study is the 
first to provide evidence of increased placental Phlda2 expression in 
response to a high fat diet in an animal model. Importantly, these results aid 
interpretation of observations on maternal lifestyle effects on human 
placental gene expression. While a maternal western diet (characterised by 
increased consumption of high fat foods) was associated with increased 
human placental PHLDA2 expression, it is not possible from human studies 
alone to establish causation. The increased placental Phlda2 expression 
observed as a result of a high fat diet in the mouse model, suggests that the 
association between a maternal western diet in humans and aberrant 
placental PHLDA2 expression may be causative.  
 In summary, the findings of the current study support previous reports 
of a role for placental PHLDA2 in negatively regulating fetal growth. In 
addition, this study uniquely contributes to the current knowledge of PHLDA2 
in a number of ways. Novel findings include evidence supporting a role for 
PHLDA2 in symmetric FGR, placental growth and placental hormone 
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production. In addition, aberrant placental PHLDA2 expression was 
demonstrated for the first time in LGA pregnancies and in PE pregnancies 
with or without FGR. Finally, this study demonstrated a previously unreported 
association between human placental PHLDA2 expression and maternal 
caffeine consumption and a maternal western diet, with work in a mouse 
model further highlighting an effect of a maternal low protein and high fat 
diet. Given the potentially large number of SGA pregnancies caused by 
aberrant placental PHLDA2 expression, interventions aimed at preventing 
adverse lifestyles associated with altered expression will be of paramount 
importance.  
 
 
7.1.2. CDKN1C 
There was no significant association between placental CDKN1C 
expression and birth weight or custom birth weight centiles in the two 
independent cohorts examined, after controlling for mode of delivery. Diplas 
et al. (2009) similarly reported no significant difference in placental CDKN1C 
expression in IUGR placentas. However, in general, previous studies of 
human placental CDKN1C expression in relation to fetal growth have yielded 
conflicting results (McMinn et al. 2006; Diplas et al. 2009; Rajaraman et al. 
2010). The current study demonstrated a significant difference in placental 
CDKN1C expression between labouring and non-labouring placentas and 
therefore proposes that conflicting results in previous studies may have 
arisen due to failure to control for mode of delivery. In conclusion, this study 
does not support a role for placental CDKN1C in the control of human fetal 
growth. Although Cdkn1c over expression is associated with fetal and 
postnatal growth retardation in a mouse model (Andrews et al. 2007), it is 
possible that this represents a mouse-specific effect or that the association in 
humans is relatively modest such that it cannot be detected in a cohort of this 
size.  
 Imprinted genes have been proposed to regulate the 
spongiotrophoblast cells of the mouse placenta (John 2013). The 
spongiotrophoblast cells serve as the endocrine lineage of the placenta, 
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producing hormones such as placental lactogens. Cdkn1c over expression in 
a mouse model negatively affects the spongiotrophoblast cells and 
decreases expression of placental lactogens. This study provides the first 
evidence that this may also be true in humans, with placental CDKN1C 
expression inversely correlated with hPL expression.  
Little is known about whether placental CDKN1C is responsive to 
environmental stimuli. In this study, placental CDKN1C expression was 
demonstrated to be significantly increased in overweight and obese 
participants. Moore et al. (2015) have previously reported no significant 
correlation between maternal weight and placental CDKN1C expression, 
although maternal BMI was not analysed. Thus, these novel findings provide 
the first evidence of an association between raised maternal BMI and 
aberrant CDKN1C expression.  
In summary, the findings of the current study do not support a role for 
placental CDKN1C in the control of fetal growth. This study does however 
uniquely contribute to the current knowledge of CDKN1C, demonstrating an 
association between maternal BMI and placental CDKN1C expression.  
 
7.1.3. PEG3 
Placental PEG3 expression was not significantly associated with birth weight 
or custom birth weight centiles in two independent cohorts. This is in line with 
four previous studies demonstrating no significant association between 
placental PEG3 expression and measures of fetal growth (McMinn et al. 
2006; Diplas et al. 2009; Kumar et al. 2011; Moore et al. 2015). Thus, the 
findings of the current study do not support a role for PEG3 in the control of 
human fetal growth. Although embryo weight was decreased (by 10%) in a 
mouse model of Peg3 loss of function (Li et al. 1999; Kim et al. 2013), it is 
possible that the relatively small effect observed on fetal growth cannot be 
detected in a cohort of this size.  
 Placental PEG3 expression was however demonstrated to be 
significantly decreased in mothers with increased symptoms of prenatal 
depression or diagnosed depression during pregnancy in two independent 
cohorts. Peg3 has been demonstrated in a mouse model to be required for 
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the induction of nurturing and nest building behaviour in rodents (Li et al. 
1999; Curley et al. 2004; Champagne et al. 2009; Chiavegatto et al. 2012). 
The novel results reported in the current study are the first evidence that 
placental PEG3 expression is associated with maternal mood in humans. 
This is consistent with the hypothesis that imprinted gene expression, via 
regulation of placental hormone production, may contribute to maternal 
psychological adaptation to pregnancy with inadequate adaptation 
manifesting as maternal mood disorders.  
Placental hPL expression was also demonstrated for the first time to 
be significantly decreased in mothers with prenatal depression in the two 
cohorts. The lactogenic hormone hPL is key to the induction of maternal 
behaviour in animals (Bridges et al. 1985; Bridges et al. 1990; Bridges and 
Freemark 1995; Bridges et al. 1997) and maternal serum levels been 
demonstrated to be reduced in mothers with symptoms of postnatal 
depression (Abou-Saleh et al. 1998; Ingram et al. 2003; Groer and Morgan 
2007. In the current study, a significant positive correlation was observed 
between placental PEG3 and hPL expression in the larger of these two 
cohorts, consistent with the reduction in placental lactogen expression 
observed in the mouse model of Peg3 loss of function (Broad and Keverne 
2011; Kim et al. 2013).  
These novel results, combined with data from previous studies in 
animal models, suggest that placental PEG3 expression contributes to the 
induction of maternal psychological adaptation to pregnancy, via control of 
placental hPL production. However, PEG3 is also known to be responsive to 
environmental stimuli. For example, placental Peg3 has been demonstrated 
to be increased in response to maternal undernutrition (Radford et al. 2012) 
but decreased in response to transient maternal starvation (Broad and 
Keverne 2011). Similarly, this study demonstrated increased placental Peg3 
expression in response to maternal low protein diet during pregnancy and a 
high fat – high sugar diet before pregnancy in a mouse model. It is therefore 
also possible that placental PEG3 and subsequent placental hormone 
production is responsive to maternal depression (or alterations in maternal 
lifestyle associated with depression) thereby establishing a cycle of aberrant 
placental gene expression, placental hormone production and increased 
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symptoms of maternal depression. Further studies on larger cohorts, 
including for example measures of maternal care such as mother-infant 
bonding, are required to corroborate the findings of the current study while 
additional animal studies will be important in further establishing cause and 
effect relationships.  
Although anxiety and depression are co-morbid, placental PEG3 and 
hPL expression was not significantly altered in women with high trait anxiety 
symptoms. O’Donnell et al. (2012) and Blakeley et al. (2013) similarly 
reported distinct effects of maternal anxiety and depression on placental 
gene expression. It is therefore possible that placental PEG3 and hPL 
expression is differentially associated with maternal depression and anxiety, 
although this remains to be confirmed in a larger cohort.  
   
7.1.4. PEG10 
Results from two independent cohorts support a role for placental PEG10 in 
the positive regulation of fetal growth, albeit with different lines of evidence. 
In the Manchester Cohort placental PEG10 expression was significantly 
positively associated with birth weight and expression significantly decreased 
in SGA pregnancies. This is consistent with the positive correlation reported 
between umbilical cord PEG10 expression and birth weight (Lim et al. 2012). 
Moreover, this study provides the first evidence to suggest that placental 
PEG10 expression may play a role in asymmetric growth restriction. 
Although not significant, PEG10 expression was reduced only in asymmetric 
SGA placentas. Placental PEG10 expression was also significantly 
associated with ultrasound measures of fetal growth including abdominal 
circumference and femur length. In contrast placental PEG10 expression 
was not significantly associated with ultrasound measurement of head 
circumference or with head circumference at delivery. This is consistent with 
a role for placental PEG10 expression in asymmetric growth restriction, 
which is characterised by reduced length and abdominal circumference but 
relative sparing of the head. These novel results are intriguing but require 
further replication in a larger cohort.  
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While placental PEG10 expression was not significantly reduced in 
SGA pregnancies of the Wales Cohort, additional lines of evidence did 
suggest a role for placental PEG10 in the positive regulation of fetal growth. 
In this cohort, placental PEG10 expression was significantly increased in 
LGA and macrosomic placentas; these novel results provide the first 
evidence to suggest a role for aberrant placental PEG10 expression in 
pregnancies complicated by fetal overgrowth. Discrepancies between the two 
cohorts may arise for a number of reasons such as different proportions of 
AGA, SGA and LGA pregnancies in the two cohorts, differences in the 
control population to which gene expression is compared and/or that the 
Manchester Cohort is comprised of a population of pregnancies also 
complicated by reduced fetal movements. Although demonstrated in different 
ways in the two cohorts, this study provides the first evidence of a positive 
association between placental PEG10 expression and fetal growth, 
specifically growth of the femur and abdomen during pregnancy. 
Furthermore, this association is suggested to be causal given the growth 
retardation observed in the mouse model of Peg10 loss of function (Ono et 
al. 2006).  
Placental PEG10 expression was also demonstrated to significantly 
positively correlated with apgar scores at 1 and 5 minutes after delivery. 
These novel results may be explained by the positive association 
demonstrated between placental PEG10 expression and fetal growth, with 
infants reaching their full growth potential expected to exhibit better 
outcomes at delivery. Further research is required to determine whether 
placental PEG10 expression can be used as a biomarker to predict adverse 
outcomes at delivery.  
Given the role of PEG10 expression in the control of fetal growth, it is 
important to identify maternal lifestyle factors associated with aberrant 
placental PEG10 expression, as these may be amenable to intervention. 
However, few studies have examined whether placental PEG10 is 
responsive to environmental stimuli. In this study, placental PEG10 
expression was demonstrated for the first time to be significantly increased in 
response to a carbohydrate rich diet in the mother. The increased placental 
PEG10 expression observed may underlie the positive association between 
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frequency of consumption of carbohydrate-rich foods and custom birth weight 
centiles demonstrated in this study. In addition, maternal low protein diet 
resulted in decreased placental Peg10 expression and a maternal high fat – 
high sugar diet associated with increased placental Peg10 expression in a 
mouse model. These novel results suggest that PEG10 expression is 
responsive to maternal diet in both the human and mouse placenta.  
In summary, the findings of the current study support a role for human 
placental PEG10 in the positive regulation of fetal growth. In addition, this 
study contributes to the current knowledge of PEG10, demonstrating a 
specific association with fetal abdominal and femur growth and highlighting a 
role for aberrant PEG10 expression in asymmetric growth restriction. Finally, 
placental PEG10 expression was uniquely demonstrated to be responsive to 
environmental stimuli, with expression significantly associated with maternal 
diet in humans (specifically carbohydrate consumption) and in a mouse 
model (both low protein and a high fat – high sugar diet).  
 
7.2. Strengths and limitations 
One of the strengths of this study was the thorough optimisation of the 
placental dissection protocol. No guidelines currently exist on placenta 
sampling, which would ensure consistency between studies (Burton et al. 
2014). In addition, a number of factors including time to sampling, sampling 
site, mode of delivery and fetal sex are known to affect placental gene 
expression (Burton et al. 2014). This study demonstrated that placental 
samples taken within two hours of delivery were of sufficient quality for qPCR 
analysis in line with previous reports (Fajardy et al. 2009; Avila et al. 2010). 
For the first time, placental PHLDA2 expression was demonstrated to vary 
significantly according to placental sampling site, with increased expression 
observed at the distal edges of the placenta compared with sites closer to the 
umbilical cord. This finding highlights the importance of consistency in 
placental sampling and most likely has implications for the design of future 
studies. Another novel finding was that of increased placental CDKN1C 
expression in labouring compared with non-labouring placentas. This result 
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may explain conflicting results previously reported with respect to placental 
CKDN1C expression and fetal growth (McMinn et al. 2006; Diplas et al. 
2009; Rajaraman et al. 2010) and has implications for the interpretation of 
results in future studies. Thus, the dissection protocol optimisation carried out 
as part of this study ensured that good quality, consistent and comparable 
gene expression data was obtained from the placentas sampled.  
Another advantage of the current study was the wealth of information 
available on the study participants. Clinical information necessary for 
interpretation of the study results was provided, including parity, gestational 
age, ethnicity, prescribed medication and mode of delivery, as specifically 
recommended for studies of the human placenta (Nelson and Burton 2011). 
This comprehensive characterisation of the study cohort enables 
identification of potential confounding factors and therefore strengthens study 
results (Nelson and Burton 2011).  
The use of custom birth weight centiles in the identification of growth 
restricted pregnancies was another strength of this study. Custom birth 
weight centiles are adjusted for maternal height, weight, ethnicity, parity, fetal 
sex and gestational age and therefore provide an indication of the optimal 
growth potential of each individual fetus (Gardosi 1992). Use of custom birth 
weight centiles has been demonstrated to better identify infants at risk of 
adverse outcomes (De Jong et al. 1998; Clausson et al. 2001; Gardosi 
2009).  Previous studies of imprinted genes and fetal growth have used 
population growth centiles or birth weight as the outcome measure. Using 
custom birth weight centiles in the current study uniquely identified a role for 
aberrant imprinted gene expression in pregnancies complicated by 
pathological growth restriction rather than constitutional smallness.  
Finally, another advantage in the analysis of maternal lifestyle effects 
on placental gene expression was that only Caucasian women were included 
in this part of the study. This was done so as to limit possible genetic 
variation (in comparison to ethnically diverse populations) and therefore 
focus on environmental factors and their effects on placental imprinted gene 
expression and fetal growth. This is particularly important given that 
differences in culture may impact on maternal lifestyle during pregnancy and 
the known ethnic differences in birth weight and pregnancy complications. 
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Furthermore, a recent study analysed SNPs in Caucasian participants in 
different regions of the UK and demonstrated a distinct genetic cluster in 
Wales, differentiating Wales from the rest of the UK (Leslie et al. 2015). In 
light of these findings and given that 78% of participants in the current study 
were Caucasian-Welsh, it is likely that genetic diversity in this population was 
further reduced.  
There are however a number of limitations to this study which should 
be considered. Firstly, although described as strength, including only 
Caucasian participants in the study of maternal lifestyle effects on placental 
gene expression could limit the relevance of these findings to other ethnic 
groups.  Studies of large populations with greater ethnic diversity will aid in 
determining whether the findings reported underlie complications of 
pregnancy in other ethnic groups.   
Another limitation of the current study is that only one housekeeping 
gene was used for normalisation of placental target gene expression data. It 
has been argued that due to intrinsic variation in housekeeping gene 
expression, use of a single housekeeping gene can result in inaccuracies in 
expression data normalisation (Vandesompele et al. 2002). Therefore, it has 
been suggested that target gene expression should be normalised to the 
average expression of three housekeeping genes (Vandesompele et al. 
2002). However, it should be noted that the housekeeping gene used in the 
current study, YWHAZ, has been demonstrated in a number of studies to be 
stably expressed in the human placenta of normal pregnancies (Meller et al. 
2005; Cleal et al. 2009; Cleal et al. 2010) and in pregnancies complicated by 
IUGR (Murthi et al. 2008).  
With respect to the participant questionnaire, another important study 
limitation is the reliance on maternal self-report data, particularly information 
on diet during pregnancy and symptoms of depression and anxiety. 
Therefore, where possible data from the participant questionnaire was 
compared with that in the participant medical notes (e.g. smoking, alcohol 
consumption and illegal drug use) and found to be highly correlated, as 
previously reported in other studies (Rice et al. 2007). Another limitation was 
that participant questionnaires were completed and returned by only 80% of 
the cohort such that lifestyle data is missing for a number of participants. 
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Importantly, it is not possible to know whether participants not completing the 
participant questionnaire were those with a particularly adverse lifestyle 
during pregnancy. Finally, the FFQ used in the current study was non-
quantitative and did not include as comprehensive a list of food items as 
FFQs used in previous studies of maternal diet during pregnancy, which 
typically include around 100 food items (for example Robinson et al. 1996; 
Moore et al. 2004; Rao et al. 2001). Use of dietary records would have 
provided more detailed, quantitative information on maternal diet during 
pregnancy, however this method is more time consuming and is associated 
with reduced return rates (Thompson and Subar 2008).   
Another limitation, particularly with respect to analysis of placental 
imprinted gene expression in pregnancy complications (Chapter 4) is the 
relatively small sample size. For example, only 16 GDM placentas and 22 
PIH/PE placentas were available for analysis. In particular, placental 
dissection rates were lower for these pregnancies complications (67% for 
GDM and 71% for PIH/PE pregnancies) compared with dissection rates in 
the overall cohort (84%). This may reflect the increased risk of maternal and 
fetal complications around the time of delivery in these pregnancies, such 
that placental sampling was not a key priority. As a result, caution must be 
taken when interpreting results from these samples and replication is 
required in a larger cohort.   
Finally, use of placental hPL and PGH expression as a proxy for 
placental hormone production could be argued as another potential 
weakness. Koutsaki et al. (2011) have previously demonstrated differences 
between placental gene expression and maternal serum levels of these 
placental hormones, which was proposed to be due to posttranscriptional 
and/or posttranslational modifications. In contrast, it could be argued that 
placental gene expression is more constant than maternal serum levels, 
which may vary according to factors such as time of day, stress and maternal 
lifestyle. The associations observed in this study between placental imprinted 
gene and hormone gene expression must be further examined in a cohort 
where maternal serum levels of these hormones can be measured. This is of 
clinical relevance since levels of these hormones in the maternal blood may 
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serve as a biomarker for inadequate maternal adaptation to pregnancy, such 
as in cases of maternal depression.  
 
 
7.3. Future work 
 
There are a number of potential future studies arising from the findings of this 
thesis, which have been discussed in each individual chapter. In addition, 
there are three main areas of interest that warrant further investigation.   
Firstly, fetal growth restriction is known to negatively impact on long 
term offspring health, increasing the risk of certain diseases in adulthood 
such as hypertension, cardiovascular disease and type II diabetes (Godfrey 
and Barker 2001). Interestingly, in the mouse model of Phlda2 over 
expression, offspring are growth restricted at birth but show increased 
adiposity and impaired glucose tolerance in adulthood (from the thesis of S 
Tunster). This suggests that aberrant placental Phlda2 expression causes 
fetal growth restriction and programmes an increased risk of disease in adult 
life. No study to date has analysed long term child outcomes resulting from 
human fetal growth restriction characterised by aberrant placental PHLDA2 
expression. Long term follow up of child health including measures of 
postnatal catch up growth, glucose tolerance and adiposity will determine 
whether aberrant placental PHLDA2 expression at birth can predict future 
risk of disease in later life. This would be beneficial in informing postnatal 
care of the child given that the increased risk of adult disease (such as type II 
diabetes) is greatest in growth restricted infants that subsequently grow up in 
a nutrient rich environment (Gluckman et al. 2005). Long term effects of the 
growth restriction resulting from Peg10 loss of function have not been 
examined due to the embryonic lethality observed in this mouse model. 
However, given the role of placental PEG10 in the positive regulation of fetal 
growth demonstrated in this study, analysis of long term child outcomes 
associated with aberrant placental PEG10 expression may also be of 
interest.  
 Secondly, this thesis suggests a possible role for imprinted genes in 
maternal adaptation to pregnancy. Inadequate adaptation to pregnancy may 
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result in lasting effects on the mother. For example, a number of studies 
have demonstrated that mothers carrying SGA infants or suffering from 
preeclampsia during pregnancy are at an increased risk of cardiovascular 
disease in later life (Bukowski et al. 2012; Pariente et al. 2013; Catov et al. 
2011; Ngo et al. 2015; Hutcheon et al. 2011). Similarly, women suffering from 
gestational diabetes during pregnancy are at an increased risk of developing 
type II diabetes after pregnancy (Hartling et al. 2013). It is therefore of 
interest to follow up not just the infants of pregnancies characterised by 
aberrant imprinted gene expression but also their mothers. This will establish 
whether placental gene expression at delivery can predict future maternal 
disease risk and thereby inform postnatal care. This may be particularly 
relevant in the case of maternal mood disorders. In the current study 
placental PEG3 and hPL expression were demonstrated to be significantly 
reduced in pregnancies complicated by maternal prenatal depression. Follow 
up of mothers in the postnatal period will determine whether placental PEG3 
and hPL expression can predict the subsequent development of postnatal 
depression.  
 Finally, a particular area of interest is the development of biomarkers 
for fetal growth restriction in order to enable early detection, decrease rates 
of false FGR diagnosis and to provide optimal prenatal care of the pregnant 
mother. This is similarly true for other complications of pregnancy including 
preeclampsia, gestational diabetes and maternal mood disorders. The finding 
of altered imprinted gene and placental hormone gene expression in these 
pregnancy complications, suggests a possible foundation on which to further 
explore development of a biomarker. Although, Demetriou et al. (2014) 
reported no significant correlation between PHLDA2 expression in first 
trimester chorionic villus samples and birth weight at delivery, this cohort did 
not examine prediction of other pregnancy complications and therefore does 
not discount the possibility of using placental imprinted gene expression in 
chorionic villus samples in the early detection of pregnancy complications 
such as PE/PIH and GDM. Moreover, results from this thesis support the 
proposed regulation of placental hormone production by imprinted genes 
(John 2013). Future studies examining placental imprinted gene expression 
in relation to maternal serum hormone levels will aid in determining whether 
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serum levels of placental hormones can be used as a biomarker for aberrant 
placental imprinted gene expression and therefore predict complications of 
pregnancy.  
 
7.4. Concluding remarks 
In conclusion, this thesis provides new evidence for important but differing 
roles of the imprinted genes PHLDA2, PEG3 and PEG10 in the control of 
fetal growth and maternal adaptation to pregnancy. The data presented 
supports negative regulation of human fetal growth by placental PHLDA2 
expression and positive regulation by placental PEG10 expression, uniquely 
expanding on the current understanding of these associations. In contrast, 
the current study did not support a role for PEG3 in the control of human fetal 
growth but instead suggested an involvement of this gene in maternal 
adaptation to pregnancy with aberrant gene expression observed in 
pregnancies complicated by maternal depression. Furthermore, this study 
provided evidence that the imprinted genes PHLDA2, CDKN1C, PEG3 and 
PEG10 are responsive to environmental stimuli, in particular maternal diet, in 
both human pregnancies and in a mouse model. Thus, this thesis highlights 
the importance of imprinted genes in achieving a successful pregnancy for 
both mother and fetus and the possible role of maternal lifestyle in 
influencing this.  
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Appendix 1: Participant Information Sheet 
 
Participant Information Sheet 
 
Version 4.1 
Date:  14.05.13 
REC ref no. 10/WSE02/10 
 
 
Study title: Examining imprinted gene expression in human placenta.  
  
 
Part 1 of information sheet 
 
 
Invitation paragraph: 
 
We would like to invite you to take part in our research study.  Before you decide we 
would like you to understand why the research is being done and what it would involve 
for you. One of our team will give you the information sheet and answer any questions 
you have. We‘d suggest this should take about 10 minutes. Talk to others about the 
study if you wish.   
 
Ask us if there is anything that is not clear. 
 
What is the purpose of the study? 
 
We want to look at the factors in the placenta that effect growth of the baby. We know of 
a group of genes (instructions) that are important for building the placenta. If these 
“instructions” are incorrect or misread, then normal growth and development does not 
happen. We will look at these instructions in a large number of placentae, including 
yours, so that we can understand them better. This will help us predict which 
pregnancies might need closer monitoring and more support from our Obstetrics team 
to ensure a safe delivery and a long and healthy life for babies born in the future. 
 
What is the placenta? 
 
The placenta is the afterbirth. After your baby is born, more contractions push the 
placenta out through the vagina. The placenta at this stage is also called the afterbirth. 
Normally it is destroyed. 
 
What does the placenta do? 
 
The placenta is the organ that links you to your baby via the umbilical cord. The job of 
the placenta during pregnancy is to pass oxygen and food from your blood supply to the 
baby. Waste products from the baby, such as carbon dioxide, are returned along the 
umbilical cord back to the placenta and then into your bloodstream. 
 
Why do we need to collect the placenta? 
 
Following the birth of your baby your placenta is normally destroyed. By collecting 
placentae and studying them, we can hope to learn what is needed for a normal, healthy 
pregnancy and what may cause a difficult pregnancy.  For example, we would like to 
learn more about why some babies are born smaller or larger than average or why 
some women develop pre-eclampsia or gestational diabetes. 
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Why have I been invited?  
 
Any pregnant women can participate. As of April 2007 a new legislation came into effect 
(The EU Directive for Tissue and cells), which states that consent for the use and 
testing of your placenta must be obtained prior to the birth of your baby or before labour 
is so advanced that you do not have time to make an informed decision(which includes 
active labour). 
 
This ensures that you have had plenty of time to ask us any questions you have relating 
to the collection, testing and storage of your placenta. We encourage you to make an 
informed decision about donating your placenta. 
 
Do I have to take part?  
 
It is up to you to decide to join the study. We describe the study in this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are 
free to withdraw at any time, without giving a reason.  This would not affect the standard 
of care you receive.   
  
What will happen to me if I take part?  
 
You will be asked to complete a short questionnaire about your pregnancy. Any 
questions that you feel unhappy answering can be left blank. This information will be 
given a unique identification number so that your details are kept confidential.  
 
Once your baby has been born, your midwife will confirm that consent has been given 
and will pass your placenta to our staff, along with your signed consent form. Small 
pieces of the placenta are then placed in collection tube. We need to collect only a few 
small pieces the size of a thumb tip. The rest will be destroyed by the normal Hospital 
procedures. 
 
Your donation is given a unique identification number. All the information provided to us 
uses this number only. Your details are therefore kept confidential. We will not know 
your name or address, just the babies weight and a few details about your pregnancy i.e 
head and abdominal measurements of baby and any medical problems you have 
experienced. We will collect the details about the pregnancy and newborn at the time of 
birth and then the details will be anonymised therefore we will not be able to collect any 
further information and can not identify you after wards. 
 
We expect study to last approximately 1 year. 
 
Expenses and payments?  
 
Your placental sample will be collected at the time of birth. Therefore it will not cost you 
any money. We do not pay for your donation. 
 
What are the side effects of any treatment received when taking part?  
 
The procedures we use to collect a placental sample are safe and risk-free for both you 
and your baby. This is because the collection of the placenta happens AFTER the baby 
is born, AFTER the cord is cut and AFTER the placenta has been delivered. Donating 
samples of your placenta does not interfere with the management of labour and 
delivery, or with the aftercare of you or your baby. 
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What are the possible disadvantages and risks of taking part?   
 
There are no disadvantages of taking part in the research as we will only take the 
sample from the placenta after the delivery of placenta before it is sent for destroying 
destruction as per hospital policy.  
  
 
What are the possible benefits of taking part?   
 
We cannot promise the study will help you in current pregnancy, but the information we 
get from this study we can learn what genetic activity in the placenta is needed for a 
normal, healthy pregnancy and what may cause a difficult pregnancy.  For example, we 
would hope to learn more about why some babies are born smaller or larger than 
average or why some women develop pre-eclampsia or gestational diabetes.  
  
What if there is a problem?  
   
Any complaint about the way you have been dealt with during the study you will be 
addressed. The detailed information on this is given in Part 2.  
  
 
 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
 
 
Part 2 of the information sheet  
 
 
What if relevant new information becomes available?    
  
As this study is anonymous we will not be able to contact you. 
 
 
What will happen if I don't want to carry on with the study?  
  
If you withdraw from the study by just informing your midwife and we will not use your 
placental sample for the study. You can withdraw from the study before the placenta is 
passed on to the research team, after which the samples will not be identifiable.  
 
What if there is a problem?  
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number at the 
end).  If you remain unhappy and wish to complain formally, you can do this [ e.g.  NHS 
Complaints Procedure].   
   
What will happen to any samples I give?   
 
The placenta will be stored for a short time (weeks) and then we will prepare RNA and 
DNA (in order to look at the genes) from it. This will be stored for the duration of the 
study. These samples will be anonymous and we cannot identify you or your baby from 
them. 
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What If a participant, who has given informed consent, loses capacity to consent 
during the study? 
 
No further data or tissue will be collected once the placental samples have been taken. 
It will not be possible to identify the tissue related to the participant if she loses the 
capacity to consent during the study after the samples have been taken. If between 
giving consent and the donation of the tissue sample, the woman looses capacity to 
consent she will be withdrawn from the study and placental tissue samples will not be 
taken. as the samples will be anonymised after they have been taken.  
 
What will happen to the results of the research study? 
 
This is an anonymous study. We will not know who you are. We will not have your name 
or address. This means we cannot contact you to tell you anything about your placenta. 
We aim to publish the results of our research in scientific journals, and will also provide 
feedback via the hospital newsletter, and local media. 
 
Who is organising and funding the research?  
 
University Hospital Wales & University of Cardiff (Biosciences) 
 
Who has reviewed the study?  
  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests.  This study has been reviewed and given 
favourable opinion by South East Wales Research Ethics Committee.  
  
6.2.11 Further information and contact details   
 
Mr R Penketh (Consultant Obstetrician & Gynaecologist)  
 
Email: Richard.Penketh@wales.nhs.uk 
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Appendix 2: Participant Consent Form 
  
 
 
 
Centre Number:  
 
REC reference number: 10/WSE02/10 
 
CONSENT FORM VERSION 4 
 
Date: 15.12.11 
 
Title of Project: Examining imprinted gene expression in human placenta.  
 
 
Name of Researcher                                                                                                                                                        
 	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Please initial box 	  	  
1.  I confirm that I have read and understand the information sheet dated 
15.12.11 (version 4) for the above study, have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected.  	  
3. I understand that only relevant sections of my medical notes and data 
collected during the study may be looked at by research team 
members, from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in research. I give permission for these 
individuals to have access to my records, but the data retrieved will be 
anonymised. 	  
4. I agree to take part in the above study.  	  	  
 
__________________________        _____________      _________________________   
Name of Patient    Date   Signature  
 
 
_______________________        ___________      _______________________  
Name of Person taking consent Date          Signature  
 
 
When completed: 1 for participant; 1 for researcher site file: 1(original) to be kept in medical 
notes.
Study of Imprinted 
Gene Expression in the 
Placenta 
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Appendix 3: Participant Questionnaire  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for answering these questions. It would help us if you could answer all the 
questions, however if you feel unhappy about answering any of them, please feel free to leave 
them blank. All information is kept in the strictest confidence and will not affect the standard 
of care you receive. 
 
Where known, please provide us with the answers to the following questions : 
 
About You  
 
 
! To which of these ethnic groups do you consider you belong? (Please tick)  
Caucasian (White)       Indian/Pakistani/Bangladeshi        Middle Eastern 
Far Eastern        African/Afro-Caribbean          
South American/Hispanic  Mixed (please specify)        ………………………… 
Do not wish to say                           Other (Please specify)  ………………………… 
 
! What is your country of birth? (Please tick)  
Wales   England     Ireland     Scotland        Other   
 
! What is your age?  ………............ 
! What was your weight before pregnancy? ……….... kg  or    ……….... lb 
! What is your height? ……….... m  or    ……….... ft 
Study ID:  
Date:  
Study of Imprinted Gene 
Expression in the Placenta 
Participant Questionnaire 
Version 1 
15.12.11 
REC Ref no: 10/WSE02/10 !
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! Towards term (37 weeks), we will ask for your final weight which will be recorded here by 
yourself or your midwife as ……….... kg  or    ……….... lb   at …………….. weeks   
 
! Do you know your birthweight? (Please tick)  
Yes   it was ………………….. 
 
No 
 
! What is your highest level of education? (Please tick) 
Left before GCSE    GCSE/O levels       A levels    University 
 
About your family 
 
 
!  To which of these ethnic groups does your baby’s father belong? (Please tick)  
Caucasian (White)       Indian/Pakistani/Bangladeshi        Middle Eastern 
Far Eastern        African/Afro-Caribbean          
South American/Hispanic  Mixed (please specify)        ………………………… 
Do not wish to say                           Other (Please specify)  ………………………… 
 
! What is your baby’s father’s country of birth? (Please tick)  
Wales   England     Ireland     Scotland        Other   
 
! What is your family income per year before deductions? (Please tick) 
<£18,000        £18,000 - £25,000          £25,000 - £43,000 
>£43,000        Do not wish to say 
 
About your pregnancy 
 
 
! How many weeks pregnant are you today? ………............ 
 
! Is this pregnancy a natural or assisted conception? (Please tick)  
Natural  Assisted (IVF)  Do not wish to say  
 315	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! Did you smoke in the three months before you found out you were pregnant? 
(Please tick)  Yes (daily)       Yes (Occasionally but not every day)       No  
  
! Have you smoked during your pregnancy?   (Please tick)   
During the first 12 weeks:  Yes (daily)            Yes (Occasionally but not every day)                 
                                           No     
After 12 weeks:          Yes (daily)           Yes (Occasionally but not every day)                                                                                
                                           No     
! Did you drink alcohol in the three months before you found out you were pregnant? 
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
 
! Have you had alcohol during your pregnancy? 
 
During the first 12 weeks:  
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
 
After 12 weeks:  
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
 
! Have you taken any illicit drugs during your pregnancy?   Yes  /  No 
If yes, what kind of drugs did you take?   …………………………………………… 
 
! Have you done any strenuous exercise during your pregnancy?  Yes  /  No 
(Strenuous exercise could be for example: running, jogging, squash, swimming, aerobics, cycling or 
football done for at least 30 minutes, at least once a week) !
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After you found out you were pregnant, how often did you eat the following foods? For each food 
type, please tick one box that best describes how often you ate this food. If this is different to before 
you found out you were pregnant, please circle in the right hand column whether you ate more or less 
of this food before. If this was not different, please leave the right hand column blank.  
 
Example: If you typically ate chocolate 4 times each week during your pregnancy (but ate 
less before you found you were pregnant) you would complete the row as shown: 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Chocolate           More  /  Less 
 
Fruit and Vegetables 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Fresh Fruit       More  /  Less 
Dried fruit e.g. raisins, 
dried apricots  
     More  /  Less 
Salad and Cooked 
vegetables  
     More  /  Less 
 
Dairy and Carbohydrates 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Milk      More  /  Less 
Cheese, yoghurt      More  /  Less 
Bread, cereals, 
potatoes, rice, pasta 
     More  /  Less 
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Meat, Meat alternatives and Fish 
 
Snacks 
 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Meat alternatives e.g. 
beans, peas, tofu, soy 
     More  /  Less 
Meat (unprocessed) 
e.g. steak, ham, chicken 
slices 
     More  /  Less 
Meat (processed) e.g. 
Burgers, sausages, fried 
chicken 
     More  /  Less 
Fish/shellfish      More  /  Less 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Chocolate      More  /  Less 
Chips, Crisps      More  /  Less 
Cakes, biscuits, ice 
cream 
     More  /  Less 
Take away meals e.g. 
Chinese food, Curry 
     More  /  Less 
 More than 
once/day 
Once/day 2-3 times 
per/week 
Once in 
2 weeks 
Never/ 
Rarely 
Before you found 
out you were 
pregnant 
Soft drinks      More  /  Less 
Caffeine e.g. tea, 
coffee, power drinks   
     More  /  Less 
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Mother Information: General 
 
Mother Information: Current Pregnancy 
 
Maternal weight at booking 
 
…………………….   (week:               ) 
 
BMI ……………….   (week:               ) 
 
Prescribed medication (incl. week) 
 
 
 
Maternal age at delivery 
 
 
 
 
Bleeding 
 
 
Yes       /       No     (Week                 ) 
 
Mother Information: Obstetric History 
 
Concern over fetal growth 
 
Yes       /       No     (Week                 ) 
 
Previous no. pregnancies 
 
  
IUGR/SGA Diagnosis 
 
Yes       /       No     (Week                 ) 
 
Previous no. live births 
 
  
Ultrasound: Amniotic Fluid Index 
 
Normal / High / Low  (Week              ) 
 
Previous Stillbirth 
 
 
Yes       /       No 
 
Ultrasound anomalies  
 
Yes       /       No 
 
Previous LBW baby (<2.5kg) 
 
 
Yes       /       No      
 
 
 
Doppler Anomalies 
 
Yes       /       No 
 
Previous Macrocosmic baby 
(>4kg) 
 
 
Yes       /       No      
 
 
Ultrasound: SGA centile 
 
 
Yes       /       No      
 
Centile                    (Week                 ) 
 
 
Illegal Drug use 
 
 
Yes       / No     (Week                       ) 
 
Smoking 
 
 
Alcohol 
 
Yes       /       No     (Week                 ) 
 
 
Yes       /       No     (Week                 ) 
 
 
 
 
Ultrasound: LGA centile 
 
 
 
 
Yes       /       No      
 
Centile                    (Week                 ) 
 
 
 
Study ID:     
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Current Pregnancy: Preeclampsia!  Delivery Time! !
 
Diagnosis PE 
 
Yes       /       No     (Week                 ) 
 
Maternal Weight at Delivery!                                 (Week                 )!
 
Previous PE Pregnancy 
 
Yes       /       No     (Week                 ) 
 
Mode of Delivery (& Indication) 
!!
 
Hypertension 
 
Yes       /       No     (Week                 ) 
 
Complications during Delivery 
!
 
Proteinuria 
 
Yes       /       No     (Week                 ) 
 
Baby Information!!
Gestational Age 
! 
Treatment for PE 
 
 
Yes       /       No     (Week                 ) 
 
Treatment:  
 
 
Sex of Baby 
 
 
Current Pregnancy: Gestational Diabetes 
 
Arterial Cord Blood pH 
 
 
Abnormal Glucose Tolerance Test 
 
Yes       /       No     (Week                 ) 
 
 
Apgar Scores 
 
1 min…………….   5 min …………… 
 
Diagnosis GDM 
 
Yes       /       No     (Week                 ) 
 
 
Birthweight  
 
BW:  
 
Centile:  
 
Previous GDM Pregnancy  
 
Yes       /       No      
 
Head Circumference 
 
   
Management 
 
Diet                  Yes       /       No      
 
Exercise           Yes       /       No      
 
Medication       Yes       /       No      
 
  
 
Delivery Information 
  
 
Delivery Date 
 
 
  
!
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Appendix 5: Placenta Proforma 
 
Placenta Proforma 
 
Study ID: 
Date: 
Time of Delivery:      Time dissection completed: 
 
Type of Delivery: 
 
Please note sampling sites: 
 
 
 
 
 
 
 
 
Total placental weight: 
 
Gross placental abnormalities:  
 
Date and time collected and stored in Biosi 3:   	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Appendix 6: STAI 
 
DIRECTIONS: A number of statements which people have used to describe 
themselves are given below. Read each statement and then tick in the appropriate 
box on the right to indicate how you generally feel. There are no right or wrong 
answers. Do not spend too much time on any one statement but give the answer 
which seems to describe how you generally feel, even before pregnancy 
 
  Almost 
never 
Sometimes Often Almost 
always 
1. I feel pleasant 4 3 2 1 
 
2. 
 
I feel nervous and restless 1 2 3 4 
3. I feel satisfied with myself 4 3 2 1 
 
4. I wish I could be as happy as 
others  seem to be 
1 2 3 4 
5. I feel  like a failure 1 2 3 4 
 
6. I feel rested 4 3 2 1 
 
7. I am "calm, cool and collected" 4 3 2 1 
 
8. I feel that difficulties are piling 
up so that I cannot overcome 
them 
1 2 3 4 
 
9. I worry too much over 
something that really doesn't 
matter 
1 2 3 4 
 
10. I  am happy 4 3 2 1 
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11. I have disturbing thoughts 1 2 3 4 
 
12.  I lack self-confidence 1 2 3 4 
 
13.  I feel secure 4 3 2 1 
 
14. I make decisions easily 4 3 2 1 
 
15. I feel inadequate 1 2 3 4 
 
16. I am content 4 3 2 1 
 
17. Some unimportant thought runs 
through my mind and bothers 
me 
1 2 3 4 
 
18. I take disappointments so 
keenly that I can't put them out 
of my mind 
1 2 3 4 
 
19. I am a steady person 4 3 2 1 
 
20. I get in a state of tension or 
turmoil as I think over my recent 
concerns and interests 
1 2 3 4 
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Appendix 7: EPDS 
 
Appendix X: Edinburgh Postnatal Depression Scale  
 
Please UNDERLINE the answer which comes closest to how you have felt in the 
past week, not just how you feel today. Here is an example already completed:           
I have felt happy: 
Yes, all the time 
              Yes, most of the time 
               No, not very often  
               No, not at all 
This would mean: I have felt happy most of the time in the past few days. 
Please complete the other questions in the same way. Do not take too long over it 
and make sure you answer all the questions. 
 
                            IN THE PAST WEEK 
 
1.  I have been able to laugh and see the funny side of things:  
               As much as I always could  0 
               Not quite so much now  1 
               Definitely not so much now  2  
               Not at all    3 
 
 2.  I have looked forward with enjoyment to things 
               As much as I ever did  0  
               Rather less than I used to  1 
               Definitely less than I used to 2 
               Hardly at all    3 
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3.  I have blamed myself unnecessarily when things went wrong 
               Yes, most of the time  3 
               Yes, some of the time  2 
               Not very often   1 
               No, never    0 
4.  I have been anxious or worried for no good reason 
               No, not at all   0 
               Hardly ever    1 
               Yes, sometimes   2 
               Yes, very often   3 
 
5.  I have felt scared or panicky for no very good reason 
               Yes, quite a lot   3 
               Yes, sometimes   2 
               No, not much   1 
               No, not at all   0  
                                   
6.  Things have been getting on top of me 
               Yes, most of the time I haven't been able to cope at all  3 
               Yes, sometimes I haven't been coping as well as usual  2 
               No, most of the time I have coped quite well   1 
               No, I have been coping as well as ever      0                   
    
 
7.  I have been so unhappy that I have had difficulty sleeping 
               Yes, most of the time   3 
               Yes, sometimes    2 
               Not very often    1 
               No, not at all    0 
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8.   I have felt sad or miserable 
               Yes, most of the time   3 
               Yes, quite often    2 
               Not very often    1 
               No, not at all    0 
 
9.  I have been so unhappy that I have been crying 
               Yes, most of the time   3 
               Yes, quite often    2 
               Only occasionally    1 
               No, never     0 
 
10.  The thought of harming myself had occurred to me 
               Yes, quite often    3 
               Sometimes     2 
               Hardly ever     1 
               Never     0 
 
 
 
 
 
 
 
 	  
